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ABSTRACT 
This thesis records a series of experiments conducted to gain further 
insight into factors which influence the expression, ligand binding 
and functional activity of the beta-2 adrenergic receptor. These 
studies were prompted by previous reports that the postulated beta-2 
adrenergic receptor abnormality in allergic asthma could be induced, 
induced by autoantibodies. 
I established and optimised beta-2 adrenergic receptor ligand binding 
and functional assays in guinea pig lung membranes and then conducted 
an original study of beta adrenergic receptor expression in the guinea 
pig foetal lung. I found that beta adrenergic receptor expression in 
the foetal lung was dormant for 80% of the gestation period. After 
day 53 there was a surge in receptor expression which increased beyond 
term. 
Using the guinea pig lung membrane as a source of beta-2 receptors, I 
investigated the inhibitory effects of serum from normal and allergic 
subjects on [125 I]cyanopindolol ([ 1251]-CYP) binding to beta-2 
adrenergic receptors and have found that ligand inhibition can be 
mediated by DEAE cellulose purified IgG fractions from both allergic 
and non-allergic individuals. Although a pilot study indicated that 
there may be significant differences between asthmatic and 
non-asthmatic sera, a larger prospective study showed no significant. 
differences between the inhibition of [1251]-CYP binding mediated by 
asthmatic and non-asthmatic sera (p - 0.289, Kruskal-Wallis test) and 
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there was a marked overlap in the values obtained. My data did not 
support an important role for autoantibodies to the human beta-2 
adrenergic receptor in the pathophysiology of asthma. 
In order to study genetic factors which may influence beta-2 
adrenergic receptor expression regulation and ligand binding, I used a 
human beta-2 receptor cDNA probe (CLFV-108) to identify a 2.3kb beta-2 
adrenergic receptor mRNA species in Wl-38 human diploid lung cells. 
Extending the genetic studies, I partially characterized 9 new mutant 
beta-2 receptors. These studies have confirmed that Aspartate 79 is 
important for agonist binding; that point mutation of Asn 6, increased 
antagonist binding, but point mutations of Asp 130, Ser 262, Asp 79 
and Ser 346 had no effect on antagonist binding; and that Asn 6, Ser 
262 and Ser 346 have normal isoproterenol stimulatable adenylate 
cyclase activity. Mutants involving Cys 191, His 172, Cys 190-191 and 
Asn 15 displayed impaired antagonist binding. 
In order to explore conceptual models of the ligand binding domain and 
to investigate possible interactions of inununoglobulins with the 
beta-2 adrenergic receptor, I raised a mouse monoclonal antibody 
(designated B4A8-PWL) to a synthetic 20 amino acid peptide (spanning 
amino acid Aspartate 79-Methionine 99) which is located in the second 
hydrophobic transmembrane domain of the human beta-2 adrenergic 
receptor. Characterization of this IgM isotype monoclonal antibody 
revealed that whilst recognising the Asp79-Met99 peptide in an ELISA 
it did not recognize the intact beta-2 adrenergic receptor. It did, 
however, specifically recognised a 49kDa protein identified on Western 
blots of human and mouse cell lysates. I also transfected the human 
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beta-2 adrenergic receptor gene into B82 mouse L cells. These cells 
stably express human beta-2 adrenergic receptors at different levels. 
One clone stably expresses human beta-2 adrenergic receptors at higher 
levels than previously published (4000-6000 fmol/mg membranes) and the 
human beta-2 adrenergic receptors couple with mouse adenylate cyclase. 
I have designated this clone: Wt-7 Cape Town. 
I also raised rabbit polyclonal antibodies to the Asp79-Met99 
transmembrane peptide. These antibodies demonstrated [ 1251]-CYP 
inhibition but, paradoxically, also stimulated adenylate cyclase 
activation in the Wt-7 Cape Town cells. 
I used the Wt-7 Cape Town clone to investigate the functional effects 
of human allergic and non-allergic serum on beta-2 receptor coupled 
adenylate cyclase activation and have confirmed that certain sera 
exert markedly inhibitory effects. The inhibitory effects in this 
system, however, appear to be due to complement mediated cell damage 
via heterophile antibodies, rather than inhibition of beta-2 
adrenergic receptor function. Purified IgG and products of activated 
platelets and lymphocytes were not inhibitory for adenylate cyclase 
activation but products of activated neutrophils were markedly 
inhibitory. I confirmed that IgG and sera from asthmatic and 
non-asthmatic individuals also inhibit [ 1251]-CYP ligand binding to 
human beta-2 receptors using the Wt-7 Cape Town clone; that the degree 
of inhibition is related to the level of beta-2 adrenergic receptor 
expression in the Wt-7 Cape Town cells; and that the inhibition is 
non-competitive. 
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Finally, I examined the distribution of Ban 1 restriction fragment 
length polymorphism in 72 subjects in Cape Town and have found no 
significant difference between the gene frequency of either the 2.9 or 
3.1 kb allele when allergic subjects were compared with non-allergic 
controls, but that the gene frequency for the two alleles was quite 
different to the gene frequency reported in North American subjects. 
Further studies, using a unique 326bp probe of the genomic sequence, 
suggested that the Ban 1 polymorphic locus was not only in the coding 
region of the gene but within a ligand binding domain. 
These studies demonstrate that in vitro beta-2 receptor ligand 
binding, function and expression may be modified by factors which may 
operate at the level of gene regulation (e.g. steroids), the gene 
sequence (mutants) directly on the receptor (non-competitive 
inhibition by irrununoglobulins) or via post-receptor (coupling) 
mechanisms or by factors which damage the cell membrane non-
specifically. These factors may initiate or sustain the beta-2 
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65. Inhibition of cAMP production and [125I]-CYP binding by sera 
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66. The effect of sera from moderate and severe asthmatic children 
on cyclic AMP production in Wt-7 Cape Town cells. 
67. Inhibition of cAMP production by serum from six non-asthmatic 
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68. The effect of the acute phase response as measured by an 
increase in C-reactive protein on the serum inhibitory effects 
on cAMP production in Wt-7 Cape Town cells. 
69. Comparison of the inhibitory effect of asthmatic sera on 
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production. 
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85. Inhibition of [1251]-CYP binding to human beta-2 receptors by 
serum (1:10 dil) or purified IgG (equivalent concentration). 
86. Distribution of the Ban 1 restriction sites in a 3500 bp 
sequence including coding and flanking regions of the human 
beta-2 receptor gene. 
87. Autoradiograph of Southern blots of Ban 1 digested DNA from 
allergic and non-allergic subjects, probed with a nick 
translated 2.6kb human beta-2 receptor cDNA probe. 
88. Autoradiograph of Ban 1 digested 2.6kb cDNA probe confirming 
predicted restriction fragments. 
89. Autoradiograph of human Ban 1 digested DNA showing 
identification of only the larger (3.1kb) polymorphic fragment 
with the 326bp probe. 
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INTRODUCTION AND LITERATURE REVIEW 
1.1 Adrenergic innervation of the airways. 
Catecholamines elicit their characteristic effects through the 
activation of effector cells via the adrenergic receptors. 
Partial activation or failure of activation of effector cells could 
arise from impaired catecholamine release, poor delivery of 
circulating catecholamines to their receptors, or factors which 
compete with, or sterically hinder access of the catecholamine to its 
receptor. Structural abnormalities of the adrenergic receptor itself 
modifying its coupling with G proteins and adenylate cyclase, or post 
receptor defects may also result in an impaired effector response. 
Before considering factors which block the adrenergic system, it is 
important to review the known mechanisms of adrenergic receptor 
activation. Control of the airways by the adrenergic system may be 
direct or via circulating catecholamines. The neurotransmitter of the 
direct system is noradrenaline, released by sympathetic nerves whose 
preganglionic nerve fibres arise from the upper six segments of the 
thoracic spinal cord, synapse in the middle and inferior cervical 
ganglia and the upper four thoracic paravertebral ganglia and whose 
post ganglionic nerves enter the lung at the hilum, intermingling with 
cholinergic nerves to form a plexus around airways and blood vessels 
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(Richardson 1979, Laitinen 1985, Barnes et al 1986c). In contrast to 
the dense innervation of the parasympathetic system, the sympathetic 
innervation is sparse. Histochemical studies show that human airways, 
unlike those of cats, have sparse adrenergic innervation of submucosal 
glands, bronchial arteries and smooth muscle (Partenen et al. 1982). 
It is believed that adrenergic nerves probably influence bronchomotor 
tone indirectly, by an interaction with the cholinergic innervation at 
ganglionic or post-ganglionic level. Baker et al (1983) has shown 
that norepinephrine inhibits nicotinic neurotransmission in airway 
ganglia of the ferret trachea through presynaptic alpha receptors, and 
Vermeire and Van Houte (1979) has suggested that norepinephrine 
probably inhibits the release of acetylcholine from post-ganglionic 
nerve terminals. The fact that neither alpha- nor beta-adrenoceptor 
antagonists have any influence on airway smooth muscle tone in healthy 
individuals suggests that the role of sympathetic nervous control of 
airway smooth muscle is small under normal conditions. However, since 
a substantial number of asthmatics develop bronchoconstriction after 
administration of beta blockers, which may be reversed by atropine, it 
is suggested that in the asthmatic, unopposed sympathetic drive is 
critical to counteract parasympathetic effects (Grieco and Pierson 
1971). These important differences between asthmatics and normal 
individuals in their requirements for unopposed beta adrenergic 
receptor stimulation and in the differences in the responses of their 
airways to beta receptor blockade, imply that factors which block the 
normal function of beta adrenergic receptor in human asthma are likely 
to be important and should be identified and explored. 
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The role of circulating catecholamines, particularly adrenaline, in 
maintenance of airway smooth muscle tone in asthma, has been stressed 
by the studies of Ind et al. (1985). Endogenous adrenaline is capable 
of effecting bronchodilatation, and infusion experiments demonstrate 
that adrenaline can antagonise the effects of inhaled histamine 
(Warren et al. 1984). Noradrenaline has no effect on airway tone in 
both normal and asthmatic subjects (Berkin et al 1985, 1986). 
Noradrenaline functions as a neurotransmitter and not as a circulating 
hormone. Adrenaline is secreted by the adrenal medulla and plasma 
adrenaline concentrations are normal at rest in asthmatics compared 
with age matched controls (Barnes et al 1982). It is also known that 
nocturnal wheezing correlates closely with the normal circadian fall 
in circulating adrenaline (Barnes et al 1980). Normal circulating 
concentrations of adrenaline probably protect against 
bronchoconstriction and endogenous adrenaline probably exerts its 
effect at the level of airway smooth muscle as well as on airway mast 
cells. In acute asthma (Ind et al. 1985), exercise induced asthma 
(Warren et al. 1982) and isocapnic hyperventillation (Barnes et al. 
1981a) there is no significant rise in plasma catecholamines as would 
be expected in normal individuals, but a normal catecholamine response 
to hypoglycaemia and histamine infusion is observed. There would 
appear to be a selective or partial defect in adrenaline release in 
asthmatics which may be a contributory factor, but is not a primary 
cause of the asthma. 
The distribution of beta adrenergic receptors in the lung increases 
progressively from the trachea to the terminal bronchioles (Barnes et 
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al. 1983) and relaxation of human central and peripheral airways is 
mediated only by beta-2 adrenergic receptors (Zaagsma et al. 1983, 
Goldie et al. 1984), which are autoradiographically the predominant 
airway receptors of the human airway smooth muscle, from bronchi to 
terminal bronchioles (Carstairs et al. 1985). 
Although intact function of beta-2 adrenergic receptors on smooth 
muscle is generally considered to be of critical importance in asthma, 
the function of beta-2 adrenergic receptors on other cells in human 
airways must also be considered. Beta agonists stimulate ion 
transport on human epithelium (Knowles et al. 1984), inhibit antigen 
induced mast cell mediator release from passively sensitised human 
lung fragments (Butchers et al. 1980) and also from isolated lung mast 
cells (Peters et al. 1982). Beta adrenergic receptor integrity is 
also important for the inhibition of pulmonary oedema (Persson et al. 
1982) and increased airway microvascular permeability induced by 
mediators of anaphylaxis. 
1. 2 Factors influencing beta adrenergic receptor number and 
functional integrity. 
Since the hypothesis of Szentivanyi (1968) that asthma was a disease 
of "impaired beta adrenergic receptor function" or "partial receptor 
blockade", there have been many studies investigating beta-2 receptor 
numbers and function in human asthma and in guinea pig asthma models. 
The major findings of the reported studies of beta adrenergic 
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receptors in human asthma are listed sequentially in Table 1, and in 
guinea pig asthma models, in Table 2. 
While many of the studies listed in Tables 1 and 2 indirectly support 
Szentivanyi's hypothesis by demonstrating reduced beta receptor number 
and/or function, the original suggestion that there was a primary 
defect in fi receptor function in asthma has never been substantiated. 
Svedmyr (1984) was unconvinced that beta receptor abnormalities 
previously reported are of any clinical significance and has 
questioned whether a beta-2 receptor 'abnormality' contributes to the 
pathophysiology of asthma at all. 
Since reports of cholinergic and alpha adrenergic hyperresponsiveness 
(Henderson et al. 1979, Kaliner et al. 1982) in asthma, and the 
discovery of non-adrenergic non-cholinergic (NANG) airway innervation 
(Coburn and Tomita 1978, Taylor et al. 1984), the relative importance 
of different neural, cellular and humoral pathways in the regulation 
of airways tone is not clear. Consequently the effects of a defect in 
any one of these components cannot be viewed in isolation. 
The importance of a sound understanding of human beta-2 receptor 
function in relation to drug therapy in asthma has recently been 
stressed by Wang et al. (1991) and Sears et al. (1991), who have 
drawn attention to dangers of regular beta-2 agonist treatment in 
asthma. They have found that regular inhalation of a beta 
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sympathomimetic agent is associated with a deterioration in the 
majority of asthma subjects, in a double blind, placebo controlled 
randomised cross-over study. 
In order to monitor the effects of drug therapy on beta receptor 
responsiveness, there is a need to examine the validity and clinical 
relevance of current methods of assessment of beta-2 adrenergic 
receptor function in asthmatics, most of which are indirect, and to 
develop reliable, more direct methods. In order to understand the 
basis of beta-2 receptor dysfunction in the pathophysiology of asthma, 
the role of serum factors, products of inflammation and beta agonists 
on human beta-2 receptors requires critical appraisal. 
In reviewing the literature it is not clear to what extent the 
reported beta adrenergic receptor hyporesponsiveness is primary (i.e. 
genetic) or secondary (i.e. acquired), whether it is total or partial 
(organ selective), or whether abnormal receptor numbers and functional 
responses found in vitro, are indeed of any clinical significance. 
Furthermore, a specific structural or molecular abnormality of the 
beta-2 adrenergic receptor has never been described in any human or 
animal disease. 
In order to place my own studies in perspective with what is already 
known about the nature and regulation of beta-2 adrenergic receptors, 
it is important at the outset to review the factors known to regulate 
the beta-2 adrenergic receptors. It is convenient to consider the 
published biochemical factors in this introductory chapter and to 
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address the factors which are important in the genetic expression of 
the beta-2 receptor in Chapter 4, in which I have discussed genetic 
aspects of the human beta-2 receptor. 
In 1948, Ahlquist classified the adrenergic receptors as alpha and 
beta based on the relative potencies of the adrenergic agonists 
norepinephrine, epinephrine and isoproterenol on effector cells. 
Typical alpha adrenergic responses which he observed were smooth 
muscle contraction in most tissues, for which epinephrine and 
·norepinephrine were the most potent and isoproterenol the least 
potent. By contrast, the beta adrenergic receptors typically mediated 
smooth muscle relaxation for which isoprenaline was more potent than 
either epinephrine or norepinephrine. 
In 1967 Lands et al. reported two distinct beta receptor subtypes. By 
comparing the effects of various sympathomimetics on laboratory 
animals such as the rabbit, dog, guinea pig and rat they found a 
positive correlation between the effects on adipose tissue and cardiac 
stimulation (Beta-1) and between the effects of bronchodilatation and 
vasopression (Beta-2) and concluded that the receptor in each pair was 
the same. It is now known that even within a single organ, e.g. the 
lung, beta receptors may exist in both subtypes, however it is not 
known as yet whether more than one receptor subtype can be expressed 
on the same cell. The human beta 3 adrenergic receptor has recently 
also been characterised by Emorine et al. (1989). Novel beta 
adrenergic receptor agonists having high thermogenic anti-obesity and 
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anti-diabetic activities in animal models are among the most potent 
stimulators of the beta-3 adrenergic receptor. 
With the development of sensitive high affinity radioligand assays for 
measuring beta adrenergic receptor number (Levitsky et al 1974, 
Lefkowitz 1974, Auerbach et al 1974) and the development of functional 
assays to measure beta adrenergic receptor mediated adenylate cyclase 
activation (Salomon 1979), it soon became apparent that beta 
adrenergic receptors were present on almost all cells studied, and 
that their numerical expression and function was not only variable in 
different tissues studied, but subject to hormonal, pharmacological, 
and physiological processes. Furthermore, it was also found that 
under certain circumstances refractoriness, desensitization or 
tolerance to catecholamine stimulation occurred (Su et al. 1980) 0 
Stiles et al. (1984) have reviewed the published factors influencing 
beta adrenergic expression and function under two main headings: 
Homologous regulation of receptor number and function by hormones 
and/or drugs that bind to receptors directly (e.g. epinephrine or 
propranalol) and heterologous regulation of the receptor by hormones 
or drugs that do not ordinarily bind to the receptor (e.g. 
glucocorticoids). Biochemical and cellular mechanisms of homologous 
regulation of beta receptors may involve uncoupling from the 
G-proteins, internalisation of the receptors (Chuang and Costa 1978), 
and sequestering of the receptor in vesicles away from the components 
of the adenylate cyclase system (Stadel et al 1983b). Fusion studies 
using the Xenopus laevis erythrocyte (Strulovici et al. 1983) 
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have investigated the functionality of sequestered receptors. Stadel 
et al. (1983) also demonstrated that agonist induced desensitization 
involved beta adrenergic receptor phosphorylation of the turkey beta 
adrenergic receptor and Benovic et al. (1986) and Bouvier et al. 
(1988) have reported that a specific beta adrenergic receptor kinase 
is involved. 
It was thus apparent that while homologous regulation occurred at a 
receptor level, heterologous regulatory factors could possibly operate 
at a pre-receptor (e.g transcriptional or post-translational level) or 
post-receptor level (e.g.coupling) with G protein or non-specific 
membrane effects. 
Studies of factors influencing beta adrenergic receptor number and 
function which have been conducted in animals, in cell culture and in 
humans, during the past ten years are too numerous to discuss in this 
introduction. I have, therefore, summarised and grouped the major 
published studies which form an important background to my own studies 
in Tables 1-4 and will focus any discussion on the studies which 
address the issues which must be considered in evaluating my own work. 
I have listed the studies which focussed on human asthma (Table 1) 
separately from studies on beta-2 receptors in non-asthmatic subjects 






Studies of beta adrenergic receptors in human asthma 
Recent studies of beta adrenergic receptors in guinea pig 
asthma models. 
Factors influencing beta adrenergic receptor 
number/function : animal studies. 
Factors influencing human beta adrenergic receptor 
number/function in non-asthmatics 
A number of clear and consistent general observations about beta-2 
receptor regulation are evident from the animal studies listed. In 
the first instance, adrenergic receptors may be down-regulated by 
agonists (Stadel et al 1983, Pecquery et al 1984, Su et al 1989). 
There is also an independent regulation of beta-1 and beta-2 
adrenergic receptors by hormones, which may be organ specific e.g. 
glucocorticoids increase beta-1 receptor number in rabbit lung 
(Roberts et al 1985) and beta-2 receptors in the guinea pig lung 
(Salonen 1985) but do not increase beta-1 receptors in the rabbit 
myocardium. At critical developmental times, susceptibility to 
steroid induction of receptors may be dramatic (Cheng et al 1980). 
Differential susceptibility of beta adrenergic receptor subtypes to 
hormonal induction also occurs with thyroid hormone treatment: for 
example, rat heart beta-1 receptors are increased by thyroid hormone 
but no increase was observed in lung beta-2 adrenergic receptors 
(Scarpace and Abrass 1981, Tse et al 1980). However, the normal 
developmental increase in rat fetal lung receptors are dependent on 
thyroxine (Whitsett et al 1980). 
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Effect on beta receptor 
Marked reduction in airway 
calibre 
Inversely proportional to the 
severity of the disease in 
children 
Reference 
Zaid & Beal 1966 
MacDonald et al. 
1967 
Inoue 1967 
Asthmatic subjects have reduced Lockey et al. 1967 
response compared with normals Middleton & Finke 1968 
Twin studies Peripheral Reduced basal and isoproterenol Falliers et al. 1971 























Correlation with Lymphocytes 
disease severity 
Systemic receptor Pulse pressure 
sensitivity 
activity in asthmatic compared 
with non asthmatic twin 
Urinary cAMP increased in 
normals but not asthmatics 
Reduced cAMP response compared 
with controls 
Reduced heart rate, responses 
to catecholamines 
Subsensitivity induced by 
chronic administration 
Beta receptors reduced in 
patients with active asthma 
but not inactive asthma 
Discontinuation of adrenergic 
agonists reversed diminution 
of receptors induced by agonist 
therapy 
Reduced number 
Reduction in beta receptor 
number correlated with disease 
severity 
Larger doses of catecholamines 
required to raise pulse pressure 
Bernstein et al. 1972 
Parker & Smith 1973 
Larsson 1977 
Nelson et al. 1977 
Kariman & Lefkowitz 
1977 
Galant et al. 1978 
Brookes et al. 1979 
Brookes et al.1979 











































Effect on beta receptor Reference 
Inhibition of ligand 
c125 JIHYP binding, 
Venter et al.1980 
Fraser et al. 
precipitation of solubilised 1981 
receptors 
No differences in beta receptor Galant et al.1980 
number or adenylate cyclase 
responsiveness in untreated 
asthmatics compared with controls 
Decreased beta receptor 
hyporesponsiveness 
with increased cholinergic and 
Ct adrenergic responsiveness 
Kaliner et al.1982 
Response to inhaled epinephrine Barnes et al.1982 
greater at 04h00 than 16h00 
No difference in receptor 
number or isoproterenol 
stimulation 
cAMP response to exercise 
blunted 
Wolfe et al.1982 
Warren et al.1982 
Ind et al. 1983 
Reduced inhibition of lysosomal Busse et al. 
enzyme release by isoproterenol 
Reduced cAMP response 
Age dependent increase in 
receptor number 
Greater inhibition of ligand 
binding in certain asthmatic 
children 
Reduced beta receptor number 
Reduced number 
Reduced number 
Candell et al. 1984 
Reinhardt et al.1984 
Blecher et al. 1984 
Galant & Britt 1984 
Reinhardt et al.1984 
Sano et al.1984 
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Factor studied Organ or cell 
Allergen Lymphocytes 
(house dust mite) 
Diurnal Lymphocytes 
variations 
Bronchial asthma Lymphocytes 












Exercise induced Lymphocytes 
asthma 
Atopic asthma Pulse pressure 
Bronchial Lymphocytes 
responsiveness 
Exercise induced Lymphocytes 
asthma 
Ketotifen Lymphocytes 
Autoantibodies Human sera 
Effect on beta receptor Reference 
Reduced number and adenylate Meurs et al.1984 
cyclase responsiveness 1987, 1988. 
Circadian variation in affinity Titinci et al.1984 
and number of receptors 
Reduced number 
Reduced number 
Lower affinity (in polyps) 
Blunted cAMP response 
Plasma epinephrine response 
to hospitalization blunted 
in asthmatics but plasma 
norepinephrine response 
not blunted 
Diminished in asthmatics 
Reduced number. Reduced 
responses (cAMP and fall in 
diastolic BP) to isoproterenol 
Asthmatics require a bigger 
dose of isoproterenol to 
raise pulse pressure 22.nxnHg 
Sano et al.1984 
Kinkel et al.1989 
Cundell et al.1984 
Ind et al. 1985 
Potsma et al.1985 
Martinssen et al.1985 
Davis et al.1986 
No correlation between receptor Davis et al. 1986 
numbers and bronchial 
responsiveness 
Failure of increase in 
receptors in asthmatics 
Reinhardt et al. 
1987 
Restoration of the up regulation Reinhardt et al. 
of beta receptors following 1987 
exercise 
Inhibition of ligand binding in Potter & Dakers 1987 






































Effect on beta receptor 
Reduced receptor number 
Receptor density 2- to 3-fold 




Gamboa et al. 1987 
Korholz et al. 1988 
Polson et al. 1988 
Low numbers of receptors Bittera et al. 1988 
Enhanced recovery of lymphocyte Brodde et al. 1988 
beta-2 adrenoceptor 
responsiveness to beta agonists 
No difference between ligand 
inhibition between asthmatics 
and controls. 
Attenuated responsiveness to 
beta sgonists (isoproterenol 
and Fenoterol) not due to 
reduced receptor density 
Reduction of beta receptor 
number unrelated to IgE levels 
or sensitivity to histamine 
challenge 
Prevention of tachyphylaxis 
to inhaled sympathomimetics 
Increased cAMP responsiveness 
to isoproterenol in asthmatics 
4-5 fold reduction in relaxant 
properties to isoproterenol and 
Fenoterol attributed to 
reduced smooth muscle 
beta-2 receptor function 
Kokuba et al. 1989 
Spina et al. 1989 
Bittere et al. 1988 
Pauwels et al. 1989 
Polson et al. 1988 

















Organ or cell 
Guinea pig lung 
Guinea pig lung 










Effect on beta receptor 
Prevention of terbutline induced 
decrease in receptor density 
Reference 
Koshino et al. 1987 
Significant decrease in beta receptor Mu and Bi 1989 
sites in bronchi and bronchiolar 
smooth muscle and in bronchial and in 
alveolar epithelium 
Significant reduction in beta 
receptor number in ovalbumin 
challenged group 
Removal of epithelium removes 
protective effect of broncho-
dilators in vitro in guinea pig 
Significant quantitative reduction 
in [3HJ-DBA binding in alveolar and 
conducting airway epithelium and 
bronchiolal smooth muscle in oval-
bumin asthma model. 
Reduction in beta receptor 
number 25%. Reduction in adenylate 
cyclase activity 68% 
Motojima et al. 1989 
Goldie et al. 1986 
Gatto et al. 1987 
Taki et al. 1986 
20% reaction of beta receptor number Barnes et al. 1980 
in asthmatic animals (ovalbumin 
model) 
Prevention of down regulation 
of beta receptors induced by 
terbutaline 
Koshino et al. 1988 
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to adenylate cyclase 
Energy dependent cycling 
of receptor 
Airway muscle Guinea pig Decreased develo:pnental 



















Guinea pig Increased number 
Rabbit Increased number 
Rabbit 














Erythrocyte Bl Turkey 
Increased alveolar 










of up regulation 
Decreased number 
Decreased number 
decreased adenylate cyclase 
Reference 
Chuang and Costa 
1979 
Su et al. 1980 
Doss et al. 1981 
Stadel et al. 1983 
Stadel et al. 1983 
Tse et al. 1979 
Little et al. 1984 
Pecquery et al.1984 
Limas & Limas 1984 
Duncan et al. 1982 
Kaumann 1972 
Mano et al. 1979 
Cheng et al. 1980 
Foster & Harden 
1980 
Salonen 1985 
Roberts et al. 1985 
Barnes 1985 
Barnes 1985 
Sporn et al. 1976 
Kajiyama et al.1982 
Glaubinger et al. 
1978 
Miles et al. 1984 
Kennedy & Donnely 
1982 
Giudicelli 1978 
Furukawa et al.19ao 







































Organ or cell Species 
studied 
Adult lung B2 Rat 
Heart Bl Rat 
Lymphocyte B2 Rat 
Foetal lung B2 Rat 
Heart Bl Rat 
Foetal lung B2 
Myocardium Bl Rat 










Heart cells Chick 






is thyroxine dependent 
Increased 
Increased with potentia-










Binds to beta receptors 
and increased contractili ty 
Spontaneous motility 
inhibited 
Blunted desensitization of 
contractile response and 
recovery 
Reference 
Scarpace & Abrass 
1981 
Whitsett et al.1980 
Tse et al 1980 
Williams et al.1977 
Das et al. 1985 
Scarpace et al.1986 
Maisel et al. 1985 
Yocca & Fredman 1984 
Hatjies et al. 1985 
Moawad AH et al.1985 
Tsuchihashi H et al. 
1985 
Borda et al. 1985 
Borda 1984 
Marsh et al. 1985 
Tracheal strip Guinea pig Reduction in isoprenaline 
induced inhibition of 
mediator release 


























50% fall in myocardial 
beta receptors 
Petrovic et al. 1981 
Jordaan 1981 
Talone et al. 1979 
Woodcock et al. 1979 
1980 
De.creased number and Voelkel et al. 1981 
blunted responses 
Decreased number (50%) but Olson et al. 1981 
no effect on function 
Decreased 
Rebound increase 
Decreased receptor number 
and response to isopro-
terenol 
Banerjee et al. 1978 
Kuriyama 1981 


































Effect on beta 
receptor 
Increase in beta-1 
receptors day 26-29 
Increase in beta-1 and 
beta-2 receptors from 
day 18 to day 28 
Increase in number and 
sensitivity from day 13 
to 21 
Increases in receptor 
number. Function 
dependent upon changes 
in N protein 










Whitsett et al. 1981 
Chen et al. 1979 
Lai et al. 1981 
Limbird et al. 1980 
Gulick et al. 1989 
Norris et al. 1987 
Non competitive inhibition Sterin Borda et al. 
of 3e-DNA binding 1988 
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TABLE 4 
FACTORS INFLUENCING BETA ADRENERGIC RECEPTOR FUNCTION/NUMBER 
















Effect on beta receptor 
Decreased receptor number 
Decreased number 
Increased receptor density 
on granulocytes and 
lymphocytes, increased 
coupling efficiency 
Lung cells Wl-38 Increased number 
Astrocytoma cells Increased number 







No evidence for hyper-
sensitive response to 
catecholamines 
No change in number or 
adenylate cyclase activity 
Congestive heart Myocardium 
failure 
Increased no. of receptors 










induced contraction 54-75% 
High numbers in April/May 







Davies & Lefkowitz 1981 
Basso et al. 1985 
Davies and Lefkowitz 
1983 
Fraser and Venter 1980 
Foster and Harden 1980 
Piantarelle et al. 1984 
Boudoulas et al. 1977 
Nattel et al. 1977 
Lindenfeld et al 1980 
Williams et al 1979 
Ginsberg et al. 1981 
Bristow et al. 1982 
Haen et al. 1988 
Sato 1984 
Tawara Ket al. 1984 



























Reduced sensitivity to 







No reduction in 
responsiveness 
Reduced cAMP 
Reduction in 3H DNA 
Reduction in 3H DNA 
binding 
Vestal et al. 1974 
Stern and Kunos 1988 
Nakane et al. 1990 
Mancini et al. 1989 
Davis and Byerd 1990 
Limas et al. 1989 
Limas et al. 1989 
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The demonstration by Stern and Kunos (1988) of a synergistic effect 
between the regulation of pulmonary ~-adrenergic receptors by 
glucocorticoids and interleukin-1 suggests that regulatory factors of 
beta receptors are unlikely to be functioning independently, in vivo. 
There are no animal models in the literature of autoimmunity to the 
beta adrenergic receptor but the studies demonstrating functional 
effects of human immunoglobulins on beta receptors on rat myocardium 
(Borda et al. 1984a) and of alloirnmune sera on isolated oviducts 
(Borda 1984b) raise intriguing questions as to the possibility of 
similar antibodies occurring naturally. Besides endogenous factors, a 
number of exogenous factors e.g. ethanol (Banerjee et al 1979, 
Kuriyama et al 1981), antidepressant therapy (Hertz et al 1981), 
hypoxia (Voelkel et al 1981) and stress (Yocca and Fred.man 1984) may 
have marked effects on beta adrenergic receptors. Furthermore, a 
number of as yet unknown factors operate at critical periods in 
gestation to stimulate beta adrenergic receptor development in the 
heart (Chen et al 1979) and in the lung (Giannopoulis 1980, Whitsett 
et al 1981). 
Factors influencing beta receptors in human studies tabulated in Table 
4, are consistent with the tissue and subtype specificity of the 
factors influencing beta adrenergic receptors reported in the animal 
studies (Table 3) but introduce the concept of a possibly disordered 
expression or function of beta adrenergic receptors in human diseases 
e.g. congestive heart failure (Bristow et al 1982, Mancini et al 
1989), cardiomyopathy (Limas et al 1989), cystic fibrosis (Sato and 
Sato 1984, Tawara et al 1984) and phaeochromocytoma (Tsujimoto et al 
1984). 
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Beta adrenergic receptors may also be affected by drugs used for 
therapeutic purposes (Boudoulas et al 1977, Piantarelle et al 1984, 
Basso et al 1985) and the sensitivity of beta-2 receptors to agonists 
may be modified by lymphokines e.g. Interleukin-1 (Nakane et al 1990). 
Liggett et al (1988), in a detailed study of the correlations between 
tissue adrenoceptor function and the receptor and adenylate cyclase 
characteristics of easily accessible circulating cells, has shown that 
in the case of mononuclear leucocytes (MNL) the adrenoceptor densities 
on circulating cells reflect those on extravascular tissues in a 
subtype specific fashion, but that physiological inter-individual 
variation of adrenergic receptor characteristics were not of 
sufficient magnitude to alter sensitivity to epinephrine in vivo. In 
fact, adrenergic receptor adenylate cyclase from circulating cells 
(MNL and platelets) was found to be unrelated to the hemodynamic and 
metabolic responses to epinephrine in normal humans in vivo. 
One of the most important questions which arise upon finding 
disordered beta receptor number and function in a given disease is 
whether these abnormalities have led to the disease, or whether they 
have occurred as a result of a disease process. 
It is in the field of asthma (Table 1) that a review of the factors 
influencing beta adrenergic receptors is of particular relevance to 
the studies I have embarked upon. Increased sensitivity of asthmatic 
subjects to beta adrenergic receptor blockade following the 
administration of propranalol to allergic subjects was first reported 
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by Zaid and Beal in 1966. The development of the "beta adrenergic 
theory of atopic abnormality in asthma" was then developed by 
Szentivanyi (1968). 
Early studies, conducted before radiolabelled high affinity specific 
ligands for beta receptors became available, reported reduced beta-2 
receptor mediated responses in asthmatics. These included a reduced 
hypoglycaemic response (Inoue 1967, Lockey et al 1967, Middleton 
1968), reduced isoproterenol stimulated adenylate cyclase activity in 
leucocytes (Falliers et al 1971, Parker and Smith 1973), reduced 
urinary cyclic cAMP (Bernstein et al 1972) and reduced cardiovascular 
responses to beta adrenergic stimulation (Larsson et al 1977, 
Shelhamer et al 1980). 
Reduction in beta-2 numbers on lymphocytes of active asthmatic 
patients was reported by Kariman and Lefkowitz in 1977. These initial 
findings raised a critical question as to whether lymphocyte beta-2 
receptor number or function reflected receptor status in the lungs and 
even the early studies suggested that this might not be the case. 
Galant et al (1978) suggested that reduced neutrophil beta adrenergic 
receptor number was related to agonist therapy, but Brooks et al 
(1979) found that a reduced lymphocyte beta receptor number correlated 
with the disease severity in asthma. In 1980, Galant et al found no 
differences between untreated asthmatics and normal controls in 
neutrophil beta receptor numbers or adenylate cyclase responsiveness. 
There was thus an apparent difference between the changes found on 
beta-2 receptors on lymphocytes compared with those found on 
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neutrophils in asthmatic subjects. It was only after the studies of 
Holgate et al. (1980) documenting development of resistance to 
intravenous Salbutamol in normal individuals, that differences in the 
regulation of beta-2 receptors in asthmatics became apparent. Wolfe 
et al. (1982) studying lymphocyte receptor numbers and isoproterenol 
stimulation, were unable to find any differences in patients with 
aspirin induced bronchospasm. 
It is now apparent that certain discrepancies in the early studies 
could have been due to failure to take into consideration normal 
diurnal variations (Titinci et al. 1984), circannual variations (Haen 
et al. 1988), age of the patient (Reinhardt et al. 1984) and 
differences in beta adrenergic receptor numbers in different 
lymphocyte subsets (Korholz et al. 1988). 
It is clear from Table 1 that most investigators have found 
significantly reduced numbers of beta-2 receptors on lymphocytes in 
patients with asthma. Lymphocyte beta-2 receptor numbers can be 
reduced by Salbutamol treatment (Reinhart et al. 1984), Terbutaline 
treatment (Sano et al. 1984), exercise (Martinson et al. 1985, 
Reinhardt et al. 1987) and even allergen (house dust mite) challenge 
(Meurs et al. 1984, 1987 and 1988). It was furthermore shown that 
atopy itself (Cundell et al. 1984, Gamboa et al. 1987) is associated 
with a blunted cyclic AMP response in patient's lymphocytes. Reduced 
receptor responses to catecholamines and lymphocytes have more 
recently been shown to be reversed by steroid therapy (Brodde et al. 
1988) and Ketotifen therapy (Reinhardt et al. 1987, Polson et al. 
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1988). Reports of impaired adrenaline (but not noradrenaline) 
secretion (Ind et al. 1985) in acute asthma add further dimension to 
and are consistent with a disordered beta-2 adrenergic receptor 
response in asthma. The mechanisms for the reported blunted 
adrenaline responses have not yet been explained. 
Central to any appraisal of the published abnormalities of beta-2 
receptor function reported in asthma is that most of the studies 
showing reduced beta-2 receptor number and function have been 
conducted on circulating lymphocytes. While the reduced number and 
function seems to be a consistent finding from the combined published 
data, there are very papers examining the relationships, if any, 
between lymphocyte beta-2 receptors and lung beta-2 receptors (Davis 
et al. 1986, Gamboa et al. 1987). Goldie et al. (1987) have shown a 
4-5 fold reduction in relaxant properties of isoproterenol and 
fenoterol, and have attributed this to reduced smooth muscle beta-2 
receptor function, in post-mortem studies of bronchial muscle strip 
preparations. 
Studies in guinea pig models (Barnes et al. 1980), Mu and Bi 1989, 
Motojima et al. 1989, Gatto et al. 1987) have shown significant 
decreases in beta-2 receptor numbers in the lungs of asthmatic animals. 
In spite of the large number of studies (Table 1) attempting to define 
the beta adrenergic receptor defect in asthma a number of unresolved 
questions relating to the theory of beta-2 adrenergic receptor 
dysfunction in asthma remain. 
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1. What is the molecular nature and organ distribution of the 
dysfunction? 
2. Is the dysfunction present in all asthmatics or only in a 
subgroup? (e.g. Atopic or exercise induced asthmatic group) 
3. To what extent do genetic factors contribute to the 
beta-adrenergic receptor dysfunction? 
4. Why are the lungs of asthmatics (unlike normals) so susceptible to 
beta-adrenergic receptor blockade? 
5. To what extent do environmental (e.g. drugs, allergens) or other 
factors (e.g mediators, immunoglobulins) influence beta-2 receptor 
function in asthmatics. 
6. Do the beta-2 adrenergic abnormalities reported in vitro (e.g. 
reduced receptor number or lymphocytes) have clinical significance. 
7. Is the beta-adrenergic dysfunction part of a more generalised 
membrane disorder or related to post-receptor abnormalities? 
Novel in vitro evidence suggesting that serum factors may directly 
interfere with catecholamine binding to beta-2 adrenergic receptors 
was initially advanced in reports by Venter et al. (1980) of 
autoantibodies to the beta-2 adrenergic receptor and by Fraser et al. 
(1981) of the association of autonomic abnormalities with 
autoantibodies to the beta adrenergic receptor in patients with 
allergic asthma and atopic rhinitis. The initial criteria for the 
identification of autoantibodies to beta-2 receptors included (1) the 
ability ·of serum to affect [ 125I] -protein A binding to membranes 
containing beta-2 receptors, (2) the ability of serum to 
imrnunoprecipitate solubilised lung beta-2 receptors in an indirect 
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immunoprecipitation assay (3) the demonstration that the serum factors 
were immunoglobulins and (4) inhibition of specific binding of 
[ 125I]hydroxybenzyl pindolol to canine and calf lung (beta-2) but not 
to canine heart (beta-1) membranes. Studies attributing the serum 
effects to the immunoglobulin fraction were however indirect (using 
anti-human IgG to deplete IgG). It was suggested by these workers 
that "autoantibodies to beta-2 receptors may mediate a state of 
beta-adrenergic hyporesponsiveness" which in turn may "exacerbate 
atopic conditions in much the same manner as the administration of 
beta adrenergic blocking drugs" (Venter et al 1984). The finding of 
autoantibodies, using the above criteria, in apparently normal 
individuals (without atopy or asthma) and in only 10-15% of the atopic 
patients studied raised questions as to the true significance of the 
phenomenon in relation to clinical disease and further studies were 
required to explore the level of interaction with the receptor and to 
look for functional effects of autoantibodies on human beta-2 
adrenergic receptors. 
The concept of anti-beta-receptor autoantibodies playing a major role 
in the pathogenesis of asthma has not gained wide acceptance and since 
the original reports, Kokubu (1989) and Stiles et al (1984) have 
stressed the need for further studies. The only subsequent study 
suggesting that autoantibodies may be of clinical relevance was 
published by Blecher et al. (1984) and these studies were conducted in 
collaboration with Venter. (Personal communication). 
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1.3 Outline of Studies 
The relative importance of blockade of beta receptors on smooth muscle 
compared with the effect of blockade the other cell types is as yet 
unknown and it is possible that beta adrenoceptor blockade induced by 
serum factors or mediators may initiate, or sustain, not only the 
smooth muscle bronchospasm (in acute asthma) but facilitate the 
increased mucosal oedema, inhibit adrenergic regulation of cholinergic 
·transmission and facilitate the increased mast cell mediator 
releasability encountered in chronic and more severe forms of asthma. 
Based on the foregoing studies and prompted by the need for further 
studies on the unresolved significance of the effects of serum on 
ligand binding to beta-2 receptors, I have set up in vitro methods to 
investigate the effects of serum on beta-2 adrenergic receptors. As 
an initial source of beta-2 adrenergic receptors I chose the guinea 
pig lung, since this was a well established animal model for asthma 
and also had a ratio of beta-2:beta-l receptor of 80:20% which is very 
similar to the ratio of beta-2:beta-l found in human lung. 
In the first instance, since this field was new to the University of 
Cape Town, it was necessary to set up reliable ligand binding assays 
for beta-2 receptors in lung membranes, and to establish a functional 
assay for beta-2 receptor activity in guinea pig lung tissues. The 
establishment of these assays is described in Chapter 2. 
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I then conducted a pilot study, in order to assess whether published 
reports of autoantibodies may have clinical relevance in the children 
with asthma attending my allergy clinic at the Red Cross Childrens 
Hospital, at the University of Cape Town. 
These studies confirmed that dilutions of many of the patients' sera 
did indeed inhibit [1251]-CYP binding to lung membrane beta-2 
receptors, that the degree of [1251]-CYP inhibition was variable and 
in some patients, fairly marked (Chapter 3.2). 
Since these initial exploratory studies confirmed a serum inhibitory 
effect on binding of ligand to beta-2 adrenergic receptors, I embarked 
upon the more extensive studies reported in this thesis, in order to 
gain further insight into the origin, regulation and molecular nature 
of serum and cellular factors which could influence the development, 
expression and functional integrity of human beta-2 receptors. I have 
also examined in vitro selected biochemical and theoretical genetic 
models for beta-2 adrenergic receptor dysfunction. 
I have started my studies, in Chapter 2, with an original study of the 
ontogeny of the expression and function of beta-2 receptor in the 
developing guinea pig foetal lung, and in selected human foetal lungs. 
In Chapter 3 the inhibition of ligand binding to guinea pig lung 
membrane beta adrenergic receptors by human serum was investigated. 
These initial studies using guinea pig lung membranes indicated that 
it would be important to obtain a source of human beta-2 receptors to 
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more adequately and precisely investigate the serum inhibitory effects 
in further studies, and it was with this intention that I accepted the 
opportunity to work in the laboratory of Receptor Biochemistry and 
Molecular Biology at the N.I.H. (Bethesda, Maryland, U.S.A) as a 
visiting fellow. The original studies which I conducted at the N.I.H. 
concerning the identification of the beta-2 receptor mRNA and its 
induction by glucocorticoids and the partial characterization of 
mutant beta-2 receptors are presented in Chapter 4. On my return to 
the University of Cape Town I continued with the studies on human 
serum using cloned, expressed human beta receptors transfected into L 
cells using the beta-2 receptor gene obtained from the NIH. These 
studies are presented in Chapter 6. In Chapter 5, I have presented 
the partial characterization of a monoclonal antibody which I raised 
to a 20 amino acid peptide derived from a hydrophobic domain of the 
beta-2 receptor. Studies of rabbit polyclonal antibodies and the 
immunogenicity of lung membranes are also presented. I have reviewed 
antibodies raised to beta adrenergic receptors by others. In an 
attempt to investigate a possible genetic basis for beta adrenergic 
receptor abnormality in asthma, I have extended the published studies 
of restriction fragment length polymorphism of the human beta-2 
receptor in an attempt to define the site of the polymorphism, and to 
determine its frequency in asthmatic and normal children living in 
Cape Town. These studies are described in Chapter 7. 
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CHAPTER 2 
BETA-2 ADRENERGIC RECEPTORS IN THE GUINEA PIG LUNG 
2.1 Introduction 
The guinea pig is a well described and convenient laboratory model of 
asthma (Gatto et al. 1987, Goldie et al. 1986, Mu and Bi 1989). 
Sensitization of guinea pigs with ovalbwnin readily leads to severe 
bronchospasm upon subsequent challenge with ovalbwnin (Motojima et al. 
1989), which is mediated by anaphylactoid (IgG subclass) antibodies. 
While there are differences between the guinea pig asthma model and 
asthma in man, important similarities include the ability to respond 
with biphasic (late phase) pulmonary responses following allergen 
challenge (Wieslander et al. 1985) and an almost identical percentage 
of distribution between beta-1 and beta-2 adrenergic receptors (22:78 
in the guinea pig and 30:70 in hwnan lung), with an identical 
cardioselectivity ratio for beta adrenergic receptor ligands (Engel 
1981). An understanding of the normal regulation of beta-2 receptor 
expression in the guinea pig lung is necessary before perturbations in 
beta-2 receptor expression in the guinea pig asthma model can be 
intelligently interpreted. 
Since ligand binding assays to beta adrenergic receptors had not been 
previously performed at the Medical School of the University of Cape 
Town, my initial project was to set up reliable and reproducible beta 
receptor ligand binding assays. In this chapter methods for lung 
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membrane preparation, protein assays, storage and standardization and 
variables of the beta receptor ligand binding assays and Scatchard 
plots were evaluated. Alternative methods for improving established 
assays were also considered. 
In order to evaluate the functional capacity of beta-2 receptors in 
the guinea pig lung I set up a membrane adenylate cyclase assay based 
on the method of Salomon (1979) and applied both the receptor binding 
and the functional adenylate cyclase assays to an original study of 
the ontogeny of the beta-2 receptor in guinea-pig and human foetal 
lungs. 
2.2 Methods 
In my exploratory experiments I attempted, as a start, to reproduce 
the original studies of Venter et al (1980) and Fraser et al (1981) 
using foetal calf lungs (obtained from the State Abbatoirs, Maitland, 
Cape Town) and the ligand [ 125I]HYP (Iodohydroxybenzyl pindolol). I 
obtained highly variable ligand binding and high levels of 
non-specific binding to calf lung membranes prepared by the method of 
Strauss et al (1979), and in view of considerable practical 
difficulties experienced in obtaining fresh foetal calf lungs from the 
State Abbatoirs, I discontinued studies with the foetal calf lungs and 
decided to establish and develop the binding and functional assays in 
the guinea pig lung, since this was a convenient laboratory model for 
the study of asthma. 
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2.2.l Isolation of cell membranes from guinea pig lungs 
The method for the preparation of lung membranes was derived from the 
method of Strauss et al (1979a), but the protease inhibitors NPGB and 
EGTA were added and a sucrose phosphate buffer was used for the 
homogenisation step. 
Lungs were removed immediately from adult guinea pigs freshly killed 
by asphyxiation in CO 2 . The trachea and major bronchi were removed and 
then the lungs were weighed to the nearest O.Olg and washed in 
homogenization buffer at 4°C (1 mM NPGB,20mM NaP0 4 , lmM EGTA in 250rnM 
sucrose, pH 7.2). The lungs were then cut up finely with scissors, 
immersed in nine volumes of ice cold homogenization buffer and 
homogenised on ice using a Kinematica PCU-2 Polytron, for two 30 sec 
bursts. The crude homogenate was transferred into 15ml Sterilin 
polystyrene conical bottomed tubes and centrifuged in an IEC model 
PR-6 centrifuge for 8 min at 4°C at 1000g. The supernatant was then 
decanted into Beckman polycarbonate tubes and centrifuged at 45000g at 
4°C for 60 min in a Beckman L8-80 centrifuge, using a 70 Ti model rotor. 
After centrifugation, the supernatant was discarded and pellet 
suspended in 2ml 10% sucrose in 20mM NaP04 , 4mM MgS0 4 pH 8.0, loaded 
on to a 12ml discontinuous sucrose gradient of 20%, 30% and 40% 
sucrose in 20mM NaP04 , 4mmMgS04 pH 8.0, and centrifuged at 22000 rpm 
in a model SW 28 rotor for 80 min, at 4°C, in the Beckman L8-80 
centrifuge. Visible bands of lung membranes at the 20%:30% interface 
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and 30%:40% interface were removed, pooled and centrifuged for 60 min 
at 100000g at 4°C using the model 70 Ti rotor. The pellet was 
suspended in 2ml 20mM NaP04 , 4mM MgS04 pH 8.0, aliquotted into 100 µl 
volumes, snap frozen and stored in liquid nitrogen. 
Protein determination of lung membrane preparations was determined 
using the commercially prepared Biuret reagent (Worthington). 
2.2.2 Beta adrenergic receptor ligands 
a) Choice of ligand. 
The initial experiments and binding assays were performed with 
Iodohydroxybenzyl pindolol ([ 1251]-HYP) obtained from New England 
Nuclear (Du Pont). [ 1251)-HYP was obtained with a specific activity 
of 2200 Ci/mrnol. This ligand had been found to be specific for beta 
receptors by Brown et al (1976) and was used in the studies of Venter 
et al (1980) and Fraser (1981). However Pocret et al (1978) and 
Dickinson et al (1981) reported labelling of alpha receptors and 
serotonin binding sites by this ligand. In view of the reported dual 
labelling by [ 1251]-HYP I obtained the new ligand (±)[ 1251] 
Iodocyanopindolol ([ 1251]-CYP) developed by Engel et al. (1981) which 
has a high affinity for beta receptors (Kd range 27-40 pM) but no 
affinity to either alpha receptors or serotonin receptors. 
[ 1251)-~YP was obtained from New England Nuclear (Du Pont), specific 
activity 2200Ci/mrnol. 
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b) Supply and storage of ligands. 
[ 1251]-HYP (Cat. no. NEX-125) and [1251]-CYP (Cat. no. NEX-174) were 
shipped frozen on dry ice in 1-propranalol:water:phenol (50:50:1.2). 
Ligands were aliquotted in 100µ1 volumes and stored at -20°C. Prior to 
use n-propanalol and water were evaporated under dry nitrogen in a 
gentle stream. A volatile radioiodide safety trap supplied by New 
England Nuclear was used for the evaporation process. 
c) Radiochemical purity. 
Radiochemical purity of the iodinated compounds was checked 
periodically using ascending thin layer chromatography on silica 
plates using the solvent system methanol:water:acetic acid 
(90:10:0.15). One microlitre of cold compound (hydroxybenzyl 
pindolol(HYP) and cyanopindolol(CYP), gift from Dr. Engel,Sandoz 
Limited, Basel, Switzerland) (lmg/ml), was dispensed on to the lower 
end of the plate in duplicate. One of the duplicates was spiked with 
lµl of the radiolabelled ligands. The plate was then lowered 
vertically into the solvent and left for 45-60min, after which it was 
dried at room temperature. Aromatic compounds such as CYP and HYP 
fluoresced when the plates were placed under an ultraviolet light 
source. To assess the degree of degradation of the label the "hot" 
track was cut into 0.5mm strips and counted in the Packard model 3003 
gamma counter, (counts at ±70% efficiency). It was found for example 
that lµl [ 1251]-HYP at 74 days from the date of iodination gave 60,000 
cpm of which 52 955 cpm moved with the fluorescent band and 5282 cpm 
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moved with the phenol front. No degradation was found up to 3 months 
of the labelling date. 
2.2.3 [1251]-CYP Binding Assay Protocol 
Binding assays were adapted from those of Maguire et al. (1976). For 
the binding assays 5-lOµg of lung membrane protein in 20mM NaP04 pH 7.2 
was incubated with [1251)-CYP in the presence or absence of 10-7M 
laevopropranalol (a gift from Dr. P. Venables, ICI, Pharmaceuticals 
Division, Macclesfield, Cheshire, U.K.). The Laevopropranalol 
hydrochloride (Batch ADM 46051/77 MW 295.8, specific optical rotation 
-21.73°C) was received as a white crystalline powder. 
Incubation of lung membranes was performed in triplicate in a 
waterbath at 30°C for 30 minutes in polypropylene tubes (Greiner), and 
the incubation volume was 500µ1. The reaction was stopped by addition 
of 1.25ml 20mM potassium phosphate pH 8.0 containing lmM magnesium 
sulphate and O.lmM ± propranalol (ICI) and filtered immediately through 
25mm glass fibre filters (G/F-C). Filters were washed with 25ml of 
the same buffer at 60ml/min at 30°C and radioactivity of protein bound 
to the glass fibre filters was counted in a Packard Model 3003 tricarb 
scintillation spectrophotometer. Changes in specific activity 
allowing for decay of the [1251) GYP or [1251] HYP were taken into 
account in the calculations. 
Specific binding was calculated by subtracting the counts per minute 
bound in the presence of 10-7M L(-) propranalol from the counts per 
minute bound in the absence of L(-) propranalol. 
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Binding assays (using [ 1251]-HYP) were initially performed on calf 
lung membranes, turkey erythrocytes and human lymphocyte preparations, 
but assays using [ 1251]-CYP and guinea pig lung membranes were found 
to be the most convenient, reliable and reproducible. Although a 
variation in total binding (Bmax) was seen with different guinea pig 
lungs (range 180-670 fmol/mg) the dissociation constant did not vary 
markedly between guinea pigs (Kd 26-35pM). In order to eliminate any 
possible differences in receptor density or Kd in the assays described 
in Chapter 3, pools of 6-12 guinea pig lungs were prepared on the same 
day, and stored in liquid nitrogen and served as a standard membrane 
preparation for the ligand inhibition assays in Chapter 3. 
2.2.4 Saturation curves Scatchard plots and Hill plots to the 
ligand binding of ( 1251]-CYP to guinea pig lung membranes. 
The quantitative approach to drug receptor interaction has its basis 
in Michaelis-Menten kinetics. According to the law of Mass action, 
drug-receptor interaction may be represented as follows: 
k + 1 
R + A -->.. -,-- RA 
k - 1 
At equilibrium velocity of association 
(R) (A) 
(RA) 
k - 1 
k + 1 
R = receptor 
A= drug 
RA= receptor drug complex 
k+l = forward rate constant 
k-1 = reverse rate constant 
velocity of dissociation 
Ka 





Saturation isotherms of (1251]-CYP binding to 5-lOµg lung membranes 
were conducted in triplicate using 8-9 increasing concentrations of 
radioligand (range 10 - 800pM) in the presence or absence of 10-7M 
(-)L propranalol. A curve of the [1251]-CYP binding to adult guinea 
pig lung membranes is shown in Fig. 1. Plots of specific binding 
versus log free ligand were 'S' shaped (Fig. 2) and Scatchard 
transformation of the data as shown in Fig. 3 (Bmax 670 fmol/mg, Kd 27 
pM). Binding was rapid (within minutes) and equilibrium binding 
reached within 10 minutes was stable for 3 hours at 30°C. 
Having established saturation data and Scatchard plots for [ 1251]-CYP 
binding to lung membranes, it was necessary to confirm that one 
molecule of ligand bound one receptor and that there was no 
co-operativity between multiple receptor sites. This was done by 
constructing a Hill plot of the data. 
A Hill plot (Hill 1909) is constructed by plotting Log (y)/(1-y) on 
they axis and Log ligand on the x axis where y is the fraction of the 
total number of sites bound occupied by ligand molecules. Where 
approximately 50% of ligand is bound the slope is determined, giving 
the Hill co-efficient. A Hill co-efficient equal to one implies that 
there is no co-operativity between receptors, i.e. that the 
interaction is due to simple Michaelis-Menten kinetics and one 
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Figure 2. Plot of specific [ 1251]-CYP binding versus log free 
[1251]-ClP to adult guinea pig lung membranes (data derived 
from Fig.l) showing 'shouldered' curve . 
. 48 • 
Q) 
Q) 





0 200 400 600 
125I-CYP Specific Binding (fmol/mg) 
Figure 3. Scatchard transformation of binding of [125I]-CYP to guinea 
pig lung membranes (data derived from Fig. 1). Bmax 670 
fmol/mg; Kd = 27pM. 
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Fig. 4 shows a Hill plot using data obtained for binding of 
[[ 12 51]-CYP to guinea pig lung membranes in a saturation experiment on 
which Bmax= 670 fmol/mg. 
2.2.5 Beta receptor subtypes in the guinea pig lung membrane 
In order to confirm that both beta-2 and beta-1 receptor subtypes were 
measured in the guinea lung membrane [ 1251]-CYP binding assay, the 
method of Engel (1981) was employed. 
ICI 118-551 a potent, highly beta-2 selective adrenoceptor antagonist 
(O'Donnel and Wonstall 1980) (erythro-DL-1)(7 methylindan-4-yloxy)-3 
isopropyl aminobutan-2-ol) was a gift from Dr. P. Venables ICI 
Pharmaceuticals Division, Macclesfield, Cheshire. 
The ring structure in ICI 118-551 is unique among beta-2 selective 
antagonists and must also be important for selectivity, since it is 
the only structural feature which distinguishes it from the less 
selective alpha-methyl propranalol. (O'Donnel and Wonstall, 1980). 
Using this ligand Nahorski and Barnett (1981) showed that beta-1 and 
beta-2 adrenoceptors can co-exist in tissues in a non-interacting 
manner and are probably quite separate entities. 
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Figure 5. A non-linear pseudo Scatchard or Hofstee plot using the 
beta-2 selective ligand ICI 118, 551, demonstrating that 
both beta-1 and beta-2 receptors in the guinea pig lung 
membrane preparation are labelled by [1251]-CYP. 
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Several investigators have attempted to use receptor binding assays to 
classify beta adrenergic subtypes (Rugg 1978, Minneman 1980). All 
methods so far in use involve examination of the characteristics of 
displacements of a radioligand by a drug which shows in vitro 
selectivity for beta-1 or beta-2 receptors. 
Fundamental assumptions underlying available methods for measuring beta 
adrenergic receptor subtypes with radioligand binding assays have been 
outlined by Minneman and Molinoff (1980) as follows: 
1. There are only two beta adrenergic subtypes in the tissues being 
examined. 
2. The interaction of agonists and antagonists with each receptor 
subtype follows simple Michaelis-Menten Kinetics with Hill 
coefficients of 1.0. 
3. The radioligand has the same affinity for both receptor subtypes. 
Using the highly selective ligand such as ICI 118,551 to inhibit 
radioligand binding by [1251)-CYP and plotting the inhibition in a 
modified Scatchard, or Hofstee plot (Fig. 5), a biphasic graph confirmed 
that the guinea pig lung membranes which I had prepared have two 
subclasses of beta receptors. Engel (1981) has previously shown that 
beta-2 adrenergic receptors predominate over beta-1 receptors in the 
guinea pig lung. 
Analysis of non-linear Hofstee plots is preferably performed by the 
computerised procedure described by Minneman et al (1979). Hancock et al 
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(1979) have however applied the computerised non-linear least squares 
curve fitting techniques of Feldman (1972) to quantitate receptor 
subtypes since these methods are more accurate than graphical methods 
such as the Hofstee plot. The main objection to the use of the 
Hofstee plot is the nature of data transformation techniques in which 
numbers subject to experimental error are divided by the low 
concentrations of competitor to produce graphical co-ordinates. These 
transformed values are exceedingly sensitive to small errors in the 
data obtained and can produce large fluctuations in the shape of the 
curve. 
More simply the formula of Engel (1979) may be applied to competition 
curves for binding 
RT 
RA l+Ka . 1 + ~ 
A Kb 
RA Concentration of bound ligand under steady state 
R Free concentration of receptor 
a Concentration of radioligand A 
RT Total receptor concentration 
b Selective beta blocking agent 
Ka Dissociation constant of A 
Kb Dissociation constant of B 
In this equation radioligand A binds with equal affinity to beta-1 and 
beta-2 receptor subclasses. 
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In the experiments to study the stereoselectivity of the binding sites 
in the guinea pig lung membranes by competition with the beta-2 
selective ICI 118-551 and beta non-selective L(-)propranalol the 
inhibition constants Ki (Ki - EC 50%) obtained were as follows: 
Ki of ICI 118,551 = 2.6 x 10-8M 
Ki of L(-) propranalol - 1.32 x 10-9M 
The theoretical Ki for L(-)propranalol to glioma membrane beta 
receptors is 1.2 x 10-9M (Engel 1981). 
The displacement curve for L(-) propranalol was uniphasic whereas a 
flatter and shallower curve obtained with ICI 118,551 was consistent 
with the presence of beta-1 and beta-2 receptors in the membrane 
preparation. 
The Kd of the competing ligand may be obtained by applying the 
Prussoff equation. 
Kd EC 50 





- Concentration of [U5I]-CYP 
- Kd for [ 1251] -GYP 
- Concentration of competing 
ligand at 50% inhibition of 
binding. 
Thus in the above experiment where inhibition studies were performed 
at the Kd of [1251]-CYP, Kd - EC 50/2 
Kd ICI 118,551 - 1. 3 x 10-8M 
Kd L propranalol - 0. 66 x 10-9M 
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These data confirmed that I had established an assay for guinea pig 
lung membrane beta-2 receptors which was consistent with expected 
values. 
2.2.6 Specific binding of [1251]-CYP to different fractions of the 
lung membrane preparation. 
Binding assays were performed at the Kd of [1251]-CYP on lung 
preparations at several stages of the extraction to determine which 
fraction had the greatest density per 50µg protein, to assess the 
extent of beta receptor loss during extraction, and to investigate an 
alternative method of preparing receptors in cell membranes, namely, 
dismembranation. Guinea pig lungs were snap frozen in liquid nitrogen 
and then dismembranated using a Brawn Micro dismembranator type 853062 
prior to homogenizing in order to facilitate even homogenization of 
the lungs and possibly reduce the time of homogenization. 
Homogenization with the PCU-2 Kinematica Polytron homogenizer was 
found to raise the temperature of membranes above 4°C. Results of this 
assay performed in triplicate (at the Kd 27pM [1251]-CYP) are shown in 
Table 5. 
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Table 5. Specific binding of [1251)-CYP to preparative fractions 
of beta-2 receptors with or without dismembranation. 
Lung fraction Specific Binding of [ 125I)-CYP/50µg protein 
Without dismembranation With dismembranation 
(Mean cpm) (Mean cpm) 
Crude Homogenate 866 413 
50000g pellet 2953 1074 
Sucrose gradient pellet 1255 407 
Sucrose gradient 30:40 4207 2389 
interface 
Sucrose gradient void 490 39 
This experiment confirmed that the best yield of beta receptors was 
obtained at the 30:40 sucrose gradient interface, as expected, but that 
dismembranation reduced the number of receptors recovered by 
approximately 50%. This reduction is probably due to the additional 
freezing and thawing required for dismembranation. Noteworthy is the 
significant amount of [ 1251)-CYP binding discarded in the sucrose 
gradient pellet, possibly due to incomplete homogenization. These 
experiments confirmed that homogenization as applied to the preparative 
method of Straus et al (1979) was superior to dismembranation. 
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2.2.7 The effect of storage on ligand binding. 
(i) Liquid nitrogen, 4°C, -20°C and room temperature. 
Storage conditions were studied as follows:-
Lung membranes were stored at 4°C, room temperature, -20°C and in liquid 
nitrogen. Specific [125I]-CYP binding was compared on membranes 
stored at different temperatures for varying time intervals . 
. Liquid nitrogen storage resulted in the highest [125 I]-CYP binding 
values which were reproducible for several months. Storage at 4°C 
overnight did not result in loss of radioligand binding but, storage 
at -20°C overnight (which involved freezing and thawing) resulted in 
loss of radioligand binding. Storage at room temperature resulted in 
an appreciable loss of radioligand binding. 
(ii) Glycerol-sucrose cryopreservation. 
Since storage facilities in liquid nitrogen were limited, in order to 
store batches of guinea pig lungs, the cryopreservation method 
published by Crawford et al. (1984) was investigated. Dissected 
fragments of lung tissues obtained freshly were immediately immersed 
in 3mM MgC12 , 20mM Hepes in O.SM sucrose pH 7.4, mixed with an equal 
volume of glycerol and stored at -20°C. No loss of radioligand binding 
to membranes of lungs stored in glycerol-sucrose was detected in the 
first two months of storage. However, assays performed on lungs after 
two months storage showed a fall off in radioligand binding. For the 
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studies reported in this Chapter and Chapter 3, lung membranes were 
prepared freshly and stored in liquid nitrogen. 
2.2.8 Investigation of an alternative method for separating bound 
from free [1251]-CYP 
Using the binding assay of Maguire et al (1976), it was found that the 
volume of 20mM K2HP0 4 buffer used to wash the Whatman GF-C filter paper 
influenced the amount of bound [ 125IJ-CYP that was detected. This is 
illustrated in the following data set: 
lOOµg guinea pig lung incubated for 30 min with 25000 cpm [ 125 I]-CYP 











In order to minimise the possibility of non-specific binding to the 
GF-C filters and the need to wash each filters with relatively large 
volumes of wash buffer, the method of Penefsky (1977), using Sephadex 
G50 columns was investigated as an alternate method for separating 
membrane bound from free [ 1251]-CYP. The binding assay volume (in 
2.2.3) was scaled down to 100µ1 total volume, since a volume not greater 
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greater than 100µ1 can be loaded on to the Sephadex GSO column in a 
Tuberculin syringe. Since this method would require less receptor and 
ligand (one fifth) it seemed worthwhile to investigate fully. 
125µ1 of the assay binding mixture (as in 2.2.3) was incubated for 30 
min at 30°C in a water bath, after vigorous mixing on a vortex, 100µ1 
was then loaded on to Sephadex GSO columns which had been prepared as 
follows:-
Sephadex GSO fine was swollen in twice the bed volume of the 
incubation buffer (Na2HP04 pH 7.4) overnight and suspended by gently 
stirring with a magnetic stirrer. 1 ml of Sephadex GSO suspension was 
pipetted in to a 1ml Tuberculin syringe (Becton Dickinson) which had 
been fitted with a 5mm diameter polyethylene disc at the base, 
previously soaked in 0.1% Triton in incubation buffer, and centrifuged 
in a 15ml Sterilin test tube in a PR6 centrifuge at 800 rpm for 2 
minutes. The Sephadex GSO gently packed by this procedure occupied 
about 50% of the height of the syringe. 
In preliminary experiments investigating the columns using iodinated 
sheep or mouse gammaglobulin, a 97% recovery obtained if the 
polyethylene discs had been soaked in 0.1% Triton. If dry 
polyethylene discs were used (i.e. not previously soaked in 0.1% 
Triton) the recovery was only 75%, suggesting that polyethylene discs 
not treated with 0.1% Triton could trap protein and reduce the 
recovery. In order to determine how much guinea pig lung membrane is 
retained in Sephadex GSO columns, lung membranes were iodinated by the 
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Lactoperoxidase method (Appendix A) prior to spinning through Sephadex 
GSO. 
Lactoperoxidase labelled membranes were loaded on to Sephadex GSO 
columns, eluate collected and reloaded on to fresh Sephadex GSO columns 
3 times. It was found that each time the labelled membranes were spun 
through the Sephadex GSO columns approximately only 50% of the counts 
were recovered in the eluate. Data from this experiment is shown in 
Appendix Al. 
It was found that incubation of the membranes at 4°C with 0.1% Triton 
100 prior to spinning through the Sephadex columns increased the 
specific binding recovered by 100% without increasing non-specific 
binding. This effect was probably due to the solubilising effect of 
the Triton removing the receptors from the membranes. The method of 
Penefsky for separating bound from free ligand, although theoretically 
attractive, was therefore not applicable for membrane preparations and 
I therefore used the Whatrnan G/FC filters. 
2.2.9 The effect of magnesium concentration on the [ 125IJ-CYP binding 
assay. 
4mM MgS04 was used in the (1251]-CYP binding assays on calf lung 
membranes by Maguire et al.(1976). I examined the effect of varying 
concentration of Mg++ ions on the [1251]-CYP binding assay using guinea 
pig lung membranes to determine how sensitive the ligand binding was to 
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pig lung membranes to determine how sensitive the ligand binding was to 
changes in the Mg++ concentration. SOµg guinea pig lung membrane 
protein was incubated with [ 1251]-CYP at the Kd in the presence of 
concentrations of Mg++ ions between 1-lOOmM. No differences in 
specific binding were observed between 1.0-lSmM Mg++ but concentrations 
between 20mM and lOOmM inhibited 25% of the binding. Venter (personal 
communication) has also found that although some Mg++ is necessary in 
the binding assay, a fairly wide range of concentrations is 
permissible. My findings would support this observation. 
2.2.10 Effect of protease inhibitors 
Recent studies have alluded to the importance of proteases in 
decreasing receptor number. Using the fluorometric assay of Heussen et 
al., (1984) which measures the ability of proteases to cleave an 
artificial substrate, CBZ-gly-gly-arg-AMC* by following the increase in 
fluorescence (measured over 5 min) as the Arg-Arnc bond is cleaved by 
the protease, it was found that the guinea pig lung membrane 
preparation had an average protease activity of 156.8 Fluorimetric 
units/ml compared with a protease activity of 25 Fluorimetric units/ml 
in normal plasma. Various protease inhibitors were investigated. 
Protease activity in both guinea pig and calf lung membrane 
preparations was completely inhibited by lmM NPGB. Concentrations of 
NPGB up to lOmM and lmM EGTA in the homogenization buffer did not 
reduce ligand binding to guinea pig lung membranes. In view of the 
fact that lmM NPGB did not influence ligand binding directly, I added 
lmM NPGB and EGTA to the homogenization buffer, when membranes were 
isolated from the guinea pig lungs for ligand binding assays. 
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2.2.11 Photo affinity labelling of guinea pig lung beta-receptors 
with (+)-3-[ 125I] iodocyanopindolol-diazirine 
Since it would be convenient if beta receptors in guinea pig lung 
membranes could be covalently labelled, so that receptors which have 
had been immunoprecipitated by antibodies could subsequently be 
identified by autoradiography, labelling with a carbene generating 
photo-affinity probe for beta adrenergic receptors was investigated. 
(±)-3-[ 125!] Iodocyanopindolol-diazirine has been synthesised by 
Burgermeister et al. (1983). The long wavelength absorption of the 
diazirine permits formation of the carbene by photolysis under very 
mild conditions. [125!]-CYP-diazirine was previously shown to label at 
least 5 proteins in guinea pig lung membranes of which one with 
approximate MW 67 000 was labelled specifically. 
Method of Photolabelling 
The method of Burgermeister (1983) was followed. Briefly 5 mg guinea 
pig receptor protein was incubated in the dark at 30°C for 60 min in 2 
ml lOmM Tris-HCl pH 7.4 (which had been nitrogen saturated) with lnM 
[ 125I]-CYP diazirine, in the presence or absence of 10-sM propranalol. 
At the end of the incubation, samples were cooled on ice for 10 min. 
made up to 6ml with ice cold lOmM Tris HCl pH 7.4 and purged with 
nitrogen for 15 seconds in the dark. 
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Figure 6. Autoradiograph of 11% polyacrylamide gel electrophoresis of 
guinea pig lung membranes labelled with 
[ 125I]-CYP-diazirine in the absence (left lane) or presence 
(middle lane) of 10-sM L(-)propranalol. Molecular weight 
markers are shown on the right. 
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Photolysis was performed using a Quartz GES m.b.H. type 5241 U.V. lamp 
placed 8-10 cm above the incubation tubes for 60 min. Guinea pig lung 
membranes were then pelleted at 30 OOOg for 20 min at 4°C, washed with 
lOrnM Tris-HCl pH 7.4 at 30 OOOg for 20 min at 4°C. 0.5ml Triton in 20rnM 
sodium phosphate pH 7.4 was added to each tube and the tubes gently 
shaken for 60 min. 80µ1 of this suspension plus 20µ1 of sample buffer 
(312.SrnM Tris-HCl pH 7.4,10% SDS,50% glycerol,25% 2-mercapto 
ethanol,0.005% Bromophenol blue pH 6.8) was mixed and loaded to an 11% 
polyacrylamide gel with molecular weight markers (Pharmacia) and 
electrophoresed for 8 hours in an LKB vertical electrophoresis unit. 
After staining the gel with Coomassie blue, destaining and drying on 
filter paper, autoradiography was carried out at -70°C using a Kodak 
Xray film in casettes with intensifying screens. Exposure time was 10 
days. 
Prior to photolabelling experiments, thin layer chromatography of 
[ 125 ]-ICYP-diazirine in 90% chloroform 9% methanol 1% acetic acid 
demonstrated that 99% of the photo-affinity reagent moved as a solid 
front. Initial experiments also showed that lnM [1251)-CYP-diazirine 
bound to albumin on exposure to U.V. light and that this was not 
inhibited by the presence of 10-5M L(-) propranalol. 
[ 1251]-CYP-diazarine was also found to bind to other human, serum 
proteins. 
Photolabelling of guinea pig lung membranes with [125 ]-ICYP-diazirine 
(Fig. 6) shows a broad band of labelling between 67 kDa and 94 kDa 
which was inhibited by 10-5M L(-) propranalol, corresponding to the 
molecular weight for the beta adrenergic receptor in the guinea 
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pig. [1251]-CYP-diazirine also labelled at least five other proteins 
in the guinea pig lung membranes which are not inhibited by 10-sM 
L(-)propranalol. Photolabelling was also applied to mouse L cells in 
studies of glycosylation mutants of the beta-2 receptor discussed in 
4.3.5. 
2.2.12 Establishment of a functional assay for adenylate 
cyclase activity in guinea pig lung homogenates. 
With the view to investigating possible effects of human serum 
fractions on beta-2 adrenergic receptor function and to study 
developmental changes in adenylate cyclase activity, a functional 
adenylate cyclase assay based on the method of Salomon et al (1979) 
was established for the guinea pig lung homogenates. 
This functional assay for adenylate cyclase is based on the fact that 
adenylate cyclase (ATP pyrophosphate-lyase) catalyses the conversion 
of ATP to 3'5'-cyclic AMP and pyrophosphate in the presence of GTP and 
magnesium ions, when activated by hormone. 
Adenosine 5'- *P-P-P adenosine 3'5'- P* + P-P 
GTP,Mg2++ hormone 
Difficulty in assaying this enzyme in vitro results from the fact that 
it is present in the membrane preparation in very small amounts, so 
that only a minute fraction, usually less than 0.05% of the substrate 
ATP undergoes cyclization to form cyclic AMP. Assay sensitivity and 
reliability is dependent upon and proportional to the efficiency with 
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which cyclic AMP is separated from ATP and its breakdown products. 
Separation of the reaction product is achieved by sequential 
chromatography on Dowex 50 cation exchanger and on neutral alumina. 
Adenylate cyclase assay protocol. 




Adenosine 3'5' cyclic phosphate ammonium salt [2,8- 3H] 
specific activity 31.5 Ci/mmol Lot 1763-165 (NET-275) 
Adenosine 5'-Triphosphate, Tetra (triethylammonium) salt 
[a- 32P] specific activity 760 Ci/mmol. Lot 2102-208 (NEG 
003X) 
Adenosine 5'-Triphosphate, Tetrasodium salt (U- 14C] 
specific activity 593mCi/mmol Lot 1827-117 (NEC 417] 
Radiochemical purity of (U- 14C]ATP and [2,8- 3H] cAMP was 
checked periodically using isobutyric acid:ammonium 
hydroxide: EDTA (0.lM): water (66:1:1:32) and 
isopropanol: ammonium hydroxide: water (7:1:2) on 
Whatman No. 1 paper, descending, respectively. 
The incubation mixture used in the adenylate cyclase assay was based 
on the method of Whitsett et al. (1981) for rat lung homogenates and 
was made up as follows:-
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For 10 assays: 
Reagent Vol µl Final Concentration 
lM Tris-HCl pH 7.6 100 lOOmM pH 7.4 
42mM MgC1 2 100 4.2mM 
125mM Sucrose 100 12.5mM 
0.5mM EGTA 100 0.05mM 
lOOmM ATP 10 1 mM 
lOmM cAMP 100 1 mM 
Creatinine phosphate (Boehringer) 2.7mg and Creatinine phosphokinase 
0.125mg (Boehringer) was added to the above mixture (510µ1) as an ATP 
regenerating system. Activity of the Creatinine phosphokinase was 860 
units/mg dry compound. 
50µ1 of above reaction mixture is added to sodium fluoride (NaF), 
Isoproterenol, guanosine triphosphate (GTP) or Gpp(NH)p in distilled 
water, crude homogenate (20 µg) (which had been prepared in 50mM 
Tris-HCl (pH 7.4) lOmM MgC12 ) and [a32PJ ATP or [U-
14CJ ATP O.lµCi to a 
final volume of 100 µl. After incubating for 15 min at 30°C, 100 µl 
stopping solution (2% sodium lauryl sulphate, 45mM ATP, l.3mM 
3'5'-cyclic AMP) was added and after adding the stopping solution, 50 µl 
[ 3H] AMP(± 20 000 cpm) tracer, (volume now 250 µl) was added. The test 
tubes were placed into a boiling water bath for 3 min and then allowed 
to cool to room temperature, to allow complete solubilization of all 
the membrane proteins. Thereupon 0.8 ml double distilled, deionised 
H20 was added and the final mixture was decanted on to freshly washed 
Dowex AG 50W-X4 columns, the column was washed twice with 1 ml H20, and 
allowed to drain (to elute [a- 32PJ ATP). 
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The Dowex columns were then placed over a rack containing alumina 
columns, (prepared as in Appendix B), freshly washed with O.lM 
imidazole pH 7.3, and 3 ml H20 was added on to Dowex columns and 
effluent allowed to drain completely through both columns into the 
collecting tray. (In this step the cyclic AMP was eluted from the Dowex 
columns and is adsorbed quantitatively on to the alumina columns). 
The rack containing the alumina columns was placed over scintillation 
vials filled with 4 ml scintillation fluid. 4 ml of O.lM imidazole 
buffer pH 7.3 is added to each column and the effluent was allowed to 
drain completely from all the columns (eluting the 3' :5'-cyclic AMP 
into the scintillation vials). 
Scintillation vials were capped, shaken vigorously for a few minutes 
and counted on a Beckman LS 3800 using 32P/3H or 14C/2H dual label 
counting programmes. Cyclic AMP formed was determined by converting the 
cpm in the 32P or 14C channel to pmoles/lSmin/mg membrane allowing for 
the recovery of (3H]-cAMP (usually 60-80%). 
2.2.13 Isoproterenol, forskolin and sodium fluoride stimulated 
adenylate cyclase activity in guinea pig lung homogenates. 
Before assessing functional effects of development, or serum factors on 
guinea pig lung beta-adrenergic receptors, it was important to document 
the normal activation of adenylate cyclase in the system I had set up. 
Assays for adenylate cyclase activity were performed on crude 
homogenates of fresh lung specimens. Briefly lungs were removed by 
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dissection, cut into small pieces with scissors and homogenised in 9 
volumes of ice cold homogenisation buffer (SOmM Tris-HCl pH 7.4 lOrnM 
MgC12 ) on ice using a kinematica PCU polytron for 2 x 30 sec bursts. 
The crude homogenate was transferred to 15 ml sterilin polystyrene 
conical bottomed tubes and centrifuged in an !EC model PR-6 centrifuge 
for 8 min at 4°C at 1000g. Supernatants from this centrifugation were 
assayed in duplicate or triplicate for adenylate cyclase activity. 
In comparative experiments, using 5 µl crude guinea pig lung homogenate 
(approx. 20µg protein), 10-sM lsoprenaline, 10-sM GTP or lOmM NaF, I 
found that the percentage stimulation of adenylate cyclase activity in 
this system, as measured by cyclic AMP recovery from labelled 
substrate, was equal when either [a- 32PJ ATP or (U- 14C] ATP was used as 
substrate (Fig. 7). Thus, for example, using fresh guinea pig lung 
homogenates in a comparative experiment, the mean% of stimulation of 
adenylate cyclase activity above basal levels with (a32PJ ATP as 
substrate for lOmM NaF was 576%, for 10-5M GTP 81%, for 10-6M 
isoproterenol 42% , 10-6M isoproterenol and 10-sM GTP 148%. Using 
[U- 14C) ATP for lOmM NaF was 571%, for 10-5M GTP 52%, for 10-6M 
isoproterenol 38% and 10-6M isoproterenol and 10-5M GTP 121%. Since it 
was more economical to use the more stable (U- 14C)ATP (in view of the 
very short half life of [a- 32PJ ATP), (U-14C) ATP was used in the 
definitive experiments of guinea pig lung development (in 2.3.3). 
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Figure 7. Comparison of the% stimulation of guinea pig lung crude 
homogenate adenyl cyclase measured by cAMP production 
(Salomon 1979) above basal levels with lOmM sodium fluoride 
(1,5), 10-5M GTP (2,6), 10-5M(-) isoproterenol (3,7) and 
10- 5M GTP with 10-5M (-)isoproterenol (4,8), using 14 C(U)ATP 
(Bars 1-4) or o32pATP substrates (Bars 5-8). Bars represent 
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Figure 8. Gestational plot showing variability of mean lung weights 
(left and right) of foetal guinea pigs within each litter. 
(.) represents each foetal lung pair weighed). 
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2.2.13(i) Effect of protease inhibitors 
Although lmM NPGB was an essential protease inhibitor which had no 
effect in the [ 1251]-CYP binding assays, it was found that lmM NPGB 
markedly inhibited Na fluoride and isoproterenol stimulated adenylate 
cyclase activity but not basal activity in the crude homogenates. 
Homogenates were therefore prepared in SOmM Tris HCl lOmM MgC1 2 pH 7.4 
without protease inhibitors and used freshly. 
2.2.13(ii) Effect of Guanosine triphosphate 
Concentrations of GTP greater than 10-4M inhibited adenylate cyclase 
activity to below basal levels. However, activation of adenylate 
cyclase stimulation was observed in the presence of 10-sM GTP and 
produced a synergistic effect with 10-sM isoproterenol. 
The synergistic effect on adenylate cyclase stimulation when GTP 
(10- 5M) was added to isoproterenol 10-sM (or 10-6M) was highly 
reproducible. Activation of adenylate cyclase by GTP in the absence of 
hormones previously described by Lad et al. (1984) in neutrophil 
membranes prepared by gas cavitation, was indicative of a state of 
receptor cyclase uncoupling, while membranes from sonicated cells 
displayed normal GTP dependent coupled activation by isoproterenol. 
Crude homogenates used in my assays clearly display both patterns, 
suggesting that a mixed population of coupled and uncoupled receptors 
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exists in these homogenates and that no conclusions should be drawn as 
to the overall state of coupling in assays of crude homogenates. 
2.2.13(iii) Effect of storage 
Fresh crude homogenates were used for the adenylate cyclase assays 
since it was found that adenylate cyclase activity was markedly 
depressed by freezing and thawing. (Guinea pig lungs which had been 
stored in glycerol sucrose at -20°C retained good basal activity and 
sodium fluoride stimulatable activity, but isoproterenol stimulated 
activity was variable i.e. normal in some samples but depressed in 
others). 
2.3 Functional and numerical ontogeny of beta receptors in the 
developing guinea pig foetal lung. 
The normal ontogeny of the expression of beta adrenergic receptors and 
their ability to couple with adenylate cyclase via the G proteins has 
been reported in the foetal rat (Whitsett et al. 1981), and in the 
foetal rabbit it has been reported that glucocorticoids increase 
pulmonary beta-adrenergic receptors and surfactant production at term 
(Cheng et al. 1980). Little is known about the normal expression and 
function of the beta adrenergic receptors in the foetal guinea pig. 
Using a Medline search, I could find only one reference referring to 
developmental changes in the guinea pig lung beta receptors and this 
study merely compared newborn with adult guinea pig lungs (Gatto et al. 
1984). I considered that it would be worthwhile to apply the 
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techniques for receptor measurement and adenylate cyclase activity 
which I had established, to conduct an original study of the 
developmental expression of the guinea pig lung beta receptors during 
foetal life. I reasoned that identification of a well defined 
gestational period of rapid beta-2 receptor expression, would be 
extremely useful for future studies of the genetic, hormonal or 
biochemical factors responsible for inducing and sustaining normal 
beta-2 receptor expression in the guinea pig lung. 
2.3.1 Breeding Colony 
A breeding colony involving 80 guinea pigs was established. Females 
with estrus were selected by checking for a perforated vaginal membrane 
and lordosis, separated from the colony and mated in the dark, noting 
the date of the mating. Successful mating was confirmed by checking 
for a vaginal plug and these females were then transferred to 
individual cages. Using this system 10 out of 40 matings resulted in 
pregnancy and lungs from litters of guinea pig foetuses obtained at 10 
points between 24 and 68 days were studied. 
Pregnant females were killed by CO2 asphyxiation. Maternal lungs and 
the lungs of the fetuses were removed and crude homogenates and 
membranes were prepared from the lungs according to the method 
described in 2.2.1. Mean weights of the left and right foetal lungs 
were recorded and plotted as a function of gestational age. The right 
lungs were used in the functional adenylate cyclase assay and beta 
adrenergic receptor number was measured by Scatchard analysis of the 
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saturation binding of [ 1251)-CYP to maternal or foetal lung membranes 
prepared from the left lungs. 
2.3.2 Foetal lung weight as a function of gestational age. 
The average size of the guinea pig litters was 3 foetuses (range 2-6 
foetuses). A wide range of variability in the weight of the lungs of 
litters of the same gestational age was noted (Fig. 8). Even within a 
litter there was sometimes one foetus whose lungs weighed markedly less 
than the others. The left foetal lung always weighed less than the 
right foetal lung. There was also a variation in the wet weight of the 
maternal lungs (mean maternal right lung 2.3g (range l.58-3.3g; mean 
maternal left lung 1.95 (range 1.53-2.15)). 
2.3.3 Beta adrenergic receptor expression in the developing foetal 
guinea pig lung. 
[ 1251)-CYP binding assays were performed on guinea pig foetal lungs to 
study the developmental expression of beta-2 receptors, and to identify 
periods of increased receptor expression for future biochemical and 
mRNA studies. 
Lung membranes were prepared from the maternal and foetal guinea pigs 
at ten gestational time points from 23 days gestation to day 1 post-
natally. Maternal [ 1251)-CYP binding data at each gestation point 
served as an internal reference of acceptable binding for each assay. 
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Adenylate cyclase assays were performed on fresh homogenates from the 
same maternal-foetal pairs used in the [125I]-CYP binding assays 
(2.3.4). Saturation curves were performed on pooled foetal lungs at 
each gestational point studied and Scatchard plots of the binding data 
were used to determine the maximal binding (Bmax) and ligand affinity 
(Kd) at each point. Binding data has been plotted using Enzfitter 
non-linear iterative regression data analysis programme for IBM PC 
designed by R.L. Leatherbarrow, Department Chemistry, Imperial College 
of Science and Technology, South Kensington, London. 
Saturation curves of [125I]-CYP binding to foetal guinea pig lung 
membranes at 23 days, 42 days, 46 days, 47 days, 49 days and 53 days 
(Fig. 9) showed low dormant levels of beta-2 receptor expression with a 
Bmax of between 20-40 fmol/mg lung membrane protein (on Scatchard 
plot). However, between day 53 and day 62, induction of beta-2 
receptor expression occurred. The levels of expression in foetal lungs 
assayed at 5 points after day 62 were variable, but were approximately 
half the values found in the adult lungs (mean adult binding 425 
fmol/mg range: 380-500fmol/mg protein) Fig. 10. 
Some guinea pigs gave birth at 64 days whereas others had not delivered 
by 65 days gestation. Scatchard plots of [125I]-CYP binding to foetal 
lungs earlier in gestation showed similar affinity (Kd 27-35pM) of 
[ 125IJ-CYP binding for the beta-2 receptors found in maternal lungs (Kd 
30pM). Scatchard plots and saturation curves of the binding of 
[ 125I]-CYP to guinea pig foetal lungs early, (49 days), and at the end 
(64 days) of the gestation period, are shown in Fig. 11 and Fig. 12. 
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from 23 to 49 days gestation. Foetal lung saturation 
curves shown (from below upwards) were performed at 23 days 
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Figure 10. Saturation curves of [ 125I]-CYP binding to Adult (A) and 
pooled foetal guinea pig lung membranes at 53 days (-·· ...... ), 
62 days (-----), 63 days (······), 64 days (.,-), 64* days 
(newborn)(---) and 65 days gestation. 
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Having defined the 53-62 day gestational period as the critical period 
for beta receptor induction in the guinea pig, it will be important to 
re-examine this period in detail with the view to trying to identify 
the serum/hormonal/genetic factors which induce receptor expression at 
this gestational point and in particular to study mRNA induction in the 
foetal lung. In view of the expense and complexity of repeating this 
study, I postponed further studies on the guinea pig foetal lung beta-2 
receptor expression until I had acquired the genetic probes to study 
beta-2 receptor on RNA induction. RNA studies however proved difficult 
and are discussed in Chapter 4. 
2.3.4 Adenylate Cyclase Activity in the guinea pig foetal lung. 
Adenylate cyclase activity was studied at 9 points during the 68 day 
gestation period by the method adapted from Salomon et al (1979) and 
Whitsett et al (1981) in 2.2.12, using fresh homogenates of pooled 
guinea pig foetal lung. Guinea pigs were killed by asphyxiation in CO2 
and foetal and maternal lungs were removed immediately and placed in 
ice cold buffer. Adenylate cyclase was assayed in both foetal and 
maternal lungs in the same assay, the maternal lung acting as a 
"positive control" and reference for each experiment (Table 6). With 
two of the litters the sodium fluoride and isoproterenol stimulation of 
maternal lungs was well below the other maternal control values and 
hence the data obtained on the corresponding foetal lungs was discarded. 
Basal adenylate cyclase activity was consistently found to be markedly 
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Figure 13. Mean basal adenylate cyclase activity in foetal guinea pig 
lungs measured by production of 14C(U) cAMP 
(pMoles/mg/15min) at 23, 46, 47, 49, 62, 65 and 68 days 
gestation. Values for five maternal lungs, designated 1-5 
are shown on the right. (Actual values are shown on Table 
6). 
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basal cyclic AMP levels were 217 pmol/mg/15 min, but fell progressively 
with increasing gestation. Levels of basal adenylate cyclase activity 
observed in the maternal guinea pig lung homogenates were much lower 
(Mean cAMP = 15.1 pmol/mg/15 min, range 7.05-19.9 pmols/mg/15min), than 
in the foetal lung homogenates. 
Isoprenaline (10-6M) stimulatable adenylate cyclase activity in foetal 
lungs was poor up to 49 days gestation. However a sharp increase in 
10-6M isoprenaline stimulated adenylate cyclase activity was found at 
62 days which was equal to adult levels. (Fig.14). 
Sodium fluoride stimulatable adenylate cyclase activity was also low up 
to 49 weeks gestation and found to have increased by 62 days. (Fig. 
15). 
Superimposition of the data obtained from the ligand binding assays 
(2.2.3) on the data obtained with functional assays of adenylate 
cyclase activation showed that the gestational increase in both sodium 
fluoride and isoproterenol stimulated adenylate cyclase activity 
accompanied the increase in beta adrenergic receptor expression, that 
significant increases occurred between 49 days and 62 days gestation 



















Figure 14. Mean 10-6M isoproterenol stimulation of cAMP production 
(expressed as% stimulation above basal levels, see Fig. 
13) in homogenates of guinea pig foetal lungs at 23, 46, 
47, 49, 62, 65 and 68 days gestations. (Two maternal values 
designated Ml and M2 shown on the right). 
from Table 6) . 
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Figure 15. Mean lOmM sodium fluoride stimulation of cAMP production 
(expressed as a% stimulation above basal levels, see Fig. 
13) in homogenates of guinea pig foetal lungs at 23, 46, 
47, 49, 62, 65 and 68 days gestation. (5 maternal values 
designated 1-5 are shown on the right). (Data derived from 
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2.4 Identification of beta adrenergic receptors in mid trimester 
human foetal lungs. 
Studies of the expression of beta receptors and adenylate cyclase 
activity in human foetal lungs have not been previously published. In 
order to investigate the functional integrity of beta adrenergic 
receptors in the developing human mid trimester foetal lung, I obtained 
lungs from fresh abortuses from pregnant women from 13 weeks to 28 
weeks gestation. The foetuses were gestationally aged using ultra 
sound head circumference charts (Groote Schuur Hospital). Lungs were 
removed and stored in liquid nitrogen for assay of both beta receptors 
and adenylate cyclase activity. Unfortunately binding data from 
spontaneous abortions was not found to be reliable. 
Lungs obtained from 4 therapeutic abortuses were also studied, since it 
was possible to remove the lungs within minutes of death. Data 
demonstrating adenylate cyclase activity in foetal lungs obtained from 
a therapeutic abortions (performed for anencephaly) at 13, 15 and 18 
weeks is shown in Table 7. 
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Table 7. 
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Although the numbers of these studies are small the results do, in 
fact, indicate that certain adrenergic receptors in the crude human 
foetal lung homogenates are in fact functional, early in mid trimester. 
The significance of these findings would have to be tested in an 
extended gestational study. Of greater importance would be to define 
the cells in which beta-2 receptors are induced. However, the ethical 
and practical problems which are involved in obtaining fresh viable 
human foetal lungs as they approach term preclude further studies of 
this nature until non-invasive methods are developed to measure beta-2 
receptors in vivo. 
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2.5 Summary and Discussion 
The experiments described in this chapter were conducted to set up 
reliable techniques for the measurement of beta adrenergic receptors as 
a foundation for the serum studies I had planned and have described in 
Chapter 3. Although most of the techniques were based on previously 
published methods, by looking critically at the assays, I have found 
that certain modifications were necessary to improve their reliability. 
Modifications which I have introduced and major findings of the 
experiments in this chapter may be summarised as follows:-
1. During isolation of the cell membranes from guinea pig lungs I 
have added the protease inhibitors 1 mM NPGB and lmM EGTA to 
inhibit inherent protease activity. Protease inhibitors were 
not used in the membrane preparations of Strauss (1979) or 
Venter (1980). 
2. I have used [ 125!] -GYP rather than [ 125I] -HYP as the beta- 2 
receptor ligand in view of its greater specificity. 
3. Since a wide range of maximal [ 125I]-CYP binding was obtained 
for different adult guinea pig lungs (range 180-670 fmol/mg) 
it is important to use a pool of guinea pig lungs to obtain a 
"standardised" membrane population if assays are to be 
conducted over a period of days or weeks. 
4. Saturation curves and Hill plots confirm that the [ 125I]-CYP 
binding to guinea pig lung membranes obeys Michaelis Menten 
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kinetics and that one molecule of ligand binds one molecule of 
receptor. 
5. Competition curves using !Cl 118, 551 confirmed that the 
guinea pig membrane preparations contain a mixed population of 
beta receptors, previously shown to be predominantly beta-2 
(Engel 1981). 
6. Although glycerol sucrose cryopreservation (Crawford 1984) can 
reliably be used to store guinea pig lungs for receptor 
binding assays for up to two months, liquid N2 is superior for 
long term storage. 
7. The method of Penefsky (1977) for separating bound from free 
ligand was not suitable for beta receptor membrane binding 
assays. 
8. A fairly wide range of Mg++ (l-15mM) is permissable in the 
[1251]-CYP ligand binding assay. 
9. Photo-affinity labelling of membranes using 
[125!]-CYP-diazirine showed L(-) propranalol displacable 
binding in the 68-90000 daltons molecular weight region. 
10. In the functional adenylate cyclase assays using fresh crude 
guinea pig lung homogenates, comparable% stimulation by 
sodium fluoride or isoproterenol was obtained when (a32P]-ATP 
or [U- 14C] ATP was used as a substrate. 
11. In the guinea pig foetal lung an increase in beta adrenergic 
receptor expression is found after 53 days which is 
accompanied by a fall in basal adenylate cyclase activity and 
an increase in isoproterenol and sodium fluoride induced 
stimulation of cyclic AMP. 
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13. Increasing isoproterenol inducible adenylate cyclase activity 
is present in the human fetal lung as early as 15 weeks 
gestation. 
Studies of the expression of beta adrenergic receptors and the 
ontogenic changes in cell or organ sensitivity of beta receptors to 
beta receptor agonists provide temporal clues to the presence of 
inducing regulatory factors, particularly when defined periods of 
increased receptor expression are documented. By studying a well 
defined developmental stage of increased receptor expression, inducing 
factors are more readily identified. In the case of the rabbit, the 
foetal lung beta adrenergic receptor expression has been shown to 
increase towards term (Giannopoulos 1980), and is associated with 
increased surfactant production. This increase is believed to be 
stimulated by endogenous glucocorticoids (Cheng et al. 1980). In the 
rat lung, beta adrenergic receptor expression increases 11-fold from 
day 18 of gestation to day 28 of post natal life (46 ± 7 to 491 ± 69 
femtomole mg- 1 protein) and this increase in beta adrenergic receptor 
number is accompanied by an increased percentage stimulation by 
isoproterenol and sodium fluoride (Whitsett et al. 1981). 
The critical period of induction of guinea pig lung membrane receptors 
in foetal life has not been previously reported. The results of the 
studies which I have performed on the developing guinea pig lung are 
similar to the rat studies, and beta receptor expression was found to 
be quiescent for 80% of the gestation period (53 days out of the 68 day 
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gestation period in this study). This indicates that increased beta 
adrenergic receptor expression is not necessary for early lung growth 
and development (up to 25% of adult lung weight). Increased receptor 
expression occurred after 53 days but the affinity of the beta receptor 
for the ligand [ 125I]-CYP did not vary significantly during development 
as in the studies with rabbit lung by Giannopoulos (1980). Since lung 
weights also increased more rapidly after 53 days gestation, it is 
possible that increased receptor expression could simply reflect 
increased cellular mass and that the growth and differentiation factors 
influencing cell mass indirectly induce beta receptor expression. 
A moderate variability in the wet lung weights within the same litter 
was observed. Foetal lung weights were also quite variable when lungs 
of similar gestational ages were compared and increased lung weight was 
not always associated with increased receptor expression. It would 
have been more accurate to measure dry lung weights, but this was not 
possible, since in this study the fresh lungs were used for adenylate 
cyclase assays after they were weighed. 
Of great interest was the finding of a high basal adenylate cyclase 
activity early in gestation (at 23 days) which fell progressively 
during foetal development, but at term did not reach the much lower 
levels encountered in adult guinea pig lung homogenates. The reasons 
for such high basal adenylate cyclase activity early in gestation are 
not known. High basal adenylate cyclase activity has also been 
reported in the immature rabbit lung by Barrett et al. (1974), and may 
represent an "unregulated" or higher activity of an enzyme which 
couples with receptors other than the beta adrenergic receptor. 
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The developmental data obtained in these studies does not differentiate 
between the induction of beta-1 and beta-2 receptors in the lung 
membranes. The differential induction of beta receptors in different 
cell types in the lung must be considered, since it is well known that 
beta-1 and beta-2 receptors may be independently regulated (Table 3 and 
Table 4). 
Following the studies of cortisol enhanced isoproterenol induced 
surfactant secretion in the A549 pulmonary adenocarcinoma cell line 
(Smith 1977), Dobbs and Mason in 1979, in a study of pulmonary alveolar 
type II pneumocytes isolated from rats, found that treatment with beta 
adrenergic agonists caused an increase in the release of [ 14C) 
desaturated phosphatidylcholine from type II cells in culture. 
Maniscalco and Shapiro (1983) have, using foetal rat lung explants, 
shown that glucocorticoids have a direct effect on foetal lung to 
increase beta adrenergic receptor density and that new protein 
synthesis was required for this effect. It is thus likely, on evidence 
published to date that the gestational surge in beta receptor 
expression, at term, is due to glucocorticoids. 
It has been suggested that while steroids only cause a modest increase 
in beta receptor density in the normal adult lung. The effect is much 
more pronounced when the density of beta receptors is reduced due to 
diseases such as bronchial asthma (Salonen 1984) and under conditions 
associated with a lower level of cellular differentiation, such as the 
foetal state. This suggests that pulmonary beta receptors are subject 
to regulation by factors that 
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affect cellular growth and differentiation. It is tempting to postulate 
that disorders in the release or control of such factors could also 
contribute to pathology of the beta-receptors in certain respiratory 
diseases. Recently the regulation of beta-2 receptors in hamster 
smooth muscle cells has been studied at the level of mRNA (Collins et 
al 1988). 
Reasons for the relative resistance of lung beta receptors to induction 
by steroids in normal adults, compared with term foetuses, are unknown. 
Stern and Kunos (1988) have shown that lymphocytes and macrophages may 
be involved in a paracrine regulation of beta receptors in surrounding 
lung cells. Furthermore, the importance of appropriate beta-2 receptor 
expression in neuronal development is emphasised by the demonstration 
by Schwartz (1988) that nerve growth factor mRNA is also stimulated by 
exposure of C6 glioma cells to isoproterenol, suggesting that a complex 
relationship may exist between functional beta-2 receptor expression 
and neuronal development. 
Recently Skinner et al. (1989) have also shown that there is a 
differential selectivity between fibroblasts and type II epithelial 
cells in their adenylate cyclase responses to beta agonists and 
prostaglandin E2 in the foetal rat lung. 
Barnes et al. (1983) and Carstairs et al. (1985) using autoradiographic 
localization have demonstrated that most of the beta receptors in the 
mature lung are in the conducting airways and in the alveolar 
epithelium and that reduction in terminally distributed beta receptors 
112 
occurred in the ovalbumin guinea pig asthma models. Thus, 
identification of the inducing and regulatory factors of the conducting 
airways and terminally distributed alveolar epithelial receptors may be 
of importance in understanding mechanisms underlying the 
pathophysiology of allergic asthma. It is as yet not clear whether 
these changes are a primary cause of the asthma, or are secondary to 
the release of immunological and biochemical activation products from 
the cellular infiltrates occurring in the airways in allergic asthma. 
Clearly ontogenic changes in cell sensitivity depend not only on 
changes in beta adrenergic receptor sites expressed,but will depend 
upon the catecholamine concentration at the site, the affinity of the 
receptor for agonist, the state of the membranes, G proteins and post 
receptor transduction mechanisms and cell differentiation. 
The ontogenic model of beta-2 receptor expression·in the guinea pig is 
an important physiological developmental model which should be 
explored. There are clearly not only factors which facilitate steroid 
induction of beta-2 receptors at the end of gestation, but others which 
maintain the beta-2 receptor expression at the higher level and induce 
a relative resistance to further induction by steroids in mature 
animals. The optimal number of receptors/mg membrane protein for 
different cells has not yet been studied. From the developmental 
studies I have performed in the guinea pig it is apparent that adequate 
and normal pulmonary function is possible in new born guinea pigs even 
although they have a complement of beta-2 receptors per mg lung 
membrane which is only half the complement found in adult guinea pigs. 
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Furthermore, the wide variation in the number of beta-2 receptors per 
mg lung membrane which I found expressed in different adult guinea pigs 
suggests that a fairly marked overall reduction in beta-2 receptor per 
mg lung membrane is permissable in an animal which is highly 
susceptible to the development of asthma. Until the relationship 
between numerical expression and functional capacity can be determined 
with certainty, data attributing only modest reductions to the primary 
development of asthma should be interpreted with caution. I have 
studied the effect of receptor number on adenylate cyclase activation 
by isoproterenol using mouse L cells which I transfected with the human 
beta-2 adrenergic receptor gene, in Chapter 6. 
It is likely and highly desirable that in the normal mature animal a 
certain receptor reserve or excess should be present to compensate for 
factors causing partial beta receptor blockade or down regulation 
particularly when adequate function of a receptor such as the beta-2 
adrenergic receptor is critical for life. Unless "blocking factors'' -
previously described by Venter et al (1980) and Blecher et al (1984) 
reduce the receptors below the critical functional level of expression 
for normal, or adequate adenylate cyclase responses to catecholamine, 
their relevance to clinical disease is likely to be small. 
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CHAPTER 3 
Inhibition of [125I)CYP binding to guinea pig lung membrane 
beta-adrenergic receptors by human serum. 
3.1 Introduction 
Unimpaired binding of circulating catecholamines to beta-adrenergic 
receptors to airway smooth muscle is critical for maintenance of the 
balance between the cholinergic and the adrenergic nervous systems and 
hence the maintenance of normal airway tone in asthmatics (Griew and 
Pierson 1971, Ind et al. 1985, Warren et al. 1984). Blocking of lung 
beta adrenoceptors by high affinity antagonists e.g propranalol 
results in bronchospasm in asthmatic subjects. Circadian falls in 
catecholamine levels correlate well with nocturnal wheezing (Barnes 
1980a) and partial defects in adrenaline release in asthmatics during 
exercise (Warren et al. 1982), acute asthma (Ind et al. 1985) and 
isocapneic hyperventilation (Barnes et al. 1981) are well described. 
The possibility that serum factors, in particular, may also play a 
modulatory effect on circulating catecholamine binding to beta 
adrenergic receptors, was raised by the studies of Fraser et al (1981) 
who found that dilutions of serum from asthmatics and certain non 
asthmatic individuals could indeed inhibit [ 125I]HYP binding to canine 
and calf lung membrane beta adrenergic receptors. 
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Although these studies raised very interesting possibilities in 
relation to asthma when they were initially published, there has only 
been one published study (Blecher et al. 1984) to support the initial 
data. The pathogenetic significance of the inhibitory effects on 
antagonist binding has not been resolved to date, since detailed in 
vitro studies investigating the nature of this phenomenon have been 
undertaken. In some quarters the original studies of Fraser and 
Venter have even been regarded with a degree of sceptism, and 
recently, (Kokubu et al. 1989) using canine lung membranes reported 
that they could find no evidence for autoantibodies to the beta 
adrenergic receptor in asthmatics in Japan. By contrast the evidence 
for autoantibodies to beta-1 adrenergic receptors is mounting. Limas 
(1989a) has found that sera from certain patients with idiopathic 
dilated cardiomyopathy inhibit [ 3H] alprenalol binding in vitro and 
that following cardiac transplantation, the inhibitory effect of the 
sera decreased. Evidence for autoantibodies to beta-1 adrenergic 
receptors in human cardiomyopathy has also been reported by Sterin 
Borda et al. (1984) and Borda et al. (1984a). 
An investigation into possible inhibitory effect of serum on ligand 
binding to beta-2 receptors is important in asthmatics. Beta-2 
receptors on smooth muscle in the lung are not normally bathed in 
serum. If, however, during bacterial inflammation, for example, in 
chronic bronchitis, or as part of the allergic inflammatory response 
following mast cell degranulation, or viral infection, beta-2 
adrenergic receptors are exposed to serum, endogenous catecholamine 
binding to beta adrenergic receptors in smooth muscle, and other cells 
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in the airways may be blocked by these serum factors. The use of high 
affinity beta-2 agonists may be necessary to overcome any blocking 
effect of serum factors to restore normal airway calibre, particularly 
in those asthmatic individuals whose airways are critically dependent 
on an intact adrenergic drive. 
It is, important to identify the serum factor(s) mediating receptor 
blocking, their regulation and the role they play in flare-up of 
asthma, since these factors may influence the effectiveness of beta-2 
stimulators in the therapy of asthma. 
A pilot study was conducted (3.2.1), firstly to investigate whether 
[ 1251]-CYP binding was inhibited by serum in a reproducible fashion 
using the guinea pig lung membranes and secondly, to determine whether 
there was in fact any statistical evidence that the inhibitory effects 
found with asthmatic sera were any different to those found with 
normal control sera. Based on the results of the preliminary study, I 
then conducted further experiments in which the inhibitory serum 
effects from groups of asthmatics, in different clinical categories of 
severity, are compared (3.2.2). 
These experiments were extended in a specific study of the effect of 
purified IgG on ligand binding (3.3), and an investigation into the 
cross species immunogenicity of lung membranes containing beta 
adrenergic receptors in the New Zealand White rabbit. 
117 
3.2 Inhibition of [125I]-CYP binding by human sera. 
3.2.1 Preliminary Study. 
(i) Sera 
(a) Asthmatic sera. 
10ml clotted blood was taken from 54 children with atopic asthma 
sequentially attending the Allergy clinics of the Red Cross 
Childrens Hospital, Cape Town. All children had elevated IgE 
levels (PRIST, Pharmacia) for age (Kjellman, 1976) and positive 
skin or RAST tests (Pharmacia, Uppsala) to two or more common 
environmental allergens. Serum was aliquotted and stored at -20°C. 
(b) Non-asthmatic control sera. 
10ml clotted blood was taken from 24 children who did not have a 
history of allergic disease or a family history of allergy. All 
of the sera had normal IgE levels. Sera were aliquotted and 
stored at -20°C. None of the controls were on any drug 
medication at the time of collection of the sera. 
(ii) Ligand inhibition assay. 
SOµg of guinea pig lung membrane protein was preincubated with a 
1/50, 1/250 or 1/500 dilution of serum from asthmatic or non-
asthmatic control subjects, for 1 hour in 20mM sodium phosphate 
buffer 2mm MgS04 pH 7.6, prior to the addition of [
125I]-CYP at 
the Kd for beta receptors in the guinea pig lung membrane 
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preparation, (determined by Scatchard analysis to be 30pM) and 
10-6M L(-) propranalol (or buffer) for 30 minutes at 30°C. At 
the end of the incubation period, the reaction was stopped by 
the addition of 1.25ml cold 20mM potassium phosphate buffer, 2mM 
MgS0 4 , pH 8.0 and 1 mM D-L propranolol. Samples were 
immediately filtered under low vacuum through Whatman GF/C glass 
fibre filters, the filters were then washed with 25ml 2mM MgS04 
20mM potassium phosphate buffer and sucked dry under vacuum 
using a 6 place Millipore filter (Millipore Incorp.) and 
radioactivity retained on the membranes was measured using a 
gamma counter (Beckman Gamma 4000). Specific binding was 
determined by subtracting the radioactivity retained on the 
Whatman GF/C filters from samples incubated in the presence of 
(-) propranalol, from the radioactivity retained from samples 
incubated in the absence of(-) propranalol. 
(iii) Paediatric asthmatic sera compared with non asthmatic control 
sera:-
Inhibition studies were conducted using 1/50, 1/250 and 1/500 
dilutions of sera. Fig. 16 shows the serial inhibition of 
specific [125I]-CYP binding obtained with 5 typical asthmatic 
sera compared with a non-asthmatic control serum (lower graph). 
Both asthmatic and non-asthmatic demonstrated dose responsive 
inhibition of [125I]-CYP binding to lung membrane beta receptors. 
In the comparative study inhibition of [125I]-CYP binding by a 
1:100 dilution of serum from 54 atopic asthmatic children was 
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Figure 16. Serial inhibition of [1251]-CYP binding to guinea pig lung 
membrane beta receptors using sera from 5 asthmatic 
children ( O). Serial inhibition was also observed with 
non-asthmatic sera ( •). 
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compared with the 23 non-asthmatic, non-atopic controls. % 








27.4 ± 2.97 




The difference in the mean inhibition between the two groups was 
highly significant p = < 0.0026 t-test (p=0.0018 Kruskal-Wallis Test), 
but there was clearly a marked overlap between the groups. 
3.2.2 Inhibition of 125I-CYP binding to beta receptors by sera in 
different severity categories. 
Since certain sera from unselected asthmatic children inhibited the 
binding of [ 125I]-CYP to guinea pig lung membrane beta receptors 
significantly more than serum from the non-asthmatic control subjects 
in the preliminary study, further inhibition studies were performed in 
a prospective study to investigate whether inhibition was a feature of 
mild or severe asthma and whether significantly greater inhibition of 
binding was present in the sera of asthmatic patients during an acute 
attack of asthma. 
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Figure 17. Inhibition of [ 125I]-CYP binding to guinea pig lung 
membrane beta receptors by asthmatic sera (1:100 dil.) N=54 
and control sera (N-23). 
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(i) Patients 
Sera from 76 patients with asthma in different clinical categories 
were obtained. Sera were obtained from patients in each group 
consecutively, within a period of one month, in the order in which 
they presented to the Allergy clinic or asthma emergency room to avoid 
bias in selecting the patients. 
Categories of asthmatic subjects studied as follows: 
























Daily maintenance therapy 
No medication 
on intermittent or daily therapy 
not having an acute attack at time of sampling 










For this study, patients were categorised as severe if they were on 
daily prednisoue, as well as requiring both salbutamol and 
theophylline to control their disease. 
Sera were coded, aliquotted and stored at -20°C until used in the 
[ 1251]-CYP inhibition assay or for IgG purification. 
A pooled guinea pig lung membrane preparation expressing 555fmol/mg 
protein beta receptors (i.e. 27.75fmol beta-2 receptors per assay 
point) was used for the ligand inhibition assays. Patient sera were 
studied at both 1:50 dilution and a 1:250 dilution of the serum, in 16 
consecutive assays, with dilutions of each sample studied in 
triplicate. 
To monitor reproducibility of the [ 1251]-CYP inhibition obtained with 
the sera, 30 sera were re-tested in 16 assays and follow-up 
results were compared with initial results obtained. In general, 
results were acceptably reproducible in the samples re-tested. 
An analysis of variance of interassay results of the degree of serum 
inhibition (N = 30) showed good reproducibility, with no significant 
difference in the results obtained in repeat assays using the Sign-Rank 
test (p ~ 0.2131). 
Dialysis of the serum against 20mM sodium phosphate buffer pH 7.4 
overnight or pre-incubation of the membranes with serum for up to 3 
hrs did not make any significant difference to the degree of 
inhibition obtained in the [ 1251]-CYP inhibition assay. 
124 
( ii) Results 
The mean of inhibition of [1251]-CYP binding obtained with 1:50 
dilution of sera from 4 categories of asthma patients (B-E) is shown 
in the following table, and compared with the control group: 
CONTROLS ASTHMATICS 
Category A B C D E 
Number 25 17 23 21 15 
Mean% 32.92 36.64 40.65 35.22 37.2 
inhibition 
Std deviation 7. 72 18.61 17.94 6.92 11.1 
Std deviation 1. 56 4. 51 3.74 1. 51 2.86 
of mean 
Lowest value 13 21 10 20 22 
(%) 
Highest value 49 94 83 49 66 
(%) 
There were no significant differences between the% inhibition exerted 
by the asthmatic sera within the asthma groups, or when any of the 
asthma groups were compared with control non-asthmatic subjects. By 
analysis of variance between the groups, F value= 1.09 and p = 0.367 
and applying the Kruskal Wallis Test (Chi Square approximation), 
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Figure 18. Inhibition of [1251]-CYP binding to guinea pig lung 
membrane beta receptors by human sera (1:50 dil.) in 5 
categories A-E (see 3.2.2). 
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The range of% inhibition obtained in the 5 groups studied is shown in 
Fig.18. 9/76 (11%) of the asthmatic sera, but none of the normal 
control sera produced inhibition of greater than 50%. Six out of 
these 9 asthmatics fell into the steroid-dependent group and on 
reviewing the clinical history of the one patient from category E he 
probably should have been on steroids. An important finding was the 
absence of a significantly greater degree of [1251]-CYP inhibition in 
sera from patients during an acute attack. 
Three sera were encountered, two from mild asthmatics in this study 
and one from a non-asthmatic, (in a follow-up study, Chapter 6) whose 
sera inhibited [1251]-CYP binding by greater than 85% with good 
reproducibility of the triplicates within the assay but which was not 
reproducible in subsequent assays using either fresh sera or stored 
sera from the patients. (% inhibition in subsequent assays less than 
50%). The intermittent ability of these sera to markedly inhibit 
[1251]-CYP binding to beta receptors in membrane preparations is not 
explained and difficult to study further in view of the isolated 
nature of the phenomenon. 
Analysis and comparison of the serum inhibitory capacity when studied 
at 1:250 dilution of serum also showed no significant differences 
between the groups. 
Table 8 
An analysis of 8 asthmatic patients whose sera inhibited ( 1251)-CYP 
binding by greater than 50% at a dilution of 1:50 
Patient % inhibition Treatment regime Clinical 
Prednisone Theophylline Salbutamol status 
AF 54 + + + Stable* 
CH-Cl4 60 + + + Stable 
DL-ClS 63 + + + Stable 
JA-Cl6 67 + + + Stable 
RY-Cl2 83 + + + Difficult 
to 
control 
ID ES 66 + + Difficult 
to 
control 
B2 94 + + Stable 
B3 70 + + Stable 
*Stable: These patients had PEFR within predicted levels and were well 
controlled on their medications at the initial assessments. 
A clinical follow-up of the first six patients in Table 8 over a period 
of five years reveals that their clinical course has been stormy, 
characterised by steroid dependence and repeated hospital admissions. 
Follow-up studies of the ligand inhibitory effect of their sera (6.6.1), 
showed that all of the sera on subsequent testing, using cloned human 
beta-2 receptors in the membrane preparation, inhibited [1251]-CYP 
binding by less than 50%. 
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3.3 Inhibition of 125 -CYP binding to beta adrenergic receptors in lung 
membranes by DEAE cellulose purified immunoglobulin G 
In the initial experiments by Venter et al. (1980) reporting 
autoantibodies to the beta adrenergic receptor it was found that selected 
sera which inhibited [125IJ Hydroxybenzylpindolol binding to canine lung 
membranes could also immunoprecipitate the beta adrenergic receptor. 
Lung membranes incubated with such sera also demonstrated increased 
binding of [125IJ protein A. These autoantibodies were thought to be of 
the IgG class. Blecher et al. (1984) showed that by immunodepleting IgG 
from asthmatic sera, using a 2.5 fold excess of goat anti-human IgG 1 
chain and anti-human IgA a chain, the inhibition of [125I]-HYP binding to 
canine lung membranes could be reversed and these workers indirectly 
attributed the inhibitory effect to the immunoglobulin fraction in 20 of 
28 high risk asthmatic sera. Direct inhibition of [125I]-CYP binding to 
beta adrenergic receptors by purified immunoglobulin fractions has not 
been previously reported. 
In order to verify these findings in asthmatic sera and to extend these 
studies to the guinea pig lung membrane, IgG fractions were purified from 
asthmatic sera and applied directly to the [125 IJ-CYP inhibition assay. 
Since inhibitory activity was encountered more frequently in the severe 
asthmatics, only severe asthmatic sera were subjected to DEAE cellulose 
purification. Total immunoglobulin G levels were measured in 26 
non-asthmatic sera and compared with IgG levels in 19 severe asthmatics, 
randomly chosen from Groups C and D (3.2.2), by Nephelometry using a 
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Beckman Immunochemistry analyser. There was no significant difference 
between the IgG levels in the asthmatics and non-asthmatics (Table 9), 
using Wilcoxon - 2 sample test p-0.703 and Kruskal-Wallis test p=0.694. 
Table 9: 
N 
Comparison of the total IgG levels in 24 non-asthmatic 
children with 19 severe asthmatic children 
Non-asthmatic Severe asthmatic 
children 
24 19 
Mean IgG(g/L) 10.05 10.50 
SEM 0.355 0.84 
Range (g/L) 7.0-14.5 6.00-20.0 
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3.3.1 IgG purification 
A saturated ammonium sulphate (SAS) solution was prepared by dissolving 
760g of ammonium sulphate in 1 litre of distilled water at room 
temperature and the pH was adjusted to 6.5 with ammonium hydroxide. 
Gammaglobulins were precipitated out by adding 1 volume of SAS to 2 
volumes of serum, thus effecting one third saturation and adjusting the 
pH to 7.8 with O.SN NaOH. After stirring for 3 hours, the suspension was 
centrifuged at 1400g for 30min and the precipitate was suspended in the 
original serum volume in normal saline. In order to remove the 
(NH4 ) 2S04 , the sample was dialysed overnight against lSmM sodium 
phosphate buffer pH 8.0. 
Following dialysis the globulin fraction was chromatographed on DEAE 
cellulose which had been equilibrated with 0.02M phosphate buffer pH 8.0, 
allowing 1 ml of packed DEAE per 50mg semi-purified globulin. IgG 
concentrations prior to and after purification were measured by 
Nephelometry (Beckman Immunochemistry Analyser). IgG recovery from the 
DEAE column was monitored for each specimen using an LKB ultraviolet 
absorption control unit UVICORD Type 8301A. 
Purity of IgG 
IgG fractions prepared by ammonium sulphate precipitation and DEAE 
cellulose chromatography were loaded on to 11% polyacrylamide gels. PAGE 
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of IgG fractions stained with Coomassie Blue from 4 asthmatic patients 
shown in Fig. 19. Bands are detected in the 150-180 kDa, and except for 
small traces of albumin, other serum proteins are removed by the 
purification procedure above. 
3.3.2 IgG inhibition assays 
Inhibition of [ 125I]-CYP binding to guinea pig lung membranes by purified 
human IgG was performed using the same experimental protocol as the serum 
inhibition assays, except that dilutions of purified IgG were used in 
place of dilutions of whole serum. In order to ensure that an identical 
concentration of IgG was employed in these assays, the corresponding IgG 
concentrations in each serum were was measured by Nephelometry and an 
identical cdncentration of the purified IgG was added in the [125 I]-CYP 
inhibition assay, to determine whether any component of the inhibition 
observed in the serum inhibition assays, could in fact be attributed to 
the immunoglobulin G fraction of the serum. Each experiment was 
performed in triplicate and the inhibition obtained compared with an 
equivalent dilution of whole serum. 
Results of a representative inhibition experiment with purified IgG from 
three patients are given in Table 10. Equivalent concentrations of IgG 
purified from 14 patients (6 non-asthmatic and 8 asthmatic) were compared 
with dilutions of serum. 
Using the same concentrations of IgG as in the 1/50 serum dilutions used 





A B C D 
Figure 19 . 11% PAGE of DEAE cellulose purified IgG fractions from 4 
asthmatics (A,B,C,D) (unreduced)_ Molecular weight markers 
are shown on the left. 
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of inhibition to the corresponding serum in a some but not all sera. A 
plot of percentage [125!]-CYP inhibition by 1:50 dilution of serum 
against percentage inhibition mediated by an equivalent IgG concentration 
is shown in Fig. 20. Spearman Rank correlation co-efficient= 0.075; 
p=0.79 confirmed that there was no direct correlation. There was also no 
consistent relationship between the total IgG level in a given patient 
and the% inhibition obtained in the inhibition assays. 13 patients were 
studied and% inhibition of [125!]-CYP binding plotted against µg IgG/500µ1 
in the assay (Fig. 21). Spearman Rank correlation co-efficient - 0.0248; 
p - 0.935. 
Table 10. 
Serum Code Dilution [ 125!] -GYP % inhibition IgG in assay 
or IgG bound cpm of control µg/500µ1 




Falken serum 1/50 6378 so 79.S 
Falken IgG 1/50 5785 54 79.5 
Falken IgG 1/250 11080 18 
Falken IgG 1/500 11393 10 
Christian 
serum 1/50 5028 60 59.7 
Christian IgG 1/50 9129 28 59.7 
Christian IgG 1/250 11384 10 
Christian IgG 1/500 11735 6 
Non asthmatic 
42 serum 1/50 9406 25 78.7 
Non asthmatic IgG 1/50 9783 22 78.7 
Non asthmatic IgG 1/250 11900 6 
Non asthmatic IgG 1/500 12527 0 
No serum(control) 12643 
Representative examples of the 14 patients studied are illustrated in 
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Figure 21. Plot of X inhibition of [ 1UI]-CYP binding to guinea pig 
lung membranes as a function of amount of IgG (µg/500µ1) in 
the inhibition assay. 
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much inhibition was obtained with purified IgG as was obtained with 
whole serum containing an equal amount of IgG. In all instances a 
dose responsive inhibition mediated by IgG could be demonstrated. 
In the case of Christians, a much greater inhibition (60%) was 
observed by a dilution of whole serum than an equivalent amount of the 
purified IgG alone suggesting that [ 125IJ-CYP inhibitory factors other 
than IgG may be present in the sera of some patients . 
. These experiments demonstrated that DEAE purified IgG functions from 
asthmatic and non-asthmatic patients can influence the binding of 
[125I]-CYP to beta receptors in the guinea pig lung membrane, and that 
in most instances, the degree of inhibition approximates the degree of 
inhibition mediated by the equivalent dilution of whole serum. The 
degree of inhibition is not a function of the total IgG concentration 
in each patient. 
As a result of the foregoing observations the following questions are 
raised and have been addressed in further studies reported in this 
thesis: 
1. Is the inhibition of beta receptor [125I]-CYP binding by 
immunoglobulin due to specific competition for the ligand 
binding site, or is the inhibition possibly due to steric 
obstruction? (6.6.2) 
2. Do immunoglobulins interact with cell membranes in a non-
specific way, do they bind to Fe IgG receptors or do they alter 
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the expression or orientation of membrane receptors so that 
their ability to bind ligands is impaired? (3.5)(6.4.7) 
3. What is the nature of the ligand binding domain of the beta-2 
adrenergic receptor? (4.3) 
4. Does the degree of inhibition of [125I]-CYP binding vary with 
the level of beta-2 receptor expression in the cell membranes? 
(6.6.1) 
5. Does the inhibition of [125IJ-CYP binding by serum have 
functional significance with respect to adenylate cyclase 
activation and cyclic AMP production? 
While answers to some of these questions could be partially answered 
by further studies using the guinea pig lung membrane preparation, it 
was clear to me that a more precise molecular understanding of the 
ligand binding site was required before specific interactions between 
immunoglobulins and the beta-2 receptor could be studied 
intelligently. The studies conducted in this chapter were performed 
before the beta-2 receptor gene was cloned and sequenced. In the 
following sections (3.3.3 - 3.5) I have described the additional 
exploratory experiments I performed on the guinea pig lung membranes. 
I have described my further investigations of this phenomenon using 
cloned human beta-2 receptors in Chapter 6.6. 
3.3.3 Adherence of IgG to lung membranes. 
In order to demonstrate that immunoglobulins do in fact associate with 
lung membranes either by low affinity specific binding or by other 
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non-specific interactions (e.g. hydrophobic, van der Waals) a 
[ 125I] -Protein A assay was employed. 
Briefly, 50µ1 of a 1/100 dilution of serum from 4 patients was 
incubated in triplicate with 50µ1 (lOOµg) guinea pig lung membranes 
(final dilution 1/200) for 60 min at room temperature in Beckman 
airfuge cellulose propionate 5 x 20mm tubes. After incubation 
membranes were washed twice with 100µ1 0.1% ovalbumin in lOOmM sodium 
phosphate buffer, pH 7.4. with 150 OOOcpm [125I] Protein A 
[ 125I]-labelled with Bolton and Hunter reagent, 30mCi/mg, Amersham 
lM.112) in 100µ1 sodium phosphate buffer. The membrane preparation was 
then incubated for 30 min. at room temperature. Membranes were washed 
twice with 0.1% ovalbumin using the airfuge and the pellets (in the 
tubes) counted in a Packard model 3003 gamma counter. Controls, 
without serum, or without receptor were included in the assay. 
Results for the Protein A assay are shown in Table 11. 
Table 11 
Control Control 
no membrane membrane 
no serum 
Mean cpm 6788 21718 
% increase 






















Table 11 suggests that immunoglobulin G maybe binding to the guinea 
pig lung membranes upon incubation, as indicated by an increase in 
[ 1251] Protein A binding. An increase of up to 299% of binding was 
obtained in the presence of a 1:200 dilution of serum from patient 
III. However, it was found that some of the apparent increase in 
binding was due to IgG sticking to the cellulose propionate tubes. 
The extent of this was demonstrated in an experiment in which 50µ1 of a 
1/100 dilution of patient III serum was incubated in the cellulose 
propionate tubes, in the presence or absence of 0.5% Tween. Mean 
~ounts obtained when [ 1251] protein A (100 OOOcpm) was subsequently 
added and washed were 4109 cpm in the presence of 0.5% Tween and 
31801 cpm in the absence of Tween. 
Coating of the airfuge tubes with 10% foetal calf serum did not reduce 
non-specific adherence of IgG to the tubes. The [ 1251] protein A 
assay was thus repeated on sera III and IV in the presence of 0.5% 
Tween and results obtained when 100 OOOcpm [ 1251) Protein A was added 
were as follows: 
Mean 
£.Q.!!L 
Control no membranes no serum 1468 
Control membranes no serum 3786 
Patient IV serum no membranes 2141 
Patient IV with membrane protein 6780 
Patient III serum no membrane 7308 
Patient III serum with membrane protein 13766 
Non-specific binding to the tubes was thus reduced and only a marginal 
but a consistent increase in the Protein A binding was observed when 
1/100 serum dilutions from patient's III and IV were incubated with 
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the guinea pig lung membranes in the presence of 0.SX Tween. Patient 
III serum still demonstrated significant binding to the tubes in the 
presence of 0.5% Tween. These experiments demonstrated that the 
[ 1251] Protein A assay (Fraser et al. 1981) has distinct limitations, 
and direct studies demonstrating immunoglobulin association with 
purified beta receptors in ELISA or Western blot are necessary. 
3.3.4 The effect of varying the incubation period for membrane 
interaction. 
The following experiment was performed to determine whether 
preincubation of the membrane receptor with IgG would in fact increase 
the inhibition of binding of [ 1251)-CYP to membranes observed. For 
this study lung membranes preincubated with a fixed concentration of 
IgG for 10, 20, 40 and 60 min prior to the addition of (1251)-CYP were 
compared with membranes to which IgG and [ 1251]-CYP were added 
simultaneously. The effect of pre-incubation of membranes is shown in 
as follows: 
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Values shown, cpm and% inhibition are the means of triplicates. 























These results show that pre-incubation of the lung membranes with IgG 
does not increase the degree of inhibition observed in the inhibition 
assay. In a further experiment in which the IgG fraction was added 
immediately at the end of the 30 min incubation period with [125I)-CYP, 
just before the reaction is stopped and the reaction mixture filtered, 
it was found that there was no inhibition, confirming that the 
inhibition is not simply occurring due to the presence of IgG on the 
Whatman G/FC filters during the filtration stage. 
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3.4 Immunoprecipitation of beta adrenergic receptors with sera 
from asthmatic subjects. 
In order to show that IgG was in fact associated with the beta receptor 
I attempted to immunoprecipitate the beta receptor using sera from the 
severe asthmatic patients whose sera inhibited ligand binding. 
3.4.1 Immunoprecipitation of solubilised beta adrenergic receptors. 
Briefly, beta receptors from lung membranes (lOOµg protein) were 
specifically labelled with SOpM [1251]-CYP, membrane receptors were 
solubilised with 0.5% Triton X-100 for 15 minutes at 30°C and then 
centrifuged at 48 OOOg in thick walled polypropylene centrifuge tubes 
for 30 min. Labelling with SOpM [1251]-CYP was performed in the 
presence or absence of 10-sM L(-) propranalol. After centrifugation 
the supernatant contained the solubilised receptors. The supernatant 
was then treated with Biobeads (O.lg/0.Sml) for 30 min at 4°C. 100µ1 
aliquots of the solubilised receptor in the supernatant were incubated 
with 100µ1 patient serum (at a range of dilutions from 1:25 to 1:5000) 
for 18 hours at 4°C. Immunoprecipitation of [1251]-CYP-receptor 
complexes was accomplished by the addition of antiserum to human IgG, 
which had I raised in rabbits (see Appendix C), at a 1/12 final 
dilution for 4 hours at 4°C and then centrifuging at 12 OOOg for 5 min, 
collecting the pellet and counting the radioactivity in a gamma 
counter. The concentration of solubilised beta receptors precipitated 
was calculated by subtracting the counts obtained in the presence of 
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L(-) propranalol from the counts obtained in the absence of L(-) 
propranalol. 
Incubation of [125I]-CYP with serum alone did not result in 
immunoprecipitation of [125IJ-CYP upon subsequent addition of rabbit 
anti-human IgG. 
Applying a 1/12 dilution of rabbit anti human serum, and a range of 
dilutions of patient serum from 1:25 to 1:5000 (in control serum) 
immunoprecipitation of beta adrenergic receptors was demonstrated with 
only one patient's serum (VDM). Attempts to immunoprecipitate beta 
receptors with 10 further ligand inhibitory sera were unsuccessful 
(Fig. 22). 
Since beta receptors with bound [125!]-CYP were precipitated, these 
experiments suggested the human immunoglobulins were not, in fact, 
binding to the ligand binding domain, but to another domain of the 
receptor. This also suggested that by its very nature, a ligand 
inhibitory assay may not be the best assay for the detection of 
anti-beta receptor antibodies. 
3.4.2 Size of solubilised labelled protein. 
In order to check the size of the solubilised [125I]-CYP labelled 
protein in 3.4.1, 140µg of guinea pig membrane was incubated with lOOpM 
[ 125IJ-CYP in the presence or absence of L(-) propranalol for 30 
minutes followed by solubilization in 0.5% Triton X-100 for 15 min and 
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Figure 22. Immunoprecipitation of increased propranalol displacable 
[ 1251]-CYP binding to solublised guinea pig beta-2 
adrenergic receptors using patient serum (VDM) and a 1:12 
dilution of rabbit anti human serum (see 3.4.1). 
o Binding in the presence of (L) propranalol. 
• Binding in the absence of (L) propranalol. 
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centrifugation at 48 OOOg for 30 minutes. The supernatant was treated 
with Biobeads (O.lg/0.Sml) for 30 min at 4°C and 100µ1 loaded on to 1 ml 
spin columns using the method of Penefsky (1977) employing Sephadex G75 
(retains MW 1500 to 70 000) and Sephadex GSO (retains MW 1500 to 
















Thus the size of the solubilised [ 125I] labelled protein was less than 
70 kDa but greater than 30 kDa, consistent with the reported size of 
the guinea pig beta receptor of approximately 68 kilodaltons. 
3.5 Western blotting of guinea pig lung membranes with patient 
1z.Q 
Since both the [125I]-Protein A assay (3.3.3) and the 
imrnunoprecipitation assay (3.4.1) have clear limitations, a more direct 
assay for antibody interaction with beta receptors is necessary. In 
order to see whether human imrnunoglobulin bound to any protein bands in 
the guinea pig lung membranes, polyacrylarnide gel electrophoresis 11% 
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(PAGE) of 20µg GP lung membrane proteins was performed (Fig. 23) and 
proteins transferred electrophoretically on to nitrocellulose paper by 
Western blot (Towbin et al. 1979). After blocking overnight with 0.3% 
Tween and 1% foetal calf serum in Tris buffered saline pH 7.4, a 
dilution of DEAE purified IgG, from eight subjects, equivalent to their 
serum concentration of 1/200 (measured by Nephelometry) was incubated 
with the nitrocellulose paper under gentle agitation for 90 minutes and 
then washed three times with TBS-Tween. After further incubation of 
nitrocellulose paper with a 1/500 dilution of HRPO conjugated goat 
anti-human IgG and incubation with the HRPO substrate 4 chloronaphthol 
no bands were seen with IgG prepared from 4 asthmatics or with IgG 
prepared from 4 non-asthmatics. These patients included those patients 
who were initially positive in the Protein A (3.3.3) assay and the 
patient who was positive in the immunoprecipitation assay (3.4.1). 
It was concluded that non-specific adherence by IgG to the proteins in 
guinea pig lung membranes was not occurring to guinea pig lung membrane 
proteins separated under reducing or non reducing conditions. 
However, since femptomolar binding of IgG would not be detected by 
immunoblotting (Towbin, personal communication), these experiments do not 
exclude the possibility of IgG interactions with the beta receptors at a 
very low concentration via other mechanisms but sufficient to interfere 
with [ 125 I)-CYP binding. In order to demonstrate IgG binding to 
receptors on Western blots, a much higher concentration of beta-receptors 
per lane is mandatory (picamolar to nanomolar). However, even if it is 
possible to obtain nanomolar concentrations of beta-2 receptors on 







Figure 23 . 11~ PAGE of 20µg guinea pig lung membranes. Molecular 
weight marker'S are shown on the right. 
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adequate numbers of receptors may be as a result of alteration of 
important conformational epitopes during electrophoresis of the 
receptors. These problems may be eliminated if it is possible to 
demonstrate immunoglobulin binding to intact beta receptors on fixed or 
permeabilised cells. This may be possible by light microscopy if a line 
of cells could be obtained ~ith expresses human beta-2 adrenergic 
receptors at high levels, or alternatively could be studied using a 
fluorescent activated cell sorter on established human cell lines. 
3.6 Immunogenicity of lung membrane preparation in the New Zealand 
White Rabbit 
Anti-beta-2 receptor autoantibodies may theoretically be induced by 
exposure of the immune system to intact a partially degraded beta-2 
receptors either from altered self, by exposure to beta receptor ligands 
and the development of anti-idiotypic antibodies (Strosberg et al. 1985), 
or by anti-idiotypic antibodies to viruses (e.g. reovirus which bind to 
the beta receptor) or possibly by exposure to epitopes of intact or 
partially degraded beta receptors from another species in which the 
receptor displays homology but is not identical in its amino acid 
sequence (e.g. avian receptors or calf receptors in diet). 
I have investigated whether direct exposure of New Zealand white 
rabbits to membranes prepared from calf lungs and human lungs would 
induce "ligand inhibiting" antibodies to beta receptors, which could be 
measured in a [ 1251]-CYP binding assay. Before immunization I 
confirmed that the membranes prepared from calf and human lungs had 
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beta-receptors by [ 125I]-CYP binding and functional cAMP assays. The 
immunization protocol, the course of the rabbits, the antibody 
responses and post-mortem findings are described in detail in Appendix 
D. In short, both animals developed a curious, severe wasting disease 
and developed antibodies to proteins in human and calf lung membrane 
which also cross-reacted with the rabbit lung membranes, as shown by 
Western blotting. There was, however, no evidence of the development 
of anti-beta receptor antibodies in the rabbits, as measured by 
[ 125IJ-CYP inhibition assay of 1:50 dilution of rabbit serum and there 
was no evidence of asthma in the rabbits although the lungs of both 
rabbits were congested and haemorrhagic at post-mortem. 
While these experiments do not disprove that anti-beta receptor 
antibodies can be induced by exposure of an animal to foreign cell 
membranes containing foreign beta receptors (since a number of 
different immunization protocols may need to be tried to raise the 
desired antibodies), they do suggest that the induction of 
autoantibodies to the ligand binding site of beta receptor in this way 
is not likely to be easy. Clearly, the immunogenicity of the beta 
receptors in a given animal will depend partially on the amino acid 
sequence differences of the receptors and also on the hydrophilicity or 
hydrophobicity of the different domains of the receptor. Sequence 
differences between the human, calf and rabbit beta receptors have as 
yet not been studied. 
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3.7 Discussion. 
The studies in this chapter have largely been conducted to confirm the 
phenomenon of ligand inhibition to beta receptors using a more specific 
ligand, [ 125I]-CYP, than previously reported and a different lung 
membrane preparation. 
I have confirmed that both serum and purified IgG fractions from 
asthmatic and non-asthmatic subjects influence the in vitro binding of 
the ligand [ 125I]-iodocyanopindolol to guinea lung membrane beta 
receptors. Sera from 178 individuals have been studied. 
In both the preliminary study of 77 subjects (54 asthmatic and 23 
controls) at 1:100 dilution and in the prospective study of 101 
subjects (76 asthmatics and 25 controls) at 1:50 dilution, greater than 
50% inhibition of [ 125I]-CYP binding only occurred in the asthmatic 
patients. In the prospective study, 88% of the asthmatic patient's 
sera displayed inhibitory activity which was within the range obtained 
with non-asthmatic sera. Significant differences between the 
asthmatics and non-asthmatics were not found (p - 0.287, Kruskal Wallis 
Test) at 1:50 or 1:250 dilutions of sera. (In previous analysis of this 
data using the Mann Whitney test and Student T tests, I did, in fact, 
obtain a significant difference (p - <0.05) between groups A and C but 
this was not borne out by the Kruskal Wallis test which is more 
suitable for this data). A marked inhibition (92%) was also obtained 
with a fresh serum sample from a non-asthmatic control subject, in the 
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experiments with cloned human beta-2 receptors in Chapter 6, again 
deonstrating that significant ligand inhibitory activity is not 
exclusive to asthmatic sera. Comparison of the patients whose sera 
inhibited ligand binding more than 50% also revealed no obvious 
clinical differences with respect to clinical course or treatment 
requirements when compared with the asthmatic patients whose sera were 
less inhibitory (detailed lung function tests were not performed). 
These studies therefore do not suggest that "autoantibodies" to the 
beta receptor as defined by the original assays reported by Venter et 
al. (1980) and Fraser et al. (1981) are clinically important in 
asthmatic children. The laboratory observations suggest that these 
"autoantibodies" play a very small role, if any, in the pathogenesis 
of the disease. Furthermore, it is doubtful whether these 
immunoglobulin fractions should be called "autoantibodies" at all. 
In the first instance before one can assign significance to 
"autoantibodies", the assays for detecting autoantibodies must be 
specific and reproducible. The [ 1251]-HYP ligand binding assays used by 
Venter et al. (1980) and Blecker et al. (1984) while lacking a degree of 
specificity for the beta adrenergic receptor (Pocret, 1978). Although 
this was implied there was no firm evidence that the "autoantibodies" 
previously described, in fact, interact directly with the ligand binding 
domain. Conceptually, at the time of these studies, it was believed 
that the ligand binding domain resided in an extra-membranous location 
(Venter, 1983). However, since the cloning of the beta-2 receptor, 
molecular modelling based on the gene sequence Dixon et 
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al. (1987) has suggested that the ligand binding domain is not 
extramembranous but involved its rhodopsin-like core. This concept has 
been supported by my own studies on mutant human beta-2 receptors 
(4.3.1-4.3.6) and by those of others (Kobilka et al. 1988, O'Dowd et 
al. 1988, Strader et al. 1989, Chung et al. 1988). It is difficult to 
imagine with more recent concepts of the topography of the beta-2 
receptor and its ligand binding domain, how antibodies could inhibit 
the binding of a small ligand such as [ 125I]-CYP or [1251]-HYP 
sterically, without the immunoglobulin somehow gaining access to the 
ligand binding pocket. I have extended this discussion in more detail 
in Chapter 5, in which I have addressed the theoretical possibility of 
an antibody binding to a ligand binding domain, by producing a 
monoclonal antibody to a peptide derived from the proposed ligand 
binding domain. 
I have invested considerable experimental effort in evaluating the 
[1251)-CYP ligand binding assay itself, in order to obtain binding data 
which was reproducible (Chapter 2). I have also critically re-examined 
the (1251]-CYP inhibition assay and have found that a dose responsive 
inhibitory effect does not require a long (30 min) pre-incubation 
period, is not removed by dialysis of the serum against 20mM sodium 
phosphate buffer, is not destroyed by heating the serum to 56°C. The 
inhibitory activity is present in a DEAE purified IgG fraction and 
serum and is also reproducible. 
While the [125I]-CYP inhibition assay was reproducible, it is clear 
that it may not be the best assay to detect auto-antibodies to the beta 
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receptor since it will, by definition, exclude sera with antibodies 
which interact with other non-ligand binding domains. The [ 1251) 
Protein A assay is non-specific and the immunoprecipitation assay, 
which depends on intact ligand binding for identification of 
precipitated receptors, will detect sera which have antibodies to 
non-ligand binding domains. One would, therefore, not expect a good 
correlation or even concordance between the results of the [ 1251)-CYP 
inhibition assay and the immunoprecipitation assay. 
A clear demonstration of direct interaction between human antibodies 
and the human beta receptor has never been reported using Western 
blotting or direct immunofluorescence, mainly because of the 
difficulties in obtaining a sufficient amount of human beta-2 receptors 
in the right conformation for such studies. Mammalian beta-2 receptors 
are difficult to purify and tend to be unstable with respect to their 
ligand binding characteristics, when they are outside of their normal 
intramembranous milieu (Cuberop and Malbon, 1984). In the past, 
amphibian beta receptors were preferred for molecular studies of 
purified bet~ receptors (Shorr et al. 1981). The indirect methods of 
demonstrating interactions between immunoglobulins and receptors were 
employed. The assay which seemed more promising was the 
irnrnunoprecipitation assay, but since antibodies detected by this assay 
do not inhibit ligand binding their possible pathological significance 
is less clear, although antibodies to non-ligand binding domains are 
known to be important in the pathogenesis of myasthenia gravis. 
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In considering the possibility that auto-antibodies may play a role in 
asthma, it is critical to have some information on the sensitivity and 
specificity of the auto-antibody testing (Galen and Gambino 1975). 
Sensitivity may be defined as "positivity in disease", or the 
probability of a positive test given the presence of disease. 
Specificity on the other hand is often referred to as "negativity in 
health" or the probability of a negative test, in the absence of the 
disease in question. However, to apply these criteria one must have a 
reliable cut-off for a positive result for the assay being evaluated. 
In evaluating autoantibody testing it may be assumed (Dawkins 1985) 
that: 
1. A given autoantibody can be treated as a continuous variable and 
that it will be present in any given serum to a greater or lesser 
degree. 
2 The test used to measure this antibody is capable of 
distinguishing between at least several amounts of the antibody. 
3. Health is associated with less antibody than disease. 
4. There will be some overlap between health and disease since the 
amount of autoantibody will not be the sole determinant of 
whether or not disease is present at that particular time. 
An important consideration in applying formulae to any disease is to 
take into consideration the prevalence of the disease in the population 
as a whole. If the assumptions of Dawkins, above, are to be applied 
theoretically to the results of 3.2.2 using a 1:50 dilution of serum 
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with a cut-off of 50% inhibition as being a positive result the data 
may be displayed as follows: 
Disease Group (Asthma) 














Thus for the diagnosis of asthma, the sensitivity of the [1251]-CYP 
inhibition assay was thus 11.8%, the specificity is 100%, the 
predictive value of a positive test was 100% but the predictive value 
of a negative test was 27%. However, this relatively small data set in 
3.3.2 poses a problem in defining a positive result. Since the 
prevalence of asthma in Cape Town children is 7%, it is necessary to 
give information on approximately 1064 normal individuals if 81 
patients with asthma are compared, if one is going to make reliable 
calculations of sensitivity and specificity. 
Milgrow and Witebsky (1962) applied five criteria for judging that an 
autoimmune disorder is the cause of a disease. 
1. A circulating antibody or a cellular immune reaction is documented 
in the patient with the disease. 
2. A specific antigen is involved. 
3. It is possible to produce an antibody in an experimental animal by 
immunizing with the antigen. 
4. The disease should develop in the immunized animal. 
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5. Passive transfer of the disease is possible with serum or 
immunocytes. 
It is immediately apparent that it would be difficult to apply the 
above criteria to an evaluation of anti-beta adrenergic receptor 
antibodies in human asthma until a pure source of human beta receptors 
was available for immunization in an experimental animal. An 
autoimmune pathogenesis to asthma based on autoantibodies to the beta-2 
receptor could still theoretically exist, but there are as yet no 
animal studies fulfilling Milgrow and Witebsky's criteria in 3-5 above. 
I have demonstrated that both crude human and foetal calf lung 
membranes are immunogenic in the New Zealand White Rabbit and induced a 
wasting disease with cross-reacting antibodies in these animals 
(Appendix D) but the rabbits at no stage developed any evidence of 
asthma. Serum from the immunized animals did not inhibit [ 1251]-CYP 
binding to beta receptors in the ligand binding inhibition assay above 
the degree of inhibition obtained with control rabbit serum (10-35%) 
suggesting that the ligand domains of human and calf beta receptors 
were not highly immunogenic in the rabbit. 
The immunogenicity of cross-species beta-receptors may better be 
theoretically investigated if an immunogenic quantity (micrograms) of 
purified receptors could be obtained, however, such a model would not 
represent a physiological state, since under normal conditions 
individuals are not likely to be exposed to such high concentrations of 
purified receptors out of their normal intramembranous context. 
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Furthermore, with recent cloning of the beta-2 receptor gene, it is 
clear that mammalian beta receptors are highly conserved in their amino 
acid sequences, particularly in the hydrophobic ligand binding domains. 
It is thus most unlikely that if antibodies were induced to other 
domains by cross species exposure, these antibodies would influence 
ligand binding at all, unless they induced further conformational 
changes in the molecule. 
Sterin-Borda et al. (1984, 1988) have repeatedly confirmed that IgG in 
the sera of patients with Chagas disease non-competitively inhibits 
antagonist ligand ( 3H-DNA) binding to rat heart Bl receptors and that 
Chagasic IgG induced a significant increase in cAMP levels in cardiac 
homogenates and spleen homogenates which was not seen with IgG from 
normal individuals. These findings are somewhat paradoxical in that an 
immunoglobulin which inhibits antagonist ligand binding, also 
stimulates cAMP levels suggesting that the sites of action for the two 
effects are likely to be different. 
Reports by Limas (1989a) on the presence of autoantibodies in patients 
with idiopathic cardiomyopathy are remarkably similar to our own data, 
with respect to the degree of inhibition of ligand binding, the overlap 
with normal individuals and non competitive inhibitory effects of 
purified IgG fractions in ligand inhibition. 
Recently increased and aberrant HLA DR II expression has been 
demonstrated in the airways of asthmatic subjects (Holgate 1990, 
personal communication). Analogous to Graves disease (Botazzo et al 1983) 
157 
this provides an attractive theoretical mechanism for the amplification 
of the production of autoantibodies to membrane proteins and 
particularly beta-2 receptors in the airways of allergic subjects. 
However, this mechanism has not yet been tested and remains speculative. 
More definitive information about the mechanism of [ 125!]-CYP 
inhibition by serum/IgG was obtained, in 6.6.2 using membranes 
containing cloned human beta-2 receptors in which I demonstrated that 
the [1251)-CYP inhibition was non-competitive. This data confirmed 
that the serum inhibitory factors are not in fact competitively binding 
to the [ 1251)-CYP binding site in the proposed hydrophilic pocket of 
the ligand binding site. 
However to explore a theoretical possibility of an immunoglobulin 
interacting with the ligand domain, I have constructed a monoclonal 
antibody to a synthetic peptide derived from a proposed ligand binding 
domain and these experiments are described in Chapter 5. 
It is relevant at this juncture, to consider and debate the possible 
significance of ligand inhibitory human serum. The demonstration of 
immunoglobulin fractions from several human subjects inhibiting 
[ 1251]-CYP binding to beta adrenergic receptors in guinea pig lung 
membranes, may simply be an in vitro observation. One may postulate 
that immunoglobulins or other serum fractions exert some as yet 
unidentified and undefined role in modulating catecholamine binding to 
beta adrenergic receptors in vivo, or may modify normal regulation of 
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the beta adrenergic receptors in a physiological sense. 
Immunoglobulins may "block" or attenuate beta receptors which are 
normally bathed in plasma (e.g. on lymphocytes, endothelial cells, or 
platelets) and are continually exposed to catecholamine bursts. 
However, any modulatory role of such immunoglobulins on beta receptors 
on cells which are not normally directly in contact with plasma, e.g. 
brain or muscle cells, is likely to be negligible. One could postulate 
that this could result in a differential sensitivity of different cells 
(e.g. smooth muscle versus lymphocytes) to small changes in 
tatecholamine levels, independent of the number of beta receptors 
expressed on each cell, since the levels of catecholamines surrounding 
cells which are not in the intravascular compartments, (e.g. neuronal), 
i.e. by simple diffusion, are likely to be much 'lower than the serum 
catecholamine levels. Receptors in direct contact with plasma are thus 
more likely to be in a state of down regulation than beta receptors not 
normally exposed to plasma, unless they are protected by other (serum) 
factors. 
While this postulate makes physiological sense, it needs to be tested 
experimentally before it can be accepted, and in particular the 
following questions must be addressed: 
1. Are the results with guinea pig membrane preparations purely cross 
species in vitro phenomena, or are they applicable to membranes 
from cells expressing human beta receptors? 
2. Do serum or IgG fractions of sera also block beta receptor agonist 
activity (e.g. isoproterenol) in vitro? 
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3. What is the relationship between agonist and antagonist inhibition? 
4. How are the serum blocking factors for [ 125!]-CYP binding induced 
or regulated? 
To answer these questions adequately the following experimental 
reagents are necessary: 
1. A reliable source of human beta-2 adrenergic receptors. 
2. A cell system expressing high levels of human beta-2 receptors in 
which functional activity can be measured. 
3. A "control" monoclonal or polyclonal antibody specifically 
directed to the ligand domain of the beta-2 receptor. 
4. Further purification and identification of the factors in the 
serum responsible for the inhibitory effects. 
I have systematically attempted to address these four questions in this 
thesis. Chapter 4 describes the molecular biological approaches I 
have utilised to obtain a cell system expressing human beta receptors 
for further studies of the effects of serum on agonist (functional) and 
antagonist ligand binding which I have described in Chapter 6. 
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CHAPTER 4 
IDENTIFICATION OF THE BETA-2 ADRENERGIC RECEPTOR MESSENGER RNA SPECIES 
AND STUDIES OF THE LIGAND BINDING DOMAIN USING MUTANT BETA-2 
ADRENERGIC RECEPTORS. 
4.1 Introduction 
Extremely low levels of the beta-2 receptors normally expressed on 
cell membranes, i.e. femtomoles/mg protein, make direct studies of 
antibody interactions with the ligand domain of the receptor protein, 
using conventional immunological methodology (e.g. immunofluorescence, 
Western blotting) difficult. In the past studies demonstrating 
immunoglobulin binding to beta-2 receptors have used receptors, which 
have been affinity purified and concentrated up to 1500 fold (Caron et 
al. 1979, Wang et al. 1989). Affinity purification of beta-2 
receptors is difficult and had only been perfected in a few major 
centres. One disadvantage of affinity purified beta-2 adrenergic 
receptors is that they are not in a functional state and the effects 
of serum, or other factors, on agonist stimulated receptor function 
cannot be studied. 
With the advent of recombinant DNA technology, the prospect of 
obtaining genetically engineered human beta-2 receptors expressed in a 
mammalian cell at high levels provided an alternative approach to 
obtain a ready source of human beta-2 receptors for further studies 
necessary to answer some of the questions I raised in Chapter 3. 
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It was fortuitous that at the end of 1986, I was invited to join, as a 
Visiting Fellow, the research programme directed by Dr. Fuzon Chung, 
in Dr. Craig Venter's unit in the laboratory of Receptor Biochemistry 
and Molecular Biology at the N.I.H., Bethesda, Maryland. Dr. Chung 
was attempting to clone and sequence the human beta-2 receptor gene 
from a human neonatal brainstem cDNA library (constructed by Dr. R.A. 
Lazzarini, N.I.H.) in A-gtll, using an oligonucleotide probe (51-mer) 
prepared from the C terminus (base pair 1384-1435) of the hamster lung 
beta adrenergic receptor cDNA sequence (Dixon et al. 1986). At this 
time the human beta-2 receptor gene had not been sequenced and the 
size and distribution of the mRNA species for the human gene was 
totally unknown. I thus decided to temporarily stop my biochemical 
studies with the asthmatic sera and devote some time to learning the 
techniques of molecular biology with the view to obtaining ultimately 
a genetically cloned source of human beta-2 receptors for further 
studies. 
My initial project was to extract and identify the size of the human 
beta-2 receptor mRNA transcript and to study its regulation by 
steroids in the Wl-38 human fibroblast cell line. These studies were 
initially difficult and tedious since RNA work had not previously been 
performed in Venter's Unit and I had to set up and select and evaluate 
RNA preparative methods on my own, before I could commence any 
definitive studies. These studies enabled me to construct sense and 
anti-sense riboprobes of the beta receptor. Once the human 
beta-receptor gene was cloned, sequenced and had been expressed in B82 
mouse fibroblasts, I attempted to purify human beta-2 receptors, for 
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further antibody studies, from the fibroblasts, using alprenalol 
affinity chromatography, but the low yields of receptor I obtained 
were not suitable for antibody studies. Dr. Fuzon Chung in the mean 
time had made a full length cDNA beta-2 receptor probe designated 
CLVF-108. 
The intriguing idea that allergic subjects may have a genetic defect 
in beta-2 receptor structure, makes the in vitro examination of 
theoretical genetic models of dysfunctional beta-2 receptors most 
interesting. The opportunity to do this using site-directed 
mutagenesis arose. I therefore decided to work with Chung on mutant 
beta-2 receptor construction and characterization, since this provided 
and exciting opportunity to learn more about the nature of the ligand 
binding site and to examine the in vitro behaviour of dysfuntional 
beta-2 receptors. 
In an attempt to identify the residues important for ligand binding 
and to select mutants for further studies, I conducted the initial 
ligand binding studies on nine mutant beta-2 receptors constructed by 
Dr. Chung and then proceeded with more detailed characterization of 
the Aspartate 79 mutant (Chung et al. 1988) and the Asn 6 
glycosylation mutant. I also attempted, while at N.I.H., to express 
the wild type beta-2 receptor in prokaryotic cells using the Pttq 
expression vectors developed by Stark, Leicester U.K. (1987) but did 
not at any stage identify the expected fusion product on 
polyacrylamide gels. 
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The expression vectors and probes constructed in these studies 
enabled me to extend my early studies with human sera (described in 
Chapter 3) to an evaluation of the effects of serum on the function of 
cloned human beta-2 receptors expressed in B82 cells (described in 
Chapter 6), to make and evaluate a monoclonal antibody to a peptide 
derived from the beta-2 adrenergic receptor sequence (described in 
Chapter 5) and to study a polymorphism of the human beta-2 receptor in 
allergic subjects, (described in Chapter 7). 
4.2 
4.2.1 
Identification of the mRNA transcript of the human beta-2 
adrenergic receptor 
Isolation of RNA 
Total cellular RNA was isolated using a Cesium chloride gradient 
according to the method of Chirgwin et al. (1979). 
Fresh tissues from guinea pig lung, rat epididymal fat pad (±lgm), 
murine B82 cells (Gilman 1973), Wl-38 human lung fibroblasts and Va4 
cells (± 5xl07 cells) (Hayflick 1961) (see 4.2.4) were dispersed in 4 
ml of 4M guanidinium isothiocyanate, 5mM sodium citrate (pH 7.0) O.lM 
~-mercaptoethanol and 0.5% sarkosyl. RNA pellets were prepared on 
cesium chloride gradients using the method of Maniatis (1982). RNA 
pellets were dissolved in lOmM Tris-HCl pH 7.4, 5mm EDTA, 1% SDS, and 
extracted twice in 4:1 mixture of chloroform:l butanol. The two 
aqueous phases were combined and the RNA recovered by centrifugation 
after precipitating with 0.1 volume of 3M sodium acetate (pH 5.2) and 
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2.2 volumes of ethanol at -20°C for 4 hrs. Pellets were dissolved in 
H20, re-precipitated with ethanol and stored at -70°C. 
I prepared Poly(A)+ RNA using two methods. Initially Hybond™MAP 
(messenger-affinity paper) Amersham (Code RPN 1511) was employed. In 
this method, crude RNA is spotted on to Hybond-MAP, washed twice in 
0.5M NaCl (to remove free RNA), rinsed in 70% ethanol and then washed 
in distilled H20 at 70°C which releases the Poly(A)+ RNA into the H20. 
Although good yields of Poly A+RNA were obtained from MAP, I did not 
obtain good signals when slot blots or Northern blots of Poly(A)+ RNA 
prepared by this method were probed. I therefore purified mRNA by 
Oligo(dT) cellulose chromatography. 
Oligo(dT)-cellulose Type 3 (Collaborative Research Incorporated, 
Bedford, MA, Cat. 20003) was used and the columns prepared essentially 
according to the protocol of Davis, Dibner and Battey (1986). Strict 
attention was directed to maintaining an RNase-free environment at all 
times. Gloves were worn, all glassware was baked at 250°C, diethyl 
pyrocarbonate treated (DEPC)(Sigma) water was used and wherever 
possible, disposable plastic/polycarbonate containers were used. 
4.2.2 Agarose gels and Northern blots 
(i) Glyoxal gels. 
Based on the methods published by Thomas (1983), 10-20µg total RNA or 
2-3µg Poly(A)+ RNA was heated at 50°C for 1 hour in lM glyoxal in the 
presence of 50% DMSO prior to electrophoresis on a 11 x 14cm 
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horizontal gel in 1% agarose (molecular biology grade) in lOmM sodium 
phosphate buffer (pH 7.0) with xylene cyanol and bromophenol blue as 
dye markers. After electrophoresis at 100V for 2 hours, by which time 
the dye had migrated 9 cm, gels were stained in the dark for 15 mins 
in 5µg/ml ethidium bromide in H20 and destained in H20 in the dark for 
1-2 hours. RNA ladder (BRL, Gaithersburg) was used as a molecular 
weight marker. 
(ii) Formaldehyde gels. 
Dry RNA samples (10-20µg total RNA or 2-3µg Poly(A)+ RNA were dissolved 
in 2.2µ1 buffer A (294µ1 0.5M MOPS (pH 7.0)/0.0lM EDTA(pH 7.5) and 706µ1 
H20) to which was added 4.8µ1 formaldehyde/formamide (final 
concentrations of 2.2M formaldehyde and 50% formamide), heated at 70°C 
for 10 minutes before quenching on ice. 1.5µ1 of gel loading buffer 
(xylose cyanol/bromocresol green/sucrose) was added prior to 
electrophoresis on an 11 x 14cm horizontal submarine 1% agarose gel 
(prepared by mixing 0.5g agarose, 5 ml lOxMOPS/EDTA buffer and 36 ml 
H20 after which the agarose was allowed to cool to 60°C and 9 ml 37% 
formaldehyde (2.2M) was added before pouring the gel). After running 
for 2 hours at lOOV, gels were stained in the dark with 5µg/ml ethidium 
bromide in H20 and destained in the dark for 2 hours. The bands were 
visualized using a short wave U.V. transilluminator. 
I found that formaldehyde gels gave much less background staining with 
ethidium bromide than glyoxal gels and thus selected formaldehyde gels 
for further studies. The need for prolonged staining and destaining 
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was also circumvented by the addition of ethidium bromide directly to 
the sample buffer just before RNA was loaded on to the gel. 
For hybridization of RNA species with beta-2 receptor cDNA or 
riboprobes, RNA was either applied directly onto nitrocellulose paper 
using slot blots (BRL Hybrislot, Gaithersburg) and dried at 80°C in a 
vacuum oven, or Northern blotted (Davis, 1986; Thomas 1980) on to 
Hybond N (Amersham) followed by U.V. irradiation. After 
prehybridization for 1-4 hours in 50% formamide 50 mM NaP0 4 pH 6.5, 
5 x SSC, 0.1% SDS, lmM EDTA, 0.05% Ficoll, 0.05% Polyvinyl pyrrolidone 
(PVP), 200µg/ml salmon sperm DNA and 5 mg/ml Yeast tRNA (Melton et al. 
1984) slot blots or Northern blots were probed with nick translated 
cDNA probe CLFV 108 (bp 170 of the 5' coding region to 30 bp of the 3' 
untranslated region of the human beta-2 receptor gene)(Chung et al. 
1987). Nick translations were performed using the Amersham Nick 
translation kit [ 32P] specific incorporation: - 10-8cpm/µg DNA.) 
Filters were hybridised overnight (16 hours) at 45°C and then washed 
3-5 times (20 minutes each) at 65°C in 0.1 x SSC, 0.1% SDS (pre-heated 
to 65°C. For some blots higher temperatures (up to 80°C) were required 
to remove background binding during the washing stage and with 
riboprobes, blots were hybridised at 65°C. 
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4.2.3 Identification of the human beta-2 adrenergic receptor mRNA 
species. 
When I commenced these studies the size and distribution of the human 
beta-2 receptor mRNA species was unknown. My initial goal was to 
identify the human beta-2 receptor mRNA species in order to extend the 
developmental studies of the guinea pig foetal lung I had commenced in 
Chapter 2 and to investigate whether the level of induction of beta-2 
receptors by steroids previously reported by Fraser et al. (1980) was 
at the level of mRNA transcription. 
Total RNA was prepared (using the guanidinium isothiocyanate/cesium 
chloride method) from frontal lobe of human brain (stored at -70°C) 
(supplied by Dr. C. Venter, N.I.H.), fresh foetal guinea pig lung (54 
day gestation) and adult lung tissues, and mRNA was purified by 
oligo(dT) chromatography. Several agarose gels separating 20µg foetal 
and 20µg adult guinea pig lung total RNA were Northern blotted and 
probed with CLFV-108 nick translated beta-2 receptor gene probe. In 
my initial studies, weakly positive hybridisation signals were seen as 
diffuse bands about 2.0-2.6 kb on autoradiography of blots of crude 
RNA from both adult guinea pig and human brain and no signal was 
obtained with foetal guinea pig lungs (Autoradiography -70°C for 18 
hrs to 30 hrs). This result was promising but difficult to reproduce. 
I then embarked upon a series of experiments of a trouble shooting 
nature, to attempt to obtain good yields of clean RNA. RNA was 
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prepared using alternative protocols described by Morrison (1981) 
using Cesium chloride, Parker, (personal communication 1986, UCT), 
and the rapid methods published in Davis (1986). 
With each method Poly(A)+ RNA was prepared using Amersham MAP paper 
and oligo(dT) chromatography. Each of the above methods yielded 
undegraded RNA as visualised on agarose gels, but autoradiography of 
Northern blots of up to 50µg of crude RNA and lOµg Poly(A)+ RNA from 
adult guinea pig lungs probed with CLFV-108 were negative. I also 
P.robed these Northern blots with a 5' end labelled 51 mer 
oligonucleotide (C-terminal) probe (base pair 1384-1435) derived from 
the hamster lung B-adrenergic cDNA sequence (which was used by Dr. 
Fuzon Chung to isolate the human beta-2 receptor gene), but was 
repeatedly unsuccessful in identifying a clear mRNA species even when 
hybridization times, stringency washes and autoradiographic exposures 
were varied and dextran sulphate was added to the hybridization 
mixture. I also attempted to get rid of any DNA contaminating the RNA 
preparations by treating with RNAse free DNAse and lithium chloride 
(2.5M x 4hr at 4°G) and to improve the Northern blots by omitting 
ethidium bromide staining of the RNA before transfer. 
Failure to identify the mRNA from the human brain or guinea pig beta-2 
receptor gene using the above methods suggested that the beta-2 
receptor mRNA was a rare species, or that more than lOµg Poly(A)+ RNA 
was necessary, or that it was unstable and had a short half life in 
the organs studied. I therefore decided to study the human beta-2 
receptor mRNA in a more controlled in vitro system using Va4 and 
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Wl-38 cells, since beta-2 receptors were previously found to be 
steroid inducible in these cells by Fraser and Venter (1980b), but the 
level of induction was not known. 
As an alternative to Northern blots, I attempted to identify the 
beta-2 receptor mRNA using the BRL Hybrislot apparatus. In these 
experiments, l-16µg of Poly(A)+ RNA (which I had prepared from Wl-38 
cells, Va-4 cells, guinea pig lung, rat heart rat adipose tissue, and 
human cerebellum was applied on to wetted nitrocellulose (Schleicher 
and Schuell), dried in a vacuum oven at 80°G, denatured in 
formaldehyde, prehybridised for 4 hours and then hybridised at 45°G for 
10 hours with nick translated CLFV 108 probe, washed with 1 x 
SSC,0.1% SDS at 60°G for 1 hour and then autoradiographed for 4 hours. 
Good sharp hybridization signals were obtained on the autoradiographs 
of the slot blot with mRNA prepared from Va4 cells (an SV40 
transformed subline of Wl-26 cells) and human cerebellum (Fig. 24) but 
no signals, or very weak signals, were obtained from mRNA prepared 
from adult guinea pig lung, foetal guinea pig lung, rat heart and rat 
adipose tissues. 
These results were encouraging and suggested that, in my hands, beta-2 
adrenergic receptor mRNA studies were more likely to succeed using 
cells grown in tissue culture than with mRNA prepared from organs. 
Furthermore, if the beta-2 receptor mRNA was, in fact, such a rare 
species in organs, it was more likely to be detected using an 
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Figure 24. Autoradiograph of slot blots to which increasing amounts 
(1-16µg) of poly(A)+ RNA from human cerebellum (1-6), Va4 
lung fibroblasts (7-12), adult guinea pig lung (13-18), and 
foetal guinea pig lung (19-24) was applied and probed with 
nick translated CLFV 108 human beta-2 receptor probe. 
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anti-sense riboprobe of the beta-2 receptor gene. I thus proceeded to 
develop and study riboprobes of the beta-2 receptor gene. 
I reasoned that construction of a sense beta-2 receptor RNA strand 
could serve as a quantitative and qualitative control (or reference) 
for the natural beta-2 receptor mRNA in both the slot blots or 
Northern blots. 
Initial studies with riboprobes were conducted with a 2.6kb fragment 
of the beta-2 receptor gene sequence. The 2.6kb riboprobe was derived 
from a Pvu-II fragment of a genomic clone LCV 517 (Chung et al. 1987) 
which had been cloned into pGEM-32 with the assistance of 
Dr. Ulrich Lentes. 
Using a protocol adapted from the Promega Biotec catalogue (1985/1986, 
DB4-5) I synthesised cold sense and anti-sense RNA transcripts of the 
human beta-2 receptor gene, and confirmed on agarose gels that the 
molecular size of the transcripts were 2.6kb (Fig. 25). Limits of 
detection of a single RNA transcript by Northern blots were then 
investigated. Sense and anti-sense RNA transcripts were denatured 
(according to 4.2.2(ii)) run on agarose gels and Northern blotted on 
to Hybond N. Autoradiographs of sense and anti-sense 2.6kb RNA 
transcripts on Northern blots probed with cDNA CLFV-108 probe are 
shown in Fig. 26. The cDNA probe detected as little as 5ng of sense 
RNA and 5 pg of anti-sense RNA on the Northern blots. Reprobing the 
same blots after stripping the CLVF-108 probe, with a shorter 
anti-sense riboprobe (326bp) which I constructed (see section 4.2.6) 
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Figure 25. Agarose gels stained with ethidio.m bromide and photographed 
under U. \7. light showing RNA ladder ( lane 1), calf 
riboso1n'al RNA (lane 2), sense (lane 3) and anti-sense 
(lane 4) 2.6 kb RNA transcripts . 
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after 20 min at room temperature. No hybridization was detected with 
the anti-sense RNA on the same autoradiograph (Fig. 27) confirming the 
specificity of the riboprobe and a 10-fold increased sensitivity in 
detection of the sense RNA strand over the CLVF-108 cDNA probe. 
Longer periods of autoradiography (-70°C x 12 hrs) enabled detection of 
as little as 20 femtograms of sense and anti-sense beta-2 receptor RNA 
transcripts with the cDNA probe. 
A source of cold sense beta-2 receptor RNA proved to be extremely 
useful as a control transcript for the Northern blots, which I also 
used as a reference from which to calculate the size of the human 
beta-2 receptor mRNA species in the Wl-38 cells. Poly(A)+ RNA was 
again prepared from adult guinea pig lung (40µg), foetal guinea pig 
lung 54 days (SOµg), B82 cells (lOOµg), Wl-38 cells (30µg) and run on an 
agarose gel, with calf ribosomal RNA (20µg) as a negative control and, 
Sµg sense and Sµg anti-sense 2.6kb beta receptor RNA as positive control 
transcripts. A Northern blot probed with cDNA probe, CLFV-108, 
overnight, washed down to a stringency of 0.1% SDS, 0.2xSSC at 45°C and 
autoradiographed by exposure to Kodak XAR is shown in Fig. 28. 
Autoradiography for 20 min at room temperature produced sharp signals 
of the 2.6kb sense and anti-sense transcripts. On further 
autoradiography at -70°C for 4 hours a clear mRNA species 2.2-2.4 kb 
was identified in the lane containing 30µg Poly(A)+ RNA from Wl-38 
cells (dexamethazone pulsed x 24 hrs) but no positive signals were 
obtained in any of the other lanes (other than the control sense and 
anti-sense RNA species) on further exposure at -70°C. Reprobing the 
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blots with the 2.6kb anti-sense riboprobe failed to detect any beta-2 
receptor mRNA species in the guinea pig lungs but was associated with 
high non-specific binding of the riboprobe to the Hybond which was 
difficult to remove even at high stringency and at high temperatures 
(80-90°C) for prolonged periods (2-3 hrs). I prepared several further 
Northern blots with guinea pig Poly(A)+ RNA which I probed with the 
2.6kb riboprobe but, disappointingly, high background binding of the 
probe to the Hybond remained a problem. 
These studies demonstrated that the size of the mRNA for the human 
beta-2 receptor gene was 2.2-2.4 kb. This had not been previously 
reported. The difficulties I experienced in detecting the beta-2 
receptor mRNA species were also alluded to by Kobilka et al. (1987a) 
when they mapped the beta-2 adrenergic receptor to q31-q32 on 
Chromosome 5. These workers required as much as 90µg of Poly(A)+ RNA 
from human placental tissue to obtain a signal on a Northern blot and 
commented on the rarity of the beta-2 receptor messenger RNA species. 
The technical difficulties I experienced in attempting to identify and 
study the mRNA of the guinea pig beta-2 receptor gene using Northern 
blotting made the feasibility of pursuing studies of mRNA induction in 
the developing guinea pig lung questionable, since it was clear that 
large amounts of Poly(A)+ RNA would be required from the foetal lungs. 
Since repeated attempts to clearly identify the mRNA of the beta-2 
receptor in adult guinea pig lungs with the riboprobe were also 
negative, further studies of mRNA levels during the foetal lung 
ontogeny were abandoned. Clearly methods such as solution 
175 
Figure 26. Autoradiograph of a Northern blot of sense and anti-sense 
2.6 RNA transcripts probed with cDNA CLFV-108 probe. 
Exposure Kodak XAR film -70°C for 6 hours. 
RNA standards: 
Lane 4 (50ng) 
Lane 10 (lµg) 
Lane 1 (2µg) Lane 2 (lµg) Lane 3 (0.Sµg) 
Lane 6 (500pg) Lane 7 (Spg) Lane 9 (2µg) 
Lane 11 (O.Sµg) Lane 12 (50ng) Lane 13 (Sng) 
Lane 14 (500pg) Lane 15 (Spg). 
5 6 7 9 10 11 12 13 14 15' 
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2.6kb sense 2.6kb anti-sense 
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Figure 27. Autoradiograph of Northern blot (in Fig. 26) after 
stripping of CLFV-108 probe and reprobing with 326bp 
anti - sense riboprobe confirming the specificity of the 












Figure 28. Autoradiograph of Northern blot of 5µg 2.6kb sense RNA 
(lane 1), 5µg 2.6kb anti-sense RNA (lane 2), crude RNA from 
adult guinea pig lung (lane 3), Poly(A)+ RNA from adult 
guinea pig lung (40µg)(lane 4), Poly(A)+ RNA from foetal 
(54 day) guinea pig lung (50µg)(lane 5), Poly(A)+ RNA from 
B82 cells (lOOµg), crude RNA (50µg) from Wl-38 cells (lane 7) 
and Poly(A)+ RNA from Wl-38 cells (30µg) probed with 
CLFV-108 cDNA probe at -70°C for 20 min (A)(lane 8), showing 
recognition of sense and anti-sense transcripts. At 4 
hours (B) in addition, the 2.3 kb human beta-2 receptor 
mRNA transcript is just identifiable and is shown clearly 
by 10 hours (CA in lane 8. RNA markers (kb) using BRL RNA 
ladder are shown on the left. 
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hybridization (RNAse protection assays) would have to be explored, a 
shorter riboprobe (less than SOObp) would have advantages over the 
2.6kb riboprobe, and in situ hybridization should also be considered 
as a technique to investigate induction of the developing guinea pig 
rnRNA of the beta-2 adrenergic receptor. Rarity of the beta-2 receptor 
rnRNA species has been also alluded to by Dixon et al (1986) and 
confirmed by Hadcock and Malbon (1988a). 
Since I was able to detect the human beta-2 receptor mRNA using Wl-38 
cells grown in culture, (in the presence of dexamethazone), I embarked 
on a series of experiments to study the timing and intensity of the 
induction of human beta-2 receptor rnRNA following pulsing with 
dexamethazone. 
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4.2.4 Induction of beta-2 receptor mRNA by dexamethazone 
The ability of dexamethazone to induce beta-2 receptor mRNA in 
cultured cells was studied using 2 cell lines: the Wl-26 Va4 human 
lung SV40 transformed line (ATCC CCL 95.1) and the Wl-38 cell line 
(ATCC CCL 75). 
The Va4 cells are an SV40 virus transformed derivative of Wl-26 cells, 
a human diploid cell line established from the embryonic lung tissue 
of a male Caucasian. 
The Wl-38 cells are a human diploid cell line derived from normal 
embryonic (3 month gestation) lung tissue of a Caucasian female. 
Wl-38 cells have a doubling time of 24 hours (Exp. Cell. Res. 37:614, 
1965). 
Cells were grown in Ham's Fl2 media (Gibco) supplemented with 10% 
fetal calf serum in an atmosphere of 95% air, 5% carbon dioxide and 
studies were conducted with Wl-38 cells which had less than 40 
population doublings. It has been previously shown that incubation of 
Va4 or Wl-38 cells with hydrocortisone results in a 100% increase in 
[ 125I]-HYP specific binding (Fraser 1980) and that this increase is 
dependent upon new protein synthesis. In those studies Wl-38 cells 
showed an approximate doubling time of [ 125 I]-HYP specific binding 
within 48 hours with an ED50 for hydrocortizone of 3 x 10-7M and a 
maximum response evident within 24 hours. 
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For the RNA studies, cells were grown to semi-confluence, fresh medium 
was added and cells stimulated with 10-6M dexamethazone were compared 
with control cells. [ 1251)-CYP ligand binding assays conducted on the 
cells at time intervals between O and 48 hrs confirmed the induction 
of beta adrenergic receptors by steroids previously published by 
Fraser (1980). 
Cell membranes were prepared by homogenization of hypotonically lysed 
cells, using a dounce glass homogeniser (Wheaton) (20 strokes) in SmM 
NaP04 pH 7.4 1 mM MgS04 (at 4°C) followed by centrifugation at 
1000g x lOmin to remove intact cells and nuclear debris. The 
supernatant was centrifuged at 40 OOOg x 30min (using a Beckman 70 Ti 
rotor) and the membrane fraction in the pellet resuspended in 20mM 
NaP0 4 2mM MgS0 4 pH 7.4 buffer at a protein concentration of 3-4mg/ml 
and stored at -70°C. 
RNA was prepared by the guanidinium isothiocyanate method (section 
4.2.1). At each time point cells were scraped off the dish using a 
'rubber policeman', into guanidinium isothiocyanate and RNA isolated 
using the cesium chloride gradient method of Chirgwin et al. (1979). 
Poly(A)+ RNA was prepared by oligo(dT) chromatography of the crude RNA 
and RNA concentrations calculated by measuring the optical density by 
U.V. absorption spectrophotometry at 260nm. Purity of the RNA was 
assessed by determining the ratio of 0.D. at 260nm to O.D. at 280nm. 
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To investigate optimal concentrations of RNA for slot blotting, crude 
RNA (0.06µg to 2µg) was blotted in 50µ1 on to Hybrislot apparatus (BRL, 
Gaithersberg) and probed with nick translated cDNA probe CLFV 108. 
Good positive hybridization signals were obtained with lµg mRNA from 
Wl-38 cells and the dose responsive effect of dexamethazone 10-9M, 
10-8M and 10-6M on the intensity of the hybridization signal was 
measured using densitometry. (Fig 29). 
In the definitive experiments both Va4 and Wl-38 cells were studied 
and steroid induction of mRNA was studied at a concentration of 10-6M 
dexamethazone. 
Va4 cells were pulsed with 10-6M dexamethazone at O hours and mRNA 
prepared from pulsed and control cells at 2.5 hrs, 4 hrs, 6 hrs, 8 
hrs, 12 hrs and 24 hrs. lµg mRNA (denatured in formaldehyde) was slot 
blotted onto nitrocellulose, vacuum dried (80°C) for 2 hours and probed 
with nick translated (a- 32P]dCTP labelled cDNA probe CLFV 108 (specific 
activity 10-8cpm/µg) for 8 hrs, successively washed with 2 x SSC, 0.1% 
SOS at room temperature and 0.2 x SSC 0.1% SDS at 45°C for 2 hours and 
exposed to Kodak XAR film for 16 hours at -70°C. 
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Autoradiographs (Fig. 30) of the Va4 cells showed an increase in mRNA 
signal at 4 hrs which was sustained through 24 hrs in the 
dexamethazone stimulated cells but not in the control cells. 
Similarly, autoradiography of the Wl-38 cell RNA slot blots studied at 
4 hrs, 8 hrs and 24 hrs showed a slight increase of mRNA at 4 hrs, but 
a marked increase was noted at 8 hrs which was sustained at 24 hrs in 
the dexamethazone pulsed cells but was not seen in control cells (Fig. 
31). No positive signals were obtained with Poly(A)+ RNA from guinea 
pig lungs on the slot blots. 
Several experiments were conducted to demonstrate a dexamethazone 
induced increase in the 2.2-2.4 kb mRNA species on Northern blots. 
Although both the 2.6kb riboprobes and cDNA probes of the beta-2 
receptor gene were employed and as much as SOµg Poly(A)+ RNA 
transferred on to the Northern blots, at the time points studied, an 
increase in mRNA was not demonstrated on the Northern blots (4 hrs, 6 
hrs, 18 hrs, 24 hrs). High background binding occurred with the 2.6kb 
riboprobe. I decided to construct a shorter riboprobe to reduce 
background. It also seemed that solution hybridization with RNAse 
protection may be a better alternative approach to measuring the 
dexamethazone induced RNA of the beta-2 receptor gene. This has 
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Figure 29. Intensity of hybridization of CLFV Nick translated probe 
to lµg poly(A+)RNA from Wl-38 cells pulsed overnight with 
10-9M, 10-8M and 10-6M dexamethazone. Autoradiographic 
signals were measured by densitometry and are expressed in 
densitometric units. Bar values represent the mean of 
duplicate assays (.). 
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The slot blots suggested, for the first time, that the beta-2 receptor 
expression could be transcriptionally regulated by steroids and I 
reported this at the 1987 FASEB congress (Federation Proceedings Vol. 
46:4, 1463 April 1987, Washington). However, subsequent attempts to 
demonstrate an increase in mRNA transcription on the Northern blots 
were unsatisfactory and clearly further studies which included 
negative internal RNA reference/standards (e.g. ~ actin) were 
indicated. I was unable to explain the relative ease with which 
increases in binding of the probe to mRNA from dexamethazone pulsed 
cells on slot blots was demonstrated at high stringency using small 
amounts of poly(A)+ RNA, (lµg), but not readily demonstrated on 
Northern blots. It is possible that these hybridization signals could 
have been non-specific although they were highly reproducible and dose 
responsive. 
A year later, Collins et al. (1988) successfully demonstrated steroid 
inducible ~-2 adrenergic receptor mRNA by Northern blot hybridization 
using Hamster vas deferens cells (DDT1 MF-2) and reported that a peak 
of ~-2 adrenergic receptor mRNA was reached within 1-2 hours. These 
cells demonstrated a peak of beta-2 adrenergic receptor induction 
between 6 and 12 hours, which is more rapid than the rate of increased 




2.5 4 6 8 12 24 Hours 
Figure 30. Time study of the induction of human beta-2 receptor mRNA 
in Va4 cells. lµg poly(A)+ RNA prepared from Va4 cells (in 
duplicate)(harvested at 2.5, 4, 6, 8, 12 and 24 hours after 
pulsing with 10-6M dexamethazone)(A) or control cells (not 
pulsed with dexamethazone)(B), slot blotted on ro 
nitrocellulose paper and probed with [o32P]dCTP nick 
translated CLFV-108 probe. Stringency 0.2xSSC and 0 . 1%SDS 
at 45°C for 2 hours. Exposure Kodak XAR, -70°C for 16 hours. 
A sustained increase in uptake of the probe is seen in the 
dexamethazone pulsed cells. A transient increase in uptake 
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Figure 31. Time study of the induction of human beta-2 receptor mRNA 
in Wl-38 cells. lµg poly(A)+ RNA (in triplicate) prepared 
from Wl-38 cells harvested at 4, 8 and 24 hours after 
pulsing with 10-6M dexamethazone (A) or controls without 
dexamethazone (B). Stringency 0.2xSSC and 0.1% SOS at 45°C 
for 2 hours. Exposure Kodak XAR -70°C for 16 hours. 
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Using solution hybridization Hadcock and Malbon (1988), studying the 
DDT1 MF-2 hamster vas deferens cells have shown an increase of steady 
state beta adrenergic receptor mRNA from 0.37 pg mRNA per µg total 
cellular RNA in untreated cells to 1.05 pg of mRNA per µg of RNA in 
cells treated with dexamethazone for 2-4 hrs, followed by a sharp 
decline by 6 hours to a level approximately twice that of untreated 
cells. The half life of the receptor mRNA in the presence of 
actinomycin D was found to be 12 hrs in both untreated and 
dexamethazone-treated cells. Even at low concentrations of 
dexamethazone (1 nM), significant increases in mRNA were observed. 
In studies of beta receptor rnRNA in S49 mouse lymphoma mutants, 
Hadcock et al. (1989) showed that cAMP dependent protein kinase 
activity, and functional receptor coupling to GS was required for 
agonist induced down regulation of beta-2 receptor mRNA. In these 
studies the steady state of levels of mRNA were 1.72 ± 0.08 attomoles/µg 
total cellular RNA. Hadcock and Malbon (1988b) have also demonstrated 
that cholera toxin and forskolin treatment of DDT 1 MF-2 cells also 
down regulated beta receptor mRNA. More recently Bouvier et al. 
(1989) have demonstrated that cyclic AMP exerts a feedback control of 
beta-2 receptor number associated with a reduction in steady state 
mRNA levels. 
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Transient mRNA accumulation and transcriptional enhancement has been 
reported for other steroid regulated genes e.g. rat 
phosphoenolpyruvate carboxykinase, and rat tyrosine hydroxylase (Tank 
1986). 
The ability of the beta receptor gene to respond to glucocorticoids 
also has a sound structural basis. Four consensus sequences for 
glucocorticoid responsive elements have been identified in the cloned 
beta-2 adrenergic receptor gene sequence by Chung et al. (1987), 
Kobilka et al. (1987) and Emorine et al. (1987): two in the coding 
region, one in the 3' non-coding region and one in the 5' upstream 
region. The functional significance of each of these glucocorticoid 
responsive elements has not yet been elucidated. Studies by Samuelson 
and Davies (1984) showed that hydrocortizone could reverse prior 
agonist induced uncoupling of beta-adrenergic receptors in 
neutrophils, without an observable effect on down regulation. It is 
apparent that the effects of steroids on beta-2 receptor number and 
function may be dependent on cell type, prior agonist treatment, or 
the state of down regulation, and it is likely that the beneficial 
effects of steroids in the airways of asthmatic subjects may also be 
due to effects at levels other than that of gene transcription of the 
beta-2 receptor. 
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4.2.5 Construction of a short 326bp riboprobe of the human beta-2 
adrenergic receptor. 
A shorter riboprobe would have several potential advantages over the 
2.6kb riboprobe. It would be useful in the future for in situ 
hybridization and should also give less background on the Northern 
blots than the 2.6kb probe. I selected a 326bp segment derived from a 
Kpn-1- Pst-1 digest of the coding region of the beta-2 receptor gene. 
A cDNA probe derived from this 326bp piece was also found to be most 
useful for studies I conducted to identify a probable site of the 
reported polymorphism of the human beta-2 receptor gene. (see Chapter 
7). I also used a riboprobe of this 326bp segment to check the 
authenticity of the sense and anti-sense 2.6kb RNA transcripts which I 
constructed in 4.2.4. 
I obtained the 326bp piece by digesting a PVU 11 fragment of the 
genomic DNA LCV 517 which had been cloned into PSMG, with Pst-1 and 
Kpn-1 (373 bp-699 bp). The predicted 326bp piece was identified on an 
agarose gel (Fig. 32), purified by electroelution from the gel and 
ligated into the multiple cloning site of pGEM-3Z which had been 
previously digested with Kpn I and Pst 1. Electroelution was 
performed by cutting out the 326bp band in the agarose placing it in 
lxTBE in Spectropor membrane tubing and applying a voltage of 150V for 
30 min. DNA moved to the positive electrode; the polarity was then 
reversed for 30 seconds and the DNA transferred to a fresh tube. lOµg 
of tRNA and an equal volume of n-butanol was added. After 
centrifugation for 10 min the infranatant was collected and extracted 
with phenol/chloroform, before precipitation in ethanol:sodium 
acetate. After air drying the precipitate was suspended in dd H20. 
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For the ligation reaction, 4µg of Kpn-1-Pst-l digested DNA 
(concentration 1.7 µg/µl) was incubated with Sµg pGEM-3Z, 4µ1 (Sx ligation 
buffer), 2µ1 T4 ligase and Sµl dd H20. 
To transform the competent cells, 3µ1 of the ligation mix was added to 
300µ1 of competent TG-1 E. coli cells made competent according to the 
method published in Davis et al. (1986) in SOmM calcium chloride after 
glycerol had been removed, incubated at 4°C for 30 min and then heat 
shocked at 42°C for 2-3 min. 0.7 ml of warm 2X TY medium was added and 
after 30 min incubation at 37°C plated on to L Ampicillin plates (50, 
100 or 300µ1 in 2.5 ml soft agar (spiked with 40µ1 Xgal, 40µ1 ITPG and 
25µ1 (25mg/ml) Ampicillin) and cultured at 37°C overnight. Numerous 
(white) recombinants were obtained and colonies were amplified by 
adding four colonies to 5ml TX medium with 50µ1 Ampicillin (25mg/ml) 
and shaking overnight at 37°C in a waterbath. A plasmid preparation of 
the pGEM blue was performed according to the method of Davis et al. 
(1986). 
Orientation of the insert was such that in the PGEM-3Z vector the 
Kpn-1 end of the insert orientates 3' to the Pst-1 site. To obtain an 
anti-sense RNA transcript the PGEM-3Z is cut with Hind III and the T7 
promoter is used for the transcription reaction. 
Dot blots of the plasmid preparation (lµl) probed with nick translated 
CFLV-108 probe, confirmed that the PGEM plasmid preparation contained 






Figure 32. Agarose gel of 326bp Kpnl-Pst-1 human beta-2 receptor probe 
(lane 2) purified by electroelution. 1 kb ladder (lane 1) . 
1.9 l 
Cold 326 bp RNA transcripts were generated using the Promega Gemini Tm 
system in a 100µ1 reaction volume with reagents added in the following 
order: 39µ1 DEPC treated H20, 20µ1 5x transcription buffer, 10µ1 lOmM 
DTT, 4µ1 RNasin (25 units/µl), 20µ1 (2.5mM each of ATP, CTP, DTP and GTP 
made by mixing 5µ1 of lOmM stock ATP, CTP, DTP and GTP together), 5µ1 of 
DNA (-2µg in T.E. buffer, linearised with Hind III) and 2µ1 T7 RNA 
polymerase. After a 2 hour incubation at 37°C, 2µ1 of RNase free 
DNase-1 was added, incubated for a further 20 min at 37°C, after which 
the RNA was extracted with an equal volume of phenol and chloroform, 
the riboprobe was precipitated with a 1:10 volume of 3M sodium acetate 
pH 6 and 2.5 volumes of ice cold 95% ethanol. The RNA transcript was 
visualised directly on agarose gels and confirmed to be 326bp. 
A RNA probe of high specific activity was synthesized in a reaction 
volume of only 20µ1, containing 5µ1 (lOmCi/ml) of [o- 32P] CTP (according 
to the Promega manufacturer's instructions). Transcription reactions 
resulted in specific activity of the riboprobe of 0.9 x 108 - 5 x 109 
cpm/µg template. 
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Specificity of the anti-sense 326bp beta-2 receptor riboprobe for the 
2.6kb sense transcript of the beta-2 receptor RNA was confirmed (Fig. 
27). While I was still at the NIH, this probe was given to Dr. Jean 
Paul Giaciobino of the University of Geneva, Department of Physiology, 
for studies on adipocyte RNA induction (4.2.6) and was subsequently 
also sent to the Brampton Chest Hospital (London), personal 
communication (Dr. P. Barnes) for in situ hybridization studies of the 
human lung beta-2 receptor (which were presented at the 8th Congress 
of SEP European Society of Pneumology and European Paediatric Society, 
September 1989 at the University of Freiburg (FRG)). 
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4.2.6 Identification of the beta 1 receptor mRNA using the 326bp 
probe. 
The 326bp fragment which I cloned into pGEM-3 is derived from a highly 
conserved second transmembrane region of the beta-2 adrenergic 
receptor gene. Comparison of this gene sequence of the human beta-2 
adrenergic receptor with the published gene sequence (Yarden et al. 
1986) of the turkey erythrocyte beta adrenergic receptor, (beta-1 
receptor) using Gen Data base, revealed a 69.6% homology, suggesting 
that this 326bp probe could be used to identify the beta-1 receptor 
gene. This possibility was particularly interesting, since previous 
attempts to identify the human beta-1 receptor gene with human beta-2 
adrenergic receptor probes had not been successful (Frielle et al. 
1987). I reasoned that if an RNA species could be identified which 
differed in size from the human beta-2 receptor mRNA which I 
identified in 4.2.3, using this probe, the 326bp probe could be 
successful in screening an adipocyte cDNA library to isolate the 
human beta-1 gene, since adipose cells were believed to express the 
beta-1 receptor exclusively. 
Briefly, 50µg Poly(A)+ RNA was prepared from rat fat epididymal fat pad 
(beta-1 receptor subtype specific), rat heart (beta-1 receptor subtype 
predominant) from normal and from hypothyroid rats (a gift from Dr. 
J.P. Giaccobino, University of Geneva), northern blotted on to 
nitrocellulose, and probed with a random primer labelled 326bp probe. 
A mRNA species of 2.5kb (Fig. 33) was detected in the rat heart and 
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Figure 33 . Autoradiograph of Northern blots of poly(A)+ RNA from 
normothyroid rat heart, (SOµg)(lane 2), hypothyroid rat 
heart (SOµg)(lane 3), brown fat (39µg)(lane 4) probed with 
326bp random primer labelled probe identifying a 2.5kb RNA 
species in each . BRL RNA ladder (lane 1) demonstrated non-
specific labelling to 2 . 4kb and 4.8kb markers. 
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than the 2.2kb beta-2 receptor mRNA species which I had detected using 
the CLFV-108 (beta-2 receptor) probe in the Wl-38 cells. A 2.5kb mRNA 
species was confirmed in rat heart (SOµg Poly A) when a riboprobe of 
the 326bp construct was used (Fig. 34). At about the same time that 
these experiments were performed, the human beta-1 receptor gene was 
cloned and sequenced by Frielle et al. (1987) using the human genomic 
clone G21. These workers also found a mRNA of 2.5kb for the B-1 
receptor in Northern blot hybridization studies of rat mRNA. 
4.2.7 Summary of the beta-2 receptor RNA studies 
At the time when these studies were commenced nothing was known about 
the human rnRNA species for the beta-2 receptor gene. I assumed that 
the mRNA species would be reasonably abundant in organs expressing 
beta-2 receptors and thus guinea pig lung tissues were selected for 
the initial studies. Once the preliminary experiments were conducted 
to optimise the yield and quality of RNA isolation, I attempted to 
identify the mRNA species in the guinea pig lung using Northern 
blotting. Repeated failure to identify beta-2 receptor mRNA in 
Northern blots of as much as SOµg Poly(A)+ RNA suggested that the RNA 
species was rare, readily degradable, or had a short half life, 
possibly related to the fact that the beta-2 receptor gene has no 
introns. These results also indicated that further studies on 
induction of beta-2 receptors in the developing guinea pig lung at the 
level of gene transcription were unlikely to succeed using the 











Figure 34. Autoradiograph of a Northern blot of poly(A)+ RNA from rat 
heart (SOµg)(lane 1) probed with the 326bp riboprobe 
identifying the 2 . 5kb RNA species. Non-specific labelling 
of 2.4kb marker on BRL RNA ladder shown in lane 2. 
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species in placental tissue was alluded to by Dixon (1986) and Kobilka 
(1987). 
In spite of the initial difficulties with the guinea pig lungs, I did 
attempt a second gestational study while I was at the NIH. I prepared 
foetal lungs from pregnant guinea pigs at 16 gestational time points 
from 48 days to 66 days gestation. (Timed matings were performed by 
Hazelton Research Laboratories, Denver). Animals were killed by 
intraperitoneal injection of pentobarbitone (Somnifer, Richmond 
Veterinary Supply Company, Virginia) and foetal lungs (total 73 
foetuses) were snap frozen and stored at -70°C before RNA (total and 
Poly(A)+ RNA was isolated using the method of Chirgwin et al. (1979). 
Northern blots of up to SOµg of Poly(A)+ RNA from the term foetuses did 
not identify a positive rnRNA species when probed with either the cDNA 
probes or with the beta-2 receptor riboprobes I had constructed, 
confirming the difficulties I had encountered previously with the 
guinea pig lung tissues and thus further studies on the more immature 
lungs were abandoned (for both technical and economic reasons). 
In view of the apparent rarity of the rnRNA species, a 2.6kb riboprobe 
for the beta-2 receptor gene was then constructed and sense and 
anti-sense transcripts were used as positive controls in the 
subsequent Northern blots. The riboprobe was no more successful in 
identifying the rnRNA species in guinea pig lung tissues than the cDNA 
probes on the Northern blots. 
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Positive identification of a 2.3 kb beta-2 adrenergic rnRNA species in 
Wl-38 cells (using Northern blots) with the CLFU 108 cDNA probe, was 
followed by studies of the induction of beta-2 receptor rnRNA by 
steroids in Wl-38 and Va4 cells at the level of gene transcription. 
Preliminary studies using slot blots showed a clear increase in 
hybridization signals in the RNA from dexamethazone probed cells which 
were not seen in controls. However, these increases were difficult to 
demonstrate convincingly on Northern blots. Use of the 326bp probe 
(cDNA or riboprobe) did not improve the detection of the rnRNA species 
on Northern blots, but it did identify a different, 2.5kb rnRNA species 
in tissues selectively expressing beta-1 receptors which was 
compatible with the beta-1 receptor RNA species. Durnan et al. (1989) 
were more successful in detecting changes in beta receptor RNA with 
development and has shown, using Northern blots, that in the post-
natal rat brain, the level of beta-1 and beta-2 adrenergic receptor 
rnRNA followed a pattern which parallelled that of receptor binding 
sites. 
The studies on Wl-38 cells and the studies of Collins et al. (1988) 
demonstrate that beta-2 receptors can be transcriptionally regulated 
by glucocorticoids leading to a rapid rise in the steady state of 
beta-2 adrenergic receptor rnRNA. These findings have implications for 
a possible mechanism of the beneficial effect observed when patients 
with asthma are treated with steroids, implying that one of the 
effects of steroid therapy is to induce beta-2 receptor expression at 
the level of gene transcription. 
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The possibility that disturbances in transcriptional regulation of 
beta-2 receptors may occur in the airways of allergic asthmatic 
subjects has not previously been investigated, but may be an 
interesting area for future studies. 
4.3 In vitro models of dysfunctional beta-2 receptors: Studies of 
the beta-2 adrenergic receptor ligand binding domain using 
mutant beta-2 adrenergic receptors. 
Cloning and sequence analysis of the beta-2 adrenergic receptor has 
shown that this receptor belongs to a family of transmembrane proteins 
which are coupled to guanine regulatory proteins (G proteins). This 
family includes rhodopsin, the visual colour opsins, the muscarinic 
receptors, the alpha2 adrenergic receptor and the serotonin le 
receptor, all of which have seven hydrophobic transmembrane regions. 
Comparison of the gene sequences and deduced protein sequences of 
several receptors which utilise similar transduction mechanisms, 
facilitates the identification of common residues which participate 
in, and are necessary for, coupling to the G proteins and, 
furthermore, facilitate the identification of the residues which 
confer the selective structural or conformational specificities to the 
molecule which are complimentary to their different respective ligands. 
The theoretical possibility that the beta-2 receptor gene sequence may 
be subject to spontaneous point mutations in vivo, leading to varying 
degrees of receptor dysfunction which may result in, or aggravate 
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clinical disease processes is worth investigating, since point 
mutations of other human proteins leading to clinical disease are well 
described (eg. in cystic fibrosis). Genetic differences, however, 
rarely occur within the coding region of the gene, and are more 
commonly attributed to mutations in regulatory sequences of the gene. 
Polymorphic differences in the DNA sequences of the beta-2 receptor 
were first reported by Lentes et al. (1988) who described a 
restriction fragment length polymorphism of the human beta-2 receptor 
(using the enzyme Ban 1) in normal North American subjects. 
These studies were remarkable in that no polymorphism was found when 
47 other restriction enzymes were used, suggesting that variations in 
the beta-2 adrenergic receptor gene sequence are uncommon. This is 
not surprising if one notes that the beta-2 receptor gene structure is 
highly conserved in nature (Venter et al. 1988) and it is likely that 
mutations in critical ligand binding domains of the receptor may be 
lethal. 
Once the beta-2 receptor gene was cloned and sequenced, an expression 
vector was constructed by Chung et al. (1987, 1988) and stable 
transfection of the wild type receptor in B82 cells was achieved. 
The mutant beta-2 receptors which I studied and describe in this 
section were constructed by Dr. Fuzon Chung at the N.I.H., Bethesda. 
and I assisted him with and performed several of the mutant gene 
transfections of the B82 cells. My own specific project, however, was 
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to perform the initial biochemical characterization (binding assays) 
on the first nine (of a total of 20) mutants in order to identify 
mutants which would be worth studying in more detail by other members 
of the group and myself after the initial characterization. Data I 
obtained for each of these mutants is presented in 4.3.2. I then 
proceeded to study in more detail two of the mutants, (Asp 79 as part 
of a team and the glycosylation mutant Asn 6 on my own) while the 
other six mutants were allocated to other members of Dr. Craig 
Venter's group for further characterization. 
While these mutants were constructed primarily to identify the 
critical ligand binding and coupling residues, they provide, at the 
same time genetically engineered models of mutations which if 
occurring spontaneously could theoretically result in dysfunctional 
beta-2 receptors in human disease. 
4.4.1 Mutant construction and transfection 
A total of nine point mutations of the human beta-2 receptor amino 
acid sequence were constructed after studying the model proposed by 
Kobilka et al. (1987) which proposed an N-terminal extracellular tail 
of 34 amino acids, seven transmembrane hydrophobic domains and an 
extended C-terminal intracytoplasmic domain of 85 amino acids. The 
sites of the mutant beta-2 receptors which I studied are shown in Fig. 
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Figure 35. Sites of point mutations performed on 9 mutant human beta-2 
adrenergic receptors studied (4.4.1) Sequence model 
adapted from O'Dowd et al (1989). 
Point mutations were constructed by oligonucleotide directed 
mutagenesis, according to the method of Kunkel et al. (1987), using 
the Biorad Muta-geneTm in vitro mutagenesis kit (Cat. 170-3571). 
Authenticity of the mutations was checked and confirmed by dideoxy 
sequencing of the mutated genes, with the assistance of Dr. Dianne 
Wang. 
For receptor expression, the mutated coding region of the human beta-2 
receptor gene originally derived from the wild type genomic clone 
LCV-517 (base pairs - 6 to+ 1267) was cloned into the Mlu and Eco RV 
sites in the polylinker region of pMSV neo vector (Chung et al. 1988) 
and we then transfected the genes into B82 cells and selected clones 
with successful transfections using Geneticin (G418-Sulphate Gibco Cat 
860-1811) in the same way as I transfected the wild type beta-2 
receptor gene into B82 cells when I returned to Cape Town (described 
in detail in Chapter 6.2.1). 
The amino acid substitutions and gene sequence changes in the nine 
mutant receptors studied are listed in Table 12. 
Prior to commencing the studies with the mutants I performed saturation 
binding curves and Scatchard plots on three other clones (Clone NE, 
82A, 82C) of wild type receptors which we had transfected into B82 
cells (Fig. 36), (these were different clones to those reported by 
Fraser et al. (1987)) to obtain reference binding data with which to 
compare the nine mutants. Binding data for the three wild type 
receptors and the mutants have been analysed using the non linear 
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Figure 36. Saturation curves and Scatchard plots of [ 1251)-CYP binding 
to 3 clones of B82 fibroblasts transfected with the wild 
type human beta-2 adrenergic receptor gene. 
Clone NE Bmax 626 fmol/mg kD 26.9 
Clone 82c Bmax 490 fmol/rng kD 25.8 
Clone 82A Brnax 135 frnol/mg kD 34.8 
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iterative regression data analysis programme ENZFITTER (IBM, PC) by 
Leatherbarrow, Department of Chemistry, Imperial College of Science, 
London. 
While the level of expression in the three wild type human beta-2 
receptor clones was fairly variable, the affinity of the wild type 
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4.3.2 Partial characterization of 9 beta-2 adrener~ic receptor 
mutants 
B82 cells, transfected with 9 mutant and 3 wild type beta receptors 
were cultured to semi-confluency in 25 cm culture dishes (in 40% 
Dulbecco's medium, 40% F-12 medium and 10% fetal calf serum, 
supplemented with glucose, glutamine, non essential amino acids, 
Penicillin and Streptomycin)(see appendix E) in the presence of 
Geneticin (G418 sulphate, final concentration 500µg/ml) and then pulsed 
overnight with 10-6M dexamethazone (Sigma) to induce beta adrenergic 
receptor expression. 
Cells were lysed at 4°C using hypotonic 5mM sodium phosphate 2mM MgS0 4 
pH 7.4 for 30 min, scraped off the dishes and homogenised with a glass 
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homogeniser and then centrifuged at 1000g at 4°C for 10 mins to remove 
cell nuclei and other cell debris. The supernatant was then 
centrifuged at 40 OOOg for 40 mins at 4°C to pellet the cell membrane 
fraction. Membranes were resuspended in 100µ1 aliquots in 20mM sodium 
phosphate 2mM MgS0 4 at an approximate concentration of 4mg/ml and 
stored at -70°C or in liquid nitrogen. For these studies membrane 
protein was assayed using the fluorescamine assay with bovine serum 
albumin as a standard (Bohler, 1973). 
Saturation of [ 125I]-CYP binding to membrane preparations of the 
mutant beta-2 receptors and Scatchard plots of the binding data are 
shown in Figs. 37-39. Binding data was obtained using ENZFITTER. 
The binding studies of the nine mutants were most informative. 
Certain mutants appeared to have normal antagonist binding (Asn 6, Asp 
79, Asp 130, Ser 262, Ser 346) while a significant reduction of 
[ 125I]-CYP binding affinity data was observed with the mutant Cys 191. 
No specific binding was obtained with Asn 15 and only non-specific low 
affinity binding was observed with mutant His 172 and Cys 190-191. 
Maximal binding (Bmax) and [125I]-CYP dissociation constants obtained 
from the saturation curves and Scatchard plots of these nine mutants 
are summarised in the following table: 
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Table 14 
Mutant Studied Amino Acid 
change 
Asn 6 Asn-Gln 
Asn 15 Asn-Gln 
Asp 79 Asp-Asn 
Asp 130 Asp-Asn 
His 172 His-Asp 
Cys 191 Cys-Ser 
Cys 190-191 Cys-Ser 
Ser 262 Ser-Ala 
Ser 346 Ser-Ala 












(Cys 190-191 was a double mutant) 
[ 1251]-CYP binding 










Expressed mutants which displayed [125!]-CYP binding were chosen for 
detailed functional characterisation and it was decided that we would 
characterise Asp 79 mutant as a group, Dr. Claire Fraser the Asp 130 
and the two cysteine mutants, Dr. Chung was assigned the mutant for 
Ser 262, and I would study the Asn 6 mutant. (The serine mutant 346 
was not part of the initial characterization performed at the NIH but 
I transfected the mutant gene into L cells for the first time on my 
return to Cape Town, using the protocol I have discussed in Chapter 6, 
after receiving the plasmid containing the mutant from Dr. Chung.) 
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Unfortunately, Dr. Chung could not proceed with further 
characterization of the 262 serine mutant since he left the NIH to 
take up a commercial appointment. 
4.3.3 Mutants displaying absent or altered [125I]-CYP binding: 
The mutants which displayed no apparent [ 125I]-CYP specific binding, 
i.e. His 172, and Asn 15, or very low affinity binding (e.g. Cys 
190-191) presented the possibilities that either the mutant protein 
was not expressed at all and the cells retained the geneticin 
resistant gene, or that the mutation in fact conferred important 
effects on the conformation of the expressed receptor, which impaired 
antagonist ligand binding. The laboratory in which I was working at 
the N.I.H. did not, at that time, have available good polyclonal or 
monoclonal antibodies to the beta-2 adrenergic receptor (Venter and 
Fraser had lost their anti-beta receptor antibody secreting clones 
during a move), thus it was not possible, at that time, to be sure 
that immunoreactive receptor was indeed expressed in the mutants in 
which no specific [125I]-CYP binding was detected. I did attempt to 
obtain anti-beta-2 receptor antibodies from two other laboratories but 
was unsuccessful. Mutant sequences were checked by Dr. Diane Wang by 
dideoxynucleotide sequencing. 
The Cys 191 mutant (Fig. 37) was of great interest because although 
L(-) propranalol displacable [125I]-CYP binding was present, the 
binding was of low affinity (Kd 258.52pM) suggesting that the 
cysteine residues in the extracellular domain of the beta-2 receptor 
211 
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Figure 37. Saturation curve and Scatchard plot of [125IJ-CYP binding 
to Cys 191 (Cys-Ser) mutant of the human beta-2 adrenergic 
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Figure 38. Saturation curve and Scatchard plot of [125I]-CYP binding 
to Asp 79 (Asp-Asn) mutant of the human beta-2 adrenergic 
receptor. Bmax 227fmol/mg Kd 19.l pM. 
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may either be involved directly in ligand binding, or may confer 
important conformational specificities necessary for normal ligand 
binding. 
Subsequent studies (by Fraser 1989) involving re-transfections with 
the Cys 190-191 and Cys 191 mutants on which I had conducted the 
initial studies, and the construction of three more cysteine mutants, 
showed that replacement of cysteine residues with serine at sites 77 
and 327 (in the second and seventh transmembrane-spanning domains) had 
no effect on ligand binding or the ability of the receptor to mediate 
isoproterenol stimulation of adenylate cyclase. Substitution of 
cysteine 285 resulted in attenuated adenylate cyclase activation but 
mutation of residues 190 and 191 in the third extracellular loop had 
qualitatively similar effects, with a loss of affinity for ligand 
binding and a reduction of isoproterenol stimulation of adenylate 
cyclase. The replacement of both cysteine 190 and 191 with serine had 
a marked reduction in ligand affinity and functional activity of the 
receptor. 
The His 172 mutant displayed a somewhat bizarre [ 125I]-CYP saturation 
curves with no specific binding and has not been studied further. 
4.3.4 Aspartate mutants 
A saturation curve and Scatchard plot of [ 125!]-CYP binding to 
Aspartate 79 mutant is shown in Fig. 38. Binding studies showed that 
replacement of the Aspartate 130 and Aspartate 79 with Asparagine 
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residues had no appreciable effect on antagonist [ 1251]-CYP binding to 
the receptor. The Asp 130 mutant displayed normal binding affinity 
(Kd 17.5 pM) but there was a low level of expression (Bmax 20fmol/mg), 
and has not yet, to my knowledge, been characterised further. The 
aspartate residue at position 79 is highly conserved in all beta 
adrenergic, a-adrenergic muscarinic receptors and opsin proteins. (See 
Appendix G). 
The aspartate residue at position 79 in highly conserved in all beta 
adrenergic, 
Published results of our further characterization of the Asp 79 mutant 
are discussed in detail in the Journal of Biochemistry Vol 263, March 
1988. A reprint of this publication is included in Appendix G. 
Briefly, we found that substitution of aspartate 79 with asparagine 
produced a mutant receptor that displayed expected affinity and 
stereoselectivity for antagonists, but a 40-, 140- and 240-fold 
reduction in its affinity for isoproterenol, epinephrine and 
norepinephrine, respectively. This mutant also showed a marked 
impairment in cyclic AMP production when compared with wild type 
cells. These studies confirmed and extended the studies of Strader et 
al. (1987) who substituted Asp 79 with an alanine in the hamster lung 
~-2 adrenergic receptor and found a 10-fold loss in receptor affinity 
for agonists. Studies with these mutants demonstrated that a 
negatively charged aspartate was essential for normal agonist binding 
to the receptor, and also suggested that an aspartate residue at amino 
acid 79 may be necessary to facilitate coupling of the receptor to the 
G proteins. 
Studies by Dixon et al. (1987), in which the importance of sequential 
deletions in the gene for the hamster beta adrenergic receptor 
encompassing the protein coding region was studied using transient 
expression in COS-7 cells, suggested that most of the hydrophilic 
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regions appear to be dispensable for ligand binding. Deletion mutants 
encompassing amino acids 70-96 showed no ligand binding and failed to 
be translated into a detectable 67kDa protein. Other mutant receptors 
in which hydrophobic helices were deleted, including deletions of 
amino acids 33-105, and 64-140 similarly did not express 
immunoreactive protein. In a subsequent communication, Strader et al 
(1989) found that substitution of Asp 113 in helix 3 affected the 
binding of both agonists and antagonists to the receptor, but that 
coupling to the adenyl cyclase system was not affected, and suggested 
that the amino group of catecholamine ligands form an ion pair with 
the carboxylate side chain of Asp 113. It is not known to what extent 
ion pairing also occurs between the Asp 79 and the amino group of the 
ligand. Support for Strader's hypothesis carries from the observation 
that an Aspartate residue in helix 3 is conserved among all of the G 
protein linked receptors that bind amine ligands, including all the 
subtypes of a- and ~-adrenergic, muscarinic and serotonergic receptors, 
but not those receptors whose ligands are not protonated amines, such 
as the substance Kand angiotensin receptors, or the opsins. 
4.3.5 Glycosylation mutants of the human beta-2 adrenergic receptor. 
Point mutations of the beta-2 adrenergic receptor at the residues Asn 
6 and Asn 15 on the extracellular N-terminal loop of the protein, were 
constructed by Dr. F. Chung (see Table 12) and I performed the 
transfections and the partial characterization of these mutants. 
Repeat transfections with the Asn 15 (G54) mutant at no stage showed 
propranalol displacable [ 125I)-CYP binding, and this was later 
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attributed to the fact that this mutant had inadvertently been 
severely truncated (Fraser, personal communication), although a 
"proximal" sequence of the mutated gene confirmed that the Asn had 
been correctly mutated, at the amino acid residue 15. 
B82 mouse cells were successfully transfected with mutant Asp 6 beta-2 
receptor DNA and 12 geneticin G418 resistant clones were selected, 
amplified in 24 well plates and screened for L(-) propranalol 
displacable [ 125IJ-CYP binding at a single concentration (200pM). The 
highest expressing clone (G53) was chosen for further binding studies. 
The Asp 6 clone, (designated G53) showed saturable, stereospecific 
binding of [ 125I]-CYP, Bmax 276fmol/mg Kd 5.94pM, which was highly 
reproducible and a representative saturation curve and Scatchard plot 
is shown in Fig. 39. 
Photo affinity labelling using [125IJ-CYP-diazirine (as described in 
2.2.11) of the clone G53 (Asn\Gln mutant) showed propranalol 
displacable photolabelling between MW 62 000 and 94 000 daltons 
(Fig.40). [ 125!]-CYP-diazirine labelled both wild type transfected 
and Asn 6 mutant receptors, and the size of the molecules labelled 
suggested that the Asn 6 mutant receptor was still glycosylated. 
Direct comparison of [ 125I]-CYP diazirine photolabelling of lmg/lane 
of membrane proteins from non-transfected B82 cells, the beta-2 
receptor transfected wild type receptors (200fmol/mg) and Asn 6 mutant 
(200fmol/mg) receptors shows an apparent reduction in the intensity 
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and size of the photolabelled receptors in the Asn mutant suggesting 
that the mutant receptor was partially glycosylated and of apparent 
lower molecular weight. Since this finding also could have resulted 
from an "error" in the mutation, the mutated sequence of the mutant 
Asn 6 was checked again and confirmed by Dr. D. Wang. Dideoxy 
nucleotide sequencing confirmed that the mutated sequence had in fact 
changed from AAC to CAG at residue 6. 
In order to confirm that Asn 6 was partially glycosylated, membranes 
were prepared from cells grown for 24 hours in O.lµg/ml Tunicamycin. In 
several independent experiments, photolabelling of these membranes with 
[ 125I]-CYP-diazirine consistently showed an unimpressive decrease in the 
intensity of the labelling and did not result in the clear appearance of 
a lower molecular weight species as expected from the studies performed 
by George et al. (1986) of S49 mouse lymphoma cells. These data 
suggested that the glycosylation was not inhibitable by tunicamycin at 
the concentration studied, or that glycosylation due to golgi alpha-1,2 
mannosidase II may also be important. I have not done further studies 
with other inhibitors of glycosylation. Boege et al. (1988) have 
commented on different cellular sensitivities to tunicamycin treatment 
in a study of the function of non-glycosylated beta-2 adrenergic 
receptors prepared from tunicamycin (150ng/ml) treated A431 cells which 
had been reconstituted in lipid vesicles, and suggested that protein 
bound carbohydrate was indeed required for fi adrenoceptor function in 
normal signal transduction. In particular, coupling with Gs protein was 
impaired with the unglycosylated receptor. These findings were in 
contrast to those of Benovic et al (1987) who found 
217 
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Figure 39. Saturation curves and Scatchard plots of [125I]-CYP binding 
to Asp6 (Asn-Gln) mutant of the human beta-2 adrenergic 
receptor cultured in the absence (39a) or presence (39b) of 
Tunicamycin C. 
Asn mutant Bmax 237 fmol/mg Kd 4.lpM 
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Figure 40. Autoradiographs of photoaffinity labelling of membranes 
prepared from untransfected B82 cells (lanes 1 & 2) . B82 
cells transfected with the wild type beta-2 receptor gene 
(lanes 3 & 4) and B82 cells transfected with the Asn 6 
mutant gene (lanes 5 & 6). Labelling in lanes 2, 4 and 6 
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Figure 41. 10-6M isoproterenol and 10-6M prostaglandin E1 stimulation 
of cAMP production in B82 cells transfected with wild type 
human beta-2 receptor and in B82 cells transfected with Asn 
6 (G53) mutant human beta-2 receptor. Bar values represent 
the mean of duplicate assays (.). 
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unchanged coupling of non-glycosylated purified hamster beta-2 
adrenoceptor with Gs. Benovic attributed the discrepancy to the 
reconstitution system employed by Boege. 
In order to investigate the function of the transfected Asn 6 mutated 
beta-2 receptors, I performed adenylate cyclase assays (Amersham) on 
the transfected cells. A brisk cAMP response to 10-6M isoproterenol 
was obtained (Fig. 41), comparable with that of the wild type beta-2 
receptors. (The protocol for the adenylate cyclase assays is described 
in detail in 6.2.3). 
These studies have shown that mutation of the Asn-6 residue did not 
significantly alter agonist activation of adenylate cyclase or 
expression of the receptor in the cell membrane of transfected cells, 
but further studies are required. 
The role of the carbohydrate moiety in structure and function may 
differ from one receptor to another, as in the case of the turkey 
Beta-1 adrenoceptor and the mammalian beta-2 adrenoceptor (Yarden et 
al. 1986, Dixon et al. 1986). It is also evident from the literature 
that while glycosylation appears to be critical for translocation to 
the cell membrane in certain receptors, e.g. Complement receptor CRl 
(Lublin et al. 1986) incomplete glycosylation was without functional 
effect for other receptors e.g. insulin-like growth factor receptor 
(Duronio et al. 1986). 
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4.3.6 Serine mutants of the beta-2 adrenergic receptor 
Binding studies with [ 125I]-CYP have demonstrated normal affinity of 
binding for these mutants. I have achieved a level of expression for 
the Ser 346 - Ala mutant which is approximately double that achieved 
for the Ser 262-Ala mutant. Saturation curves and Scatchard plots are 
shown in Fig. 42. Both mutants displayed good 10-6M isoproterenol 
stimulated cAMP production (cAMP production in Mutant 346 is shown in 
Fig. 43) but I have not studied the affinity of agonists in further 
detail. In particular, the effects of these two mutations on 
phosphorylation of the beta-2 receptor will be important to study in 
the future. Dixon (in press) has found that amino acid substitutions 
at Ser 204 and Ser 207 in helix 5 and Ser 319 in helix 7 affected 
agonist but not antagonist binding to the receptor. 
4.3.7 Subsequent studies on other beta-2 adrenergic receptor mutants 
Since the initial studies of beta-2 receptor mutants, discussed above, 
several important mutational studies have been published by Strader et 
al. (1989) O'Dowd et al. (1989), Kobilka et al. (1988) and others. 
All of these studies, while providing vital information, have also 
illustrated some of the difficulties encountered when studying mutant 
receptors. It appears that ligand binding is more dependent on an 
overall normal molecular conformation than on isolated or specific 
residues from the studies conducted so far. 
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Figure 42. Saturation curves and Scatchard plots of [125I]-CYP binding 
to Ser 346 (Ser-ala) and Ser 262 (Ser-ala) mutants. 
Ser 346 
Ser 262 
Bmax: 424 fmol/mg Kd 10.SpM 
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Figure 43. 10-6M isoproterenol and lOmM NaF stimulation of cAMP 
production in B82 cells transfected with the Serine 346 
(Ser-ala) mutant human beta-2 receptor gene. Bar values 
represent the mean of duplicate assays (.). 
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A clear understanding of the molecular nature of the ligand 
facilitates the appropriate choice of residues within the receptor for 
mutant constriction. Main and Tucker (1985) have emphasised the 
importance of the catechol ring, which might be expected to form both 
hydrogen bonding and hydrophobic interactions with amino acid side 
chains within the ligand binding pocket of the receptor. 
Other residues have also been found to have important functions in 
facilitating normal folding of the receptor protein necessary for 
ligand binding, and conserved Phe residues at position 289 and 290 in 
helix 6 and Tyr 326 in helix 7 appear to be critical for agonist 
binding to the receptor. Taken together, Strader et al. (1989) 
suggested that residues within helices 5-7 were involved in the 
attachment of the catechol ring of the ligand to the beta adrenergic 
receptor. The model developed as a result of mutagenesis and 
presented by Strader is highly consistent with the results which I 
have obtained with the mutants. 
Site directed mutagenesis of the cytoplasmic domains of the human 
beta-2 adrenergic receptor by O'Dowd et al. (1988) confirmed the 
studies of Dixon et al. (1987) suggesting that the third intracellular 
loop was also important in coupling to G proteins. The total picture, 
however will remain incomplete, until all possible mutants have been 
tested. It is also possible that the "negative" effect of certain 
deletion mutations might be due to an allosteric rather than a direct 
effect on the actual G protein coupling domain. 
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The structural basis of receptor function has been elegantly studied by 
Kobilka et al. (1988) using chimeric o 2fi2 receptors. o 2 and ~2 adrenergic 
receptors are both activated by epinephrine but have opposite effects 
(inhibitory and stimulatory) on the adenylate cyclase system. In 
extensive studies of constructed chimeric o2fi2 adrenergic genes it was 
shown that the specificity for coupling to the stimulatory guanine 
nucleotide regulatory protein lies within the region extending from the 
5th hydrophobic domain to the carboxyterminus of the sixth hydrophobic 
domain and that major determinants of o 2 and fi2 adrenergic receptor 
agonist and antagonist ligand binding are contained within the seventh 
membrane spanning domain. 
By comparison with my own data and the mutant studies of Strader (1987) 
on the Asp 79 residue, the findings of Kolbilka et al. (1988) with 
chimeric o2fi 1 receptors designated CRl, CR2, and CR3, in which the first 
and second, first second and third, and first second third and fourth 
hydrophobic domains were replaced by o2 receptor sequences, still bound 
[ 1251]-CYP. This result may not be too surprising, since point 
mutation of Asp 79 had no effect on antagonist binding. The effect 
however of these chimeras on agonist binding was consistent with our 
own study and led Kobilka to conclude that most of the hydrophobic 
domains influence agonist ligand binding specificity, while antagonist 
binding specificity is influenced primarily by the seventh hydrophobic 
domain, or by a combination of the 6th or the 7th. This was supported 
when he proceeded further and constructed "split receptors". 
Amazingly, co-transfection of split receptors SR 1-5 (containing only 
226 
the first five hydrophobic domains) and SR 6-7 (containing only the 6th 
and 7th hydrophobic domain) resulted in a functional "receptor" which 
bound agonists and antagonists and could activate adenylate cyclase. 
While chimeric receptors do provide insight into important residues for 
binding, there is always a concern that in constructing these 
receptors, molecular incompatibilities introduced might be expected to 
destabilise the molecule significantly making it less efficient, or 
even non-functional. 
Dohlman (1988) has demonstrated that the beta adrenergic receptor photo 
affinity antagonist, p-(Bromo acetamido) benzyl-1-( 1251] iodocarazolol 
covalently binds to a peptide in the second hydrophobic domain and 
suggests that this domain may form or lie adjacent to the ligand 
binding pocket. If this domain participates directly in ligand 
binding, or is very closely adjacent to the ligand binding site, it is 
conceivable that molecules with an affinity for this domain could 
sterically impede ligand binding. This domain is thus a candidate site 
for the in vitro production of antibodies as a possible model to 
investigate the antibody mediated ligand inhibition of [ 1251]-CYP 
binding discussed in Chapter 3. I have chosen this sequence as the 
irnmunogen for studies of antibody production against the beta-2 
receptor discussed in Chapter 5. 
The importance of phosphorylation in the regulation of the beta-2 
receptors function has been studied in detail by Benovic et al. (1988) 
and also by Bouvier et al. (1988) who clearly showed that removal of 
phosphorylation sites by truncation of its serine and threonine-rich 
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phosphate acceptor segment delays the onset of desensitization, and 
that by selective replacement of 11 potential phosphate acceptor 
serines and threonines by glycine or alanine delays desensitisation 
even further. 
Recently the relative importance of different receptor residues on 
beta-1 and beta-2 receptor ligand binding has become more clear. In 
studies of chimeric beta-1 and beta-2 adrenergic receptors, Frielle et 
al. (1988) have presented data that transmembrane region IV is largely 
responsible for determining binding to beta-1 vs beta-2 agonists but 
that regions VI and VII are important for beta-1 and beta-2 selective 
antagonists. 
It is also clear that physical characteristics of the receptor 
insertion in the bilipid membrane may have significant functional 
importance. O'Dowd et al. (1989) have investigated the effects of 
mutation of Cys 341 to glycine. This resulted in a non-palmitoylated 
form of the receptor, which exhibited a drastically reduced ability to 
mediate isoproterenol stimulation of adenylate cyclase and a markedly 
reduced ability to form a high affinity state for agonists, suggesting 
that anchorage of the receptor in the membrane may also be important 
for normal agonist affects. 
4.4 Swnmary and Conclusions 
In this chapter, I have presented the studies which I have conducted, 
using molecular biology, to gain further insight into mechanisms 
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whereby receptor expression may be regulated (e.g. by steroids) and to 
gain insight into the residues of the receptor which are important for 
normal agonist and antagonist binding. 
I was able to isolate and identify the human beta-2 receptor mRNA 
species and found an increase in hybridizable RNA upon induction of 
Wl-38 cells with dexamethazone. Studies of beta-2 receptor mRNA 
induction in the developing lung proved difficult to perform. I 
constructed a 326 bp cDNA probe and several riboprobes of the beta-2 
receptor gene. These probes were used to identify beta-receptor RNA 
species in other tissues (heart and adipose tissue) and were used in my 
subsequent genetic studies on the polymorphism of the receptor in 
asthmatic subjects (in Chapter 7). 
The mutant beta-2 receptors which I studied were historically among the 
first mutants of the human beta-2 receptor to be constructed and they 
provided important information which added credibility to and 
strengthened proposed models of ligand binding. Studies of the human 
Aspartate 79 mutant were published in the Journal of Biological 
Chemistry (Chung et al. 1988) and Fraser (1989) has published further 
studies on the cysteine mutants. I have partially characterised the 
glycosylation (Asp 6) and serine mutants (Ser 346 and Ser 262) but 
further more detailed biochemical studies are required. 
Studies with mutant receptors provide models for attributing functional 
importance to particular domains. All published mutants, however, 
remain informative theoretical models of beta-2 receptor 
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abnormalities, since spontaneous mutant beta-2 receptors have not yet 
been described in human disease. 
The cumulative literature on point mutations of human mutant beta-2 
receptors indicate that while a number of mutations could 
theoretically occur spontaneously in vivo without causing significant 
functional effects, there are certain residues which are critically 
important. Mutations at these critical residues are probably lethal. 
Where a mutation leads to a partial reduction in agonist binding and 
function (e.g. Asp 79), such a mutation, if occurring spontaneously, 
could theoretically underlie a disease process in which beta-2 
adrenergic receptor function is impaired or more susceptible to down 
regulation. It would therefore be important to clone and sequence the 
human beta-2 receptor gene in diseases where beta-2 receptor 
expression or function is reported to be abnormal to identify 
spontaneous or inherited mutated beta-2 receptor genes in humans. 
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CHAPTER 5 
PRODUCTION AND PARTIAL CHARACTERIZATION OF A MONOCLONAL ANTIBODY AND 
POLYCLONAL ANTIBODIES RAISED TO A PEPTIDE FROM A LIGAND BINDING DOMAIN OF 
THE HUMAN BETA-2 RECEPTOR 
5.1 Introduction 
Displacement of [ 125I]-CYP binding to beta-2 adrenergic receptors by DEAE 
purified human immunoglobulin fractions and other human serum factors 
implies either competitive or non-competitive interactions of these 
factors with the beta-2 adrenergic receptor, or its ligand binding 
domain. Alternatively, high affinity binding to [ 125I]-CYP by the serum 
factors may also reduce the concentration of free ligand available for 
receptor interaction. Any hypotheses suggesting mechanisms for the 
interaction of serum factors with the human beta-2 receptor itself 
require a working model of the molecular arrangement of the amino acid 
residues important for ligand binding. Genetic or acquired differences 
in the expression of key amino acids involved with ligand binding could 
theoretically enhance or reduce the effects of serum blocking factors. 
The experiments described in this chapter were conducted to test and 
expand the conceptual models of the ligand binding domain, derived in 
part from the mutagenesis studies in 4.3, by producing a monoclonal 
antibody to a 20 amino acid peptide derived from a sequence of an 
important ligand binding domain. 
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Evidence from the initial cloning and sequencing analysis of the human 
beta-2 receptor genes (Kobilka 1987) suggested that the human beta 
receptor protein is expressed as a seven transmembrane molecule analogous 
to rhodopsin, with seven hydrophobic regions residing within the bilipid 
layer (intramembranous region), 4 hydrophilic loops extending into the 
cytoplasm and 4 extracellularly (Fig. 35). 
Binding experiments which I performed at the NIH on nine mutant beta-2 
receptors described in 4.3 which were expressed in B82 cells were 
consistent with the suggestion that a pocket, within the hydrophobic 
domains in the transmembranous regions of the receptor, is important for 
ligand binding. 
Based on the assignment of ligand binding to predominantly hydrophobic 
domains of the receptor, I considered production of a monoclonal antibody 
to the ligand binding domain an important extension of the studies in 
Chapter 3. In order to test whether antibodies could, in fact, be raised 
successfully to residues of the hydrophobic domains in the beta-2 
receptor (their immunogenicity has not previously been investigated) and 
to probe the function of such an antibody, I have on my return to Cape 
Town produced both monoclonal and polyclonal antibodies to a synthetic 20 
amino acid peptide derived from the protein sequence of the second 
transmembrane domain. 
Previously, when it was proposed that ligand binding of catecholamines 
was to an "extracellular" domain of the receptor, it was conceivable that 
antibodies could interact directly with such a domain. 
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It is now appropriate that inhibition of ligand binding by DEAE purified 
immunoglobulin G fractions must be re-interpreted in the light of current 
models of the molecular nature of the ligand binding domain suggested by 
gene cloning. Since the ligand binding domain is, in fact, formed within 
a pocket within the seven hydrophobic transmembrane regions, direct 
access to the theoreti~al binding pocket of the beta receptor (Mr of 
67 000) would seem limited. A theoretical steric inhibition could be 
exerted if an antigen binding domain of the immunoglobulin molecule was 
directed specifically at hydrophilic loops which reside on extracellular 
aspects of the beta receptor expressed in the cell membrane. Since 
deletion of the extracellular loops did not influence ligand binding in 
deletion mutants (Dixon et al. 1987), it is unlikely that antibodies 
raised to the same extracellular loops would influence ligand binding. 
Antibodies could induce conformational changes in the receptor via weak 
ionic associations, hydrophobic interactions or charge effects and they 
could theoretically influence ligand binding by these mechanisms. 
Preliminary experiments by Dr. Claire Fraser (NIH) who raised several 
rabbit antibodies to extracellular domains of the beta-2 receptor, based 
on the model of Kobilka et al. (1987), while I was working in Venter's 
group in the laboratory of Receptor Biochemistry and Molecular Biology at 
the N.I.H. showed that rabbit polyclonal antibodies to the extracellular 
loops did not inhibit ligand binding to any significant degree (less than 
30% inhibition). Since these experiments indicated that antibodies 
directed to the extracellular loops of the beta-2 receptor were probably 
not the cause of the degree of inhibition found with the human sera, I 
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decided to study antibodies directed at hydrophobic regions. The 
effects of antibodies directed at hydrophobic domains of the beta-2 
receptor have not been previously investigated. 
Based on published information about the ligand binding domains, I 
selected the second transmembrane domain of the beta-2 receptor as an 
initial target for monoclonal antibody production because 
(i) the deletion of amino acid residues 70-96 removed normal 
[ 1251]-CYP ligand binding in the mutant constructs of Dixon 
(1987). 
(ii) Residue Asp-79 was shown to be important in agonist binding by 
Strader (1987). 
(iii) Residue Aspartate 79 was also thought to be important in G 
protein binding in the mutant studies work I conducted in Chapter 
4. 
(iv) Amino acid residues 83-96 in helix 11 were shown by Dohlman 
(1988) to contain the site of p-(Bromo acetamido) benzyl-L-[ 1251] 
Iodocarazolol binding. 
It was envisaged that successful production of a monoclonal antibody 
directed to this ligand binding domain could be used as a control 
antibody and a model for studies exploring the interactions of human 
immunoglobulin with ligand binding (if in fact antibody was able to enter 
the ligand binding domain). Such an antibody could also theoretically be 
used:-
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(i) to study the effects of anti-beta-2 receptor antibody on receptor 
function and expression in cultured cells; 
(ii) to identify beta-2 receptors in tissue sections using 
immunofluorescence or colloidal gold; 
(iii) to identify expressed mutant beta-2 receptors which did not bind 
beta receptor ligands; and 
(iv) as an affinity probe to study post-translational processing and 
5.2 
membrane insertion of the beta-2 receptor in cultured cells. 
The 20 amino acid second transmembrane beta-2 adrenergic receptor 
peptide BR-20-II. 
The peptide chosen for monoclonal antibody production comprised 20 amino 
acids derived from the 2nd transmembrane domain of the human beta-2 
receptor in the following sequence: 
Asp 79 Leu Val Met Gly Leu Ala Val Val Pro Phe Gly Ala Ala His Ile Leu Met 
Lys Met99 
Residues extending extracellularly to Met99 were included to facilitate 
possible binding of the antibody to the receptor in the intact molecule. 
The location of this peptide in the transmembrane model of Kobilka et al. 




CYTOPLASMIC SURF AC[ 
Figure 44. Location of the 20 amino acid hydrophobic peptide sequence 
in the second transmembrane domain of the human beta-2 
receptor (using a model adapted from O'Dowd et al (1989). 
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For the purposes of immunization, at my request, three peptides were 
synthesized, using the Fmoc polyamide synthesis method (Kemp 1979), in 
the Department of Biochemistry at the University of Pretoria by Marina 
Rautenbach. 
(1) Peptide I 
Asp79 - Met99_Cys(ACM)-Gly (BR-20-I) 
(2) Peptide II 
N-Palmitoyl Asp79 - Met99 -Cys(ACM) Gly (BR-20-II) 
(3) Peptide III 
N-Cys Asp79 - Met99 -Cys(ACM)-Gly (BR-20-III) 
All three peptides were highly insoluble in aqueous solvents because of 
their hydrophobic nature and their synthesis was chemically difficult 
(Rautenbach 1989). 
Peptide II (BR-20-II) was selected for the initial immunization, since by 
coupling a palmitoyl residue to the N-terminus of the peptide, direct 
immunization was possible (no deblocking of ACM-Cys or adjuvant was 
required). Since the enhanced immunogenicity of lipid-conjugated protein 
was discovered and reported by Stark (1980), it has been shown by Hopp 
(1984) that a HBsAg peptide-palmitic acid conjugate produced a 27.4 fold 
titre increase (compared with a 4.6 fold titre increase following 
immunization with a KLH derivative) and that there is no antibody 
response to the fatty acid portion of the dipalmitoyl conjugate. It is 
believed that palmitoyl-conjugated peptides form a micelle or stable 
aggregate corresponding to between 50 and 1000 copies of the conjugate 
per particle and that the dipalmitoyl peptide effectively acts as its own 
carrier. Amino acid analysis of this peptide supplied by Prof. L. Visser 
(University of Pretoria) is shown in Appendix H. 
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5.3 Immunization 
Three six week old BALB/c mice were immunised intraperitoneally with lOOµg 
of an aqueous suspension of the palmitoyl peptide (BR-20-II) and boosted 
again with 50 µg of peptide after four weeks and again at six weeks. No 
adjuvants were used. Three days after the second boost the mice were 
test bled from the retro-orbital plexus. The serum was separated, 
aliquotted and frozen at -20°C. 
5.4 Screening Assay 
I developed an ELISA test to screen sera, harvest fluids and ascites for 
anti-beta-2 receptor peptide antibody production. In order to optimise 
the conditions for the ELISA I conducted chequer-board experiments to 
standardise antigen concentrations, solvents, microtitre plates and 
antibody concentrations. 
In view of the insolubility of the BR-20-II peptide in aqueous solutions, 
peptides were dissolved in 100% methanol or dimethyl sulphoxide (DMSO). 
Ninety-six well Titertek (plastic) Seravac plates were compared with 
96-well Microelisa<R> (Greiner) polystyrene plates. Plates were coated 
overnight (14-16 hrs) and air-dried with BR-20-II peptide concentrations 
varying from 0.5µg-2µg/well. 
For detailed description of the ELISA reagents see Appendix I. Briefly, 
after an overnight coating with the peptide in methanol (50µ1), the plates 
were washed five times with phosphate buffered saline (PBS), blocked for 
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one hour with 200µ1 1% fetal calf serum in PBS and then incubated for one 
hour at room temperature with 50µ1 of dilutions of the mouse serum (or 
hybridoma fluid). After 10 further washes with Tris saline Tween (TST) 
the plates were incubated with a 100µ1 of a 1/500 dilution of goat 
anti-mouse conjugate in ELISA diluent, washed five times with TST after 
which 100 µl of ABTS substrate was added. Absorbance at 414 nM was read 
after 30 min. 
I found that Titertek plates gave higher readings and less background 
than the MicroElisa<R> plates. DMSO was an unsuitable solvent because 
it not only formed an opaque reaction on the Titertek plates, but doubled 
the background on the polystyrene plates. A peptide concentration of 
0.5µg/well gave absorbance readings between 0.5 - 1.0 with a 1:100 
dilution of the mouse serum and was used for all subsequent peptide 
ELISAs. 
Using the BR-20-II peptide antibody ELISA, all three mice were test bled 
after the second intraperitoneal boost for antibody production to the 
peptide. At 1/100 dilution of mouse serum, absorbance 414nm readings 
between 0.310 and 0.618 were obtained for all three mice (background 
readings 0.132-0.242). The BALB/c mouse whose serum gave the highest 
readings in the ELISA was selected for the fusion. 
5.5 Fusion and Cloning 
Chemical reagents, cells and media used for the production of the 
monoclonal antibody are detailed in Appendix J. 
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Three days prior to fusion, the BALB/c mouse was boosted with lOOµg 
peptide BR-20-II intraperitoneally. SP2 myeloma cells were thawed from a 
frozen stock and cultured in 10% FCS in RPMI with antibiotics. Cells 
were plated out in 35mm petri dishes at 105 cells/ml and passaged in 
100mm petri dishes prior to the fusion. On the day of fusion supernatant 
medium was removed from a 100mm dish (approximately 107 cells in mid 
exponential phase) and 10ml of lx Versene solution was added. After 10 
min incubation at 37°C the cells were dislodged by pipetting and 
transferred to a 50 ml centrifuge tube, centrifuged at 1500 rpm for 5 min 
(using a MSE minor bench top centrifuge) and resuspended in 2ml RPMI 
(without antibiotics) and viability checked under phase contrast 
microscopy, using Trypan blue. 
The immunised BALB/c mouse was killed using ether, the abdomen was 
sterilised with 70% alcohol. The spleen was removed and placed in RPMI, 
loose connective tissue was dissected off and the spleen was transferred 
to a clean dish, and the spleen was squeezed through a sterile stainless 
steel sieve into RPMI with the plunger of a 2 ml syringe. Clumps were 
broken by pipetting the suspension a few times and the larger pieces were 
allowed to settle for a few minutes before the supernatant was 
transferred to clean tubes. Cells were washed once with RPMI and diluted 
in white cell counting fluid. 
For the fusion, 6 x 107 spleen cells were mixed with 1 x 106 myeloma 
cells in plain RPMI and suspended in 30 ml RPMI in a 50 ml centrifuge 
tube and centrifuged at 1000 rpm (MSE minor) for 5 minutes. The 
supernatant was poured off and after loosening the pellet, 1.5 ml PEG was 
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added dropwise over one minute with gentle mixing, stirred gently for a 
further minute after which 1 ml of warm 37°G RPMI was added slowly over 
one minute with gentle mixing, a further 1 ml RPMI over the next minute, 
followed by 8 ml over three minutes and then topped up to 45 ml, 
centrifuged again at 1000 rpm for 3 min and the supernatant removed. The 
pellet was suspended in 50 ml HAT-HUGS and distributed in 0.5ml aliquots 
into 24 well plates after which another 0.5ml HAT-HUGS was added. 
Supernatants were tested for antibody production after 14 days, when 
they started to turn yellow, using the peptide ELISA. 
Three positive clones were obtained and the strongest positive, well AA6, 
was cloned by limiting dilution in HT-HUGS in 96-well flat-bottom 
microtitre trays. Most of the clones were positive in the peptide ELISA 
and I selected clone B4 for expansion and further cloning by limiting 
dilution. All of these clones were positive and clones B4A8 and B4E4 
were chosen for ascites production and characterization. A selection of 
positive clones were frozen down and stored in liquid N2 • Clone B4A8-PWL 
was expanded in 100mm dishes in 10% FCS and 5 x 106 cells in 0.5ml PBS 
were injected into BALB/c mice which had been pristane 
(tetramethylpartidecane) primed one week previously and ascites tapped 10 
days later. Harvest fluids from 100mm dishes were stored in aliquots at 
-20°C. 
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5.6 Characterization of B4A8-P'WL 
5.6.1 Titre in Peptide ELISA. 
Using the peptide-immunised BALB/c mouse serum and neat harvest fluid 
from seven clones as positive controls and control mouse serum and an 
irrelevant monoclonal anti-Erythrina trypsin inhibitor (ET!) as negative 
controls, ascites from clone B4A8-P'WL was tested in the peptide ELISA in 
dilutions 1:100 to 1:48 000 (Fig. 45). Strongly positive titres were 
obtained down to a titre of 1:24 000 (Absorbance 414nm readings greater 
than 0.33 were regarded as positive). The dilution of the antiserum 
providing a half maximal signal for the immobilised peptide was 
approximately 1:4000. (Mean absorbance with irrelevant monoclonal 1:200 
dil. = 0.295). Positive clones from B4A2 were also tested in the peptide 
ELISA and titres of 1:800 were obtained. 
5.6.2 Inhibition of B4A8-P'WL binding in ELISA by pre-incubation with 
the peptide. 
In order to demonstrate that the monoclonal B4A8-P'WL could bind to free 
peptide and not only to the peptide coupled to the microtitre dish, 
serial dilutions of antibody were pre-incubated with increasing 
concentrations of beta receptor BR-20-II peptide prior to the ELISA. A 
1:4000 dilution of B4A8-P'WL ascites gave maximum inhibition when 
pre-incubated with increasing concentrations of BR-20-II (Fig.46). 
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Figure 45. Binding of monoclonal B4A8-PWL to BR-20-II peptide attached 
to microtitre plate. (Mean absorbance for blank with no 
antigen= 0.24; mean absorbance for 1:100 dilution of 
immunised mouse serum 0. 51; mean absorbance for neat B4A8-
harvest fluid= 0.92). 
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Figure 46. Inhibition of binding of monoclonal B4A8-PWL to BR-20-II in 
peptide ELISA by pre-incubation overnight with O.Sµg, 2.Sµg 
and Sµg of BR-20-II peptide at a 1:4000 dilution of 

















Figure 47. Inhibition of binding of monoclonal B4A8-PWL to BR-20-II in 
peptide ELISA by pre-incubation with Sµg of BR-20-I, 
BR-20-II and BR-20-III at a 1:4000 dilution of B4A8-PWL. 
Bars represent mean values of duplicate ELISA assays (e). 
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concentrations tested. These experiments showed that the monoclonal 
recognised and bound to the free peptide which was present as an 
aggregate or micelle. In a separate experiment inhibition of antibody 
binding with peptides (5µg) BR-20-I and BR-20-III was also demonstrated 
(Fig.47), supporting the conclusion that the monoclonal B4A8-PWL 
recognises an epitope common to all three of the synthesized beta 
receptor peptides and is thus not directed against the palmitoyl residue 
of BR-20-II. 
5.6.3 Isotypin~ of B4A8-PWL 
B4A8-harvest fluid was concentrated 16x using a Centricon (Amicon). 
Isotyping was performed using rabbit anti-mouse IgGl, IgG2a, IgG2b, IgG3, 
IgM and IgA antibody (Miles). Briefly, 2µ1 of isotyping sera diluted 1/20 
was spotted on to nitrocellulose paper which had been previously wetted 
and allowed to dry. After the nitrocellulose paper was immersed in 5% 
fetal calf serum in TBS (with 0.5% Tween 20) for 30 minutes, 5µ1 of 
monoclonal antibody harvest fluid was applied to each spot and allowed to 
dry for 3-5 min, washed twice in TBS for a few minutes, and peroxidase 
conjugated goat anti-mouse antibody applied for 5 minutes, washed 2x with 
TBS and immersed in 4 chloronaphthol substrate for 15 minutes. 
Positive spots were obtained with rabbit anti-mouse IgM and an 
Ouchterlony test confirmed that the isotype of the anti-peptide 
monoclonal B4A8-PWL was in fact IgM. 
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5.6.4 Recognition of a 49 kDa expressed protein by B4A8-PWL. 
In order to determine whether the anti-peptide monoclonal B4A8-PWL 
recognised a biological molecule, Western blots of membranes of mouse 
fibroblasts (B82 L cells) which I had transfected with the human beta-2 
receptor gene (6.2) expressing high levels of beta-2 receptors (4000 
fmol/mg protein Wt-8 Cape Town clone) were compared with membranes from 
non-transfected control B82 L cells (not expressing detectable beta-2 
receptors) according to the method of Towbin et al. (1979). 
Briefly, lOOµg of membranes were prepared according to the detailed method 
described in Appendix F. Membranes containing 26ng beta-2 receptors 
(measured by saturation curves and Scatchard plots) were separated 
electrophoretically on PAGE (9%) and blotted on to Irnrnobilon™ 
Polyvinylidene difluoride (PVDF) microporous membranes which had been 
pre-wet with methanol. 
After blocking with 5% FCS and 0.3% Tween 20 for 2 hours, the Western 
blots were incubated with a 1/1000 dilution of the monoclonal antibody 
B4A8-PWL for 1 hour, washed 5 times with TBS in 0.05% Tween 20 and then 
incubated with sheep anti-mouse IgG 1/200 diluted in TBS for 30 min. 
After washing 3 times it was incubated again with PAP (peroxidase anti-
peroxidase) 1/20 in TBS for 30 minutes, washed Sx with TBS and incubated 
with DAB (Diaminobenzamidine 1/50, H202 1/1000 and cobalt 0.3%) for a few 
minutes and then washed with H20 and allowed to dry. The use of this 
sandwich technique (Lansdorp et al. 1984) using the sheep anti-mouse 
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antibody as a linker was found necessary to eliminate unacceptable levels 
of non-specific binding which I originally encountered when a peroxidase-
conjugated goat anti-mouse antibody was used. In further experiments, 
5% fetal calf serum was found to be more effective than 10% horse serum 
or 1% gelatin as a blocking agent using both PAP and APAAP (Hohmann et 
al. 1988) systems, with the sheep anti-mouse linker. 
Results of the Western blots of reduced membranes (lOOµg/lane) showed that 
the B4A8-PWL monoclonal recognised 49 kDa protein present in both 
transfected and non-transfected mouse B82 L cells (Fig. 48). The 49 kDa 
protein was not present on Western blots of lysates of human red blood 
cells, but recognised as a single band by the monoclonal antibody B4A8-
PWL in Western blots of PAGE-separated lysates of the UCT-BR-1 breast 
tumour cell line (Wilson 1982), Jurkat T cells, Bowes melanoma cells 
(Harris 1986) and in human B cells. In human B cells an additional lower 
band, approximately 40 kDa, was also detected. 
The intensity of the band did not differ when Western blots of B82 L 
cells expressing different numbers of beta-2 receptors (400 fmol/mg -
4000 fmol/mg) were compared suggesting that the 49 kDa protein was not in 
fact related to the human beta-2 receptor. Although there was no visible 
recognition of the expressed human beta-2 receptor protein by the 
monoclonal B4A8-PWL, this does not completely rule out possible binding 
to the receptor since only 26ng of human beta-2 receptor was present in 
each lane. Wang (1989) used 200ng of purified beta receptor from mouse 






Figure 48. Western blot of membranes from non-transfected mouse cells 
(lanel) and membranes from clone Wt-7 Cape Town (lane 2) 
probed with monoclonal B4A8-PWL (1:500 dil.) showing 
recognition of a 49 kDa band in both cell membrane 
preparations. Molecular weights are shown on the left 
(kDa). 
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possible that insufficient receptor may be present in my Western blots 
for detection using this system. 
5.6.5 Imrnunofluorescence Studies 
In order to investigate more precisely the topography of the 49 kDa 
protein recognised by B4A8-PWL in Western blots of membrane preparations 
of the B82 cells, and to investigate whether beta-2 receptors could be 
detected with B4A8-PWL, indirect immunofluorescence studies on intact 
cells were performed. The cell lines, and culture conditions are 
described in detail in Appendix E. 
B82 cells expressing high levels of beta-2 receptors (Clone Wt-7 Cape 
Town 4000 fmol/mg) and control non-transfected B82 cells were cultured on 
glass slides in the presence of dexamethazone (10- 6M) and 
immunofluorescence of flxed and unfixed cells with the B4A8-PWL 
monoclonal antibody was examined under UV light. The protocol used for 
the imrnunofluorescence studies is described in Appendix K. 
Positive fluorescence was only seen when fixed (permeabilised) cells were 
used, but both transfected (Wt-7 Cape Town) and non-transfected cells 
fluoresced with B4A8-PWL. The pattern of fluorescence was that of a fine 
speckling (Fig. 49(a)) distributed towards the periphery of the cells and 
quite unlike the homogenous fluorescence seen when a control monoclonal, 
anti-ET! was used on the Wt-7 Cape Town cells using the same conditions 




Figure 49. Speckled immunofluorescence seen with fixed transfected 
cells (clone Wt-7 Cape Town) with monoclonal B4A8-PWL (49a) 
compared with the homogeneous immunofluorescence observed 
when a control monoclonal (anti ETI) was used on the same 
cells (49b) . 
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These studies and the studies of membranes on the Western blots suggested 
that the 49 kDa protein recognised by B4A8-PWL is expressed in discrete 
locations in an intramembranous location. If there was any binding to 
beta-2 receptors, this was completely obscured by fluorescence of the 
more abundant 49 kDa protein which was present in both transfected and 
non-transfected cells. 
5.6.6 Immunoabsorption. 
The relationship between the anti-peptide II antibody B4A8-PWL and the 49 
kDa protein was further investigated in a series of immunoabsorption 
experiments. 
Prior to conducting the peptide ELISA (Appendix I) B4A8-PWL ascites 
(1/200 dil.) were pre-incubated with 25, 50, 100, 200 and 800µg of B82 
(high and low beta-2 receptor expressing) cell membranes overnight at 4°C, 
using a Braun shaker. The membranes were then pelleted using a Beckman 
air-driven ultracentrifuge for 5 minutes at 30 psi and the supernatants 
were tested in the peptide ELISA. An anti-ET! monoclonal antibody was 
used as a negative control. Both transfected and non-transfected cells 
absorbed out anti-peptide activity. A dose response of the absorption 
is given in Fig. 50. No absorption was found with the irrelevant 
monoclonal antibody anti-ET!, supporting the conclusion that the peptide 
and the 49 kDa protein share a common epitope. The high beta-2 receptor 
expressing cell membranes did not absorb out more anti-peptide activity 
than the low expressing cells, consistent with my original findings with 
the Western blots and provided further evidence that the 49 kDa protein 
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Figure 50. Binding of B4A8-PWL which had been pre-absorbed to lOµg, 
SOµg, lOOµg, 200µg, BOOµg of membranes from untransfected B82 
cells (el), or Wt- 7 Cape Town cells ( O), compared with 
binding of non-absorbed B5A8-PWL (1:200 dil). (Bar values 
represent the mean of duplicate experiments (.)). 
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was not a processed or expressed human beta-2 receptor, and that the 
monoclonal B4A8-PWL did not recognise the beta-2 receptor. 
In order to confirm what was previously assumed, i.e. that the non-
transfected B82 cells could not be expressing a processed or 
non-functional human beta-2 receptor, I prepared genomic DNA (based on 
methods I have described in 7.4) from confluent cultures of transfected 
(Wt-7 Cape Town) and non-transfected B82 cells. 12 µg of DNA from each 
culture was digested with Pst-I for 2 hours and then Southern blotted on 
to Hybond N prior to probing with a nick translated (32P]-labelled 2.6kb 
genomic probe (see Chapter 4.2.3) of the human beta-2 receptor. The 
absence of restriction fragments on the autoradiograph of the non-
transfected cells (shown in Fig. 51) demonstrates absence of the beta 
receptor gene in the non transfected B82 cells. No explanation has 
previously been reported for the absence of expression of beta-2 
receptors in the B82 cells. These experiments provided firm evidence 
that the 49kDa protein was not in fact a precursor of or processed form 
of the human beta-2 receptor. 
5.6.7 Biological activity of B4A8-PWL Monoclona Antibody. 
(a) Effects on human fibroblast growth. 
Biological activity of the B4A8-PWL Monoclonal antibody (Mab) was 
investigated using human non-transformed foreskin fibroblast cultures 
established from foreskins obtained from neonatal circumcision ( a gift 







Figure 51. Autoradiograph of a Southern blot of genomic DNA prepared 
from confluent cultures of non-transfected B82 cells (left 
lane) and B82 cells transfected with human beta-2 receptor 
gene (clone Wt-7-Cape Town)(right lane) digested with Pst-1 
and probed with a nick translated [32P] labelled 2.6 kb 
genomic probe of the human beta-2 receptor gene (Stringency 
O.lxSSC, 0 . 1% SOS at 65°C for 2 hours). 
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binding, foreskin fibroblasts expressed approximately lOOfmol beta 
receptors/mg membrane (Kd 30 pM). Growth curves of the foreskin 
fibroblasts revealed a doubling time of about 48 hours. 
Preliminary studies examined the effect of beta-2 blockade and beta-2 
stimulation on the growth rate of the foreskin fibroblasts using 10-6M 
L(-) propranalol and 10-6M ± isoproterenol. Culture of the fibroblasts 
under these conditions showed a retardation of fibroblast growth at 48 
hrs in the presence of 10-6M ± isoproterenol and an enhancement in the 
presence of 10-6M L(-)propranolol. When the human fibroblasts were 
cultured in the presence of B4A8-PWL Mab 1/400 dilution (ascites) there 
was a 46% reduction in cell proliferation. No inhibition of growth was 
observed with a 1/400 dilution of an irrelevant monoclonal (algE antibody) 
ascites (Fig. 52). These experiments showed that binding to the 49kDa 
protein by the monoclonal B4A8-PWL resulted in a functional effect on 
cell proliferation, namely inhibition, but since the 49kDa protein bore 
no relation to the beta-2 receptor I did not study these inhibitory 
effects further. I have no explanation for the apparent stimulatory 
activity observed in the presence of L(-)proranolol. 
(b) Inhibition of the 1251-CYP bindin~ to the beta-2 receptor by B4A8-PWL. 
Since I originally made the monoclonal B4A8-PWL with a view to using it 
as a control antibody for ligand inhibition experiments, I proceeded to 
to investigate possible interference of B4A8-PWL on [1251]-CYP with 
ligand binding, even though experiments I had performed thus far 
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Figure 52. Growth of human foreskin fibroblasts (number of cells 
x 105 ) cultured for 72 hours in RP-10 alone (Column 2), 
RP-10 with B4A8-PWL (1:400 dil.)(Column 3), RP-10 with 
irrelevant anti-IgE ascites (1:200) (Column 4), and RP-10 
with 10-6M isoproterenol (Column S)(Number of cells at zero 
time shown in Column 1). Bar values represent mean number 
of cells counted in duplicate plates. 
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Although B4A8-PWL Mab recognised a 49 k.Da protein on Western blot and did 
not apparently recognise glycosylated (69 k.Da) or unglycosylated (43 kDa) 
forms of the beta receptor (bearing in mind that only 26ng receptor was 
present per lane), I thought it would still be interesting to investigate 
whether there was any specific or non-specific interaction with the 
ligand binding site of the beta-2 receptor when the receptors were 
functionally intact within the membranes i.e. it was conceivable that the 
monoclonal could recognise conformational epitopes in the intact 
molecule, but not sequential determinants in the Western blot. 
In the first of a series of experiments, the effect of the B4A8-PWL Mab 
on antagonist binding was examined using the [125I]-CYP ligand binding 
assay (Chapter 2.2.3). B4A8-PWL Mab ascites was used at a 1/50 dilution. 
Initial inhibition assays suggested that incubation with the Mab did 
result in mild inhibition (less than 30%) of [125I]-CYP binding, but that 
the degree of inhibition varied with the membrane preparation used. 
Inhibition was tested through a range of dilutions of the monoclonal 
antibody. The effect of receptor number in the membranes and degree of 
inhibition by the monoclonal was formally tested in experiments in which 
inhibition by B4A8-PWL (1/50 dilution) was measured using three different 
B82 membrane preparations, with three levels of human beta 2 receptor 
expression and compared with the inhibition obtained with a 1/50 dilution 
of an irrelevant monoclonal (oigE Mab) in these membranes. The results of 
this experiment were highly reproducible and confirmed that a relatively 
greater inhibition occurred with membranes from B82 cells expressing, 
lower levels of human beta-2 receptors (488 fmol/mg)(27%) than with 
membranes from B82 cells expressing high levels of human beta-2 receptors 
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(4203 fmol/mg) (9%), but surprisingly the irrelevant monoclonal algE Mab 
produced inhibition of the same order (Fig. 53). This experiment 
demonstrated convincingly that low degrees of beta receptor ligand 
inhibition (<30%) can be mediated in the ligand binding assay by 
dilutions of irrelevant immunoglobulins which are not directed against 
the ligand binding site and further confirmed that B4A8-PWL did not 
interact with the ligand binding domain to any significant degree. This 
finding (see Chapter 2.7) indicated that the ligand inhibitory effects of 
sera in vitro may be mediated by a combination of factors which may 
include immunoglobulins with ligand specificity or receptor specificity 
but can also contributed to by, irrelevant immunoglobulins and other 
non-immunoglobulin fractions which are also present in dilutions of the 
ascites fluids. 
B4A8-PWL IgM was also purified from the ascites fluids using Sephadex 
G200 chromatography. Five fractions containing IgM were identified by 
dot blotting using the method described in 5.6.3. None of these 
fractions inhibited [1251]-CYP binding in the ligand binding inhibition 
assay of greater then 25%, consistent with the experiments conducted with 
dilutions of the ascites fluids. 
5.6.8 Immunoprecipitation of the 49 kDa protein by B4A8-PWL 
Specificity of B4A8-PWL was investigated further in a series of 
immunoprecipitation experiments. It was important to investigate whether 
B4A8-P'WL Mab could immunoprecipitate the 49 kDa protein and to see if the 
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Figure 53. % inhibition of [ 1251]-CYP binding by 1:50 dilution of 
B4A8-PWL, or irrelevant anti-IgE, to membranes prepared 
from 3 different clones of B82 cells transfected with the 
human beta-2 receptor gene expressing 418 fm/mg, 1112 gm/mg 
and 4203 fm/mg human beta-2 adrenergic receptors. Bar 
values represent the median value of experiments performed 
in triplicate(.). 
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conformationally intact beta-2 receptor when solubilised from its 
membrane constraints, when access to the receptor by the antibody was 
theoretically easier. 
B82 cells transfected with the beta-2 receptor gene were cultured in 
methionine-free medium to semi-confluence prior to pulsing with 10-6M 
dexamethazone. Six hours prior to harvesting, 25µCi of [35SJ-methionine 
(Amersham) was added to the dish. Membrane preparations of the cells 
were made (Appendix F) and protein concentrations determined by the Lowry 
method. 
To solubilise the membrane proteins, 6 mg membrane protein, in 1.0 ml 
20mm sodium phosphate 2mm magnesium sulphate buffer was incubated in 0.5% 
Triton X-100 for 15 min at 40°C. Unsolubilised protein and membrane 
pellets were removed by centrifugation at 100 OOOg in 150µ1 aliquots for 
10 min using an airfuge and the supernatant was treated with Biobeads 
SM-2 (Biorad) 2g/ml for 30 min at 4°C to remove detergent. The 
supernatant was then removed from the Biobeads by gentle pipetting and 
incubated with a 1:10 dilution of B4A8-PWL (ascites) overnight at 4°C. 
200µ1 of a solution containing cyanogen bromide-activated sepharose 
coupled to sheep anti-mouse antibody, freshly prepared (see Appendix L), 
was added and tumbled for 2 hours at room temperature. After washing 5 
times with PBS using a microfuge, 20µ1 of sample buffer containing 
mercaptoethanol was added, the sample boiled for 2 minutes and after 
centrifuging in a microfuge for 10 min the supernatant was 
electrophoresed on 9% PAGE, Western blotted on to Immobilon™ and 
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autoradiographs were incubated using Cronex 4 X-ray film for 48 hours at 
-70°C. 
Results of the autoradiograph shown in Fig. 54 show clear precipitation 
of the 49 kDa protein as well as a high molecular weight protein greater 
than 97 kDa. There was no evidence on the autoradiograph, of 
precipitation of the solubilised human beta-2 receptor, even after 
prolonged autoradiography (7 days). 
I also attempted to immunoprecipitate solubilised [1251]-CYP-labelled 
beta-2 receptors directly with the B4A8-PWL monoclonal antibody. Wt-7 
Cape Town clone membranes were incubated with 0.5% digitonin for 30 min 
at 30°C and then centrifuged at 40 OOOg for 60 min to pellet the 
membranes. Solubilised receptors were measured after incubation of the 
supernatant with 30 pM [ 1251]-CYP for 30 min at 30°C. Solubilised 
receptors were precipitated on Whatman GF/B filters after the addition of 
15% PEG and ~-globulin. Although propranalol-displacable specific binding 
was present in the polyethylene glycol precipitates, only non-specific 
binding was precipitated when solubilised receptors were incubated with 
varying dilutions of B4A8-PWL (without PEG), followed by incubation 
overnight with sheep anti-mouse antibody at 4°C (Fig. 55). 
The collective data acquired independently from the Western blots, the 
[ 1251]-CYP inhibition assays and immunoprecipitation assays provided no 
evidence for recognition of the human beta-2 receptor by B4A8-PWL 





Figure 54. Autoradiograph of the immunoprecipitation of a 49 kDa band 
from solubilised membrane preparations of [35SJ-methionine 
pulsed Wt-7 Cape Town cells using B4A8-PWL monoclonal and 
sheep anti-mouse sepharose (exposure 48 hours, -70°C, Cronex 
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Figure 55. Precipitation of human beta-2 receptors solubilised using 
0.5% digotonin in the presence of 15% polyethelene glycol 
and -globulin (Column B) or B4A8-PWL monoclonal antibody 
(Column C). Total ( 1251]-CYP (cpm) in solubilised 
receptors in the absence of (-)L propranalol is shown in 
Column D (non-specific binding). Column A represents total 
number of receptors in membrane preparation prior to 
solubilization. Bar values represent the mean of assays 
performed in triplicate. 
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consistently obtained. Characterization of the B4A8-PWL monoclonal is 
summarised in Table 5.6.9. 
5.6.9 Summary of the characterisation of the B4A8-PWL monoclonal 
antibody. 
1. Recognition of BR-20-II peptide in ELISA to a titre of 1:24000 (Fig. 
45) 
2. IgM isotype (dot blot and Ouchterlony) 
3. Pre-incubation of B4A8-PWL with BR-20-II peptide inhibits binding in 
ELISA (Fig. 46). 
4. Strong recognition of a 49kDa protein in a Western blot of both~ 
receptor-transfected and non-transfected L cells (Fig. 48). 
5. Recognition of the 49kDa protein in UCT BR-1 cells, Jurkat cells, 
Bowes melanoma cells and human B cells, but not red cells. 
6. Positive speckled immunofluorescence only in fixed (permeabilised) 
transfected and non-transfected B82 cells (Fig. 49). 
7. Immunoabsorption studies confirmed that the synthetic peptide and 
49kDa biological protein shared a common epitope (Fig. 50). 
8. Biological activity of the 49kDa protein was suggested by incubation 
of the cells with a 1:200 dil of B4A8-PWL which resulted in a 46% 
reduction in cell proliferation (Fig. 52). 
9. Low degrees of [ 125I]-CYP inhibition (up to 30%) to human beta-2 
receptors were obtained by a 1:50 dilution of B4A8-PWL and the degree 
of inhibition was related to the level of beta-2 receptor expression. 
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10. Immunoprecipitation of a 35S methionine labelled 49kDa protein 
solubilised from B82 cells but no apparent immunoprecipitation of the 
human beta-2 receptor (Fig. 54). 
11. Purified B4A8-PWL IgM monoclonal antibody at a concentration of 
0.2g/L had no inhibitory effect on maximal isoproterenol stimulated 
cAMP release from Wt-7 Cape Town cells (See 6.5.2). 
5.7 Production of a rabbit polyclonal antibody to beta receptor peptide: 
BR20II 
Since it was clear that a monoclonal antibody raised to BR-20-II could at 
the most have a specificity for a single epitope on the peptide, a New 
Zealand White rabbit was immunised with the peptide in order to raise a 
polyclonal antibody which would have wider specificity and therefore 
better recognition. The effects of such an antibody on ligand binding 
are more likely to mimic those encountered in human sera, and I hoped to 
obtain an antibody which would in fact recognise the beta-2 receptor on 
Western blots or in functional assays. 
1mg of BR-20-II in complete Freunds adjuvant was injected subcutaneously 
and the rabbit boosted after six weeks with incomplete Freunds adjuvant .. 
The rabbit serum was harvested one week after boosting. 
Recognition of the peptide BR-20-II by the polyclonal rabbit antibody was 
confirmed using an adapted peptide ELISA, in which the second antibody 
was a peroxidase-conjugated goat anti-rabbit antibody. The rabbit 
antibody had a titre of 1:400 in the ELISA. In a Western blot of human 
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foreskin fibroblast membranes and Wt-7 Cape Town membranes separated on a 
9% PAGE under reducing conditions, the 49 kDa band was only recognised 
weakly, but the antibody also strongly recognised several other bands 
(64kDa, 59kDa and 22kDa (Fig. 56)). It is unlikely that the 64kDa or 
59kDa bands represented binding to beta-2 receptors since they were also 
recognized in cells (B82) not transfected with the beta-2 receptor gene 
and as in Fig. 48, only 26ng of beta-2 receptor was loaded per lane. 
In the [125I]-CYP ligand binding assay a 1:10 dilution of the rabbit 
antibody produced 41% inhibition of ligand binding to membranes from high 
expressing 4000 fmol/mg beta-2 receptor transfected B82 cells, and 50% of 
ligand binding to low expressing cells (411 fmol/mg). Unimmunised 
rabbit serum inhibited ligand binding by less than 25%. Inhibition of 
ligand binding was apparently greater than that obtained with the 
monoclonal B4A8-PWL (see 5.6.7) and was of the same order as that 
produced with some of the sera from the asthmatic patients in Chapter 3. 
It is thus likely that this rabbit antibody did in fact possess 
anti-beta-2 receptor specificities. Unfortunately the initial rabbit 
developed a viral infection and died and two further rabbits were 
immunised with BR-20-II peptide. Antibodies raised in these rabbits 
Code 700 and 701 also recognised the peptide in the ELISA and were used 
for the studies on basal and maximal adenylate cyclase activation 
described in 6.5.2. 
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5.8 Cross immunogenicity of human beta-2 adrenergic receptors: 
immunization of C3H mice with intact human beta-2 receptors in mouse 
membranes. 
B82-L cells are derived from C3H/AN mouse strain. Transfection and 
expression of the human beta-2 receptor into B82-L cells enabled me to 
conduct a completely unique experiment on the cross-species 
immunogenicity of intact human beta-2 receptors. Using this system the 
human beta-2 receptors are presented out of the context of other human 
antigens, in the C3H/AN mouse, without having to tediously affinity-
purify human beta-2 receptors from its normal human context. I 
considered that documentation of cross-species immunogenicity of this 
highly conserved mammalian receptor could have possible implications for 
its immunogenicity in man. 
Three C3H mice were immunized with 2400fmol beta-2 receptor in 800µg B82 
membrane protein intraperitoneally in complete Freunds adjuvant and 
boosted again after 6 and 10 weeks with 2400fmol beta-2 receptor in 
incomplete Freunds adjuvant. The mice were bled from the retro-orbital 
plexus and the specificity of the antibody induced was investigated using 
Western blots of membranes from B82, human foreskin fibroblasts and red 
blood cells. 
Strong bands of molecular weight between 60-68 000 daltons were found in 
both human fibroblasts and transfected B82 cells but not in the red cells 
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Figure 56. Western blot of 11% PAGE of human foreskin fibroblast 
membranes (lanes 1, 3, 5) and Wt-7 Cape Town membranes 
(lanes 2,4,6) incubated with 1:500 dilution of B4A8-PWL 
monoclonal antibody (lanes 1 & 2). 1:200 dilution of 
rabbit anti-peptide antibody (lanes 3 & 4) 
and 1:33 dilution of C3H mouse serum (immunised with Wt 
Cape Town membranes)(lanes 5 & 6). Note: Heavy blotchy 
staining at approx. 37kDa was artifact). Molecular weight 
markers (kDa) are shown on the left. 
268 
receptors, but when the studies were repeated, including membranes from 
untransfected B82 cells and transfected B82 cells with different levels 
of beta-2 receptor expression, no difference in the intensity of the 
60-68 kDa bands was found (Fig. 57) with the B82 cells. These 
experiments suggested however that the intact transfected human beta-2 
receptor was probably not immunogenic in the C3H mouse even with the 
addition of Freunds adjuvant. However the detection system for 
anti-beta receptor antibodies again may not have been sensitive enough. 
Dilutions of the mouse sera did not inhibit [ 125I]-CYP binding more than 
sera from control unimmunised mice. No evidence of the development of 
any disease was found in the mice, 18 months after the immunization. 
5.9 Discussion 
Induction of antibodies to the human beta-2 adrenergic receptor in 
laboratory animals requires that certain conformational or sequential 
epitopes of the receptors are presented to the immune system of the 
immunised animal as "foreign". 
In this chapter I have explored the immunogenicity of 20 amino acid 
hydrophobic peptide synthesised from a known sequence of the second 
transmembrane domain of the human beta-2 receptor. The immunogenicity of 
peptides derived from this domain has not previously been investigated. 
I have also investigated the immunogenicity of the intact human beta-2 
receptor, presented to the mouse within a mouse membrane context. I was 
unable to show that the mouse monoclonal antibody raised to the peptide 






Figure 57. Western blot of 11% PAGE of untransfected B82 cells (lane 
1) and transfected Wt-7 Cape Town cells (lane 2) and probed 
with 1:33 dilution of C3H mouse serum (immunised with Wt-7 
Cape Town cell membranes). 
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that the intact human beta-2 adrenergic receptor was immunogenic in the 
C3H mouse. 
There was also no direct evidence on the Western blots that the rabbit 
anti-peptide antibodies recognised the human beta-2 receptor but there 
was an increase in the [ 1251]-CYP ligand inhibitory activity above 
control serum (1.5-2 fold), and paradoxically, the rabbit anti-peptide 
antibody also stimulated adenylate cyclase activity, i.e. displayed some 
"intrinsic sympathomimetic activity", which may or may not have been 
exerted at the ligand binding site. 
The choice of the peptide derived from a single domain, of the human 
beta-2 receptor for production of these antibodies in mice and rabbits 
was influenced by the evidence supporting the role of this domain in 
ligand binding discussed in the introduction of this chapter, but 
ideally, all of the hydrophobic domains should be studied for 
immunogenicity, to produce a complete picture. More recently, Eshdat et 
al. (1989), showed that Iodocyanopindolol diazirine reacted with an amino 
acid residue which was located in a non-glycosylated region containing 
the sixth and seventh transmembrane domains of the receptor and that 
aspartic or glutamic acid residues were important for ligand interaction. 
Clearly, at the time of selecting a peptide for a monoclonal antibody 
production conceptual models of ligand binding were not as complete as 
they are at the time of writing up this thesis. 
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The peptide chosen and synthesised from Asp 79 - Met 99 of the beta-2 
receptor was extremely insoluble in aqueous solvent being composed of 
largely hydrophobic residues. Its inherent immunogenicity was unknown 
and two similar peptides were synthesized, also linked to cysteine 
residues (C and N-terminal), for possible coupling to keyhole limpet 
haemocyanin, if the peptide BR-20-II coupled to the palmitoyl residue 
failed to be immunogenic in the mouse. In view of the good response to 
the immunization of BALB/c mice with the palmitoyl peptide, the cysteine 
linked peptides BRP-20-I and BRP-20-III were not used for immunization, 
but it was useful having these peptides for the inhibition assays. 
Except for initial difficulties in establishing a peptide ELISA relating 
to the insolubility of the peptide BR-20-II in aqueous solutions, 
production of a monoclonal antibody of IgM isotype which recognised the 
peptide to a titre in 1:48 000 in the ELISA was uncomplicated. 
Inhibition experiments (5.6.2) confirmed that the antibody recognised the 
free (probably aggregated) peptide as well as the peptide attached to the 
plastic (Titertek). 
The monoclonal B4A8-PWL demonstrated no apparent recognition of 
glycosylated species of beta-2 receptors (MW 65-75kDa) on the Western 
blots of transfected L cells expressing high levels (4000fmol/mg) of 
beta-2 receptors (26ng per lane). It is possible that the amount of 
receptor protein may have been below the limits of detection for the 
immunoblot. There was no doubt that the monoclonal recognised a 49kDa 
protein, present on both transfected and non-transfected B82 mouse cells 
(5.6.4). Immunofluorescence studies (5.6.5) indicated that the 49kDa 
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protein was present in an intramembranous or intracellular location since 
positive fluorescence was only obtained with fixed (permeabilised) cells. 
Since the reported size of the unglycosylated human beta-2 receptor is 
46 480 daltons, it was important to be sure that the 49 kDa protein did 
not represent a partially processed beta-2 receptor. Although it was 
reported that the B82 cells do not express functional beta-2 receptor 
(Gilman, 1973) the mechanism for the failure to express beta-2 receptors 
has not previously been investigated. There seemed to be several 
possibilities: either the gene for the beta-2 receptor or its regulatory 
sequences have been deleted, or the B82 cells had acquired 
transcriptional or translational defects. Probing Southern blots of DNA 
from both the transfected and non-transfected cells with 2.6kb beta-2 
receptor gene probe, revealed total absence of beta-2 receptor gene 
sequences in the non-transfected cells. These autoradiographs 
demonstrate for the first time, to my knowledge, that the B82 cells in 
fact have a deletion of the beta-2 receptor gene. 
Based on the above experiment, it was quite clear that the 49kDa band 
detected by the monoclonal B4A8 PWL in the non-transfected cells, could 
not be partially processed beta-2 receptor. However, a relationship 
between the 49kDa protein to the beta receptor sequence in the peptide 
Asp 79 -Met99 does exist, since the monoclonal B4A8-PWL clearly recognises 
both. Since sequence homology between beta-2 receptor and other members 
of the seven transrnembrane supergene family is well recognized, the 49 
kDa protein could rep'resent a related or new member of this family of 
intramembranous proteins. The G21 protein (42 OOOMr) identified by 
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Kobilka (1987) also shares 43% homology with the human beta-2 adrenergic 
receptor in the transmembrane domains. RNA for the G-21 protein was 
found to be widely distributed (lymph nodes, gut, muscle). However, if 
the B82 cells have deleted the beta-2 receptor gene by chromosomal loss 
then they might also have deleted G-21, if both genes share the same 
chromosome as they do in humans (Chromosome 5). 
Definitive identification of the 49kDa protein would require affinity 
purification of the protein and either complete amino acid sequencing or 
partial sequencing of a peptide of the protein and construction of an 
oligonucleotide probe which could be used to screen a fibroblast cDNA 
library to sequence the DNA. It may also be possible to screen the 
library with the monoclonal B4A8-PWL. This investigation however is 
beyond the aims of this thesis but would be important to do in the future. 
I was unable to demonstrate that the monoclonal B4A8-PWL recognized 
solubilised intact beta receptors (removed from their membrane 
constraints) but the antibody did display some biological activity by 
inhibiting cell proliferation, (5.6.7) probably through its interaction 
with the 49kDa protein. 
[ 125IJ-CYP binding inhibition assays conducted with varying dilutions of 
the monoclonal B4A8-PWL and with an irrelevant monoclonal (aigE) were 
also informative. Firstly, similar low degree of inhibition (<30%) of 
ligand binding was obtained with both antibodies, and secondly, the 
degree of inhibition was greater when membranes from B82 cells expressing 
lower levels of beta-2 receptors were used. Since the two monoclonals 
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have very different specificities, the inhibitory effect found in these 
assays would appear to be non-specific, possibly due to interactions of 
non-variable domains of immunoglobulins with the receptor, or due to 
other factors in the dilutions of the ascites fluids or harvest fluids. 
These findings cast new light on the inhibition assays performed with 
human sera reported in Chapter 3.2 since, in addition to any possible 
specific inhibitory effects which one could attribute to the 
immunoglobulin fraction, mouse ascites also possess other non-
immunoglobulin factors which partially prevent beta-2 receptor 
antagonists from binding to their receptors. 
Inability to produce a monoclonal antibody which could recognise the 
intact human beta-2 receptor, the Western blotted receptor, or 
significantly inhibit ligand binding, could relate to differences in 
three-dimensional configurations of the peptide BR-II-20 versus the 
intact receptor and the beta-2 receptors once subjected to SOS-PAGE 
linearised and Western blotted. It is known (van Regenmortel - personal 
communication) that even for a 20 amino acid peptide, many conformational 
forms are possible and consequently a wide range in specificities of the 
resulting monoclonals raised to the peptide are possible, and one may 
have to perform several fusions and many screenings to obtain a 
monoclonal antibody which recognises the epitope in the intact molecule. 
Van Regenmortel has also stated that for such studies, polyclonal 
antibody production may be more useful. 
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Several groups have now produced polyclonal antibodies to peptides 
derived from the human beta-2 adrenergic receptor (Table 15)(Aoki et al. 
1989, Magnussen et al. 1989, Dunkel et al. 1989, Theveniau et al. 1989 
and Wang et al. 1989). The rabbit polyclonal antibody I raised to the 
BR-20-II peptide recognised a number of protein bands on the gel (Fig. 
56) including weak recognition of the 49kDa protein. This antibody also 
exerted stimulatory effects on basal adenylate cyclase activity. These 
effects could have been exerted at a non-ligand binding site, since I did 
not demonstrate direct binding to the human beta-2 receptor. I have not 
attempted to immunoprecipitate the solubilised human beta-2 receptor, 
using this antibody, but this should be done. The rabbit antibody 
produced similar degrees of inhibition of [1251]-CYP binding as many of 
the normal human sera exerted (3.2). Since stimulatory activity on basal 
adenylate cyclase activity was increased by further immunization with the 
peptide (6.5.2) one of the conformational epitopes recognised by the 
rabbit polyclonal antibody (701) may have been the beta-2 receptor. To 
confirm this it would be important to study the effect on adenylate 
cyclase activity in both transfected and non-transfected B82 cells. 
Polyclonal anti-peptide antibodies to 11 hydrophilic peptide sequences of 
the hamster beta-2 adrenergic receptor have been successfully raised by 
Wang (1989) but there are as yet no published reports of any attempts to 
raise antibodies to any of the hydrophobic intramembranous domains, with 
which to compare my own data. The studies by Wang supported the 
predictive value of hydropathy analysis for the domains which do not have 
a membrane spanning location. It is relevant to note that in their 
studies the 11 peptides varied in their immunogenicity in the rabbit and 
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that with one of the peptides (CM-10 - N terminal peptide) polyclonal 
antibodies were only obtained after immunization of 7 animals. 
Polyclonal antibodies raised to peptides derived from the second 
extracellular loops of the human beta-1 and beta-2 receptor by Magnusson 
et al. (1989) could be used immunohistochemically to visualise the beta 
adrenergic receptors on rabbit heart. The anti-beta-2 peptide antibodies 
did not show any functional effect on the beta adrenergic receptors but 
the anti-beta-1 peptide antibodies were able to displace agonist affinity 
to higher values. The studies are of particular interest since they 
identified possible T and B cell epitopes in the second extracellular 
loop which induce an immune response and they suggested that 
extracellular epitopes such as these may be important in the induction of 
autoimmune responses in vivo. 
The monoclonal anti-peptide antibody produce by Aoki et al. 1989 has been 
used to localise beta receptors in neurones and dentrites. I have 
summarised the main functional characteristics of important published 
studies of antibodies raised to beta adrenergic receptors, or to peptides 
derived from beta receptors in Table 15. 
Table 15 also illustrates that successful antibody production to beta 
adrenergic receptors is possible using partially purified adrenergic 
receptors (Fraser and Venter 1980), affinity chromatography purified 
receptors (Courad et al. 1981, Strader et al. 1983, Moxham et al. 198.6) 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































synthetic peptides of the beta receptor (Aoki et al. 1989, Wang et al. 
1989). 
These antibodies have demonstrated different specific applications e.g. 
inhibition of ligand binding, immunofluorescence, immunoprecipitation and 
some have demonstrated functional effects on adenylate cyclase activity 
(Courad et al. 1981, Strosberg et al. 1985, Sterin Borda et al. 1984). 
The immunogenicity of the intact human beta-2 receptor has not to my 
knowledge been previously investigated in the mouse. The immunization 
protocol described in 5.8 did not induce antibodies to the human beta-2 
adrenergic receptor that I could detect. It would have been most useful 
if I could have had a source of affinity-purified beta receptors with 
which to test my own rabbit and mouse antibodies, but I have obtained 
insufficient yields of beta receptors when I performed alprenalol 
affinity chromatography, for such studies. 
All of the above studies, including my own have investigated the 
immunogenicity of intact beta receptors or synthetic peptides derived 
from beta receptors using "non-physiological" systems. It would seem 
that there are no animal models which demonstrate spontaneous development 
of autoantibodies to the beta-2 adrenergic receptor. Moxham et al. 
(1986) has remarked that in their experience beta-1 receptors purified 
from S49 mouse lymphoma cells were found to be poor immunogens in the 
rabbit. In none of the above studies in Table 15 has it been reported 
that the induction of antibodies to beta adrenergic receptors led to any 
autoimmune process in the immunised animals, and in particular, there is 
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no evidence that any of these animals developed bronchospasm, or 
hypotension or cardiomyopathy. 
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The case for a functional role for antibodies to beta-1 receptors in 
disease is gaining acceptance. Since the evidence for the development of 
autoantibodies in humans to beta-1 adrenergic receptors has been 
published (Borda et al. 1984, Sterin Borda et al. 1984) it has been shown 
that these antibodies may have functional effects on adenylate cyclase 
(Limas et al. 1990, Gorelik et al. 1990) and that their induction may be 
linked to either HLA DR4 or HLA DRl. It has also been shown very 
recently (Cremaschi et al. 1990) that antibodies to H2 Class I 
histocompatibility molecules were capable of inhibiting specific beta 
adrenoceptor ligand binding to purified cardiac and smooth muscle 
membranes and simultaneously could behave as beta adrenoceptor agonists. 
The findings of Cremaschi et al. (1990) are not unlike my own findings 
with the rabbit polyclonal (701) antibody which displayed inhibition of 
antagonist binding but had a stimulatory effect on basal adenylate 
cyclase activity. While evidence for autoantibodies to cardiac beta-1 
receptors is increasing, evidence for a functional role for 
autoantibodies to the human beta-2 receptor remains scant (Fraser 1984, 
Wallerkat et al. 1987, Blecher et al. 1984). 
Autoantibodies to beta-2 receptors could "spontaneously" arise, following 
a viral infection as part of an anti-idiotypic response (Plotz 1983) and 
in this context anti-reovirus antibodies are of interest (Williams et al. 
1989). Liu et al. (1988) have shown that the reovirus 3 and [1251]-CYP 
bind to distinct domains of the beta adrenergic-like receptor. 
Anti-idiotypic antibodies to the reovirus could thus theoretically bind 
to beta-2 receptors and influence ligand binding non-competitively. 
Autoantibodies to hormone receptors may also arise in the context of 
aberrant HI.A DR expression as suggested by Hanifuzo et al. (1983) and 
Botazzo et al. (1983) in thyroid disease. Recent studies by S. Holgate, 
UK (unpublished and presented at the S.A. Pulmonology Congress, March, 
1990) have shown that there is indeed an increase in Class II expression 
in cells lining the airways of asthmatic subjects. These studies may 
have an important bearing on mechanisms of induction of anti-beta-2 
receptor antibodies in asthmatics and studies of the relationship between 
HI.A class II expression in the airways and [ 125IJ-CYP inhibitory activity 
in the serum are awaited. 
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CHAPTER 6 
STUDIES OF CLONED HUMAN BETA-2 ADRENERGIC RECEPTORS EXPRESSED IN L 
CELLS. 
6.1 Introduction 
Studies of intact cells permit receptors to be probed in their native 
environment where they are subject to regulation by intracellular 
events, organelles and constituents. Although certain properties are 
quite similar in membranes and intact cells, binding characteristics 
vary significantly. In this context, Insel (1983) reported a striking 
discrepancy between the Kd of an agonist determined in competitive 
assays with a radiolabelled antagonist and its Kact, (found to be two 
orders of magnitude less than the Kd). 
The data I have presented in Chapter 3, using the beta receptor 
antagonist [1251]-iodocyanopindolol and the guinea pig lung membrane 
preparation, confirmed that human serum in vitro does in fact modulate 
antagonist binding to guinea pig lung beta adrenergic receptors in 
membrane preparations, but also raised a number of intriguing 
questions relating to the possible physiological or pathophysiological 
significance of this phenomenon, if any, in intact cells. 
In the first instance, it was important to demonstrate that this is 
not simply a cross-species phenomenon observed with calf lung or 
guinea pig lung membranes and that human serum can indeed influence 
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ligand binding to human beta-2 receptors; It is also important to 
know whether human serum also modulates agonist activated human beta-2 
receptor function, before a pathophysiological role for the serum 
factors can be suggested. Since it is likely that, by the nature of 
its preparation, the membranes isolated in Chapter 3 from whole organ 
homogenates do not represent a physiological situation, I considered 
it important to study the phenomenon in viable cells under less harsh 
conditions than those used in the membrane preparation. 
Although the adenylate cyclase assay of Salomon (1974) used in the 
studies of Chapter 2 was sensitive and reliable for studies for 
homogenates, I did not consider it suitable for studies of the effects 
of whole or diluted serum in adenylate cyclase, since diluting the 
incubation mixture with serum is likely to induce further artefacts, 
making interpretation of the results difficult. Tissue homogenates 
are also unphysiological assay systems and an in vitro system 
utilising homogenates and membrane preparations for studies of 
functional effects of serum on beta-2 receptors certainly does not 
have an in vivo counterpart. It is not possible to study the effects 
of serum directly on cells in vivo, and studies of the modulating 
effects of serum on cloned human beta-2 receptors in cells in culture 
have not been previously reported. 
Following the cloning and sequencing of the human beta-2 adrenergic 
receptor by Chung et al. (1987) and in view of my previous experience 
with transfection of both wild type and mutant beta-2 receptors into 
B82 mouse fibroblasts at the N.I.H. (Chapter 4), on my return to Cape 
Town I considered that it would be worthwhile to conduct further 
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transfections of the wild type beta-2 receptor gene using the plasmid 
pMSV Neo in order to obtain a line of cells stably expressing the 
hwnan beta-2 receptor at a higher level than previously reported 
(Fraser et al. 1987). Such a line could be used as a rich source of 
hwnan beta-2 receptors for Western blots and antibody studies using 
irnrnunofluorescence, and could be used to study the effects of hwnan 
serwn fractions on beta-2 receptor mediated adenylate cyclase activity 
in whole cells. 
I have successfully transfected the hwnan beta-2 receptor gene into 
the B82 line of L cells and have found that certain hwnan sera 
markedly inhibited adenylate cyclase activity. However, the nature of 
the inhibition was unexpected. In this chapter I have described the 
transfections I have performed to obtain a line of cells expressing 
hwnan beta-2 receptors at high level, the experiments I have conducted 
to investigate the effects of hwnan sera and serwn factors on 
adenylate cyclase activity and the limitations of this system for 
studies with hwnan serwn. I have also used these transfected cells as 
a source of hwnan beta-2 receptors for follow-up studies of the serwn 
inhibitory effects on membrane preparations (described in Chapter 3) 
and to study the effects of purified irnrnunoglobulins and cellular 
fractions on beta-2 receptor function. 
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6.2 High level transfection of human beta-2 adrenergic receptors 
and reconstitution of hormone sensitive adenylate cyclase in 
mouse (B82) L cells. 
6.2.1 High level transfection of human beta-2 receptors into mouse 
(B82) L cells. 
The beta-2 receptor gene cloned into the new expression vector pMSV 
Neo was used for the transfections. This expression vector had been 
constructed at the N.I.H. by Dr. Fuzon Chung by replacement of the 
xanthine guanine phosphoribosyltransferase gene in plasmid pMSG with 
the neomycin-resistance gene and the construction of a new polylinker 
to facilitate cloning of the beta-2 adrenergic receptor gene. For 
receptor expression the entire coding region of the human beta-2 
adrenergic receptor derived from the genomic clone LCV-518 (Chung 
1987) (base pairs - 6 to 1267) was cloned into the Mlu and Eco RV 
sites in the polylinker region of pMSV neo. This expression vector 
pMSV neo contains the 1450 base pair long terminal repeat (LTR) of the 
mouse mammary tumour virus (MMTV) and the dexamethazone inducible 
transcription promoter within the MMTV 5' long terminal repeat 
regulates expression of the genes inserted into the downstream 
multiple cloning site. The neomycin resistance gene is expressed from 
an SV40 early promoter to ensure selection of stably transformed cells 
when grown in medium containing the Neomycin analogue Geneticin 
(G418). TG-1 E Coli were transformed with the pMSG Neo expression 
vector and grown up overnight followed by a plasmid preparation using 
the method of Davis et al. (1986). After further purification by CsCl 
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centrifugation, and precipitation in ethanol overnight, at -70°C, to 
sterilise the expression vector, lOOµg DNA (pMSV neo) was used for the 
transfection. 
On the day before the transfection, B82 cells grown to confluency in 
10cm dishes were split 1:5 and plated out in RP-10 (RPM! containing 
10% foetal calf serum). On the day of transfection the DNA was air 
dried in a laminar flow tissue culture hood (Laminaire, Bino 
Instrumentation, Sanlamhof) prior to resuspending it in 450µ1 sterile 
H20 and adding 50µ1 of 2.5M CaC12 . B82 cells (see Appendix E) were fed 
with fresh RP-10 and allowed to settle for 4 hours. One hour before 
the transfection, the DNA, in calcium chloride (550µ1), was added 
dropwise to 500µ1 2x Hepes buffered saline (HeBS) pH 7.05 while 
bubbling air through a mechanical pipettor, vortexed and the 
precipitate allowed to stand for 20 minutes at room temperature. 
Using a Pasteur pipette the precipitate was distributed evenly over 
the 10cm dish and after the dish was agitated, the cells were 
incubated at 37°C for 4 hours. The medium was then removed and 2.0ml 
of sterile 10% glycerol solution was added for 3 minutes at room 
temperature after which 5.0ml of PBS was added, the plate agitated and 
supernatant removed. After washing twice with PBS the cells were fed 
with RP-10 (without geneticin). After 2 days, geneticin G418 sulphate 
(Gibco), in a final concentration of SOOµg/ml, was added and the cells 
allowed to grow for one week. Four geneticin resistant clones were 
chosen, re-plated, and pulsed with 10-6M dexamethazone before 
screening the cell membranes of the positive clones (Appendix F) for 
beta-2 receptor expression using a [125!] cyanopindolol binding assay. 
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On initial screening all four clones expressed human beta-2 receptors 
ranging from 200fmol/mg to 3200fmol/mg membranes (Kd [ 125I)-CYP 
20-37pM). 
I also used the above protocol to transfect the serine 346 mutant 
beta-2 adrenergic receptor into the B82 cells (see 4.3.2). 
6.2.2 High level stable human beta-2 adrenergic receptor expression 
in clone B82-Wt-7, Cape Town. 
In the initial [ 125I]-CYP binding assays, clone B82-Wt-7 had the 
highest level of beta-2 receptor expression and on subsequent plating, 
freezing, thawing, re-culturing and pulsing with dexamathazone (Sigma) 
the cells have stably expressed beta-2 receptors at levels of between 
4000fmol-6000fmol/mg membrane protein during the eighteen month period 
of these studies. A saturation curve and Scatchard plot of the 
binding of [ 125I]-CYP to clone Wt-7 is shown in Figure 58. Clone Wt-7 
was used for most of the functional studies reported in this chapter. 
This new high expressing clone I have designated Wt-7 Cape Town. It 
is of interest that with this clone, beta-2 receptors were 
constitutively expressed (at approximately 400fmol/mg protein) even in 
the absence of dexamethazone pulsing. Constitutive expression is 
shown in the Scatchard insert in Fig. 58 (designated: B82 (low)). A 
photograph of Wt-7 Cape Town cells is shown in Fig. 58(a). 
To my knowledge this level of stable expression of human beta-2 
receptors in a cell line has not previously been achieved in 
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Figure 58. Saturation curve and Scatchard plot (insert) of [1251]-CYP 
binding to Wt-7 Cape Town cell membranes 95µg) after 
stimulating for 16 hours with 10-6M dexamethazone (Bmax 
4400fmol/mg, Kd - 13 pM). Scatchard plot of constitutive 
expression of human beta-2 receptors (-400fmol/mg) in 
unstimulated cells is designated B82 (low). 
Figure 58a Photograph of Wt-7 Cape Town cells in culture (B82 
fibroblasts transfected with the human beta-2 adrenergic 
receptor gene). 
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transfection experiments and thus clone Wt-7 Cape Town is a valuable 
source of human beta-2 receptors for further immunological, 
biochemical and pharmacological studies. Bouvier et al. (1989) 
attained beta-2 receptor levels of 1200fmol/mg membrane protein in 
Chinese hamster fibroblasts (CHW 1102 cells)). Three other clones 
which I transfected, expressing lower numbers of beta-2 receptors were 
used to study the effect of receptor number in the serum inhibitory 
experiments (6.6.1). Polyacrylamide gel electrophoresis and Coomassie 
blue staining revealed no new visible protein bands in membranes of 
the transfected cells. A Southern blot of genomic DNA, digested with 
Pst 1, from transfected and non-transfected cells was probed with the 
nick translated cDNA 2.6 kb genomic probe (4.2.3). An autoradiograph 
of the blot shown in Fig. 51 confirmed an absence of the beta-2 
receptor gene in non-transfected cells and gave a strong positive 
signal with the beta-2 receptor probe in the transfected cells. 
Constitutive expression of human beta-2 receptors had an inhibitory 
effect on growth of the cells in culture. Growth curves of the 
non-transfected B82 cells, "low" expressing 400fmol/mg B82 cells and 
"high" beta-2 receptor expressing B82 cells are shown in Fig. 59. (In 
the presence of 10-6M dexamethazone, and induction of beta-2 receptor 
expression, there was a further reduction (20-30%) in the rate of cell 
growth observed at 24-48 hrs.) 
6.2.3 Measurement of intra- and extra-cellular cyclic AMP. 
For the studies of the modulating effects of human serum and cellular 
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Figure 59. Growth in culture of untransfected B82 cells (•), B82 cells 
constitutively expressing low levels(•) and higher levels 
( 0) of human beta-2 adrenergic receptors (in the absence 
of 10-6M dexamethazone). lxl05 cells from each cell type 
were plated (in duplicate) and the number of viable cells 
counted at 5 time points (16 hrs, 23 hrs, 40 hrs, 47 hrs 
and 65 hrs). 
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the Wt-7 Cape Town cells, the RIANEN (R) cAMP [125]RIA kit (New 
England Nuclear) was used to measure cyclic AMP produced in the cells. 
These kits were found to be extremely reliable and reproducible, but 
an important limitation in my studies, was the cost of these kits 
which was amplified by the depression in the South African economy and 
poor Rand exchange rate. 
Samples were prepared for the cyclic AMP assay as follows:-
24 hours prior to stimulating the cells, B82 or Wt-7 Cape Town cells 
plated in 6 cm (5ml) dishes were pulsed with 10-6M dexamethazone 
(Sigma). Cells were used at half confluency (5 x 104 cells/plate). 
Kashles and Levitski (1987) have reported that confluency of cells in 
culture has an inhibitory effect on cAMP stimulation and have stressed 
the importance of conducting experiments of this nature with pre- or 
semi-confluent cells. 
At the start of the assay the medium was removed, cells were washed 
twice in PBS and then pre-incubated with 1 ml PBS with lmM isobutyl-
methylxanthine (IBMX) (Sigma) (to inhibit phosphodiesterase activity) 
and dilutions of serum, immunoglobulin, supernatant or buffer for 30 
minutes. To this was added concentrations of isoproterenol, 
prostaglandin E1 (or other agonists) for 20 min, after which the 
supernatant (containing the extracellular cAMP) was removed and 
lyophilised. 1 ml of trichloroacetate was then added to the cells 
(containing intracellular cAMP) on each plate for 1-2 minutes and then 
extracted four times with 4 ml of water-saturated ether, prior to snap 
freezing and lyophilization. Lyophilised extracts of the 
extracellular and intracellular cAMP were pooled and reconstituted to 
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a final concentration of 10-25µg/100µ1 in PBS for the cAMP assay. For 
all of the studies reported in this chapter, total cAMP (extracellular 
cAMP plus intracellular cAMP) was measured and expressed in pmol/mg/20 
min. Mean values and individual values obtained in duplicate 
experiments are shown on the bar graphs in this chapter. 
Protein concentration of the cells on the plates was determined by the 
Biuret assay after adding 1ml of 0.2N NaOH to representative plates 
for 30 min to dissolve the protein. A standard curve for cAMP was 
run, and calculation of total cAMP (pmol/mg protein/20min) produced 
was measured exactly according to the radioimmunoassay protocol, 
described in the manufacturer's instructions of the RIANEN ™ cAMP 
radioimmunoassay kit (Du Pont). The standard curve of cAMP using this 
kit was highly reproducible from assay to assay. 
6.2.4 B82 cells after transfection with the human beta-2 receptor 
gene couple with adenylate cyclase. 
It was previously known that B82 cells possess prostaglandin E1 
receptors which couple with adenylate cyclase (Chlapowski et al. 
1975). In order to confirm that the human beta-2 receptor in B82 
transfected cells coupled with the mouse adenylate cyclase, cyclic AMP 
production (pmol/mg/20 min) was compared in the transfected and 
non-transfected cells following stimulation with 10-6M 
(-)isoproterenol (Sigma) and 10-6M prostaglandin E1 (Sigma). Results 
of a duplicate experiment given in Fig. 60 show that transfection of 
the cells was accompanied by a marked increase in 10-6M 
(-)isoproterenol stimulation. Basal levels of cAMP were higher in the 
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stimulated cAMP production in untransfected B82 cells ( o) 
and Wt-7 Cape Town cells. (~) Bars indicate mean values 
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Figure 61. Dose response of(-) isoproterenol stimulation of cAMP 
production in Wt-7 Cape Town cells. Bars indicate mean 
values of duplicate experiments (.). 
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cells. Basal levels also varied with the level of beta receptor 
expression induced by 10-6M dexamethazone in the transfected cells. A 
dose response of isoproterenol stimulation of the transfected cells is 
given in Fig. 61. In studies with Chinese Hamster cells transfected 
with human beta-2 adrenergic receptors, Bouvier et al. (1989) showed 
that a reduction (by alkalization) of up to 60% of receptors was 
necessary before reduction in the maximal isoproterenol stimulation 
was observed. It was therefore important to compare maximum 
isoproterenol stimulated cAMP production in clones transfected with 
different numbers of beta-2 receptors. A comparison of maximal cAMP 
release in a low expressing clone (480 fmol/mg) with a high expressing 
clone (4800 fmol/mg) given in Fig. 62 demonstrates that a 10-fold 
reduction in receptor number only reduced the total cAMP production by 
50%. These data suggested that the excess receptors expressed are 
functionally redundant and that a dramatic reduction or inhibition of 
receptors is necessary before decreased in cAMP production are 
observed in the high expressing clones. I studied the kinetics of the 
cAMP release over time by stopping the reaction after 1, 2, 1, 20 and 
30 min and found that maximal cAMP release occurred within one minute 
and this level remained steady, i.e. no further cAMP was released even 
if the cells were stimulated with isoproterenol for 30 minutes. The 
increase in cAMP release found when the non transfected cells were 
stimulated with isoproterenol (Fig. 60) was unexpected, and may have 
represented some contamination of these clones with transfected cells 
since B82 cells are not normally responsive to isoproterenol 
stimulation. 
6.3 Documentation of a serum inhibitory effect on Wt-7 Cape Town 
cells 
6.3.1 The effects of asthmatic serum on basal and isoproterenol 
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Figure 62. Isoproterenol stimulated cAMP release in "low" (480 fm/rng) 
and high (4800 fm/mg) human beta-2 adrenergic receptor 
expressing B82 cells. Bars indicate mean values of 
duplicate experiments (.). 
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The initial experiments were conducted to investigate whether fresh 
human serum would, in fact, influence human beta-2 receptor stimulated 
adenylate cyclase production in the Wt-7 Cape Town cells. For these 
experiments, blood was allowed to clot, serum immediately separated at 
4°C and stored in aliquots at -70°C prior to the in vitro assays. Whole 
serum obtained from an asthmatic child (LJ) was used for the first 
exploratory experiments at 1:10 and 1:15 dilutions and 
(-)isoproterenol was used at 10-6M. A dose response inhibition of 
isoproterenol stimulated cyclic AMP production occurred in the 
presence of the asthmatic serum (Fig. 63). There was no inhibitory or 
stimulatory effect on basal adenylate cyclase activity in the mouse 
cells with this patient (I did subsequently encounter sera which 
stimulated basal activity (e.g. Patient LB)). Inhibition of adenylate 
cyclase activity was observed whether transfected cells expressing 
high numbers of beta-2 receptors (Wt-7 Cape Town) or cells expressing 
lower (400 fmol/mg) numbers of receptors were used for the assays. 
This assay was repeated with a separate serum sample from the same 
patient using a different batch of Wt-7 Cape Town cells. A dose 
response shown in Fig. 64 confirms the inhibitory effect exerted by 
the serum on cAMP production. 
Subsequent experiments were conducted to investigate whether different 
asthmatic sera varied in their ability to inhibit adenylate cyclase. 
For these experiments, my own serum (non-asthmatic), sera obtained 
from four asthmatic children (aged 8-14 years), two severe (steroid 
dependent) and two moderately severe asthmatics (not steroid 
dependent) were studied. Results of the functional assay and clinical 
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Figure 63. Basal, isoproterenol 
(10-6M) and Prostaglandin E1 
stimulated cAMP production in Wt
-7 Cape Town cells in the 
presence of asthmatic serum (1:1
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Figure 64. Dose responsive inhibitory effect of "asthmatic" serum on 
10-6M isoproterenol stimulated cAMP production in Wt-7 Cape 
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Figure 65. Inhibition of 10-6M isoproterenol stimulation of cAMP 
production in Wt-7 Cape Town cells by 1:10 dilutions of 
human sera. NS= normal non-asthmatic serum (PCP). 
PA= pooled asthmatic serum; ARK, AJV, AHB, ALG = sera 
from moderate and severe asthmatic children. Bar values 
represent mean of duplicate assays (.). 
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stimulation was markedly inhibited by 1:10 dilutions of the fresh 
pooled asthmatic sera and by the individual sera, but was not 
inhibited by a 1:10 dilution of my own serum. Results are expressed 
as a percentage of the maximal cAMP produced in the presence of 10-
6M 
isoproterenol (without serum). The asthmatic sera were also tested in 
the [1251]-CYP inhibition assay and results shown in Fig. 64 indicated 
that the patient (A-RK) whose serum was most inhibitory in the 
adenylate cyclase assay also displayed the greatest inhibition of 
[1251]-CYP binding to the human beta-2 receptors. 
6.3.2 Comparison of the effects of serum from well controlled and 
poorly controlled asthmatics on isoproterenol stimulated cyclic 
AMP production. 
Since the degree of inhibition of cAMP production was found to be 
variable in 6.3.1, I conducted the following experiments to establish 
whether the degree of inhibition was in fact related to clinical 
status of the patients. I studied 10 asthmatics, five of whom were 
well controlled on their medication and five of whom had severe 
asthma and were difficult to control. Clinical profiles of the 
patients are shown in Table 16. Nine of the patients were on steroid 
therapy. For these experiments I noted that a higher level of 
expression of beta-2 adrenergic receptors was induced in the Wt-7 Cape 
Town cells (-8000fmol/mg) upon dexamethazone stimulation, than I had 
found initially, although these cells were derived from a frozen stock 
of Wt-7 Cape Town. (Subsequent subcloning of these cells reverted back 
to expression of approximately 4000fmol - 6000fmol/mg). 
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Figure 66. Inhibition of 10-6M isoproterenol stimulated cAMP 
production by 1:10 dilutions of 10 asthmatic patients. 
Clinical details of each of these patients are detailed on 














































































































































































































































































































































































































































































































































































































































































































































































































































Results given in Fig. 66 show that sera from both the well controlled 
asthmatic children and the poorly controlled severe asthmatic children 
were inhibitory but that with the severe asthmatics, the inhibition 
tended to be greater. 
6.3.3 The effect of serum from non asthmatic children with other 
medical illnesses on isoproterenol stimulated cAMP production. 
Since the initial inhibition experiments (6.3.1) showed no inhibition 
with control serum and suggested a greater degree of inhibition in the 
severe asthmatics, it was important to investigate whether or not 
these "inhibitory factors" were exclusively found in asthmatic serum. 
Sera from 5 normal (non-asthmatic) healthy children were tested for 
inhibitory effects on total cAMP production. Mean inhibition was 6.6% 
(individual values were 13%, 13%, 7%, 0%, 0%). Sera from ten 
hospitalised children were also studied. These children were 
admitted to the Children's Hospital with other medical conditions and 
none were asthmatic. Six sera were found to be inhibitory(> 50%) 
and the other four sera displayed low levels of inhibition (<20%). 
The inhibition of 10-6M isoproterenol stimulation. in the presence of 
1:10 dilutions of sera from six of the ten children in Fig. 67 
confirms that these "inhibitory serum factors" are not only present in 
the sera of children with atopic asthma. Sera which were found to be 
inhibitory included patients with acute glomerulonephritis, acute 
cellulitis of the foot, epilepsy and two relatively well children with 
diabetes who were on insulin treatment. These experiments clearly 
demonstrated that inhibitory factors in sera were not exclusive to 
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Figure 67. Basal and 10-6M isoproterenol stimulated cAMP production in 
Wt-7 Cape Town cells. Inhibition of 10-6M isoproterenol 
stimulated cAMP production was marked with 1:10 dilutions 
of sera from children with other medical conditions. 
Gl - cellulitis; WN - acute glomerulonephritis; RP -
epileptic; SA - epileptic; KJ - diabetic; CW 
allergic rhinitis. 
Bars indicate mean values of duplicate assays. 
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stimulation of cAMP by 10-6M isoproterenol in the presence of sera 
from 9 non-asthmatics with 11 asthmatics and found no significanat 
difference. Mean non-asthmatic: 5628pmol cAMP (SEM - 992); Mean 
asthmatic: 5219pmol cAMP (SEM - 744). p - 0.878 (Kruskal-Wallis 
test), p = 0.908 (Wilcoxin 2 - sample test). 
6.3.4 Comparison of the effects of pre- and post-operative 
non-asthmatic sera on inhibition of cyclic AMP production. 
In order to investigate whether the functional inhibitory activity in 
patient sera was generated by or amplified during an acute phase 
response, pre- and post-operative sera from six non-asthmatic adult 
patients in a gastrointestinal surgical ward were studied. The 
patients all underwent major surgery (cholecystectomy, oesophageal 
hernia repair, colostomy, or vasectomy and antrectomy). 
Sera samples were taken on the day before major surgery and 24 hours 
after surgery and stored at -70°C. To confirm that the patients were 
undergoing an acute phase response, C-reactive protein (CRP) levels 
were measured (Beckman, laser nephelometer) on an aliquot of each 
sample. The effect of a 1:10 dilution of each patient's serum before 
or after surgery on 10-6M isoproterenol stimulated adenylate cyclase 
in Wt-7 Cape Town cells was studied. Results given in Fig. 68 show 
that there was essentially no difference between the inhibitory 
capacity of pre-operative versus the post-operative sera. 
It is also quite clear that individual patient sera again showed a 
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Figure 68. Comparison of the inhibitory effects of six pre- and 
post-operative sera on 10-6M isoproterenol stimulated cAMP 
production. C reactive protein levels pre- and 
post-operatively are given in mg/L. Bars indicate mean 










significantly over short periods of time (48 hours in this study). 
Sera code FRA and SVD were minimally inhibitory, while paired sera 
from HILL and SMI were markedly inhibitory pre- and post-operatively. 
Two patients had CRP levels less than 1 mg/L prior to surgery: one 
serum was inhibitory (Code RAB) while another (Code SVD) was not 
inhibitory. These data support a conclusion that the inhibitory 
activity of sera on adenylate cyclase activation is unrelated to the 
acute phase inflammatory response. 
6.3.5 Comparison of the inhibition of isoproterenol and fenoterol 
(Berotec) stimulated cyclic AMP production by asthmatic sera 
Since the binding of fenoterol to the human beta-2 receptor is more 
selective than that of (-)isoproterenol, I compared the difference 
between the inhibition mediated by asthmatic sera on isoproterenol and 
fenoterol mediated cAMP release from transfected Wt 7 Cape Town cells. 
Cells were stimulated by 10-6M (-)isoproterenol as described (6.2.3), 
or a Berotec metered aerosol (Boehringer Ingelheim) was held 10 cm 
above the tissue culture dish and one puff (0.2mg Fenoterol 
hydrobromide) was delivered directly into the dish, after the cells 
had been incubated for 30 min with IBMX and a 1:10 dilution of 
patient's serum. Results of a comparative experiment shown in Fig. 69 
demonstrate comparable degrees of inhibition by asthmatic sera for 
both agonists. 
Of importance was that one of the asthmatic patient's sera (JW) 
consistently did not inhibit (-)isoproterenol or fenoterol stimulated 
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Figure 69. Similarity of the inhibitory effects of asthmatic sera on 
fenoterol (Berotec) (a) or isoproterenol (10- 6M) stimulated 
cAMP production (b). Bar values represent the mean of 
duplicate assays. 
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had been stored for one month at -20°C. Previously the sera from this 
patient was clearly inhibitory for (-)isoproterenol stimulated cAMP 
release. (Inhibition by his serum was also previously not removed by 
overnight dialysis of his fresh serum - see 6.4.4). These experiments 
suggested that the "inhibitory factor" may not be stable. 
6.4 Identification of the nature of the serum inhibitory effect on 
Wt-7 Cape Town cells. 
The "inhibitory factors" for cAMP production in serum were not present 
in all sera tested and appeared to be unstable on storage. To identify 
the origin and selectivity of the inhibitory effect it was important 
to locate which component of the adenylate cyclase coupled system was 
affected and to compare the effects of whole serum with that of plasma 
and serum fractions. 
6.4.1 Comparison of the effect of serum on isoproterenol, PGE1~ 
sodium fluoride (G protein) and forskolin (adenylate cyclase) 
stimulated cAMP activity. 
For these experiments fresh serum was used from an asthmatic patient 
(LB) whose serum previously consistently inhibited maximal 
isoproterenol stimulation by ±SOX. Wt-7 Cape Town cells were 
stimulated with isoproterenol (10- 6M), PGE1 , forskolin (Sigma)(lOOµM) 
or sodium fluoride (Sigma)(lmM and lOmM). The differential effects on 
isoproterenol, forskolin or sodium fluoride are shown in Fig. 70 and 
these effects were completely reproducible and consistent in a 
subsequent separate experiment, when the concentration of 
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isoproterenol was varied between 10-10M and 10-5M and forskolin 
concentration between lµM to 200µM. Serum inhibited 10-6M 
isoproterenol, PGE1 , and forskolin stimulated cAMP release but, 
paradoxically, enhanced stimulation of cAMP release by sodium fluoride 
at both lmM and lOmM concentrations. The percentage inhibition of 
maximal forskolin, and PGE1 , stimulated cAMP release, was identical to 
the inhibition of maximal isoproterenol stimulated cAMP release and 
suggested that the inhibitory effects of serum are not specific for 
the beta-2 receptor but that they are the result of a more generalised 
and non-specific membrane inhibitory effect. 
6.4.2 The effect of pre-incubation and washing on the inhibitory 
effect of asthmatic serum on isoproterenol stimulated cyclic 
AMP activity. 
Preincubation of the cells for 30 min with a 1:10 dilution of patient 
serum resulted in inhibition of 10-6M isoproterenol stimulation, in 
the above assays. The effect of a 2 hour pre-incubation of Clone Wt-7 
Cape Town cells with asthmatic serum (1/10 dilution, patient L-BD) 
was studied at two concentrations, 10-6M and 10-8M of (-)isoproterenol. 
Cells stimulated in the presence of 1/10 dilution of L-BD serum showed 
the expected decreased total cAMP production after 30 min 
pre-incubation with serum. However, when cells were pre-incubated 
with 1:10 dilution of serum for 2 hours, followed by two washes of 
phosphate buffered saline prior to stimulation in 10-6M or 10-8M 
isoproterenol, further reductions in the cAMP response were observed .. 
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Figure 70. Inhibition of 10-6M isoproterenol, lOOµM forskolin and 
stimulation of lmM or lOOmM sodium fluoride stimulated cAMP 
production by 1:10 dilution of "asthmatic" serum. Bars 
indicate mean values of duplicate assays (e). 
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Figure 71. The effect of an extended pre-incubation (2 hours) on the 
inhibition of 10-6M or 10-aM isoproterenol stimulated cAMP 
production exerted by a 1:10 dilution of "asthmatic" serum 
(patient L-BD). Bars indicate mean values of duplicate 
assays (.). 
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the absence of isoproterenol) is shown in the bar panel on far right 
(Fig. 71). 
The marked inhibition by serum which was not removed by washing the 
cells extensively with phosphate buffered serum suggested either an 
extremely high affinity of the "inhibitory factor" for the cells or 
that serum mediated a toxic effect on the cells which was irreversible. 
6.4.3. The effect of clotting on the inhibition of (-)isoproterenol 
stimulated cyclic AMP activity by human sera/plasma 
In order to investigate the generation of the "serum inhibitory 
factors" it was important to test whether or not these factors were 
also present in plasma. For these experiments fresh venous blood was 
taken from a child with asthma and either allowed to clot for 10 min 
(and serum separated immediately), heparinised, or was treated with 
EDTA to inhibit clotting, and fresh plasma separated immediately and 
held at 4°C for 30 minutes prior to conducting the assay. Results 
illustrated in Fig. 72 show that while a 1:10 dilution of the serum 
was inhibitory, heparin, heparinised plasma, or EDTA plasma slightly 
enhanced 10-6M (-)isoproterenol stimulated cAMP release. The absence 
of an inhibitory effect with plasma was confirmed with studies of 
other sera in subsequent experiments. 
6.4.4 The effect of dialysis of serum on inhibition of isoproterenol 










Heparinsed Plasma (1:10) 









Figure 72. Comparison of the effects of
 serum (inhibitory) and plasma 
(heparinised e, or EDTA m) on 10-
6M isoproterenol 
stimulated cAMP production. The effect 
of heparin alone is 
designated "H". Bars indicate mean valu
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Figure 73. The effect of dialysis (D) f!:;j 
on the inhibition of 1: 10 
dilution of serum (ND) lit on 10-
6M isoproterenol stimulated 
cAMP production. Bars indicate mean va
lues of duplicate 
assays(.). 
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Fresh serum was dialysed against 20mM sodium phosphate buffer 
overnight using Spectropor(R) membrane tubing (Spectrum Med. Ind. 
Inc.) molecular weight cut-off 12000-14000 daltons. As found with 
antagonist [125I]-CYP inhibition (3.2.2(i)), the functional inhibitory 
factor(s) were not removed by dialysis (Fig. 73, patient JW) 
indicating that these factors have a molecular weight of greater than 
12000 daltons. 
6.4.5 The effect of fractions of asthmatic serum on isoproterenol 
stimulated cyclic AMP activity. 
Three fractions of fresh serum from two severe asthmatics whose sera 
were found to be consistently inhibitory were studied. Sera were 
precipitated in 33% ammonium sulphate (Fraction I) followed by a 66% 
ammonium sulphate precipitate of the supernatant (of the 33% ammonium 
sulphate precipitate) (Fraction II). Fraction III (Sup) was the 
supernatant of the second (66%) precipitation. All fractions were 
dialysed overnight in PBS to remove the salt (using Spectrapor (R) 
membrane tubing, 12000 - 14000MW cut-off). 
These three fractions were then reconstituted in assay buffer to the 
original serum volume and a 1:10 dilution was used in the adenylate 
cyclase assay. Inhibitory effects on total cAMP production were 
studied at 10-6M concentrations of isoproterenol. No consistent 
inhibition of cAMP production was mediated by any of the serum factors 
studied, indicating that the inhibitory factor(s) were not mediated by 
the immunoglobulin fractions alone and that the "inhibitory factors" 
were unstable. 
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6.4.6 Thermal stability of the inhibitory factors in serum. 
When performing reproducibility studies on stored samples, I noted 
that the inhibitory effects observed were greater when fresh serum or 
serum stored at -70°C was used in the assays, but that when serum was 
stored at -20°C for a month or longer, the inhibitory activity declined 
significantly. Inhibitory effects were markedly reduced when serum 
was stored at 4°C for 72 hours and totally inactivated if the serum was 
heated to 56°C for 30 min (Fig. 74). 
6.4.7 Western blots of Wt-7 Cape Town cells incubated with human sera 
Since the stability studies suggested that the inhibitory effects on 
cAMP production could be complement mediated, cell membranes were 
prepared from the Wt-7 Cape Town cells and Western blotted on to 
nitrocellulose membranes to investigate whether there were antibodies 
in the human sera which recognised mouse proteins and which could be 
involved in activation of the classical pathway of complement leading 
to cell damage of the Wt-7 Cape Town cells. 
Western blots of Wt-7 Cape Town cell membranes were incubated with 
1:50 dilutions of patient sera for 90 min, washed 3 times followed by 
alkaline phosphatase-conjugated goat anti-human Ig (G +A+ M) (Zymed) 
1:1000 dilution and addition of BCIP (5 Bromo 4 chloro indoxyl 
phosphate) substrate (Fig. 75). In no instance was there a clear 
recognition of human beta-2 adrenergic receptors (each lane had 1 
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Figure 74. The effect of method of storage of serum on the inhibitory 
effects of serum on 10-6M isoproterenol stimulated cAMP 
production F@ (Frozen at -70°C); 4°C (stored at 4°C for 72 
hours ID); 56 ° C for 30 minutes I!. Bars indicate mean values 
of duplicate experiments. 
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any mouse proteins in the blot (lane 1) whereas other sera from 
asthmatics recognised several distinct mouse proteins (lane 2, 3 and 
4). In other Western blots (Fig. 75(a)) using overnight incubation 
with first antibody human sera recognized many mouse antigens. 
Thus it was possible that certain sera had heterophile (anti-mouse) 
antibodies which, if they activated complement, could lyse the mouse L 
cells and result in damage to cell membrane function. This would 
account for the functional serum inhibitory effects I had observed on 
the Wt-7 Cape Town cells. It was thus important to study the effects 
of human serum on Wt-7 Cape Town cell viability. 
6.4.8 Effects of human serum on viability of Wt-7 Cape Town cells and 
the effect of heat inactivation on the serum inhibitory factors 
Since the experimental evidence thus far suggested that the 
"inhibitory effects" of serum could be due to complement mediated 
lysis of mouse cells by heterophile anti-mouse antibodies, I 
investigated the effects of specific individual sera which I had 
previously identified to be inhibitory, or non-inhibitory in the cAMP 
experiments, on cell viability over 2 hours using both a human 
melanoma cell line (UCT-Mel 2), and the mouse cells (Wt-7 Cape Town). 
The design and results of this experiment are summarised in Table 17. 
It was quite clear under direct microscopy that within 30 min of 
applying fresh serum (1:10 dilution) to the mouse cells they rounded 
up, became less refractile, acquired granules, became non-adherent and 
were membrane damaged (failed to exclude Trypan blue). These changes 
were not observed when serum was heated to S6°C for 30 min or when a 
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1 2 3 4 
Figure 75. Wescern blots of llX PAGE ~c-7 Cape Town cell membranes 
incubated for 1.5 hours wich 1:50 dilution of sera from 4 
aschmatic patients . Lane l : no bands detected; lace 2: 2 
bands detected; Lanes 3 and 4 · single different bands 
detected . 
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Fi gure 75a ~estern blot of 11% PAGE of ~t-7 _Cape Town cell membranes 
incubated overnight with 1:50 dilutions of sera from 
asthmatjc patients showing binding to many proteins in the 
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1:10 dilution fresh plasma was used instead of serum. Fresh serum did 
not lyse the human melanoma cells, supporting the conclusion that one 
likely explanation for the inhibitory effects observed by certain 
human sera in the mouse system was complement mediated lysis of the 
mouse cells activated by heterophile antibodies. 
I have found consistently that heat inactivation reduces the 
inhibitory effects of human sera on adenylate cyclase activation and 
cAMP production, but that there is residual inhibitory activity even 
in the heat inactivated serum, suggesting that there may be other (non 
complement mediated) mechanisms for the inhibitory effects in human 
sera (Fig. 76). 
In a comparison of the% maximal stimulation forl0- 6M isoproterenol 
stimulated cAMP production using fresh or stored sera (-20°C) from 10 
patients, the mean% stimulation for fresh sera was 63.1%, SEM = 8.1 
and for stored sera 92.5%, SEM - 1.7. This difference was highly 
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Figure 76. Partial removal of the inhibitory activity of 4 asth
matic 
sera on 10-6M isoproterenol stimulated cAMP production by 
heat inactivation (S6°C for 30 min). Bar values represent 
mean of duplicate assays (.). 
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The experiments on cell viability after incubation with human serum 
thus showed that inhibition of cAMP activity by fresh sera described 
in 6.3.1 - 6.3.5 can not be attributed solely to a specific effect on 
the adenylate cyclase system. A heat labile "factor" is present in 
serum, but not in plasma, which damaged cell membranes and resulted in 
a loss of cAMP activity. These observations are consistent with 
complement mediated cell membrane damage via heterophile antibodies, 
but may also be caused by other serum components. 
The Wt-7 Cape Town cells are thus not suitable for investigating the 
effects of heat labile components in human sera on adenylate cyclase 
activation in view of the presence of heterophile antibodies to mouse 
antigens in many of the human sera. It is likely that similar 
difficulties may be encountered with other non-human cellular systems. 
This system is however suitable for the study of the direct effect of 
purified specific components of human sera, or activated cells, on the 
beta-2 receptor coupled adenylate cyclase system. I have therefore 
proceeded to study the effects of purified IgG, monoclonal IgM, rabbit 
polyclonal anti beta-2 receptor peptide antibody, activated 
neutrophils, activated lymphocytes and activated platelets on the 
adenylate cyclase system in Wt-7 Cape Town cells in section 6.5, and 
have conducted further ligand binding studies on membrane preparations 
of the Wt-7 Cape Town cells, as a follow-up to the experiments 
described in Chapter 3. 
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6.5.1 The effect of whole human IgG and F(ab)~ IgG fragments on 
isoproterenol stimulated cyclic AMP activity. 
The effect of purified immunoglobulin G (IgG) and F(ab) 2 fragments of 
IgG on isoproterenol-stimulated adenylate cyclase activation in Wt-7 
Cape Town cells was investigated. Purified IgG fractions from a pool 
of asthmatic patients whose sera were shown to be inhibitory for 
adenylate cyclase activation, and the F(ab) 2 fragments prepared from 
the purified IgG, were used. 
DEAE purified IgG was digested overnight with pepsin (Sigma), at pH 
4.5, and after centrifuging, the pH of the supernatant was adjusted to 
7.4 (to inactivate the pepsin), dialysed overnight with phosphate 
buffered saline pH 7.4, and applied to a 40cm Sephadex GlOO column. 
Two peaks were separated: the first contained the F(ab) 2 fragments 
(Sterin Borda et al. 1988). Purity of the IgG and F(ab) 2 fragments 
was checked on PAGE. 
Samples from five asthmatic subjects containing equivalent IgG and 
F(ab) 2 fragment protein concentrations to the IgG concentration in a 
1:10 dilution of serum measured by Nephelometry (Beckman 
Immunochemistry Analyser) were compared with inhibition of 
isoproterenol stimulated cAMP release obtained with a 1:10 dilution of 
fresh serum. No significant inhibition and cAMP activity was 
mediated by either whole immunoglobulin G or F(ab) 2 fragments. The 
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finding contrasts sharply with effects of purified immunoglobulin G 
fractions in the [1251]-CYP inhibition assay (3.3). 
These data support a conclusion that factors in serum identified in 
Chapter 3 which inhibit antagonist binding ([ 1251]-CYP) to membrane 
bound beta-2 adrenergic receptors (and which may include the IgG 
fraction) are distinct from those which inhibit the functional beta-2 
adrenergic receptor activity in live Wt-7 Cape Town cells. 
6.5.2 The effect of rabbit polyclonal and mouse monoclonal anti-beta 
receptor peptide BR-20-11 antibodies on basal and maximal 
adenylate cyclase activation. 
Although immunogloblins from human sera showed no inhibitory effects 
on adenylate cyclase, it was important to investigate whether 
antibodies specifically raised to a peptide derived from the beta-2 
receptor had any functional inhibitory, or stimulatory activity. 
The polyclonal antibodies I had raised in two rabbits (700 and 701) to 
BR-20-11 peptide (5.7) and the monoclonal antibody B4A8-PWL (ascites 
fluid)(5.6) were tested at 1:10 dilutions for their effects on basal 
adenylate cyclase activity and 10-6M isoproterenol stimulated cAMP 
release in Wt-7 Cape Town. There was no inhibition or enhancement of 
maximal isoproterenol stimulated cAMP production with rabbit serum 
(1:10 dilution) or with monoclonal antibody purified IgM (0.2g/L). ~ 
degree of stimulation above basal was obtained with the monoclonal at 
1:10 dilution and with the rabbit polyclonal (rabbit 701) antibody 
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(1:10 dilution). To confirm the specificity of the stimulatory 
activity, the rabbit was boosted three times with the peptide 
(BR-20-11), and the effect of 1:10 dilution of the hyperimmune rabbit 
serum was compared with the original serum. Results given in Fig. 77 
show that the stimulatory activity increased from 85% above basal cAMP 
level, to 162% above basal levels. 
The rabbit anti-peptide antibodies were also tested for their ability 
to inhibit [1251]-CYP binding. Both rabbit sera were inhibitory, but 
that rabbit 701 was markedly inhibitory for [1251]-CYP binding (86% 
inhibition at 1:10 dilution)(Fig. 78). 
By contrast, control non-immunised rabbit sera and 1:10 dilution of 
rabbit anti-peptide sera had minimal effects on 10-6M isoproterenol 
stimulation of Wt-7 Cape Town cells (less than SX inhibition). 
Purified B4A8 monoclonal IgM, at a concentration of 0.2g/L, similarly 
had no inhibitory effect on maximal isoproterenol stimulation. 
(Monoclonal IgM was purified using a Sephadex G200 column and 
fractions containing IgM were identified using PAGE and dot blotting, 
using a goat anti-mouse IgM antibody). 
These results demonstrate that the polyclonal antibodies may have 
fairly marked effects on basal adenylate cyclase activation. They 
also demonstrate that certain sera may have significant effects on 
high affinity antagonist binding (86% inhibition) but exert minimal 
effects on maximal functional activity and at the same time 













Figure 77. The effect of monoclonal B4A8-PWL (1:10 
dil ascites)(Bar 1) 
rabbit 701 antibody (1:10 dil.)(Bar 2)( and boosted
 rabbit 
701 antibody (1:10 dil.)(Bar 3) on basal adenylate 
cyclase 
activity (Values expressed as% stimulation above b
asal 
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I have also observed that while the majority of human sera studied had 
no effect on basal cAMP release, one patient (LB) serum consistently 
stimulated basal cAMP release in the absence of isoproterenol (20% of 
maximal isoproterenol stimulation). 
6.5.3 The effect of products of activated normal neutrophils and Con 
A stimulated normal lymphocytes on isoproterenol stimulated 
cAMP release. 
In an attempt to identify other possible cellular sources of adenylate 
cyclase inhibitory activity, the effect of supernatants from activated 
neutrophils and lymphocytes were also investigated. 
Normal lymphocytes were cultured in RPMI for three days in 20µg/ml 
Concanavalin A at 106 cells/ml in 10% foetal calf serum. After three 
days, the cultures were centrifuged to remove cells and methyl 
a-D-manopyranoside (MMP) was added to a final concentration of lOmM to 
inactivate the Con A. The medium was then filtered through a 0.45µM 
Millipore filter prior to stimulating the Wt-7 Cape Town cells with 
10-6M isoproterenol either in neat supernatant, or a 1:2 dilution of 
supernatant. 
Normal neutrophils, separated on Ficoll hypaque were suspended in PBS 
at a concentration of 106 neutrophils/ml and stimulated with lOng/ml 
or lOOng/ml phorbol myristate acid (PMA). Cells were separated by 
centrifugation and the effect of the supernatants on 10-6M 
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Figure 79. The effect of products of PMA activated neutrophils, RPMI, 
and lymphocyte conditioned media on 10-6M isoproterenol 
stimulated cAMP production - A - RPMI; B - lymphocyte 
conditioned media (neat); C - Con A stimulated lymphocyte 
conditioned media (neat); D - Con A stimulated lymphocyte 
conditioned media (1:2); E - PMA stimulated (100 ng/ml) 
neutrophil products. (Bars represent mean values of 
duplicate experiments (.)). 
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Results given in Fig. 79 show that RPM! mildly enhanced isoproterenol 
stimulation, but that neat lymphocyte conditioned media, with or 
without Con A, significantly enhanced isoproterenol stimulation by 43% 
and diluted lymphocyte (1:2) conditioned media enhanced stimulation by 
53%. 
The neat products of 100 ng/ml PMA stimulated neutrophils (which 
release lysosomal granules)(but not the 1:5 dilution) were markedly 
inhibitory for 10-6M isoproterenol mediated adenylate cyclase activity 
(% stimulation of maximum - 17%). Supernatants from neutrophils 
activated with lOng/ml PMA (which do not release lysosomal products) 
were not inhibitory. (PMA is unstable under the conditions of the 
experiment and the results cannot be attributed to the effect of PMA 
alone). 
These data do suggest that neutrophil products are a possible 
candidate source of inhibitory factors for adenylate cyclase 
activation, but that lymphocytes do not release inhibitory factors 
(under normal culture conditions) but may in fact stimulate cAMP 
production (possibly through the release of prostaglandins or other 
molecules). 
The role of neutrophil products in mediating beta-2 receptor 
inhibition needs to be explored in further studies. I have, 
unfortunately, due to financial and time constraints been unable to 
extend these studies with neutrophils, but have in these studies 
identified a promising area for further research. The inhibitory 
effects of inflammatory cell mediators have recently been reported in 
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the studies by Raaijmakers (1989) who demonstrated that arachidonic 
acid metabolites PAF, LTB 4 and LTC 4 inhibit beta receptor ligand 
binding to pulmonary membranes and also inhibit isoproterenol and 
Gpp(NH)p activation of lymphocytes adenylate cyclase. 
6.5.4. Effects of products of ADP activated platelets on(-) 
isoproterenol stimulated cAMP release. 
In view of the marked inhibitory effects of activated neutrophils, I 
have also examined the possibility that inhibitory factors may arise 
from platelets which are activated during the clotting process or 
during cellular inflammation by IgE or platelet activating factor 
(PAF). 
For these experiments, platelets at a concentration of lxl09 
platelets/ml (in donor serum) were obtained freshly from the Western 
Province Blood Transfusion Service, with the assistance of Mr. Alan 
Kirby, one hour before the experiment was conducted, and maintained at 
37°c. 
Platelets were activated (as monitored by light scatter), for 15 min 
with 5µM ADP (adenosine diphosphate) at 37°C, or inactivated at 47°C for 
10 minutes, prior to stimulating with 5µM ADP at 37°C. The effect of a 
1:10 dilution of platelet products released into serum from activated, 
inactivated platelets was compared with the effect of a 1:10 dilution 
of platelet poor serum or 10-6M isoproterenol stimulation of WT-7 Cape 
Town cells. 
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Results of these experiments show that minimal and identical 
inhibition (<15%) was mediated by serum in which platelets were 
activated or inactivated, and that this inhibition was of the same 
order as the inhibition mediated by a 1:10 dilution of the platelet 
poor serum (20%). These data showed that inhibitory factors for 
adenylate cyclase are not derived from activated platelets, at least 
under the conditions of the study. 
6.5.5 Summary of the inhibitory and stimulatory effects of cellular 
components and serum on isoproterenol stimulated cAMP 
production in Wt-7 Cape Town cells. 
1. Certain fresh human sera were found to dramatically inhibit 
isoproterenol stimulated cAMP production in Wt-7-Cape Town 
cells. 
2. Inhibitory activity of serum was stable when stored at -70°C, 
relatively unstable at 4°C and totally inactivated when serum 
was heated at 56°C for 30 min, consistent with complement damage 
to the cells. 
3. Viability studies showed that inhibitory human sera (at 1:10 
dilution) produced morphological cell changes, visible under 
light microscopy when applied to mouse cells (L cells) but not 
to the human cells (Melanoma cells) studied. 
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4. Inhibitory activity on mouse cells was not present in all sera 
but was found in asthmatic sera and non-asthmatic hospitalised 
children with other medical conditions. Healthy normal and 
hospitalised sick children were identified whose sera displayed 
no inhibitory activity. (Inhibitory activity tended to be 
greater in the older patients.) 
5. Inhibitory activity of serum did not vary over the short term 
(48 hrs); was highly reproducible in a given patient, and was 
not amplified during an acute phase inflammatory response (as 
measured by C reactive protein levels). 
6. Cyclic AMP inhibitory activity was not present in plasma, (EDTA 
or heparinised), not generated by activated platelets, Con A 
activated lymphocytes, RPMI culture medium, normal rabbit 
serum, DEAE purified IgG or F(ab) 2 fragments, or 33% and 66% 
ammonium sulphate precipitates of serum. 
7. Significant inhibition of cAMP activity was mediated by the 
products released from PMA activated neutrophils. 
8. Although PGE1 , isoproterenol and forskolin stimulated adenylate 
cyclase activity in Wt-7 Cape Town cells was inhibited by fresh 
serum, sodium fluoride stimulated cAMP release was 
paradoxically enhanced in the presence of fresh serum. 
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9. Rabbit polyclonal antibodies raised to a beta-2 receptor 
peptide (BR-20-II) stimulated adenylate cyclase (raising cyclic 
AMP levels well above basal levels) but did not inhibit 
isoproterenol stimulated adenylate cyclase activity. 
6.6 Follow up studies of serum inhibition of [il1I)-CYP binding to 
cloned human beta-2 receptors in membranes of Wt 7 Cape Town 
cells. 
6.6.l Inhibition of (1251)-CYP binding to cloned human beta-2 
receptors by sera from normal children, normal adults and 
asthmatic children 
The studies conducted in Chapter 3 on the serum inhibitory effects on 
[ 1251)-CYP binding raised certain specific questions (3.6). Using the 
stable source of human beta-2 receptors from the Wt-7 Cape Town clone, 
I have re-examined the reproducibility and significance of the 
antagonist ligand inhibitory effects of serum from 34 individuals 
including those patients whose sera previously exerted greater that 
50% inhibition in Table 8. 
The inhibitory effects observed with the cloned human beta-2 
adrenergic receptors are similar to those found with the guinea pig 
lung beta adrenergic receptors: 
Human sera inhibited (1251)-CYP binding to cloned human beta-2 
receptors in a dose responsive fashion. [1251)-CYP binding to the 
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Wt-7 Cape Town human cells is of high affinity (Kd-20pM). Maximal 
binding was achieved by 30 minutes and was stable for at least 2 
hours. Inhibition of ligand binding by serum was rapid and was 
observed within one minute (no pre-incubation of membranes was 
necessary). Inhibition mediated by serum or plasma (EDTA or 
heparinised) was of the same order. Inhibition of [125I]-CYP binding 
was not removed by prior dialysis of the serum, after 10-fold dilution 
of the serum, overnight. Inhibition of [125IJ-CYP binding was not 
altered by the presence or absence of the protease inhibitor PMSF in 
the binding assay, and serum which spun through Sephadex GSO did not 
bind [125I]-CYP directly. 
Studies of the antagonist inhibitory effects of human asthmatic sera 
were extended to an investigation of the effect of heat inactivation 
of the serum (30min at S6°C) and passing the serum through a Sephadex 
GSO column, on [125I]-CYP binding to cloned human beta-2 receptors. 
Results given in Fig. 80 show that heat inactivation, dialysis and 
passing sera through a GSO column did not remove the inhibitory effect 
of pooled human asthmatic serum on [125IJ-CYP binding to human beta-2 
receptors. 
Wt-7 Cape Town membranes were incubated with a 1:50 dilution of serum 
for 30 min at 30°C after which the membranes were spun down, 
resuspended and washed in fresh buffer, before incubating with 
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Figure 80. The effect of heat inactivation, dialysis (D) and passing 
the serum through a Sephadex GSO column on the inhibitory 
effects of pooled human asthmatic serum on [ 1251]-CYP 
binding to cloned human beta-2 adrenergic receptors. Bar 
values represent mean values of duplicate assays (.). 
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partially removed by washing the membranes (mean inhibition using 
1:50 dilution after washing 26%, unwashed 35%). 
I have also attempted to identify fractions in serum containing 
significant antagonist inhibitory activity after passing 1 ml 
asthmatic serum over a Sephacryl S200 column. Sephacryl S200 beads 
were swollen in 50 mM Hepes and the column packed in a 20ml syringe. 
The flow rate was set at O.Sml/minute. The outer volume of the 
column was found to be 8ml (using 1mg/1ml dextran blue in H20). A 
hundred 0.5ml fractions were collected after 1 ml serum was loaded and 
after freeze drying and reconstitution in 20mM sodium phosphate 2mM 
MgS04 , one third of each fraction was tested for [
1251]-CYP inhibition 
at the Kd (20pM). Four major peaks of inhibitory activity were 
identified (Fig. 81). One peak preceded the first protein peak (A), 
and one peak followed the first protein peak (C) while the other two 
peaks of inhibitory activity coincided with the major protein peaks. 
These experiments indicate that inhibition of [ 1251]-CYP by serum is 
complex and serve to confirm that several components in asthmatic (and 
normal) serum may influence antagonist binding to human beta-2 
receptors in vitro. Other than investigating the inhibitory activity 
of purified IgG fractions (6.6.2), I have not attempted to 
characterise these factors in any further detail. I have observed 
however that albumin is also inhibitory in the ligand binding assay, 
in a dose responsive fashion. 
In the following experiments I have compared the degree of inhibition 
obtained by serum when membrane preparations from three transfected 
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Figure 81. Inhibition of [ 1251)-CYP binding to cloned human beta-2 
receptors by 1:3 dilutions of 0.5ml fractions of pooled 
asthmatic serum separated on Sephacryl S200 column. OD
280 
of fractions (···· -) and % inhibition of [ 125 ! J -GYP ( - ) . 
Peaks A, B, C and D indicate fractions which inhibited 
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receptors (410fmol/mg, 1174 fmol/mg and 4206 fmol/mg) were used. It 
was quite consistent in repeated experiments that in membranes 
expressing fewer numbers of beta-2 receptors the inhibitory effect was 
much greater than in cells expressing greater numbers of beta-2 
receptors (Fig. 82). These experiments show that in vitro cells 
expressing lower numbers of beta-2 receptors may be more susceptible 
to inhibitory effects than others and raise important questions 
regarding the choice of membrane preparations for [125IJ-CYP binding 
studies and may explain why the degree of serum inhibition I obtained 
using Wt-7 Cape Town membranes was consistently less than the degree 
of inhibition I had previously obtained with guinea pig lung membranes. 
Although the existence of these antagonist inhibitory factors has been 
confirmed using guinea pig lung membranes and using cloned human 
beta-2 receptors, the clinical significance of these factors as 
applied to human disease remains speculative, particularly since serum 
from control healthy subjects is also inhibitory. 
I have conducted two further studies comparing inhibition of ligand 
binding to cloned human beta-2 adrenergic receptors mediated by human 
serum in different groups of asthmatic and control subjects. It is 
noteworthy that all of the patients whose sera previously inhibited 
ligand binding to guinea pig beta receptors by greater than 50% (in 
Table 8) displayed less than 50% inhibition to human beta-2 receptors. 
In the first study sera from 14 asthmatic children were compared with 
14 non-asthmatic controls and using a 1:50 dilution of serum, no 
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Figure 82. Mean inhibition of [1251]-CYP binding to human beta-2 
receptors expressed in membranes prepared from three 
different transfected B82 clones (410 fm/mg, 1174 fm/mg and 
4206 fro/mg human beta-2 receptors). At each assay point 
there was lOµg cell membrane protein, [ 1251]-CYP: 20 pM (at 
the kD) and pooled asthmatic serum (1:50 dilution). 
Bar values represent men of triplicate experiments (.). 
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significant difference in the mean inhibition of [125IJ-CYP binding 
was observed. 
In the second study sera from 13 different asthmatic children was 
compared with sera from 9 normal control children and 12 normal 
adults. In this study, serum was studied at a 1:10 dilution. Results 
are given in the following Table 17. 
TABLE 18. Inhibition of [ 125 iJ-CYP binding to human beta-2 receptors 
by human sera (1:10 dil.) 
[ 125I] -GYP 
binding 
Group n (Mean inhibition %) S.E.M. S.D. 
A Asthmatic 13 47 3.24 11. 68 
children 
B Normal 9 31 7.27 21. 77 
children 
C Normal 12 52 3.54 12.26 
adults 
Considering that a 1:10 dilution of sera was used, the range of 
inhibition was less than that encountered with the guinea pig lung 
membrane preparations in Chapter 3. 
There was a significant difference between the normal children and 
normal adults (p = <0.05). A significant difference between the mean 
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inhibition of the asthmatic children (Group A) and the normal children 
(Group B) was also observed (p - 0.05 Student's t) but no difference 
was found between the asthmatic children and normal adult sera. There 
was as before, a wide scatter in the results obtained with the normal 
children and a marked overlap in the data was also apparent. 
6.6.2 The affinity of DEAE purified IgG on (1251]-CYP binding to 
cloned human beta-2 receptors 
Studies of the effects of purified immunoglobulin fractions on 
[125!]-CYP binding at different [125!]-CYP concentrations were also 
repeated using the human beta-2 receptors. Saturation curves of 
binding of [125!]-CYP to human beta-2 receptors expressed in B82 cells 
were conducted in the presence or absence of 1:50 dilution of whole 
serum (from asthmatic patients), an equivalent IgG (DEAE cellulose 
purified) concentration as the serum (57µg/500µ1), 10-6M L(-)propranalol 
or 20mm sodium phosphate, 2mm magnesium sulphate buffer pH 7.4 alone. 
Saturation curves and Scatchard plots of the binding data presented in 
Fig. (83), show that the competition of purified IgG for antagonist 
receptor binding was non-competitive (i.e. the Kd for [125!]-CYP 
binding to the receptor was minimally altered, but the maximum binding 
(Bmax) was reduced by both serum and IgG preparations). 
The affinity of the IgG fraction for the beta-2 receptor was 
determined using competition curves in which increasing amounts of IgG 
(range 3.8 x 10-7M - 1.5 x 10.5-5M) competed for the binding of 
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Figure 83. Saturation curves and Scatchard plots of [ 1251]-CYP binding 
to cloned human beta-2 receptors in the presence or absence 
of asthmatic serum (1:50 dilution), purified IgG 
(equivalent IgG to 1:50 dilution of serum : 57µg/500µ1), or 







0.5,10' 1.2,10·· o.s,10·, 
lgG concentration (M) 
Figure 84. Competition curve showing% inhibition of binding of 
[ 1251]-CYP to cloned human beta-2 adrenergic receptors by 
dilutions (0.5 x 105M to 1.2 x 10-7M) of DEAE cellulose 
purified IgG. Using the Prussof equation the affinity of 
the IgG was calculated to be 4.6 x 10-7M. The 
concentration of [1251]-CYP in the assay was 32pM. 
343 
10000 I 
I 8000 n ~ 
f 6000 ~ 
I . 
::::: l - I r'-1 I ~ I 
f · 1 
._..; -1000 r - __L_ -. ! 
,h 
u 





l I I ~ I oL LJ '._j l_J 
Paiient code P,\fC ?MC TA T.~ MO .\10 
Senun (1:10) + + + 
!gGU:10) + 
Proprano!o/ ( 1&6:\1) + 
Figure 85. Comparison of the inhibition of [ 125!)-CYP binding to 
cloned human beta-2 receptors in Wt-7 Cape Town membranes 
by dilutions of whole serum (1:10) or equivalent 
concentrations of DEAE cellulose purified IgG. 
Bar values represent the mean of triplicate experiments. 
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equation, the affinity of the IgG fraction was calculated to be 4.6 x 
10-7M. (Fig. 84) (of the same order as isoproterenol). 
I have repeated IgG inhibition assays using IgG purified from a 
further 18 asthmatic patients using membranes expressing cloned human 
beta-2 receptors. IgG was studied at concentrations equivalent to 
serum IgG (1:50 dilutions). The IgG fractions were dialysed against 
sodium phosphate buffer before reconstitution in assay buffer. 
Representative results from three patients studies are given in Fig. 
85 and show again that up to 50% of the total serum inhibition may be 
exhibited by the IgG fraction, but that other factors also play a 
role. There was again no difference between the mean inhibition 
exerted by serum or IgG from asthmatics (Mean - 26; SD - 10.4) and 
controls (Mean - 21.3; SD - 9.1) p - 0.24 (Kruskal Wallis test). 
6.6.3 Summary of the nature of the inhibitory effects of human sera 
on antagonist (( 125IJ-CYP) binding to guinea pig and human 
beta-2 receptors. 
1. Both normal and asthmatic sera contain factors which show a 
dose responsive inhibition of [125I]-CYP binding to guinea pig 
and human beta-2 receptors (3.2)(6.6.1). 
2. There was no significant difference in the inhibition mediated 
by sera from asthmatics when compared with normal individuals: 
Kruskal Wallis test p - 0.287 (3.2.2)(although weakly 
significant differences could be shown using the Student's t 
tests). 
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3. Inhibition was not removed by dialysis or heat inactivation 
(56°C for 30 min) i.e. heat stable (3.7)(6.6.1). 
4. Pre-incubation of the membranes with serum/IgG did not increase 
the degree of inhibition (3.3.4). 
5. Significant and, in some cases, equivalent inhibition could be 
mediated by DEAE purified IgG fractions of the patient's serum, 
but bore no relation to the total IgG level. (3.3) Although 
inhibition was mediated by the immunoglobulin fraction, other 
serum fractions were also found to be inhibitory (6.6.1). 
6. Direct antibody binding to guinea pig beta-2 receptors could 
not be demonstrated on Western blots (3.5) but heterophile 
antibodies to mouse antigens were found in asthmatics and 
non-asthmatics (6.4.7). 
7. Inhibition mediated by IgG was non-competitive (as shown by 
Scatchard analysis and saturation curves) and the affinity of 
the IgG fraction mediating inhibition was 4.6 x 10-7M (by 
Prussoff equation)(6.6.2). 
8. The degree of [125I]-CYP inhibition mediated by patient serum 
is relatively constant over a period of time (months)(3.3.l). 
9. The degree of [125I]-CYP inhibition is directly related to the 
number of beta-2 receptors expressed in the cells studied 
(6.6.1). 
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6.7 Discussion. and Conclusions. 
The expression of cloned human beta-2 receptors in a cellular system 
has enabled me to verify and extend my studies on the effects of human 
serum on antagonist [1251)-CYP binding and to conduct original studies 
on the effects of human serum on agonist mediated cyclic AMP 
production. 
A cell line stably expressing high levels of human beta-2 adrenergic 
receptors is useful for studying functional effects of serum and 
cellular components on human beta-2 adrenergic receptors in vitro, 
particularly when receptors expressed following transfection couple 
with the G proteins and adenylate cyclase. Although successful cell 
lines were constructed by Chung et al. (1988) the levels of beta-2 
receptors expressed in the clones which they characterised were 
relatively low. 
The Wt-7 Cape Town clone provides at a high level of expression a 
stable source of human beta-2 receptors which bind the ligand 
( 1251)-CYP with high affinity (Kd ±20 pM). Different levels of beta-2 
receptor expression in the other clones I obtained permit studies of 
the effect of receptor numbers on cAMP release. 
The level of receptor expression in Wt-7 Cape Town clone far exceeds 
the levels of beta-2 receptor expression encountered in the 
physiological state (e.g. in human fibroblasts, myoblasts or 
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lymphocytes) and it is likely that a considerable percentage of the 
receptors in Wt-7 Cape Town cells are redundant with respect to their 
involvement in coupling with the G proteins and adenylate cyclase. 
Venter (1978) has previously addressed the concept of "spare" 
receptors under physiological conditions. 
I have found that the number of receptors expressed per mg membrane 
protein has a direct effect on the result of the [ 1251)-CYP inhibition 
assay (6.6.1). This observation has important implications for the 
standardisation of [ 1251)-CYP ligand inhibition assays and may explain 
why other workers have found it difficult to obtain reliable and 
reproducible data using membranes derived from mammalian lungs. Even 
using guinea pig lungs, I have found that the number of receptors per 
mg membrane preparation is highly variable. These observations 
suggest that depending on the system chosen, (cells or tissues), the 
assay conditions should specify the number of receptors, rather than 
the amount of membrane preparation (in micrograms), as has been stated 
by previous workers (Fraser et al. 1981, Blecher et al. 1984). It 
follows that the use of cell lines rather than whole organs as a 
source of homogeneous membrane preparations will also improve 
reproducibility of ligand inhibition assays. 
By transfecting a given cell with different numbers of beta-2 
adrenergic receptors it may be possible to determine a critical or 
optimal nwnber of beta-2 receptors required for maximal receptor 
mediated second messenger (e.g. cAMP) release in that particular cell. 
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If, physiologically, an excess of beta-2 receptors is expressed on a 
given cell, this may have certain advantages: for example a receptor 
reserve will permit a flexibility in the numbers of receptors 
inactivated, blocked by inflammatory mediators or internalized before 
a reduction in maximal cAMP release would occur. This concept is 
important when attributing any possible in vivo functional 
significance to serum or inflammatory factors which are found to block 
beta receptors in in vitro systems. For receptors which are critical 
for life, a modest reserve would be expected to have a survival value. 
Conversely, if a cell constitutively expresses an excess of the 
optimal number of beta-2 receptors necessary for maximal catecholamine 
stimulation, the functional significance of further receptor 
expression e.g. induced by steroids may be negligible. 
My own data (6.2.4), comparing maximal cAMP release in cells 
expressing lower members (-400fmol/mg) of human beta-2 adrenergic 
receptors, with high numbers (4000fmol/mg) suggested that an increase 
in cAMP is not linearly related to the level of receptor expression. 
However, to draw firm conclusions about this observation it will be 
necessary to study different clones expressing low numbers of 
receptors which are within the range of physiological expression. 
Thus, genetically engineered beta-2 receptor expression systems with a 
high level of expression, while being of great value as a source of 
beta-2 receptors for purification purposes and antibody binding 
studies, may not be ideal for functional studies of receptor 
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activation. Little is known about the critical numbers of receptors 
necessary for optimal cAMP responses for different cells. 
The Wt-7 Cape Town cell line thus has certain advantages and 
disadvantages in any study of the effects of serum or cellular factors 
on the function of beta-2 receptors. In the first instance, by using 
this line, it is clear that for a beta-2 receptor related effect of 
the serum factor to be detected, by a reduction of cAMP release, a 
substantial reduction/blocking may be necessary at the receptor level 
(6.2.4). Thus while the Wt-7 Cape Town cellular system may lack 
sensitivity in any study of inhibitory factors, a reduction in 
isoproterenol stimulated cAMP release must imply a significant 
inhibitory effect of the factor studied, if it can be proven that the 
effect is, in fact, mediated at the level of the beta-2 receptor. 
There are, however, further limitations in studies of functional 
inhibition in a coupled system, since the inhibitory factor may also 
block the receptor mediated response at a level distal to the receptor 
(e.g. G protein or catalytic unit) or by disturbing membrane function 
non-specifically by e.g. complement lysis (6.4.8). Complement should 
probably be inactivated before any studies of serum or cell function 
are conducted. It is difficult, if not impossible therefore, to 
attribute an effect to the beta-2 receptor level unless specific 
effects are also studied at G proteins (using sodium fluoride or non-
hydrolysable analogues of GTP) or directly on the catalytic adenylate 
cyclase unit (e.g. using forskolin). 
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Serum and plasma is a complex mixture of catecholamines, stimulatory 
and inhibitory factors and while studies of inhibitory factors such as 
prostaglandins by Omini et al. (1989) and Raaijmakers et al. (1989) in 
isolation, are informative in experimental models, under physiological 
conditions mediators are not released in isolation from mast cells and 
other inflammatory cells. During inflammation serum/plasma factors 
and cellular activation products are released as a "soup" which may 
contain a mixture of factors which stimulate adenylate cyclase (e.g. 
lymphocyte activation products 6.5.3) or inhibit adenylate cyclase 
(e.g. superoxides, prostaglandins or membrane destructive enzymes 
released by neutrophil activation). This may be accompanied by 
increased serum levels of catecholamines and other membrane active 
substances (e.g. platelet activating factor) which in vitro have been 
shown by Agrawal and Townley (1987) to non-competitively block ligand 
binding. While it is thus useful to study, in isolation, the effects 
of purified individual factors released during inflammation on beta-2 
receptor coupled adenylate cyclase activation, it would be foolish to 
attribute pathophysiological significance to the results of such 
experiments unless the concentration of the factor being studied, its 
release and its stability, in the local microenvironrnent in the 
presence of other mediators, was also known. 
The ligand binding studies reported in this chapter were an extension of 
the studies by Venter et al. 1980, Blecher et al. 1984 and my own studies 
(Chapter 3) with guinea pig lung membranes. I have demonstrated that 
dilutions of human sera have a dose responsive inhibitory effect on 
antagonist [1251]-CYP binding to cloned human beta-2 receptors. On 
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analysis of [ 125I]-CYP inhibition studies in 6.6.1 there was 
consistently a large overlap between the [125I]-CYP inhibition found 
in normals and asthmatic subjects, and thus the clinical significance 
of these findings in relation to disease, if any, remains speculative. 
I have followed up after three years, the asthmatic patients whose 
sera previously inhibited the [ 125I]-CYP binding to guinea pig lung 
membranes by greater than SOX (in 3.2.2) and re-tested their sera. 
Using membranes from the Wt-7 Cape Town cells, all of the sera 
inhibited ligand binding by less than SOX (6.6) in the follow up 
studies. Clinical follow-up of these patients showed a clinical 
course which was indistinguishable from the other steroid-dependent 
asthmatics whose sera demonstrated lesser degrees of inhibition in the 
guinea pig lung membrane ligand binding assays. I could not attach 
any particular clinical significance to the fact that their sera at a 
given point in time displayed inhibitory effects in an in vitro 
[ 125I]-CYP binding assay. However, detailed pulmonary function tests 
of small airway function and reversibility were not conducted. 
In view of the presence of heterophile antibodies to mouse antigens in 
the sera of many of the patients studied, the functional effects of 
fresh sera on beta-2 receptor mediated adenylate cyclase activation 
could not be studied using the fresh sera from patients. Thus to 
investigate possible functional inhibitory effects of human serum on 
beta-2 receptors, a human cell line may be preferable and complement 
must first be inactivated. It is noteworthy that EDTA or heparinised 
human plasma was not inhibitory at all and this suggests that other 
than the release of local inhibitory mediators (e.g. PAF) or 
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neutrophil products, it is unlikely that asthmatics have in their 
serum factors which are markedly inhibitory for agonist mediated cAMP 
release. 
Future studies, taking these factors into consideration, must be 
conducted before any hypothesis that asthmatic sera may play a 
modulating effect on beta-2 receptor function, during inflammation, 
can be rejected completely. My own studies suggest that complement 
activation does not play a role in in vitro inhibition of antagonist 
binding, since [ 1251]-CYP inhibition was not removed by heating at S6°C 
for 30 min. (3.7, 6.6.1). Since residues in the ligand binding domain 
important for antagonist binding differ from those involved in agonist 
binding (and coupling with the G proteins), it is possible that the 
serum factors influencing agonist and antagonist binding may differ. 
It is clear that serum factors which do not even directly bind to the 
beta-2 receptor may disturb its function, if these factors act at the 
receptor level and at the post-receptor level. Since administration 
of beta-2 receptor antagonists (e.g propranalol) is contra-indicated 
in asthmatics, the possible significance of the serum effects on in 
vitro antagonist binding is thus extremely theoretical. 
The finding of antibodies recognising mouse proteins in the allergic 
patient's sera provided a possible explanation for the marked 
inhibitory effect of the serum on mouse but not human cells. The 
ability to mount heterophile antibodies to mouse antigens has not 
previously been studied in great detail. Since both non-allergic and 
allergic children were found to have heterophile antibodies,it is 
353 
probably not linked to the increased facility of allergic asthmatic 
individuals to respond to other environmental allergens. In a 
separate study unrelated to the beta-adrenergic receptor I have 
recently documented (Potter et al. 1991) that the clustering of immune 
responses to environmental allergens is not random. Whether there is 
any link between allergen specific immune responses to environmental 
allergens and heterophile antibody responses in allergic individuals 
would be interesting to study in the future. 
One of the original reasons for embarking on these studies on the 
beta-2 adrenergic receptor was to investigate the concept of 
autoantibodies to the beta-2 adrenergic receptor in allergic subjects. 
Although I have consistently documented that IgG fractions from 
allergic and non-allergic subjects can inhibit [
125I]-CYP binding to 
guinea pig and human beta-2 adrenergic receptors (with an affinity of 
the order of 4.6xl0-7M)(6.6.2), whole human IgG and F(ab) 2 fragments 
were not found to inhibit cAMP production in functional assays with 
any of the sera tested (6.5.1). I have not been able to demonstrate 
any functional effects of these "auto-antibodies" (as defined by 
Fraser 1981) on agonist binding. Thus before clinical significance of 
these autoantibodies can be postulated, one should consider the 
following questions: Are the "autoantibodies" simply an in vitro 
observation which has no real in vivo or clinical counterpart, or do 
immunoglobulins in fact interact with cell membrane receptors as part 
of a normal physiological process as postulated in 3.7? If one 
reconsiders the assay conditions for demonstrating [
125I]-CYP 
inhibition, it is apparent that the incubation mixtures used in the 
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assays of Fraser (1981) and Blecher (1984) and indeed in this thesis 
do not have a physiological in vivo counterpart. 
Although I could not demonstrate any antibody mediated blocking 
effects on cAMP production in my patients, I raised rabbit polyclonal 
antibodies (701) to the beta-2 receptor peptide (6.5.2) which were 
significantly stimulatory, supporting the concept that certain 
antibody containing serum fractions may, under certain circumstances, 
facilitate cAMP release. Since the rabbit polyclonal antibody 701 
also inhibited [ 1251]-CYP binding to the cloned human beta-2 
receptors, it is tempting to speculate that it had intrinsic 
sympathomimetic activity but this stimulatory activity could have been 
exerted at a site distal to the receptor. 
With the current knowledge of inflammatory factors influencing 
beta-adrenergic function, the original theories of an inherent or 
constitutional beta adrenergic receptor dysfunction in asthma should 
be adapted to accommodate a theory of an acquired beta adrenergic 
dysfunction but should bear in mind that the degree of inflammation in 
the airways has not yet been correlated with beta adrenergic 
hyporesponsiveness in the airways in vivo. 
Cells which require active catecholamine stimulation for normal airway 
function (i.e. smooth muscle cells, mast cells, ciliated epithelial 
cells) are not normally exposed to significant concentrations of 
serum, plasma or products of activated inflammatory cells. Endogenous 
catecholamines are thus free to diffuse from the intravascular 
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compartment into the tissues, unimpeded, to activate the beta-2 
receptors, thus effecting and maintaining normal airway smooth muscle 
tone, normal cilial motility and mast cell cAMP levels. Marked 
susceptibility of asthmatics to the bronchospasm when given beta 
blockers such as propranalol, supports a hypothesis that asthmatics 
are critically dependent upon unopposed catecholamine stimulation. 
In the presence of airway inflammation, whether induced by diffuse 
viral infection, noxious stimuli (e.g. sulphur dioxide) or 
aeroallergens (i.e. via mast cell degranulation) an increase in 
vascular permeability permits inflammatory factors to move into the 
tissues. Inflammatory factors block the activation of beta-2 
receptors on these cells leading to adrenergic-cholinergic imbalance, 
bronchospasm, impairment of ciliary function and may possibly further 
facilitate mast cell degranulation by making them more "twitchy" as a 
result of a fall in intracellular cyclic AMP. 
As the inflammation subsides, inhibitory effects are reduced and the 
cells will respond to circulating adrenaline. Since asthmatic 
subjects' catecholamine responses to stress (or exercise) are blunted 
(Ind et al. 1985) reduced effector responses would be compounded in 
the presence of airway inflammation. Steroids or therapy with sodium 
cromoglycate which reduces airway inflammation, will assist endogenous 
catecholamine stimulation of the beta-2 receptors and reduce the 
requirement for exogenous beta-2 stimulatory drugs. Drugs such as 
ketotifen (Koshino et al. 1988) which also prevent down regulation of 
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beta-receptors may be of greater benefit if high doses of exogenous 
beta-2 stimulators are given. 
The concept of an acquired but reversible dysfunction in beta-2 
receptors in allergic asthmatics is attractive because it explains why 
asthmatics vary in their requirements for additional beta-2 
stimulators and why some mild asthmatics only need beta-2 stimulators 
during acute respiratory tract infections, or during exercise, or 
following allergen exposure. 
In vitro evidence that inflammation results in reduced beta-2 receptor 
function has been presented by Raaijmakers et al. (1989), who studied 
the effects of PAF, LTB4 and LTC4 on [ 3H]-DHA binding to human lung 
membranes obtained from thoracotomy specimens and on cAMP release from 
human lymphocytes. While LTB4 and LTC4 induced a decrease in ligand 
binding to beta adrenergic receptors to 66.8±14.8% and 71.1±1.4% of 
control values and PAF reduced the number of high affinity sites to 
56.4±8.3% of control values. In the lymphocyte studies basal, 
isoproterenol and Gpp(NH)p stimulated cAMP release were all decreased 
after pre-incubation with PAF, LTB4 and LTC4. 
The degree of inhibition of antagonist binding reported in these studies 
is within the range of the inhibition of antagonist binding I obtained 
with dilutions of normal sera. Their data also suggested that 
inhibition of cAMP was mediated at a post-receptor or 'membrane' level. 
Raaijrnakers et al. (1986) previously demonstrated that mediators such as 
PAF not only reduced the number of receptors but also influenced 
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the affinity of the receptors for agonists. However, it is not known 
if concentrations of the mediators used in these studies are achieved 
in the lungs in vivo. 
Agrawal and Townley (1987) in studies of the effect of PAF on beta-2 
receptor function showed that a sub-threshold dose of PAF O.lµM 
significantly reduced the potency of isoproterenol to reverse 
methacholine or histamine induced contraction. They could not 
demonstrate any change in the affinity of [ 3H]-DHA binding to human 
lung membranes induced by PAF, but suggested that the down regulation 
of beta adrenoceptors was mediated through specific PAF receptors and 
that a direct interaction with the beta receptor was unlikely. Since 
PAF has been reported to induce activation of phospholipase A2 and 
phospholipase A2 has been shown to decrease the density of 
beta-adrenoceptors on guinea pig lung membranes Taki et al. 1986, it 
was suggested that activation of phospholipase A2 by PAF could be a 
mechanism underlying PAF induced down regulation of beta-adrenoceptors. 
Kramer et al. (1986) has shown that incubation with lmM cumene 
hydroperoxide causes a reduction in the number of beta receptors in 
lung membrane preparations. Engels et al. (1986) have shown that 
pulmonary macrophages induce a reduction in beta-adrenoceptor 
responses of guinea pig tracheal smooth muscle which can be blocked by 
catalase and thio-urea (an OH. scavenger), suggesting that H202 and/or 
OH. may mediate this effect. Rhoden and Barnes (1989) found that 
responses of tracheal smooth muscle to isoprenaline were unaffected by 
pre-treatment with H202 and have suggested that other inflammatory 
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mediators released by macrophages, in addition to free radicals, may 
be required to induce deterioration of ~-adrenoceptor function. Gmini 
et al. (1989) presented data to support a role for prostaglandins in 
the beta-adrenoceptor desensitization observed after antigen challenge 
in ovalbumin sensitized guinea pigs. Again it is not clear whether 
this effect was mediated at the receptor or at a post-receptor level. 
Another consequence of inflammation on beta-adrenergic receptor 
function should be considered following the studies of Mahan and Insel 
(1984) who found that catecholamines are susceptible to oxidation when 
incubated under physiological conditions with intact cells or membrane 
preparations, and that superoxide dismutase (lOµg/ml), but not catalase 
(lOµg/ml) was very effective in inhibiting the oxidation of lOnM 
isoproterenol. It is thus likely that during inflammation endogenous 
catecholamines are prevented from diffusing from the circulation to 
the beta-2 receptors since they are inactivated by free oxygen 
radicals and H2G2 . 
Evidence that allergen challenge and mediator release reduced beta-2 
receptor function/number on circulating lymphocytes has been presented 
by Meurs et al. (1982, 1984) and recently confirmed by Gehling et al. 
(1990). 
It is widely agreed that airway hyper-responsiveness is a primary 
abnormality in most asthmatic subjects (Gehling et al. 1990) but the 
relationship between beta-2 receptor dysfunction and airway 
hyper-responsiveness is not clear. If, during periods of 
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inflammation, cellular beta-2 adrenergic receptors are partially 
blocked, reduced in number or affinity, sequestrated within the 
membranes, or directly inactivated by bacterial toxins or free 
radicals and circulating catecholamines are unable to reach their 
receptors, because they are inactivated by oxidation products of 
inflammation, this may lead to the cholinergic-adrenergic imbalance 
favouring bronchospasm leading to an acute attack. If this process is 
sustained by further mast cell mediator release and cellular 
recruitment and further damage to airway cells by eosinophils or by 
viruses, this may lead to a more chronic or severe asthma attack. 
It is a general clinical observation that drugs which block the 
cholinergic system (e.g. atrovent) have not found general application 
in the treatment of asthma unless combined with a beta-2 adrenergic 
stimulator (e.g. Duovent). Thus adequate adrenergic drive elevating 
cellular cAMP levels is essential for the restoration of airway tone. 
Since beta-2 stimulators remain the mainstay of treatment of patients 
with an acute asthmatic attack, this suggests that a certain 
functional reserve of beta-2 receptors must be present in the airways 
of even the most severe asthmatics and that any dysfunction induced by 
products of inflammation must be partial. This, once again, raises an 
intriguing and critical question which is, as yet, unanswered i.e. how 
many beta-2 receptors on a given cell can be inactivated before 
functional effects result? In the genetically engineered system 
(6.2.4) in which I have obtained cell lines expressing different 
numbers of human beta-2 receptors, in the absence of inflammation a 
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large reduction in receptor number did not result in a proportionate 
reduction in cAMP production. Studies which document the critical 
numbers of intact beta-2 receptors required on cells of the airway 
before functional effects of beta-2 receptor blockade are observed 
would indicate the margin or reserve available in a given patient. It 
is not known whether this margin is reduced in asthmatic patients. If 
the beneficial effects of beta-2 receptor stimulation are mediated 
entirely by the cyclic AMP second messenger, it is possible that other 
mediators e.g. PGE 1 may, via their stimulation of adenylate cyclase, 
compensate for partial beta-2 receptor blockade on the same cells. 
Thus the overall detrimental effect of the inflammatory "soup" of 
mediators may be less than predicted from the concentration of factors 
which are known to specifically block beta-2 adrenergic receptors. 
In the past, studies to prove or disprove the beta-adrenergic theory 
of asthma have been fraught with difficulties. The studies which have 
looked at beta-2 receptor number in membranes of circulating cells 
e.g. lymphocytes and granulocytes (Brooks et al. 1979, Galent et al. 
1980, Sano et al. 1983) in asthmatics, have been done in a serum-free 
assay buffer, thus excluding any possible influence of the patients 
serum on the ligand binding obtained. If differences in individual 
sera can indeed affect the functional ability of their beta receptors 
by virtue of state of activation of lymphocytes or other mediators, 
when assessing receptor number in any tissue, the modulatory effects 
of physiological (pathological) fluids surrounding the receptor and 
local catecholamine levels must also be considered. It is possible 
that the reductions in beta receptors reported in the lungs of 
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asthmatic models of the guinea pig are secondary to non-competitive 
blocking of the receptors by inflammatory factors in the airways 
following activated mast cell or ovalbumin sensitization. 
Although a primary beta-2 receptor defect at the level of the gene or 
at the protein level has not yet been identified in any human disease, 
it remains a theoretical possibility that point mutations similar to 
those described in Chapter 4 may occur spontaneously in human beings 
and in asthma particularly, and may induce or contribute to the 
severity of cardiovascular or respiratory pathology. The effects of 
such an abnormality may be amplified if "acquired" factors such as 
mediators of inflammation are superimposed on the genetic abnormality. 
Although direct gene sequencing would be the definitive way to 
identify the occurrence of spontaneous mutant beta-2 receptor 
expression in human disease, an alternative approach would be to 
identify and study variants of the receptor identified by restriction 
fragment linked polymorphisms (RFLP) in patients with a given disease 
e.g. asthma. As an initial investigation into beta-2 receptor 
polymorphism in asthmatics, I have studied the distribution of the Ban 
1 RFLP in Cape Town allergic and non-allergic subjects and have 
presented the results of these studies in Chapter 7. 
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CHAPTER 7 
AN INVESTIGATION INTO THE BAN 1 RESTRICTION FRAGMENT LENGTH 
POLYMORPHISM OF THE HUMAN BETA-2 ADRENERGIC RECEPTOR GENE IN ALLERGIC 
SUBJECTS. 
7.1 Introduction 
Acquired alterations in beta-2 adrenergic receptor numbers and 
function are readily explained by homologous or heterologous 
regulatory pathways (Stiles 1984). Exposure of beta-2 adrenergic 
receptors to inflammatory factors from asthmatic subjects in vitro 
may be accompanied by depressed adenylate cyclase responses to 
isoproterenol stimulation (Chapter 6) and serum mediates 
non-competitive inhibition of antagonist ligand binding (6.6.2). The 
possibility that allergic individuals express a structurally abnormal 
beta-2 receptor, which facilitates or aggravates the beta-2 receptor 
abnormalities described in allergic asthma, remains an intriguing 
possibility and has not previously been studied. 
Since the majority of asthmatics appear to have normal beta-2 receptor 
responses to catecholamines between attacks in the absence of on-going 
airway inflammation and true asthma does not usually develop in the 
first few years of life (in the abscence of e.g. para influenzae or 
respiratory syncitial virus chest infections), it would appear that 
the chance of finding a significant structural abnormality in the 
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beta-2 receptors of allergic subjects would be small and any 
structural abnormalities are likely to have a subtle effect on agonist 
binding or function. In terms of the clinical expression of allergic 
diseases, it is as yet unknown why some allergic patients develop 
asthma, some develop rhinitis or eczema while others express 
combinations of these clinical entities. It is reasonable to 
speculate that if any of the known allergic diseases were to be 
associated with a structural abnormality in the beta-2 adrenergic 
receptor that asthma (in which beta-2 receptor dysfunction has been 
previously reported) would be the most likely candidate. 
The gene for the beta-2 adrenergic receptor and platelet derived 
growth factor has been mapped to the q31-q32 region of chromosome 5, 
while in the mouse both genes map to chromosome 18. 
The most direct method of identifying a structural genetic defect in 
the beta-2 adrenergic receptor in allergic individuals would be to 
construct cDNA libraries from an allergic individuals and to clone and 
sequence their beta-2 adrenergic receptor genes directly. 
Alternatively, the polymerase chain reaction may be used to identify 
abnormalities in the coding region of the beta-2 adrenergic receptor 
in allergic individuals. 
An alternative approach to the identification of a genetic basis for 
beta-adre~ergic dysfunction in allergic disease would be to identify 
genetic polymorphic variants of the beta-2 adrenergic receptor which 
occur with greater frequency in allergic individuals, and to study the 
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molecular nature and function of the proteins coded by such genetic 
variants. 
Since the cloning and sequencing of the human beta-2 receptor genes by 
Chung et al. (1987) and Kobilka et al. (1987), Lentes et al. (1988) 
have reported a biallelic restriction fragment length polymorphism of 
the human beta-2 receptor gene in a study of unrelated North American 
Caucasians, using the enzyme Ban 1, employing a full length 2.6kb 
probe of the beta-2 receptor gene. It was remarkable that although 
over SO restriction enzymes were studied, polymorphism was only 
detected with Ban 1 and (less convincingly (personal 
cornrnunication,Ulrich Lentes), with Ava-1). 
These experiments suggested that the beta-2 adrenergic receptor gene 
sequence is highly conserved in man. To detect a polymorphic variant 
which is specific for allergic asthmatics and not seen in normals 
(non-allergic individuals), DNA from allergic asthmatic individuals 
should ideally be screened again for polymorphisms, using the SO 
restriction enzymes shown to be non-polymorphic in normal individuals 
by Lentes. The financial demands of such a study, however, precluded 
this approach. 
I have carefully examined the polymorphic data reported by Lentes and 
was impressed with the observation that while individuals homozygous 
for the upper (A) allele (3.7kb), and heterozygotes for both alleles 
(3.7kb and 3.4kb) were identified, no individuals with homozygous 
lower alleles (B) were identified. This could simply be attributed to 
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the rather small population studies (20 individuals), but did suggest 
that individuals with homozygous lower allele were uncommon. It would 
thus be interesting to determine the frequency of this homozygous 
3.4kb lower allele in other population groups (non-American) and in 
particular in the allergic population. 
In assigning possible functional significance to the Ban 1 
polymorphism, it is important to define the site of the polymorphism. 
A polymorphic site within the coding region could imply a structural 
difference (i.e. amino acid substitution) in the expressed receptor 
protein (suggestive of receptor isoforms), whereas a polymorphic site 
identified in the 3 prime or 5 prime flanking regions of the gene may 
be compatible with allelic alterations in receptor susceptibility to 
regulation by glucocorticoids, or to differences in susceptibility to 
other promoter signals. Both of these possibilities are intriguing 
possible mechanisms for beta-adrenergic dysfunction in asthma. 
In this short chapter, I have studied the allelic frequencies of the 
beta-2 receptor gene as defined by Ban 1 polymorphism in South African 
allergic asthmatic and rhinitic children and compared them with 
non-allergic subjects. I have also compared the frequency of Ban 1 
polymorphic alleles in South African children with the North American 
frequencies (Lentes 1988). I have extended the original studies of 
Ban 1 polymorphism using the unique 326bp probe of the beta receptor 
gene sequence which I constructed (Chapter 4), in an attempt to define 
the site of the Ban 1 polymorphism in the human genomic sequence. 
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7.2 DNA probes. 
Two human beta-2 adrenergic receptor gene probes were used in the 
polymorphic studies: 
(a) A 2.6kb DNA fragment of the human beta-2 adrenergic receptor 
originally derived from a Pvu II digest of the human genomic clone 
LCV 517 (containing the entire coding region plus lOOObp of the 5' 
flanking region and 400bp of the 3' untranslated region of the 
gene) was obtained by digesting the plasmid PMSG containing the 
2.6kb insert (a gift from Dr. Lentes, Bonn FRG) with NheI and XhoI. 
(b) A 326bp Kpn-1 - Pst-1 digest of the coding region of the beta-2 
adrenergic receptor gene (see 4.2.5). Ban 1 restriction sites 
and genomic sequences identified by the two probes are illustrated 
schematically on Figure 86. The 2.6kb probe was labelled by nick 
translation (Amersham) and the 326bp probe was labelled using a 
multiprimer DNA labelling kit (Amersham 1601Y). 
7.3 Patients' DNA 
DNA for the polymorphism studies was prepared from 72 South African 
individuals. 
30 samples were from normal healthy individuals with no history of 
asthma, allergy or allergic rhinitis. 42 samples were from children 


















Figure 86. Distribution of Ban 1 restriction sites (designated A-G) in 
a 3500bp genomic sequence of the human beta-2 receptor gene 
(coding region and flanking regions). Relationship between 
the 2.6 kb (Pvu II) probe and the 326bp (KpnI-PstI) probe 
to the genomic sequence is shown. 
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Childrens Hospital. All of these children had documented allergies to 
one or more environmental allergens as documented by skin testing or 
RAST. 22 of the patients were asthmatics requiring regular 
bronchodilators and/or steroids, but who had minimal or no clinical 
evidence of allergic rhinitis. The other 20 patients had severe 
allergic rhinitis with no asthma. 
10ml peripheral blood in EDTA was homogenised in 30 ml lysis buffer 
(0.32M sucrose, 0.005M MgC12 O.OlM Tris, 1% Triton X-100 pH 7.6) using 
a dounce homogeniser (8 strokes up and 8 strokes down), transferred to 
50ml polypropylene tubes and centrifuged at 1250 rpm in a Beckman GPR 
bench top centrifuge at 4°C for 15 min and the pellet washed twice with 
20ml of phosphate buffered saline. The pellet was then resuspended in 
900µ1 of STE (Tris O.OlM, NaCl 0.10M and EDTA 0.001M pH 8.0) and 100µ1 
10% SOS solution added to give a final concentration of 1% SOS. 2-4mg 
of Proteinase K (Sigma) was added and the solution incubated for 16 
hours at 56°C. 
To this sample an equal volume of salt-saturated phenol was added and 
after tumbling for 10-15 minutes centrifuged at 15000 rpm in the 
microfuge at 4°C. The upper layer was transferred to a clean Eppendorf 
tube using a pipette which has had its tip cut to prevent shearing of 
the DNA and after tumbling for 15 min in an equal volume of 
chloroform, isoamyl alcohol (24:1 v:v) it was centrifuged at 15000 rpm 
for 15 min. 
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The aqueous layer was then transferred to a clean Eppendorf tube and 
DNAse-free RNAse (BRL) added to a final concentration of SOµg/ml and 
incubated for one hour at 37°C. After repeating the phenol and 
chloroform:isoamyl alcohol extractions, DNA was precipitated by adding 
1/10 volume of 3M sodium acetate pH 6.0 and 2.5 volumes of absolute 
alcohol. After standing at room temperature for 10 min DNA was 
spooled out with the end of a Pasteur pipette, washed in 80% ethanol, 
transferred to a tube containing 200µ1 distilled water and allowed to 
dissolve overnight at 4°C. DNA concentration was determined by 
measuring the optical density at 260nm. 
7.4 DNA digestion and Southern Blotting. 
Sµg human genomic DNA was digested for 6 hours with 20 units Ban 1 (New 
England Biolabs) at 37°C in SOmM potassium acetate, 20mM Tris acetate, 
lOmM magnesium acetate, lmM DTT, pH 7.9 (at 25°C). After denaturing at 
65°C for 10 min, DNA fragments were separated in lxTBE pH 8.0 on 0.8% 
agarose gels to resolve the restriction fragments. ADNA digested with 
Hind III was used as a molecular weight marker, and the gel was 
allowed to run overnight at 30mV until the bromophenol blue dye had 
moved 12.5-13cm from the origin. The gel was stained with ethidium 
bromide (l.25µg/µl) for one hour, transilluminated, molecular weight 
markers photographed and distance the dye front had moved was 
measured. After denaturation in lM NaOH for one hour the gel was 
washed in 3xSSC and Southern blotted on to Hybond N using to the 
method of Davis (1986) and ethidium bromide staining of molecular 
weight markers measured under UV light on Hybond N. Blots were 
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irradiated under UV light for one min prior to prehybridization for 6 
hr in 50% formamide, 5x SSC, 2x Denharts Solution, 20mM Na phosphate, 
pH 6.5, 200µg/ml denatured salmon sperm DNA and 0.1% SDS. The blot was 
then washed once with 30ml 5xSSC and hydridised for 24 hours at 42°C in 
a rotating perspex chamber using the [32P]-labelled probe (which had 
been denatured by boiling for 10 min followed by immediate cooling on 
ice). After washing the blots twice for 20 min in 2xSSC, 0.1% SDS, 
the nylon membrane was washed twice in 0.1% SDS, O.lxSSC at 65°C for 
one hour, dried between two sheets of Whatman 3mm, wrapped in Saran 
wrap (to keep it damp) and placed in an X-ray X-omat cassette with an 
intensifying screen exposed to Kodak AR-5 film at -70°C for 48-72 hr. 
7.5 Results 
7.5.1 Biallelic polymorphism of the beta-2 adrenergic receptor 
gene in allergic and non-allergic individuals. 
Autoradiographs of human genomic cDNA digested by Ban 1 and probed 
with [32P]-labelled 2.6kb probe revealed two clear polymorphic loci, 
3.1kb and 2.9kb. Homozygotes and heterozygotes for both loci were 
identified in the allergic and in the non-allergic individuals (Fig. 
87). Distribution of these alleles in a family study was compatible 
with the expected inheritance of these alleles within a family. 
A comparison of the frequency of the distribution of the 2.9 and 3.1kb 
polymorphic alleles on normal (non-allergic) individuals, allergic 
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Figure 87. Representative autoradiograph of Southern blot of Ban 1 
digested DNA (Sµg) from allergic (lanes 1 , 5 , 6, 8, 9 , 10 , 
11) and non allergic (lanes 2, 3, 4, 7) individuals probed 
with [32P] nick translated 2 . 6kb cDNA probe. Molecular 
weights (kb) are shown on the left . (Stringency 0 . 1% SDS 
O.lxSSC 65°C for 1 hr . Exposure Kodak AR-S film -70.C for 
48 hours). 
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19. The 3.7 and 3.4 kb polymorphic loci identified by Lentes (1988) 
using the enzyme Ban 1, were not found in any of the 72 patients 
studied. 
Table 19. Distribution of Ban 1 Polymorphism of the human beta-2 
adrenergic receptor. 
Group Number Heterozygous Homozygous 
Total Upper Lower 
3.1kb band 2.9kb band 
A.Normal 30 15(50%) 15(50%) 6 9 
individuals 
B .Allergic 20 7(35%) 13(65%) 6 7 
Rhinitis 
C .Allergic 22 9(41%) 13(63%) 9 4 
asthmatic 
Allergic 42 16(38%) 26(61%) 15 11 
(B+C) 
All indi- 72 31(43%) 41(56%) 21 20 
viduals 
Analysis of the relative frequencies showed no significant difference 
between the allergic and non-allergic groups with respect to the 
frequency of this polymorphic locus. Gene frequencies are shown in 
Table 20. 
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Table 20. Gene frequencies of beta-2 adrener~ic receptor polymorphic 
alleles. 
A. South Africans: Gene Frequency 
(Upper 3.1 allele) (Lower) 2.9 allele 
Group A: 
Normal non allergic 0.45 0.55 
individuals 
Group B & C: 
Allergic Individuals 0.45 0.55 
Group B: 
Allergic Rhinitis 0.47 0.53 
Group C: 
Allergic Asthma 0.61 0.39 
B: North American 
Subjects (Lentes 1988) 0.85 0.15 
The occurrence of homozygous 2.9kb and homozygous 3.1kb alleles in the 
same frequency in both normal and allergic individuals suggests that 
neither of these polymorphic forms are specifically associated with 
the expression of the allergic phenotype. 
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7.5.2 Defining the site of Ban 1 polymorphism of the human beta-2 
receptor gene 
It was in the first place important to confirm that Ban 1 in fact cut 
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I have located the Ban 1 restriction sites of a 3000bp genomic sequence 
of the human beta-2 receptor gene containing coding region, as well as 
three prime and five prime sequences (Fig 86). Seven potential Ban 1 
sites are present, designated A-G. It is evident that Ban 1 cuts the 
genomic DNA under consideration into fragments less than 700 bp. Sites 
B-G lie within the gene sequence spanned by the 2.6kb cDNA probe. 
Restriction fragments as large as 2.9kb and 3.1kb must lie three prime 
to site G (which lies within the coding region of the gene) if they are 
detected by the 2.6kb cDNA probe. 
To confirm the predicted restriction sites I have also digested 
purified 2.6kb cDNA fragment with Ban 1. An autoradiograph of a 1.0% 
agarose gel showing the Ban 1 digested fragments of the 2.6kb probe, 
probed with 2.6kb probe (Fig. 88) confirmed that the majority of the 




Figure 88. Autoradiograph of the 2 . 6kb genomic DNA probe after 
digestion with Ban 1. The restriction fragments observed 
are in accordance with the predicted fragments in Fig . 86. 
Most of the 2.6kb genomic probe is digested into small 
fragments (less than 700bp), but a 1.7kb fragment and 
undigested 2.6kb probe is also seen. 
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residual fragments are also clearly shown in the same figure and 
confirms that the Ban 1 restriction sites do occur as predicted from 
the restriction map. These findings suggest that the 2.9 and 3.1kb 
polymorphic gene fragments must include residues which lie three prime 
to the 2.6kb probe. 
Extending these arguments, I reasoned that if the polymorphic site was 
at site G, a probe spanning sites F-G would only detect the 3.1kb 
(larger) allele. The Kpn-1-Pst-l 326bp probe which I constructed in 
4.2.5, corresponds almost exactly to the F-G fragment. I therefore 
probed DNA from patients who were shown to be heterozygotes (using the 
2.6kb cDNA probe) with the random primer labelled 326bp probe and found 
that only the larger fragment was identified (Fig. 89). These findings 
support a hypothesis that a polymorphic locus exists within the coding 
region of the beta-2 adrenergic receptor gene. 
To confirm this hypothesis and strengthen the above conclusion, it 
would be useful to construct probes which only recognise sequences of 
the beta-2 receptor which lie five prime to the Ban 1 site F. Probes 
recognising these sequences should not identify the 3.1 or 2.9 kb 
restriction fragments. 
7.6 Discussion 
The experimental evidence I have presented in this chapter confirms 
that both allergic and non-allergic individuals display a Ban 1 
polymorphism of their beta-2 adrenergic receptor gene. In the first 
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Figure 89 . Autoradiograph of human genomic DNA dige
sted 'W'ith Ban 1 
previously shown to be homozygous or heterozygous u
sing the 
2.6kb probe and reprobed with random primed 326bp p
robe 
after stripping the 2.6kb probe . . Only the larger a
llele, 
3.1 kb 'W'as detected with the 326bp probe. Lanes 1-
3: DNA 
from Cape Town subjects. Lanes 4-6: DNA from West
 German 
subjects (from Dr . K. U. Lentes) . Lanes 1,3,4 and 6
 were 
heterozygous and lanes 2 and 5 'W'ere homozygous for 
the 
larger allele . 
instance the 2.9kb and 3.1kb fragments I consistently obtained were 
distinctly smaller than the 3.4 and 3.7kb fragments reported by Lentes 
(1988). I therefore obtained DNA from three additional patients which 
Lentes confirmed were upper band homozygous or heterozygous for the 
larger or the smaller allele, (on his return to Bonn, West Germany), 
and found that the 3.7kb allele of Lentes corresponded to the 3.1kb 
allele on my autoradiographs and the 3.4kb allele of Lentes 
corresponded to the 2.9kb allele on my autoradiographs. Furthermore, 
the 320bp probe only identified the larger allele of the same size, 
shown on a single gel, both in the DNA I had prepared and the DNA 
prepared by Lentes in Bonn (on Fig. 89). 
In contrast to the findings of Lentes, I also found several normal and 
allergic patients who were homozygous for the lower (2.9kb) allele. I 
had no explanation for the differences in size of the restriction 
fragments but Lentes (personal communication) has conceded that he may 
have over-estimated the size of the two fragments he identified. 
Since both polymorphic forms are found with equal frequency in the 
allergic population and in normal control populations, it would seem 
reasonable to conclude that both polymorphic forms are associated with 
normally functioning beta-2 receptors. 
Individuals homozygous for the 2.9kb allele presumably have Ban 1 site 
G intact (Fig. 86) whereas individual homozygous for the 3.1kb allele 
would have disturbed Ban 1 cutting at site G. The amino acid coded for 
at site G is amino acid 177 (Tryptophan) and substitution of tryptophan 
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with another amino acid could theoretically produce certain 
conformational changes is the receptor, but since this occurs in normal 
individuals as well, the functional effects of a genetic change at this 
site on the receptor expressed and on ligand binding or function appear 
to be minimal. 
Thus one would conclude that the Ban 1 restriction polymorphism is 
probably not an important genetic factor in the expression of the 
allergic phenotype. 
It would of course be interesting to compare in more detail the 
function of beta-2 adrenergic receptors from allergic and normal 
individuals who are homozygous for the 2.9kb or 3.1kb alleles in 
further studies. 
The overall gene frequency for the 2.9kb allele is 0.49 and for the 
3.1kb allele is 0.51, in the 72 South African patients studied. This 
clearly differs from the North America studies in which the gene 
frequency of the larger allele was reported to be 0.85 and the smaller 
allele 0.15. Thus I have demonstrated a clear population difference 
for this polymorphism. 
Recently several investigators have focussed studies to define the 
regulatory regions of the human and hamster beta-2 adrenergic receptor 
gene. The identification of important regulatory sites permits one to 
hypothesise that point mutations or abnormalities in the five prime or 
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three prime untranslated regions may result in differences in receptor 
expression which may lead to clinical disease. 
The start of transcription determined for the human beta-2 adrenergic 
receptor gene is at nucleotide position -219 relative to the start of 
translation. About 30 base pairs from the start site of transcription 
are two TATA box-like sequences (-238 and -252) and a reverse 
complement of the CAAT box located an additional -SObp upstream 
(Kobilka 1987). Furthermore, there are also elements in the five prime 
region which contain consensus sequences for transcriptional regulation 
by glucocorticoids (Chung et al. 1987) and cyclic AMP. In the human 
beta-2 adrenergic receptor gene two candidates for glucocorticoid 
responsive elements include a proximal element at position -248, 
adjacent to the TATA box (AGTCCTGT,) or a distal element further 
upstream at position -1447 (TGTTCT)(Collins 1989). Thus, if allergic 
individuals displayed polymorphisms at the critical regulatory loci, 
responses to steroids may be impaired. This identified another area 
for further study possibly using polymerase chain reaction to identify 
these critical sequences in the allergic population. 
From the studies I have completed in this chapter a clear genetic basis 
for beta-2 adrenergic receptor dysfunction in allergic asthmatic 
individuals has not emerged. However, the possibilities for 
investigation of a genetic defect in these patients have not been 
exhausted. These original studies also represent the first direct 
examination of the beta-2 adrenergic receptor gene in allergic 
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subjects. Besides direct gene sequencing of the coding area of the 
beta receptor, non-coding regions should also be studied in the future. 
Postulated mechanisms on acquired beta-2 adrenergic receptor 
dysfunction in asthma are supported by experimental data in this 
thesis. Until hard data can be found to confirm the contrary, the 
theory of a constitutional beta-2 adrenergic receptor abnormality in 




In the study of pathophysiological mechanisms which may explain 
clinical disease, in vitro systems are useful, if direct measurement of 
the in vivo system cannot be performed for ethical or practical 
reasons. 
In the past in vitro systems employing membrane preparations, purified 
receptors, cell homogenates and more recently whole cells have been 
used to identify factors which could influence beta-2 receptor function 
in vivo. It is important that the in vitro system should closely 
resemble the physiological state if valid comparisons are to be drawn. 
In applying published in vitro methodology to detect and investigate 
factors influencing beta receptor function, I have identified a number 
of disadvantages particularly with the use of the ligand binding 
inhibition assay. 
On first principles, the use of non-human beta-2 receptors in 
non-physiological membrane preparations to study the effects of human 
serum on the binding of a synthetic antagonist (e.g. [ 125I]-CYP), which 
has a ligand affinity in the picomolar range, can hardly be expected to 
produce .data which would have clinical significance. 
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My data has confirmed that even after optimising the conditions for 
receptor viability, ligand binding and reproducibility, the antagonist 
ligand inhibition assay produces data in which there is a substantial 
overlap between "patients" and controls (Chapter 3). This problem was 
not eliminated or improved by using cloned human beta-2 receptors in 
the ligand inhibition assay (Chapter 6). Thus the value of the 
[ 1251] -GYP or [ 1251] -HYP inhibition assay in providing useful 
information in patients with asthma is indeed questionable. 
An expression system in which cloned human beta-2 receptors are 
functionally coupled to G proteins and adenylate cyclase in living 
cells is more physiological and superior to studies in membrane 
preparations. l have found that although the transfected mouse cells 
(B82 cells) provided a rich source of human beta-2 adrenergic receptors 
in a more physiological system, unexpected factors inherent in human 
sera (e.g. heterophile antibodies) limit the use of this system in the 
study of the effects of heat labile inhibitory factors in fresh serum 
on beta-2 adrenergic receptor function. 
Factors which act distally to the receptor, (e.g. G protein, adenylate 
cyclase), or on the cell membrane itself, may also significantly 
disturb beta-2 receptor function. Thus, in future, it would be 
important to examine the effects of candidate "beta receptor inhibitory 
factors" at several levels before functional effects can be attributed 
specifically to the beta-2 receptor site. Applying a system in which 
some cells have human beta-2 receptors transfected in them while 
control cells have no beta-2 receptors (e.g. using non-transfected B82 
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cells as a control and Wt-7 Cape Town cells) will be most useful in 
identifying effects which are exerted at a receptor, or post-receptor 
level. 
Using the Wt-7 Cape Town expression system I have identified another 
area about which little is known, i.e. the optimal level of beta-2 
receptor expression for a given cell. It is likely that too high a 
level of expression of a gene product in a cell, particularly if 
regulated artificially, (e.g. by a steroid inducible promoter) may not 
represent a physiological state at all. Even in the non-functional 
assays, differences in the degree of ligand inhibition were observed 
with membrane prepartions from B-82 cells expressing different numbers 
of human beta-2 receptors. In this regard it would be important to 
document whether steroids do, in fact, increase beta-2 adrenergic 
receptor number in the lungs of asthmatic patients and whether any 
increases induced are in fact of functional importance. 
I have not been able to show that purified IgG from asthmatic patients 
(whose sera are inhibitory in the [125I]-CYP ligand binding assay) 
exerts any functional inhibitory effect in the Wt-7 Cape Town cells. 
It is possible that larger numbers of patients should be studied, 
before this possibility can be excluded completely. 
Unless human irnmunoglobulins can be shown to bind to specific 
extracellular domains or the intramembranous ligand binding pocket in 
living cells, it is likely that the concept of "autoantibodies to the 
beta-2 receptor" presents no more than an in vitro phenomenon. Milgrow 
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and Witebsky's criteria for autoimmunity (1962), have not yet been 
fulfilled for the beta-2 receptor antibodies, and no-one has yet 
produced a convincing correlation of this phenomenon with a disease 
process. It would be interesting in the future to investigate whether 
T cell clones recognising the hwnan beta-2 receptor are found in 
asthmatic patients (or normal individuals), since this may provide a 
more convincing basis for a theory of autoimmunity than the current 
evidence attributed to antibodies. 
These studies have also illustrated some of the difficulties in 
producing a "control" monoclonal antibody which in fact meets the 
desired specificities. The B4A8-PWL monoclonal antibody did not serve 
the purpose for which it was produced, but did provide useful indirect 
information. Since it is highly specific for a 49kDa molecule 
identified in several cells, it can be used to purify, identify and 
study this molecule in the future. The relationship between the 49kDa 
protein and the beta-2 adrenergic receptor (if any) would also be very 
interesting to explore. 
The level of action of the polyclonal antibodies produced in rabbit 701 
with cAMP stimulatory activity, should be studied further. While 
antibodies stimulating beta-1 receptors have previously been identified 
(Sterin Borda 1984), hwnan antibodies stimulating beta-2 adrenergic 
receptors directly, have never been identified. The Wt-7 Cape Town 
cell system could easily be used to look for beta-2 receptor 
stimulatory antibodies in hwnan sera provided that serwn is 
decomplemented or heat inactivated. Such antibodies could also be 
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investigated using expression systems developed by others or using 
lymphocytes. 
The role of the inflammatory response in the pathogenesis of asthma has 
been increasingly emphasised in recent times, and it is highly likely 
that if an acquired "defect" in beta-2 receptor function develops 
during the exacerbation of the disease, that this is due to an 
inflammatory "mediator". My own preliminary studies suggest that 
products of neutrophil activation may block or inhibit isoproterenol 
stimulated cAMP release and I have immediate plans to study this in 
more detail. It will be possible to use the Wt-7 Cape Town system to 
examine the effects of any mediator or drug on beta-2 agonist 
stimulated cAMP release in future studies and to study the effects of 
different levels of receptor expression on the susceptibility to, or 
resistance to inhibitory effects of inflammatory factors. 
My studies of the nine mutant human beta-2 receptors produced data 
consistent with more recent models of receptor topography in the 
membrane and contribute to an improved understanding of the overall 
molecular nature of the receptor, by identifying critical residues for 
ligand binding and receptor function. By utilising the available 
knowledge of the beta-2 receptor gene sequence, the effects of steroids 
and cAMP on gene transcription and the construction of highly specific 
beta-2 receptor probes, it will be possible to apply genetic techniques 
to study the regulation of beta-2 receptor expression in human airways, 
using techniques such as in situ hybridization. 
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To date, a structural defect in the human beta-2 receptor gene sequence 
has not yet been identified. In my own studies of the Ban 1 
polymorphism of the human beta-2 receptor gene, I could find no 
differences between the allergic patients and non-allergic controls. 
This, however, can only be regarded as a start to future studies. 
Mutational studies have identified several residues which are important 
for normal functioning of the beta-2 receptor. Using these mutational 
models it will be possible in the future, using the polymerase chain 
reaction to screen and identify abnormalities in short sequences of 
these critical residues in patients with disease, without having to 
sequence their entire beta-2 receptor genes. Thus, it will be no longer 
necessary to rely on indirect in vitro evidence to identify beta-2 
receptor abnormalties in human disease, and it will be possible to 
determine conclusively whether or not a structural defect in the beta-2 
adrenergic receptor gene occurs in human disease. 
It would be ideal to be able to identify beta-2 receptors directly in 
patient's lungs using non-invasive methods. Techniques involving 
scanning or imaging should be developed so that changes in their level 
of expression and state of activation of beta-2 receptor can be studied 
in relation to observed pulmonary function tests. Scanning could also 
be used to assess the effects of, and appropriate requirements for, 
beta-2 agonist therapy. Developmental models of beta-2 adrenergic 
receptor expression which show sequential and rapid changes in beta-2 
receptors such as I have found in the developing foetal and neonatal 
guinea pig lung, could be used to test the reliability and validity of 
non-invasive measurements of receptor number and function when this 
technology becomes available in the future. 
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APPENDIX A 
Lactoperoxidase iodination of guinea pig lung membranes. 
Activity of commercial lactoperoxidase was assessed as follows: 
Using a PYE UNICAM PU 8800 UV/VIS spectrophotometer, set at 25°C and 
350nm, 0.15ml of 90mM H202 was diluted in 30 ml of SmM KI in 33mM Na2P04 
buffer pH 7.0. 3.0 ml of this reaction mixture is placed in the 
cuvette and the blank read, after which 0.01ml of lactoperoxidase 
(1mg/1ml) is added and the increase in absorbance recorded for 3-4 min. 
Lactoperoxidase activity was calculated to be 138 units/mg. Glucose 
oxidase 1200U/ml (Sigma) was diluted to 0.03-0.04U/ml for the assay. 
Briefly 10µ1 lactoperoxidase (lOU/ml), 10µ1 glucose oxidase (lOU/ml), 10µ1 
glucose (lOOmg/ml), 10µ1 Na[ 125I] and 100µ1 lung membrane (1.2mg) were 
stirred for 30 minutes and loaded on to two 1 ml Sephadex GSO columns 
in two aliquots of 70µ1 which were centrifuged at 800g for 2 minutes and 
radioactivity of the eluate counted. Sµl of eluate had 9300 cpm 
measured on a Packard gamma counter (70% efficiency). 
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Preparation of alumina and Dowex columns for adenylate cyclase assay. 
Racks accommodating 24 columns each were constructed (by Mr. B. 
Orlandi) so that they fitted into each other in pairs. The racks held 
plastic columns 180mm x 6 mm (inner diameter) (Greiner 0.025 ml 
micropipettes No. 601 502) which were spaced so that the effluent from 
the lower columns drained into 24 scintillation vials arranged in a 
standard tray. 
Dowex AG 50W-X4 (200-400 mesh)(Biorad) was washed repeatedly with 
deionised water until the effluent was colour free. A 50% v/v slurry 
in deionised water was placed in a beaker and stirred vigorously. 
While stirring, 2 ml samples of homogeneous slurry were added to the 
glass wool stoppered columns. Columns were filled with water to 
allow all the beads to settle and form the column bed. Columns were 
then washed with 2 ml lN HCl. Prior to use the columns were filled 
with water(± 20 ml) and allowed to drain. 
Alumina Columns: 0.6 g dry neutral alumina (Sigma) was scooped into 
glass wool stoppered columns, washed with 15 ml l.OM Imidazole buffer 
pH 7.3 followed by 20 ml of O.lM imidazole HCl buffer pH 7.3. Columns 
were stored at room temperature. Elution volumes for ATP and cyclic 
AMP were determined using the step by step method described by Salomon 
(1979). Recovery from the Dowex columns was approximately 93% and 
from the alumina columns 89% using the [ 3H] cAMP tracer and [a- 32P]ATP. 
391 
APPENDIX C 
Determination of the optimal concentration of rabbit anti-human IgG 
for immunoprecipitation. 
Human myeloma IgG purified by triple ammonium sulphate precipitation 
was estimated to be about 95% pure. Purified human IgG was iodinated 
using the iodogen method published by Thorpe and Johnstone (1978). 1 
mg Iodogen was dissolved in 1 ml dichloromethane and dispensed in 20µ1 
aliquots into conical 10.5 x 39mm polypropylene tubes. The tubes were 
rotated in 37°C waterbath until the solvent evaporated leaving a film 
of Iodogen at the bottom of each tube. 10µ1 of 0.25M sodium phosphate 
pH 7.5 and 10µ1 purified IgG (lmg/ml) was added to an Iodogen tube and 
then vortexed. 200µCi sodium iodide (Amersham) was dispensed into the 
iodogen tube and the reaction mixture incubated for 10 minutes, mixing 
at 1 minute intervals. Upon completion of the incubation the reaction 
mixture was loaded on to a 2 ml Sephadex G50 fine column. The 0.5ml 
eluate was discarded and 6 x 0.5ml aliquots of 0.154M PBS were added 
to the column and collected separately in polypropylene tubes. 10µ1 
from each tube was diluted 1/10 000 in PBS and counted in a Packard 
gamma counter. Fractions containing radioactivity were pooled and 
10µ1 10% albumin added to each fraction. Radioactivity incorporated 
into the IgG protein was measured by trichloracetic acid precipitation 
(approximately 30%). 
Rabbit anti-human (RoH) IgG was prepared by immunization of New Zealand 
White rabbits with purified human IgG and tested against unlabelled 
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hwnan IgG using the Ouchterlony double immunodiffusion technique. 
Visible precipitation occurred using neat rabbit serwn and hwnan IgG 
neat, 1:2, 1:4 and 1:8 dilutions. 
Optimal concentrations for the rabbit anti-hwnan IgG and hwnan serwn 
dilutions was determined by constructing immunoprecipitation curves 
using [125I]-labelled hwnan IgG as a tracer. 
50 000 cpm [125I]-labelled IgG was dispensed into microfuge tubes with 
100µ1 1:25, 1:50, 1:250 and 1:500 dilutions of pooled hwnan serwn, and 
made up to a final volwne of 200µ1 with 20mM sodiwn phosphate buffer, 
pH 7.4. Ten dilutions of rabbit anti-hwnan IgG ranging from 1:10 to 
1:500 000 were prepared. IgG concentrations in each hwnan serwn 
dilution were measured using a Beckman Nephelometer. 100µ1 of RaH IgG 
was added to [125IJ IgG spiked human serum dilutions, incubated 
overnight at 4°G spun in the Beckman microfuge for 30 minutes and the 
pellet counted using a Packard gamma counter. 
Precipitin curves using three dilutions of rabbit anti-hwnan sera 
showed that good precipitation could be obtained with hwnan serwn at 
dilutions of greater than 1/50 using dilutions of rabbit serum from 
1:3, 1:12 and 1:50. A dilution of 1:12 was chosen for the rabbit 
antibody in the immunoprecipitation studies (3.4.1). 
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APPENDIX D 
Immunogenicity of lung membrane preparations in the New Zealand white 
rabbit. 
In order to investigate whether it was possible to induce [125]-CYP 
ligand inhibitory antibodies by exposing one species to intact beta 
receptors of another, lung membranes with functional beta receptors 
(confirmed by [125I]-CYP binding assay and adenylate cyclase assay) 
prepared from human, guinea pig and calf lungs (using the methods 
described in 2.2.1), were injected into New Zealand White (NZW) 
rabbits. 
Immunization protocol. 
For the primary immunization, 200µg lung membranes (human, guinea pig 
and calf) in 1 ml phosphate buffered saline, emulsified in 1 ml 
complete Freunds adjuvant was injected on to the dorsal aspect of 3 
NZW rabbits in 200µ1 aliquots. Eighteen days later the rabbits 
received a booster injection of 200µg of the same lung membranes in 
incomplete Freund's (IFA) adjuvant. A control rabbit received no 
immunization. The rabbits received a standard rabbit diet. (EPOL 
rabbit maintenance pellets). 
The rabbits were observed for any clinical sign of disease and 
baseline blood samples were taken for the measurement of 
immunoglobulins and serum chemistry. 
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Course of the immunised rabbit 
Four months after primary immunization the rabbit immunised with 
guinea pig lung membranes died. No environmental cause for the rabbit 
demise was apparent and a postmortem revealed nothing abnormal in any 
tissue. Histological examination of the tissues was not performed. 
The other two rabbits appeared to be thriving seven months after 
primary immunization. The rabbit which had received calf lung 
membranes was boosted again with 200µg calf lung membrane in IFA. 
By ten months after primary immunization both rabbits were noted to 
have developed significant alopecia on the ventral surface and on 
closer inspection there was loss of muscle bulk and obvious wasting 
which was more marked in the rabbit immunised with human membranes. 
Ten ml clotted blood was taken from each rabbit, serum separated and 
aliquotted and stored at -20°C. The animals were then weighed and 
examined regularly. 
Antibody measurements of 10 months showed that both rabbits were 
negative for anti-mitochondrial, anti-smooth muscle, anti-nuclear 
factors and anti-thyroid antibodies but that the rabbit immunised with 
calf lung membranes had developed a titer of anti-microsomal 
antibodies of 1:400. Serum (1:50 dil) from the rabbits did not 
inhibit [ 1251)-CYP binding to guinea pig lung membranes. 
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A photograph taken of the rabbit immunised with human lung membranes 
is shown in Fig. 90 and compared with the normal control rabbit. The 
wasting observed was striking. The rabbit was weak and apathetic. 
The other rabbits in the University of Cape Town Animal House showed 
no sign of any similar disease problems. 
Weights shown for the two rabbits over the next four months were 
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The weight chart confirms that the rabbits had developed a wasting 
disease which became rapidly progressive in the rabbit immunised with 
human lung membranes. Serum chemistry measured on 12.12.85 in both 
rabbits showed AST, ALT and LOH normal for both rabbits but creatine 
kinase was elevated in the rabbit immunised with human lung compared 
with normal rabbit control. The rabbit immunised with human lung died 
on 13.1.86 and a detailed postmortem was performed. A blood culture 
on 18.12.85 had revealed Staph. epidermidis sensitive to penicillin 
and the rabbit was treated with penicillin for one week. 
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Figure 90. Development of marked wasting in New Zealand rabbit 1333 
inununised with human lung membranes (left) compared with a 
non-immunised rabbit (right). 
}9 7 
The rabbit immunised with calf lung continued a slower but a steady 
downward course. On 29.1.86 serum phosphorus and creatine kinase were 
noted to be lower and alkaline phosphatase, aspartate amino-
transferase and alanine amino-transferase levels higher than 
pre-immunisation serum levels. Serum proteins, urea and electrolytes 
were normal but urinary urea was elevated 2.5 times that of the normal 
control rabbit. Serum from the rabbit again did not inhibit 
[ 1251)-CYP binding to lung membranes. The rabbit continued its 
downward course becoming progressively apathetic and wasted although a 
~mall septic lesion was found on the left leg on 29.1.86 and although 
no organisms were cultured from the septic site the rabbit was treated 
with a short course of Penicillin. The rabbit died on 22.4.86. 
Antibodies raised in the rabbits 
An 11% SDS PAGE of lOOµg human lung membranes, rabbit lung membranes 
and crude rabbit lung homogenate and guinea pig lung membrane 
preparations was immunoblotted (Western blotting technique) on to 
nitrocellulose paper using a modification of the method originally 
described by Towbin (1978). 
In order to screen for antibodies to injected lung membrane proteins, 
1:500 dilution serum from the rabbit injected with calf lung membranes 
was incubated with a nitrocellulose immunoblot of calf, guinea pig and 
rabbit lung membranes. HRPO-conjugated goat anti-rabbit antibody and 










Figure 91. Nitrocellulose irnmunoblot of calf (lane 1), guinea pig 
(lane 2), rabbit membrane (lane 3) and crude rabbit lung 
homogenate (lane 4) incubated with 1:500 dilution of rabbit 
serwn (Appendix D). 
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As shown in Fig. 91 the rabbit immunised with calf lung membranes 
developed antibodies to a number of membrane proteins in the calf lung 
preparation, but also reacted with a number of proteins in guinea pig 
lung membranes and strongly reacted with high molecular weight rabbit 
lung membrane proteins. 
Postmortem morphology and histology 
The postmortem findings and histological examination (performed by Dr. 
J. Campbell, pathologist) are shown in tabular form as follows: 
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Table 21: Postmortem findings of rabbits immunised with foetal 


















Human lung membranes 
from 16wk human foetus, 
(containing beta 
adrenergic receptors) 
Wasted rabbit with 
marked ventral alopecia 
and ulceration of the 






Large pale kidneys 
Fatty change in 
cortical tubules 
Dilated and filled with 
bile stained material 
Marked dilatation of 
caecum 
Large and Yellow 
Soft and gray 
Atrophic 
Nictitating membrane 
fixed over most of the 
the orbit 
Appear unusually densely 
calcified 
Rabbit 1335 
Lung membranes from foetal 
calf lung (containing beta 
adrenergic receptors) 
Wasted rabbit with marked 
ventral alopecia 
Congested 
large left ventricle 
Diffuse yellow mottling 
atheroma 
Autolysis 
Cortex mottled on 
Normal size 
Marked dilatation of 
caecum 
Appear normal 
Dark and atrophic 














Human lung membranes 




A severe and extensive 
tubular lesion was noted. 
Most of the renal 
tubules are replaced by 
basophilic calcor-
pherules and the 
remaining tubules were 
dilated or atrophic. 
Calcification also 
present in Bowmans 
Capsule and rarely in 
the glomerular tuft. A 
striking eosinophilia 
Rabbit 1335 
Lung membranes from foetal 




fication and renal 
fibrosis of peri-
glomerular tissue tubules 
and some vessels. Some 
vessels show degeneration 
and calcification. Cellular 
infiltrate is not a 
feature 
was noted in the glomeruli. 
Casts were present in some 
dilated tubules but 
vascular changes were not 
a feature. No evidence 
of renal infection. 
The aorta and its main 
branches show calci-
fication of the sub-
endothelial muscularis. 
Bronchitis and calci-
fication of the bronchial 
cartilage. 
Reorganization of 
lamellar bone with 
with deposition of 
amorphous calcium and 
phosphate around the 
remaining bony lamella. 
Severe siderosis 
Oedema and fibroblastic 
thickening of the iris 
Aortic medial degeneration 
with calcification and 
intimal fibrosis. Severe 
medial calcification with 
intimal fibrosis in the main 
coronary arteries with 
calcification of the heart 
valves and roots of the 
aorta and pulmonary artery. 
The left ventricle appeared 
hypertrophied. 
Focal congestion and 
haemorrhage with calcifi-
cation of bronchial wall and 
basement membrane. 
Greatly thickened 
trabeculae and lamellae 













Human lung membranes 







Discussion of the pathology of the rabbits 
Rabbit 1335 
Lung membranes from foetal 
calf lung (containing beta 
adrenergic receptors) 
Calcification of meso-




Immunization of three rabbits with lung membrane preparations employing 
a standard immunization protocol has not only induced an antibody 
response to proteins in the lung membranes, but in two out of three 
animals a severe but strikingly similar wasting disease associated with 
alopecia, renal damage and diffuse generalised calcification. 
The observation that antibodies raised to calf lung membrane proteins 
also bound to rabbit lung membrane proteins and were associated with 
disease in rabbit, suggest that either identical antigens are present 
in both species or that the antibodies bind to cross reactive epitopes. 
The fact that the effects on the rabbit lungs were small when compared -
with the dramatic effects observed on the kidneys and vessels, suggests 
that the antibodies raised in the rabbit may have been directed against 
antigens in these organs, or deposited there as immune complexes. 
The exposure of an animal species to lung membranes from a different 
species is thus able to induce a wasting autoimmune type of process. 
Clearly these experiments are preliminary and need to be followed up by 
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detailed and systematic immunization of further rabbits with lung 
membranes or homogenates but the similarity of the pathological 
processes observed in these animals suggests that this protocol may be 
useful as a model for atherosclerosis in the rabbit. 
It is furthermore tempting to speculate that in the human situation, 
exposure to intact cell membranes from other animals could also be 
immunogenic and possibly induce autoimmune processes in individuals in 
whom the regulating mechanisms for antibody production are inadequate. 
There was no evidence of antibody production to the beta receptor or 
the development of asthma in the rabbits at any stage. 
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APPENDIX E 
Fibroblast cell lines and culture conditions. 
El Cell lines 
El.l. B82-L cells 
A clonal subline of L cells (B82) lacking thymidine kinase 
(Littlefield 1966) was used in the studies conducted at N.I.H. 
(Bethesda, Maryland). These L cells originally derived from the 
C3H/AN mouse strain, were found to lack catecholamine responsiveness 
probably due to lack of the human beta-2 receptor or masking of its 
funtion (Gilman 1973). 
For the transfections and studies performed at the University of Cape 
Town B82 cells cultured from frozen N.I.H. stocks were shipped to Cape 
Town by Dr. Josephine Lai (University of Arizona, U.S.A.) in tissue 
culture flasks. These cells were found to be contaminated with 
mycoplasma and were decontaminated according to the protocol in 
Appendix E4 prior to the transfections. 
El.2 Foreskin fibroblast line 
Human foreskin fibroblasts were a gift from Dr. Colleen Fearns 
(University of Cape Town). These were derived from frozen stocks of 
primary cultures from foreskins obtained from neonatal circumcision. 
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E2 Maintenance and storage of cell lines 
Cell lines were maintained in RPMI-1640 (RP; Gibco Cat. No. 074-1800) 
supplemented with 10% FCS (heat inactivated; S6°C for 30 min) 300µg 
penicillin/ml and 200µg streptomycin sulphate/ml. The cultures were 
kept at 37°C in a humid atmosphere containing 5% CO2 in air in a 
Hotpack CO2 incubator (Hotpack Corporation, Philadelphia, PA USA). 
Cell lines were examined daily under phase contrast microscopy and 
passaged when they approached confluency. Passaging was performed by 
incubating the cells for 5 minutes in 0.25% Trypsin in medium at 37°C. 
The detached cells were dispersed by gentle pipetting and the 
suspension added to an equal volume of medium containing FCS to 
neutralise the trypsin. After centrifugation at 350g for 5 min the 
pellet was resuspended in medium and re-seeded into culture dishes. 
For long term preservation cell stocks were frozen in liquid nitrogen 
by resuspending a cell pellet in medium containing 10% FCS and 10% 
DMSO in 1 ml volumes in screw topped 38 x 12.5mm nylon tubes (Greiner 
Cat. 121 261). Tubes were wrapped in paper towelling at -70°C 
overnight prior to freezing in liquid nitrogen. 
E3 Screening for mycoplasma contamination. 
All cell lines used were tested for mycoplasma contamination according 
to the method of Chen (1977). Cells were fixed with acetic 
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acid:methanol (1:3) and stained with 0.5µg/ml of bisbenzimide 
fluorochrome (Hoechst No. 33258) in Hanks balanced salt solution for 
30 min. The cell layer was rinsed with deionised water and mounted in 
buffer containing 0.02M citric acid, 0.06M disodium phosphate and 50% 
glycerol, pH 5.5. Cultures were examined under a Nikon fluorescence 
microscope. 
E4 Eradication of Mycoplasma Contamination. 
The B82 mouse L cells which were obtained from Dr.J. Lai (University 
of Arizona), were found to be heavily contaminated with mycoplasma, 
using the Hoechst stain. To eliminate mycoplasma from the cells, I 
used the BM cycline protocol (Boehringer Mannheim). There was no 
evidence of mycoplasma contamination after the fourth week of 
treatment. The B82 cells were checked periodically, using the Hoechst 




Membrane preparation from cells in culture 
Cells were grown to semi-confluence in 15 cm tissue culture dishes and 
pulsed with 10-6M dexamethazone (Sigma Cat. 04902) for 24 hours, to 
induce beta-2 receptor expression in transfected cells, prior to 
harvesting. 6ml cold (4°C) lysis buffer 5mM sodium phosphate pH 7.4 
2mm MgS04 was added to each dish and after the cells were scraped off 
the dish with a rubber policeman, they were left on ice for 30 min. 
Cells were then homogenised by 20 strokes of a glass homogeniser 
(Wheaton, USA), centrifuged at 1000g for 10 minutes to remove intact 
cells and cellular debris. The supernatant was then centrifuged at 
40 OOOg for 45 min at 4°C using a 70Ti rotor in a Beckman L-80 
ultracentrifuge to collect the crude membranes. Membranes were 
suspended at approximately 4 mg/ml in 150µ1 aliquots in 20 mM sodium 
phosphate 2rnM MgS0 4 pH 7.4, snap frozen, in screw capped 38 x 12.5 mm 
nylon tubes (Greiner) and stored at -70°C. 
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APPENDIX G 409 
Comniunication 
Site-directed Mutagenesis and 
Continuous Expression of Human 
/3-Adrenergic Receptors 
IDENTIFICATION OF A CONSERVED ASPARTATE 
RESIDUE INVOLVED IN AGONIST BINDING AND 
RECEPTOR ACTIVATION* 
(Received for publication, October 26, 1987) 
Fu-Zon Chung, Cheng-Dian Wang, Paul C. Potter, 
J. Craig Venter, and Claire M. Fraser:j: 
From the Section of Receptor Biochemistry and Molecular 
Biology, Laboratory of Molecular and Cellular 
l'leurobiology, Natiornil lruititute of Neurological and 
Communicative Disorders and Stroke, National Iruititutes 
of Health, Bethesda, Maryland 20892 
Using a new expression vector that allows stable and 
steroid inducible expression of the human Pradrener-
gic receptor in mouse L cells, we have examined the 
functional significance of the highly conserved aspar-
tate residue in the putative second transmembrane re-
gion of the receptor. Substitution of aspartate 79 with 
asparagine produced a mutant receptor that displays 
the expected affinity and stereoselectivity for antago-
nists but a 40-, 140-, and 240-fold reduction in its 
affinity for isoproterenol, epinephrine, and norepi-
nephrine, respectively. This receptor mutant does not 
display guanine nucleotide-sensitive high affinity 
binding of agonists. Addition of saturating concentra-
tions of isoproterenol to cell cultures expressing the 
mutant receptor produces a slight, albeit significant, 
increase in intracellular levels of cyclic AMP as com-
pared to cells expressing wild type receptor. These 
observations demonstrate that substitution of aspar-
tate with asparagine at residue 79 in the human P-
adrenergic receptor differentially affects the binding 
of catecholamines and produces a functional uncou-
pling of receptors and stimulatory guanine nucleotide 
regulatory proteins (G.). These data are consistent with 
a role for aspartate 79 as a counterion to the amine in 
catecholamines and in agonist-induced activation of 
the P-adrenergic receptor associated with high affinity 
ligand binding, G. coupling, and adenylate cyclase 
stimulation. 
Recent cloning (1) and stable expression (2) of the gene 
encoding the human /1radrenergic receptor in murine cell 
lines allows for detailed examination of the significance of 
conserved amino acid residues in receptor function by site-
directed mutagenesis. The aspartate residue at position 79 
within the second putative transmembrane segment of the 
human /3-adrenergic receptor is part of a sequence domain 
• The costs of publication of this article were defrayed in pnrt hy 
the payment of page charges. This article must therefore he hereby 
marked "adt'crlisement" in accordance with 18 U.S.C. Section 1734 
solely to indirntc this fnct. 
:I: To whom correspondence should be addressed: Section of Recep-
tor Biochemistry and Molecular Biology, LMCN. NINCDS, Park 5, 
Room 405, NIH, Bethesda, MD 20892. 
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that is conserved in all /3-adrenergic (3-G), a-adrenergic (7), 
nnd muscarinic cholinergic receptors (8-10) an<l all opsin 
proteins (1 )-1:1) sc>q11cnccd to dntc. The Asp rrsidue in thi<1 
domnin haR hecn propo<1cd to form R countcrion for the 
protonated Schiff base involved in retinnldchyde binding to 
opsin (14). Similarly, it has been suggested that this residue 
may sen.:e as a counterion to the amino group of hound 
catecholamines in the /j-adrenergic receptor (14). Somewhat 
consistent with this hypothesis were data in a recent report 
on the suhstitution of Asp-79 with alanine in the hamster 
lung /12-adrenergic receptor (15). A 10-fold loss in receptor 
affinity for agonists was reported for this trnnsiently ex-
pressed mutant receptor. The transient nature of receptor 
expression precluded a more thorough investigation into the 
role of Asp- 79 in receptor function. 
In order to study the function of this important Asp residue 
in more detail, we introduced a unique point mutation in the 
human /3-adrenergic receptor to change Asp- 79 to asparngine 
and have utilized a new expression vector to obtain stable, 
glucocorticoid-inducible expression of the mutant /3-receptor 
in B-82 cells, a murine cell line lacking /3-receptors (2). Our 
data suggest that Asp-79 is involved in an agonist-induced 
activation of the /3-adrenergic receptor associated with trans-
duction of a biological signal to other membrane effectors. 
EXPERIMENTAL PROCEDURES 
Materials-Materials were obtained from sources described previ-
ously (2). 
Coruitruction of a New Expression Vector and M11tn.1;enrsis-
Expression vector pMSVneo was constructed by replncrmcnt oft he 
xanthine-guanine phosphoribosyltrnnsferase (GPT) gene in plasmid 
pMSG with the neomycin-resistance gene from pHSVnPo. A new 
poly linker was also constructed to facilitate the cloning of the tl,· 
adrenergic receptor gene. 
For receptor expression, the entire coding region of the human tl,-
adrenergic receptor derived from genomic clone LCV -S 17 ( I l (base 
pairs -6 to +1267) was cloned into the Miu and Er•JHV sites in the 
polylinker region of pMSVneo. The sin11le hn~e mutation that con· 
verts aspartate to asparagine wns introduced into the humnn ,J,. 
adrenergic receptor by oli11onurleotide-directed mutagcncsi~ accord· 
ing to the method of Kunkel (16). Authc>nticity of the mutation wn~ 
confirmed by clidcoxy ~cquencing. Cell~ were trnn~fertccl nnd sl'lertrd 
as described by Frnser et al. (2). 
Cl'll Cu/ture-R-82 cells. a murine L cell line, wpre grown in 
monolayer as described (2). 
Cell Membrane Preparation and tl-AdrcnrrRic Rrcrptor Li11nnd 
Binding Studie.~-were performed as described by Frnscr ct nl. (2l. 
Protein was assayed using the fluorescamine assay with bovine serum 
albumin as a standard ( 17). 
RESULTS 
In order to study the role of specific amino acid residues in 
neurotransmitter receptor function, we have cons! ructed a 
new expression vector that allows stable and inducible expres-
sion of eucaryotic genes in mammalian cells. As shown in Fig. 
IA, the expression vector, pMSVneo, contains the 1-t.'iO-hase 
pair long terminal repeat of the mouse mammary tumor virus. 
The dexamethasone-inducihle transcription prornoter within 
the mouse mammary tumor virus 5' -long terminal repeAt 
regulates expression of genes inserted into the downstream 
multiple cloning site. Addition of l µM rlexamet hasone to 
culture medium results in a 5- to JO-fold incrrnsr in the 
density of /3-adrenergic receptors in transfected cells (data not 
4052 
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> (+)-1soprot-trenol > (-)-norepinephrine. 
It is well ·documented that the affinity of /J-adrenergic 
receptors for agonists is decreased when assays are performed 
in the presence of guanine nucleotides. This change in recep-
tor affinity is presumed to ref1ect the dissociation of a "ternary 
complex" of agonist, receptor, and G, that is associated with 
high affinity for agonists (18). In order to examine whether 
or not the Asn· 79 receptor displayed guanine nucleotide-
sensitive changes in agonist affinity, competition binding 
studies with isoproterenol and ICYP were repe
0
ated in the 
presence of 100 µM guanyl-5' -yl imidodiphosphate 
(Gpp(NH)p) (Fig. 3). In membranes containing wild type 
receptors, addition of exogenous guanine nucleotides caused 
a shift to the right in the isoproterenol dose-response curve 
and eliminated the majority of the high affinity component 
of agonist binding. The Hill coefficient for isoproterenol bind-
ing to wild type receptor was 0.5 in the absence of guanine 
1()() 
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FIG. 3. Guanine nucleotide regulation of agonist affinity to 
wild type and mutant P-adrenergic receptors in transfected 
cells. ICYP specific binding to wild type and mutant receptors was 
determined at a concentration of 60 pM in the presence of increasing 
concentrntions of (- )-isoproterenol plus or minus 100 µM Gpp(NH)p. 
T and• illustrate the binding of ICYP to wild type receptors in the 
presence and absence of Gpp(NH)p, respectively. A and• illustrate 
the binding of ICYP to Asn-79 mutant receptors in the presence and 
absence of Gpp(NH)p, respectively. Samples were assayed and fil-
tered as described in Fig. 1. Data are representative of two separate 
experiments, each point performed in triplicate. 
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FIG. 4. Stimulation of adenylate cyclase in cells expressing 
wild type and mutant Asn-79 ,8-adrenergic receptors. Con-
fluent cultures of cells expressing wild type (WT) or mutant (ASN 
79) receptors were washed with Dulbecco's phosphate-buffered saline 
(PBS) and incubated in PBS containing 1 mM 3-isobutyl-1-meth-
ylxanthine for 30 min at 37 ·c. Isoproterenol (ISO) or PGE, at the 
indicated final concentrations was added to the cultures for 20 min. 
PBS was aspirated from the cultures and intracellular cyclic AMP 
was extracted with 2 ml of 6% trichloro11cetic acid. Trichloroacetic 
acid extracts were extracted four times with ether, and cyclic AMP 
concentrations were determined using 11 redioimmunoassay kit for 
cyclic AMP (Du Pont-New England Nuclear). Cells were dis~olved 
in 0.2 N NnOH fnr determination of cellulnr protein. Dnta nre ex-
pre~~ed 11~ picomole~ of cyclic AMP produced per milligrnm of cellular 
protein per minute. 
nucleotides nnd shifted to 0.8 in the presence of (:pp(NH)p. 
In contrast, the Hill coefficient for isoproterenol binding to 
the mutant Asn-79 receptor in the absence of Gpp(NH)p was 
1.0, indicating a single homogeneous (low affinity) population 
of ligand binding sites. (~pp(N H )p had no effect on isoproter-
enol binding to Asn- 79 receptors. These dRtn suggest thnt 
mutngenesis of ARp· 79 to Asn resulted in n f11nct ional "un-
coupling" of the G, effect on the {-l-adrenergic receptor. 
The ability of isoproterenol to stimulate Rdenylate cyrlase 
in cells expressing Asn- 79 /J-adrenergic receptors was inves-
tigated. As we previously reported (2), addition of isoproter-
enol to 8-82 cells containing wild type receptor resulted in a 
dose-dependent increage in intracellular levels of cyclic AMP 
similar to those elicited with PGE, (Fig. 4). In contrnst, 
addition of increasing concentrations of isoproterenol to cells 
expressing mutant Asn- 79 receptors had no significant effect 
on intracellular levels of cyclic AMP except Rt the highest 
isoproterenol concentrations (10-100 11M) where slight but 
statistically significant increases in intrncellulRr levels of 
cyclic AMP were seen in cells expressing Asn-79 receptors . 
This increase in intracellular cyclic Al\lP was blocked by the 
concomitant addition of (-)-proprnnolol (10 µM) to cell cul-
tures, indicating that the observed changes in cyclic AMP 
levels were mediated by a receptor specific act ivRtion of 
adenylate cyclase (data not shown). 
DISCUSSION 
In order to study the role of specific amino nrid rrsirlues in 
/J-adrenergic receptor function, we have substituted nspnrtnte 
79 with asparagine. The locus of this mutation is within the 
second putative transmembrane domain of the d-rrceptor. 
This alteration produced a mutant /J·receptor that displayed 
normal binding of antagonists but R reduced affinity for 
agonists. In addition to the obsen·ed change in receptor 
affinity for agonists, replacement of Asp-79 uncoupled the G, 
effect on receptor. While Asn-79 mutant receptor no longer 
displayed guanine nucleotide-sensitive binding of agonists, 
agonist activation of adenylate cyclase was still observed, 
albeit at significantly attenuated levels. 
These data raise the question as to the role of nspartnte 79 
in normal /J-adrenergic receptor function. Receptor modeling 
studies predict that aspartate 79 is located in the nqueous 
core formed by the hydrophilic surfaces of the seven nmphi· 
pnthic transmemhrnne S<'gments of the rec<'ptor,
0 nnd there· 
fore, it is unlikely that this amino acid directly interacts with 
G •. 
A more likely hypothesis is that aspnrtate 79 is involved in 
maintaining a receptor conformation necessary for high affin-
ity agonist binding and transfer of this binding energy to 
other effectors. Thermodynamic studies of agonist interac-
tions with ~-adrenergic receptors were consistent with a two-
step process of agonist binding and an associated conforma· 
tional change in the receptor (17, 18). As proposed by Apple-
bury and Hargrave (14), Asp-79 may serve as a counterion to 
the amine group of the catecholamines in the rl-adrenergic 
receptor. Replacement of a negatively chnrged Rspnrtate res-
idue with an asparagine having no net charge mny eliminate 
one point of catecholamine attachment to the receptor, re· 
suiting in a loss of Rgonist affinity. The differential loss of 
agonist affinity observed in the Asn-79 mutnnt rerE'ptor mny 
ref1ect differences in hydrophobic internctions hrtwren ligand 
and receptor at this locus. For exnmple, the isnpropvl suhstit· 
uent of isoproterenol Rnd the methyl group of epinephrine 
could provide differential hydrophobic internrtions that stn· 
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F1G. L Mutagenesis and expression of human P.-adrenergic 
receptor gene in transfected B-82 cells. A, expression vector 
pl\lSVneo. B, saturation isotherms of ICYP binding to membranes 
from cells expressing wild type human fj,-adrenergic receptor. Mem-
branes from cells pretreated with 1 µM dexamethasone for 24 h before 
har,esting were incubated with the indicated concentrations of lCYP 
in the presence or absence of 1 µM '(-)-propranolol for 30 min at 
3() 'C. Samples were filtered over Whatman GF /C filters using a 
Brandel M-24R Cell Harvester and washed with 20 ml of phosphate-
buffered saline. Data are representative of two separate experiments, 
each point performed in triplicate. Nonspecific binding was between 
5 and 10% of total binding. Inset, Scatchard analysis of ICYP binding 
to wild type P-adrenergic receptors (19). C, saturation isotherms of 
ICYP binding to membranes from cells expressing Asn-79 mutant /12-
adrenergic receptors. Assays were performed and analyzed as detailed 
in B. 
shown). In addition, the expression vector also contains the 
neomycin resistance gene which is expressed from an SV40 
early promoter to ensure selection of stably transformed cells 
when grown on medium containing the neomycin analogue, 
Geneticin (G-418). 
!-.lembranes prepared from cells transfected with expression 
vector containing the wild type human {J-adrenergic receptor 
and cultured in the presence of 1 µM dexamethasone for 24 h 
displayed (12'I]iodocyanopindolol (ICYP)' binding equivalent 
to 117 ± 7.4 fmol/mg protein (Fig. lB). The calculated Kd for 
ICYP binding (21 ± 5 pM) is comparable to that reported 
pre\'i0usly (2). ICYP binding to the mutant Asn- 79 receptor 
displayed a similar receptor density ( 143 ± 9 fmol/mg protein) 
and Kd (22 ± 5 pM) as the wild type receptor (Fig. lC). 
The interaction of wild type and Asn-79 receptors with 
adrenergic agonists and antagonists was examined by com-
petition binding of these ligands with ICYP. Wild type and 
mutant receptors have the same affinity for the ( + )- and(-)-
isomers of propranolol (Fig. 2A ); however, the Asn- 79 receptor 
has a significant reduction in affinity for the catecholamines, 
isoproterenol (40-fold), epinephrine (140-fold), and norepi-
'The Hbbreviations used are: ICYP, ["'lliodocynnopin<lolol; C .. 
~timulnlory gunnine nucleotide regulatory protein~: Cpp(NH)p, 
g-uanyl-fi'-yl imidodiphosphate; PGE,, prostaglandin E,: PBS, phos· 
phale-huffered saline. 
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F1c.. 2. Adrenergic ngonist nnd nntngonist competition for 
ICYP binding to expressed human ,8-ndrencrgic rcl"cplors. 
Membranes from dexamethasone-trented cells l'~pressin!( wild t\'pr 
or Asn-79 mutant /j-adrenergic receptors were incubated in thr pres-
ence of 10 pM ICYP and the indicated concentrations of ndrenNgir 
agents for 30 min at '.JO 'C. Samples were filtNrd ns descrihrd in Fig. 
l. Total ICYP binding in the absence of competing ligands wM 'i 
fmol. Data are representati\'e of two to three separate experiments 
performed in triplicate. Variability among experiment~ R,·ernged I fl 
to 20%. A,• and A represent data derived from wild type nn<l mutant 
/j-adrenergic receptor. respectively, in the presence of inrrrnsing 
concentrations of (-)-propran0lol. 0 and 6 represent datn rlnind 
from wild type and mutant receptor, resperti,·ely. in the prrsrnrr nf 
increasing concentrations of (+)-prnprnnnlnl. ll, competition binding 
to wild type 1j-adrenergic receptors in !he presence of (-)-is1Jpr11fn-
enol (0), (-)-epinephrine (0), And (-)-nnrepinephrine (t.l. Cnrnp£'· 
tition binding to Asn-i9 mutant ,8-a<lrenergic receptors in thr pres-
ence of (-)-isoproterenol (e), (-)-epinephrine 1•1. Rnd (-1-nnrrpi-
nephrine (4). 
TARLF. I 
Human d 2 -adrenerf/iC rcc('p/ors: affinitirs fnr adrrnrr11ic nc,·11/s 
The affinil\· constant (K,) for the rndinlii:::rnd ICY!' "ns rlctcr 
mined directly in equilibrium hinding st11diC's. Thl' K., fnr rnrnpctinc 
ndrenergic ngents wns cnlculnt£'<l from cntn(H'lilinn stu<lif's using thr 
nnnlvsis of Cheng nn<l l'rusoff (201. \'nl11!'S rcprrsrnt th!' nwn11 :': 
standard error of the me11n of the indicnte<l numhl'r of expl'ri111r11ts 




( + )-lsoproterenol 
(-)-Epinephrine 
(-)-Norepinephrine 
(-) · Propranolol 
(+)·Proprnnolol 
( + )-Iodocyanopindolol 
\rild type receptor 
1 i.6 ± 4 (11 = 3) 
80 ± 7 (n = 2) 
200 ± 11 (rt = 2) 
:i11.!'i ± G (n = 2) 
219 ± 27 (rt = 2) 
0.22 ± 0.1 (11 = 2) 





6:iO ± 110 ( n = 2 l 
12,167 ± 2.Jll!i (11 = 2) 
7.800 ± 1.81l0 111 = 2) 
!i2,:i00 ± Z)j()() (n = 21 
0.22 ± 0.1 (n = 2) 
'.111.R ± 0.1 (n = 21 
22 ± !'i.0 (rt = 2) 
nephrine (2-10-foldl, as compared to the wild t~·pe rrcrptnr 
(Fig. 2RL The mutant Asn-79 receptor retnins stereo 0 elrrti,e 
binding of agonists; the (- )- and (+)-isomers of isoprot rrrnnl 
display approximately the samr diffNrn<·r in pnterH·,· f"r 
displncement of IC:YP ns thr wild f\'pe rPcPptor (Tnlilr ll. 
Similar!\·. the same rank order of agonist potenr_,. is rrf:1i1H·d 
in the A~n-,9 receptor of (-)-isoproterenol > (-)-epinephrinr 
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hilize the agonist-receptor interaction even in the absence of 
th, amine counterion (Asp-79); the unsubstituted positively 
charged amine group of norepinephrine would be unable to 
participate in a hydrophobic interaction at this site. The 
oh~<'rvntion thnt nntngoni~t binding iii nrrn ffecteci hy I hi!! 
mutation suggests that the binding of ngonists nm! nntngu-
nists at this site on the /3-adrenergic receptor is fundamentally 
different. 
Strader et al. (15) did not observe a similar differential 
affinity shift for isoproterenol and epinephrine in their study 
on the substitution of Asp-79 with alanine in the hamster 
lung /3-adrenergic receptor. It is not clear whether the lack of 
such shift in agonist affinity was due to the aspartate-alanine 
substitution or to the transient expression system used for 
assay of the mutant receptor. 
The findings that the Asp-79 mutant receptor displays no 
guanine nucleotide-sensitive agonist binding and affects min-
imal stimulation of adenylate cyclase imply that the role of 
this residue in receptor function is not limited to catechol-
amine binding. Our data suggest that this locus in transmem-
brane segment II is also involved in an agonist-induced con-
formational change which facilitates its interaction with G,. 
Substitution of Asp-79 with Asn appears to limit the range of 
possible receptor conformations and thereby prevents the 
effective transfer of the energy of ligand binding to other 
effectors. The increases in intracellular cyclic AMP levels 
observed in the presence of 10-100 µM isoproterenol may 
reflect a small percentage of Asn-79 mutant receptors ran-
domly assuming a functional conformation in the presence of 
high agonist concentrations. 
All adrenergic and muscarinic cholinergic receptors and 
mammalian opsins appear to share functional homology in 
that they transfer the signal of ligand/light binding to effector 
systems via guanine nucleotide regulatory proteins. Conser-
\·ation of Asp-79 among members of the gene family implies 
an important role for this amino acid in receptor function. 
Our findings from site-directed mutagenesis of Asp-79 suggest 
that this locus in transmembrane segment II may be involved 
in the activation mechanism of the /3-adrenergic receptor. 
l\1utagenesis studies with other members of this supergene 
family will be necessary to determine if conservation of this 
amino acid residue is associated with conservation of receptor 
mechanisms. The availability of an established cell line ex-
pressing Asp-79 mutant /3-adrenergic receptors will facilitate 
further pharmacological and structural studies of this impor-
tant mutation. 
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APPENDIX H 
Analysis of the purity of the beta-2 adrener&ic peptides I and II 
provided by Professor L. Visser, University of Pretoria. 
D79 L V M G L A V V P F G A A H I L M K M99 (C - G) 
Amino acid Peptide n-palmitoyl peptide 
Asp (1) 0. 852 1.00 
Gly ( 3) (3.00) 1 (3.00) 1 
His (1) 0. 932 1.03 
Ala ( 3) 2.97 3.16 
Pro (1) 1.11 1.445 
Val (3) 2. 342 2. 802 
Met ( 3) 3. 61 4 3.14 
Cys (1) 0.63 0. 77 
Ile (1) 1. 03 3 1.132 
Leu (3) 2. 842 2.92 
Phe (1) 1. 05 1.02 
Lys (1) 1. 02 0.99 
1. Ratios calculated i. t.o. Gly - 3.00 
2. 72h hydrolysis 
3. 48h hydrolysis 
4. Contains some residual free methionine used in cleavage of 
peptide from resin. 
5. No resolution between Pro and NH3 
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The optical purity of the peptide was determined using 
enantioselective HPLC. All enantiometric pairs except for D/L Asp 
could be separated by HPLC using a chiral eluant. The separation is 
based on the differential distribution between the stationary and 
mobile phases of D- and L-amino acid complexes, which form with the 
chiral eluant Cu(II)-N,N' dimethyl-L-Phe. 
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APPENDIX I 
Beta-2 Receptor Peptide ELISA 
1. Reagents. TST Washing Solution: O.lM NaCl, 0.05M Tris pH 8.0 
Tween 20 0.05% 
ELISA diluent: 
Blocking Solution: 
PBS: (lOx stock) 
2. ELISA protocol 
0.5M NaCl 0.01 M Na2HP04 0.5% 
Triton X-100 
1% fetal calf serum in phosphate 
buffered saline 
NaCl (80g) KCl (2.0g) 
Na2HP04 .2H20 (14.4g) KH2P04 
(2g)/litre 
1. Coat Titertek plates with 0.5µg peptide/50µ1 methanol/well 
overnight. Allow to air dry. 
2. Wash the plates 5x with PBS 
3. Block with 200µ1/well blocking solution for 1 hour 
4. Discard blocking solution 
5. Add 50µ1/well mouse serumjhybridoma harvest fluid diluted in 
blocking solution, in duplicate and leave for 1 hour at 
room temperature. 
6. Wash lOx with TST. 
7. Add 100 µl of a 1/500 goat-a-mouse peroxidase conjugate 
(Cappel) to each well for 30 minutes. 
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8. Wash lOx with TST. 
9. Add 100µ1 of ABTS (2,2 Azino bis (3-ethyl benz thiazoline 
sulphuric acid (Diammonium salt)(Cat. Al888 Sigma) 
substrate freshly prepared as follows: 
O.lM sodium citrate (525mg citric acid monohydrate in 50ml 
distilled H20) adjust pH to 4 ± 0.1 with 3N NaOH. Dilute 
ABTS (40mM kept stored frozen in aliquots) 1:100 in citrate 
buffer and add 1/100 volume 30% H202 . 
10. Leave for 30 mins and read absorbance at 414 nM. 
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APPENDIX J 
Reagents used for monoclonal antibody production (in section 5.5) 
1. Foetal calf serum (FGS) from ~tate Vaccine Institute heated for 30 
min at 56°G. 
2. RPMI 1640 with glutamine pH 7.0. 
3. Human umbilical cord serum (HUGS) pooled heated 56°G for 30 min and 
filter sterilised. 
4. Penicillin 10 OOOU/ml and streptomycin 10 000 µg/ml in sterile PBS 
(stored frozen in aliquots) (lOOx P+S) 
5. Polyethelene glycol (PEG) Merck M.W. 4000. 2g PEG/2ml warm RPMI 
(37°G). 
6. Freezing medium 10% dimethyl sulphoxide DMSO and 10% FGS in RPMI 
(without antibiotics) 
7. Aminopterin (Sigma ) lOOx stock - 1.76 mg/lOOml H20 used at 4 x 
10-7M final concentration. 
8. HT medium (lOOx) hypoxanthine lx10-4M, thymidine 1.6 x 10-sM 
glycine 3xl0-6M Na pyruate lx10-3M in RPMI. 
9. HAT-HUGS medium. 1 ml lOOx aminopterin + 1 ml lOOx HT+ 10 ml 
HUGS+ 1 ml lOOx P+S made up to 100ml RPMI. 
10. HT-HUGS medium. Same as HAT-HUGS but without aminopterin. 
11. Versene solution: EDTA in buffered saline pH 7.4 
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APPENDIX K 
Immunofluorescence of binding of B4A8-P'WL to WT-7 Cape Town cells. 
Multiwell 10 slides (Titertek) were soaked in detergent (7x) for two 
hours, and then rinsed once in tap water, three times in doubled 
distilled water and twice in sterile water. After baking for 3 hrs at 
250°C (wrapped in foil) in an oven, they were coated with poly-L-lysine 
(sterile), 10µ1/ml, for two hours and then washed again using tissue 
culture water before drying in a laminar flow hood. 
4 x 105 B82 cells (transfected or untransfected cells) were seeded on 
to the multiwell 10 slides in RP-10 and cultured until almost 
confluent (2-3 days) and then pulsed overnight with 10-
5 M 
dexamethasone (Sigma) followed by immunofluorescence studies on either 
fixed, or unfixed cells, using a protocol adapted by Dr. A. 
Khalili-Shirazi. 
(i) Protocol for Immunofluorescence of fixed cells 
1. Cells were washed 3x with RPMI 
2. Cells were fixed with 4% paraformaldehyde in PBS pH 7.4 for 2-3 
min at RT. 
3. Wash 3x thoroughly with PBS 
4. Wash lx with PBS, 0.1% BSA (wash buffer) 
5. Block with O.lM ethanolamine in PBS 0.1% BSA for 30 min at 4°C. 
6. Wash lx with wash buffer. 
7. Treat gently with 0.01% Triton X-100 (1 drop of Triton X-100 in 
50ml PBS) at RT for 5 min. 
8. Wash 2x with wash buffer 
9. Dry around the well and smear silica gel around it. 
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10. Add B4A8 1/50 dilution (or control antibody) in 5% HS (horse serum) PBS for 60 min at RT 11. Wash 3x with wash buffer 
12. Add 1/50 goat anti-mouse whole immunoglobulin FITC (Cappel, USA) 
for 40 min at RT. 
13. Wash 3x with wash buffer. 14. Mount in 30% Glycerol/PBS 
(ii) Imrnunofluorescence of fresh cells 1. Wash slides 3x with RPMI and dry around each well 2. Add 25-50µ1 of 1st antibody (B4A8 or control 1/50 dil) to each 
well and leave in a moist chamber for 60 min at 4°C 3. Wash 2x with wash buffer 
4. Wash 2x with PBS 
5. Fix with 4% paraformaldehyde in PBS pH 7.4 for 2 min at RT 
6. Wash 2x with PBS 
7. Wash 2x with wash buffer and dry around each well. 8. Block with 5% HS PBS for 30 min at RT 9. Wash lx with wash buffer 10. Add 1/50 goat anti-mouse whole irnmunoglobulin FITC (Cappel USA) 
for 40 min at RT 
11. Wash 3x with wash buffer 12. Wet mount (30% glycerol/PBS 0.1% azide) 
Slides were viewed under UV light using an Olympus BH-2 fluorescence microscope and photographed at 80x magnification, average speed 40-52.5 seconds exposure using an Olympus C-35AD camera and 400 ASA Fujicolor film. 
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APPENDIX L 
Coupling of Cyanogen Bromide (GNBr) activated Sepharose to sheep 
anti-mouse immunoglobulin. 
500mg of CNBr activated Sepharose 4B (Pharmacia) was suspended in lmM 
HCl for a few minutes prior to washing by filtering through Whatman 
filter paper with 300 ml lmM HCl. Sepharose 4B was suspended in 
2.5 ml coupling buffer (0.84g 0.lM NaHG03 in 2.9g O.SM NaCl in 100 ml 
H20) containing 1 mg purified sheep anti-mouse antibody rotated 
overnight at 4°G. Excess sheep anti-mouse antibody was removed by two 
centrifugations at 100g for 2 min in coupling buffer. Active groups 
were blocked by tumbling at room temperature for 2 hours in lM 
ethanolamine and then washed in 3 cycles of alternating pH in O.lM Na 
acetate O.SM NaCl pH 4 buffer followed by O.lM Tris O.SM NaCl pH 8 and 
then stored at 4°G in the O.lM Tris buffer. Prior to use, the beads 
were washed 3x with PBS. 
In order to check that the coupling was successful, 200 µl of the final 
suspension was incubated with 500µ1 of a 2mg/ml mouse immunoglobulin 
preparation kindly provided by Dr. Jill Finlayson (University of Gape 
Town) for 90 minutes, centrifuged for 2 minutes in a microfuge and 
after washing Sx with PBS, 20µ1 of 2x sample buffer was added, the 
sample was boiled for 2 minutes, Sepharose pelleted again and the 
supernatant loaded on to 11% PAGE and Western blotted on to 
Imrnobilon™. Results of the Western blot in Fig. 92 confirmed that 
both heavy and light chains of mouse IgG were immunoprecipitated by 






Figure 92 . ~escern blot showing immunoprecipitation of light and heavy 
chains of mouse IgG by sheep anti mouse Sepharose beads 
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